WorldWideScience

Sample records for accelerator-based bnct facility

  1. Accelerator-based BNCT.

    Science.gov (United States)

    Kreiner, A J; Baldo, M; Bergueiro, J R; Cartelli, D; Castell, W; Thatar Vento, V; Gomez Asoia, J; Mercuri, D; Padulo, J; Suarez Sandin, J C; Erhardt, J; Kesque, J M; Valda, A A; Debray, M E; Somacal, H R; Igarzabal, M; Minsky, D M; Herrera, M S; Capoulat, M E; Gonzalez, S J; del Grosso, M F; Gagetti, L; Suarez Anzorena, M; Gun, M; Carranza, O

    2014-06-01

    The activity in accelerator development for accelerator-based BNCT (AB-BNCT) both worldwide and in Argentina is described. Projects in Russia, UK, Italy, Japan, Israel, and Argentina to develop AB-BNCT around different types of accelerators are briefly presented. In particular, the present status and recent progress of the Argentine project will be reviewed. The topics will cover: intense ion sources, accelerator tubes, transport of intense beams, beam diagnostics, the (9)Be(d,n) reaction as a possible neutron source, Beam Shaping Assemblies (BSA), a treatment room, and treatment planning in realistic cases. © 2013 Elsevier Ltd. All rights reserved.

  2. Present status of accelerator-based BNCT: Focus on developments in Argentina

    International Nuclear Information System (INIS)

    Cartelli, D.; Capoulat, M.E.; Bergueiro, J.; Gagetti, L.; Suárez Anzorena, M.; Grosso, M.F. del; Baldo, M.; Castell, W.; Padulo, J.; Suárez Sandín, J.C.; Igarzabal, M.; Erhardt, J.; Mercuri, D.

    2015-01-01

    In this work we provide some information on the present status of accelerator-based BNCT (AB-BNCT) worldwide and subsequently concentrate on the recent accelerator technology developments in Argentina. - Highlights: • The current status of projects and associated facilities for AB-BNCT worldwide is shown. • Only low (few MeV) energy accelerators are included. • The recent progress of the Argentine AB-BNCT program is described.

  3. Tandem electrostatic accelerators for BNCT

    International Nuclear Information System (INIS)

    Ma, J.C.

    1994-01-01

    The development of boron neutron capture therapy (BNCT) into a viable therapeutic modality will depend, in part, on the availability of suitable neutron sources compatible with installation in a hospital environment. Low-energy accelerator-based intense neutron sources, using electrostatic or radio frequency quadrupole proton accelerators have been suggested for this purpose and are underdevelopment at several laboratories. New advances in tandem electrostatic accelerator technology now allow acceleration of the multi-milliampere proton beams required to produce therapeutic neutron fluxes for BNCT. The relatively compact size, low weight and high power efficiency of these machines make them particularly attractive for installation in a clinical or research facility. The authors will describe the limitations on ion beam current and available neutron flux from tandem accelerators relative to the requirements for BNCT research and therapy. Preliminary designs and shielding requirements for a tandern accelerator-based BNCT research facility will also be presented

  4. Present status of Accelerator-Based BNCT.

    Science.gov (United States)

    Kreiner, Andres Juan; Bergueiro, Javier; Cartelli, Daniel; Baldo, Matias; Castell, Walter; Asoia, Javier Gomez; Padulo, Javier; Suárez Sandín, Juan Carlos; Igarzabal, Marcelo; Erhardt, Julian; Mercuri, Daniel; Valda, Alejandro A; Minsky, Daniel M; Debray, Mario E; Somacal, Hector R; Capoulat, María Eugenia; Herrera, María S; Del Grosso, Mariela F; Gagetti, Leonardo; Anzorena, Manuel Suarez; Canepa, Nicolas; Real, Nicolas; Gun, Marcelo; Tacca, Hernán

    2016-01-01

    This work aims at giving an updated report of the worldwide status of Accelerator-Based BNCT (AB-BNCT). There is a generalized perception that the availability of accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of BNCT. Accordingly, in recent years a significant effort has started to develop such machines. A variety of possible charged-particle induced nuclear reactions and the characteristics of the resulting neutron spectra are discussed along with the worldwide activity in suitable accelerator development. Endothermic (7)Li(p,n)(7)Be and (9)Be(p,n)(9)B and exothermic (9)Be(d,n)(10)B are compared. In addition to having much better thermo-mechanical properties than Li, Be as a target leads to stable products. This is a significant advantage for a hospital-based facility. (9)Be(p,n)(9)B needs at least 4-5 MeV bombarding energy to have a sufficient yield, while (9)Be(d,n)(10)B can be utilized at about 1.4 MeV, implying the smallest possible accelerator. This reaction operating with a thin target can produce a sufficiently soft spectrum to be viable for AB-BNCT. The machines considered are electrostatic single ended or tandem accelerators or radiofrequency quadrupoles plus drift tube Linacs. (7)Li(p,n)(7)Be provides one of the best solutions for the production of epithermal neutron beams for deep-seated tumors. However, a Li-based target poses significant technological challenges. Hence, Be has been considered as an alternative target, both in combination with (p,n) and (d,n) reactions. (9)Be(d,n)(10)B at 1.4 MeV, with a thin target has been shown to be a realistic option for the treatment of deep-seated lesions.

  5. Development of a tandem-electrostatic-quadrupole accelerator facility for BNCT

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Thatar Vento, V.; Levinas, P.; Bergueiro, J.; Di Paolo, H.; Burlon, A.A.; Kesque, J.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.; Minsky, D.M.

    2009-01-01

    In this work we describe the present status of an ongoing project to develop a tandem-electrostatic-quadrupole (TESQ) accelerator facility for accelerator-based (AB) BNCT at the Atomic Energy Commission of Argentina in Buenos Aires. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. An electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT. The machine being designed and constructed is a folded TESQ with a high-voltage terminal at 1.2 MV intended to work in air. Such a machine is conceptually shown to be capable of transporting and accelerating a 30 mA proton beam to 2.4 MeV. The general geometric layout, its associated electrostatic fields, and the acceleration tube are simulated using a 3D finite element procedure. The design and construction of the ESQ modules is discussed and their electrostatic fields are investigated. Beam transport calculations through the accelerator are briefly mentioned. Likewise, work related to neutron production targets, strippers, beam shaping assembly and patient treatment room is briefly described.

  6. Development of a tandem-electrostatic-quadrupole accelerator facility for BNCT.

    Science.gov (United States)

    Kreiner, A J; Thatar Vento, V; Levinas, P; Bergueiro, J; Di Paolo, H; Burlon, A A; Kesque, J M; Valda, A A; Debray, M E; Somacal, H R; Minsky, D M; Estrada, L; Hazarabedian, A; Johann, F; Suarez Sandin, J C; Castell, W; Davidson, J; Davidson, M; Giboudot, Y; Repetto, M; Obligado, M; Nery, J P; Huck, H; Igarzabal, M; Fernandez Salares, A

    2009-07-01

    In this work we describe the present status of an ongoing project to develop a tandem-electrostatic-quadrupole (TESQ) accelerator facility for accelerator-based (AB) BNCT at the Atomic Energy Commission of Argentina in Buenos Aires. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the (7)Li(p,n)(7)Be reaction slightly beyond its resonance at 2.25 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the (7)Li(p,n)(7)Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. An electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT. The machine being designed and constructed is a folded TESQ with a high-voltage terminal at 1.2 MV intended to work in air. Such a machine is conceptually shown to be capable of transporting and accelerating a 30 mA proton beam to 2.4 MeV. The general geometric layout, its associated electrostatic fields, and the acceleration tube are simulated using a 3D finite element procedure. The design and construction of the ESQ modules is discussed and their electrostatic fields are investigated. Beam transport calculations through the accelerator are briefly mentioned. Likewise, work related to neutron production targets, strippers, beam shaping assembly and patient treatment room is briefly described.

  7. Development of an accelerator-based BNCT facility at the Berkeley Lab

    International Nuclear Information System (INIS)

    Ludewigt, B.A.; Bleuel, D.; Chu, W.T.; Donahue, R.J.; Kwan, J.; Reginato, L.L.; Wells, R.P.

    1998-01-01

    An accelerator-based BNCT facility is under construction at the Berkeley Lab. An electrostatic-quadrupole (ESQ) accelerator is under development for the production of neutrons via the 7 Li(p,n) 7 Be reaction at proton energies between 2.3 and 2.5 MeV. A novel type of power supply, an air-core coupled transformer power supply, is being built for the acceleration of beam currents exceeding 50 mA. A metallic lithium target has been developed for handling such high beam currents. Moderator, reflector and neutron beam delimiter have extensively been modeled and designs have been identified which produce epithermal neutron spectra sharply peaked between 10 and 20 keV. These. neutron beams are predicted to deliver significantly higher doses to deep seated brain tumors, up to 50% more near the midline of the brain than is possible with currently available reactor beams. The accelerator neutron source will be suitable for future installation at hospitals

  8. Spectrum shaping of accelerator-based neutron beams for BNCT

    CERN Document Server

    Montagnini, B; Esposito, J; Giusti, V; Mattioda, F; Varone, R

    2002-01-01

    We describe Monte Carlo simulations of three facilities for the production of epithermal neutrons for Boron Neutron Capture Therapy (BNCT) and examine general aspects and problems of designing the spectrum-shaping assemblies to be used with these neutron sources. The first facility is based on an accelerator-driven low-power subcritical reactor, operating as a neutron amplifier. The other two facilities have no amplifier and rely entirely on their primary sources, a D-T fusion reaction device and a conventional 2.5 MeV proton accelerator with a Li target, respectively.

  9. Tandem-ESQ for accelerator-based BNCT

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Burlon, A.A.; Di Paolo, H.; Minsky, D.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.; Kwan, J.W.; Henestroza, E.

    2006-01-01

    A project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) is described. A folded tandem, with 1.25 MV terminal voltage, combined with an ElectroStatic Quadrupole (ESQ) chain is being proposed. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction beyond its resonance at 2.25 MeV. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the '7Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT. (author)

  10. Development of a Tandem-ElectroStatic-Quadrupole accelerator facility for Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Thatar Vento, V.; Levinas, P.; Bergueiro, J.; Burlon, A.A.; Di Paolo, H.; Kesque, J.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.; Minsky, D.M.; Estrada, L.; Hazarabedian, A.; Johann, F.; Suarez Sandin, J.C.; Castell, W.; Davidson, J.; Davidson, M.; Repetto, M.; Obligado, M.; Nery, J.P.; Huck, H.; Igarzabal, M.; Fernandez Salares, A.

    2008-01-01

    There is a generalized perception that the availability of suitable particle accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of Boron Neutron Capture Therapy (BNCT). An ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT is described here. The project goal is a machine capable of delivering 30 mA of 2.4-2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. A folded tandem, with 1.20-1.25 MV terminal voltage, combined with an ESQ chain is being designed and constructed. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is one of the technologically simplest and cheapest solutions for optimized AB-BNCT. At present there is no BNCT facility in the world with the characteristics presented in this work. For the accelerator, results on its design, construction and beam transport calculations are discussed. Taking into account the peculiarities of the expected irradiation field, the project also considers a specific study of the treatment room. This study aims at the design of the treatment room emphasizing aspects related to patient, personnel and public radiation protection; dose monitoring; patient positioning and room construction. The design considers both thermal (for the treatment of shallow tumors) and epithermal (for deep-seated tumors) neutron beams entering the room through a port connected to the accelerator via a moderation and neutron beam shaping assembly. Preliminary results of dose calculations for the treatment room design, using the MCNP program, are presented

  11. Fission reactor based epithermal neutron irradiation facilities for routine clinical application in BNCT-Hatanaka memorial lecture

    International Nuclear Information System (INIS)

    Harling, Otto K.

    2009-01-01

    Based on experience gained in the recent clinical studies at MIT/Harvard, the desirable characteristics of epithermal neutron irradiation facilities for eventual routine clinical BNCT are suggested. A discussion of two approaches to using fission reactors for epithermal neutron BNCT is provided. This is followed by specific suggestions for the performance and features needed for high throughput clinical BNCT. An example of a current state-of-the-art, reactor based facility, suited for routine clinical use is discussed. Some comments are provided on the current status of reactor versus accelerator based epithermal neutron sources for BNCT. This paper concludes with a summary and a few personal observations on BNCT by the author.

  12. Treatment planning capability assessment of a beam shaping assembly for accelerator-based BNCT

    International Nuclear Information System (INIS)

    Herrera, M.S.; González, S.J.; Burlon, A.A.; Minsky, D.M.; Kreiner, A.J.

    2011-01-01

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) a theoretical study was performed to assess the treatment planning capability of different configurations of an optimized beam shaping assembly for such a facility. In particular this study aims at evaluating treatment plans for a clinical case of Glioblastoma.

  13. A Tandem-electrostatic-quadrupole for accelerator-based BNCT

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Kwan, J.W.; Burlon, A.A.; Di Paolo, H.; Henestroza, E.; Minsky, D.M.; Valda, A.A.; Debray, M.E.; Somacal, H.

    2007-01-01

    A project to develop a Tandem-electrostatic-quadrupole (TESQ) accelerator for accelerator-based boron neutron capture therapy (AB-BNCT) is described. A folded Tandem, with 1.25 MV terminal voltage, combined with an electrostatic quadrupole (ESQ) chain is being proposed. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p, n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p, n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT

  14. Treatment planning capability assessment of a beam shaping assembly for accelerator-based BNCT.

    Science.gov (United States)

    Herrera, M S; González, S J; Burlon, A A; Minsky, D M; Kreiner, A J

    2011-12-01

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) a theoretical study was performed to assess the treatment planning capability of different configurations of an optimized beam shaping assembly for such a facility. In particular this study aims at evaluating treatment plans for a clinical case of Glioblastoma. Copyright © 2011 Elsevier Ltd. All rights reserved.

  15. An accelerator-based Boron Neutron Capture Therapy (BNCT) facility based on the 7Li(p,n)7Be

    Science.gov (United States)

    Musacchio González, Elizabeth; Martín Hernández, Guido

    2017-09-01

    BNCT (Boron Neutron Capture Therapy) is a therapeutic modality used to irradiate tumors cells previously loaded with the stable isotope 10B, with thermal or epithermal neutrons. This technique is capable of delivering a high dose to the tumor cells while the healthy surrounding tissue receive a much lower dose depending on the 10B biodistribution. In this study, therapeutic gain and tumor dose per target power, as parameters to evaluate the treatment quality, were calculated. The common neutron-producing reaction 7Li(p,n)7Be for accelerator-based BNCT, having a reaction threshold of 1880.4 keV, was considered as the primary source of neutrons. Energies near the reaction threshold for deep-seated brain tumors were employed. These calculations were performed with the Monte Carlo N-Particle (MCNP) code. A simple but effective beam shaping assembly (BSA) was calculated producing a high therapeutic gain compared to previously proposed facilities with the same nuclear reaction.

  16. Towards the final BSA modeling for the accelerator-driven BNCT facility at INFN LNL

    Energy Technology Data Exchange (ETDEWEB)

    Ceballos, C. [Centro de Aplicaciones Tecnlogicas y Desarrollo Nuclear, 5ta y30, Miramar, Playa, Ciudad Habana (Cuba); Esposito, J., E-mail: juan.esposito@lnl.infn.it [INFN, Laboratori Nazionali di Legnaro (LNL), via dell' Universita, 2, I-35020 Legnaro (PD) (Italy); Agosteo, S. [Politecnico di Milano, Dipartimento di Energia, Piazza Leonardo da Vinci 32, 20133 Milano (Italy)] [INFN, Sezione di Milano, via Celoria 16, 20133 Milano (Italy); Colautti, P.; Conte, V.; Moro, D. [INFN, Laboratori Nazionali di Legnaro (LNL), via dell' Universita, 2, I-35020 Legnaro (PD) (Italy); Pola, A. [Politecnico di Milano, Dipartimento di Energia, Piazza Leonardo da Vinci 32, 20133 Milano (Italy)] [INFN, Sezione di Milano, via Celoria 16, 20133 Milano (Italy)

    2011-12-15

    Some remarkable advances have been made in the last years on the SPES-BNCT project of the Istituto Nazionale di Fisica Nucleare (INFN) towards the development of the accelerator-driven thermal neutron beam facility at the Legnaro National Laboratories (LNL), aimed at the BNCT experimental treatment of extended skin melanoma. The compact neutron source will be produced via the {sup 9}Be(p,xn) reactions using the 5 MeV, 30 mA beam driven by the RFQ accelerator, whose modules construction has been recently completed, into a thick beryllium target prototype already available. The Beam Shaping Assembly (BSA) final modeling, using both neutron converter and the new, detailed, Be(p,xn) neutron yield spectra at 5 MeV energy recently measured at the CN Van de Graaff accelerator at LNL, is summarized here.

  17. An epithermal neutron source for BNCT based on an ESQ-accelerator

    International Nuclear Information System (INIS)

    Ludewigt, B.A.; Chu, W.T.; Donahue, R.J.; Kwan, J.; Phillips, T.L.; Reginato, L.L.; Wells, R.P.

    1997-07-01

    An accelerator-based BNCT facility is under development at the Lawrence Berkeley National Laboratory. Neutrons will be produced via the 7 Li(p,n) reaction at proton energies of about 2.5 MeV with subsequent moderation and filtering for shaping epithermal neutron beams for BNCT. Moderator, filter, and shielding assemblies have been modeled using MCNP. Head-phantom dose distributions have been calculated using the treatment planning software BNCT RTPE. The simulation studies have shown that a proton beam current of ∼ 20 mA is required to deliver high quality brain treatments in about 40 minutes. The results also indicate that significantly higher doses can be delivered to deep-seated tumors in comparison to the Brookhaven Medical Research Reactor beam. An electrostatic quadrupole (ESQ) accelerator is ideally suited to provide the high beam currents desired. A novel power supply utilizing the air-coupled transformer concept is under development. It will enable the ESQ-accelerator to deliver proton beam currents exceeding 50 mA. A lithium target has been designed which consists of a thin layer of lithium on an aluminum backing. Closely spaced, narrow coolant passages cut into the aluminum allow the removal of a 50kW heat-load by convective water cooling. The system under development is suitable for hospital installation and has the potential for providing neutron beams superior to reactor sources

  18. Spectrum shaping assessment of accelerator-based fusion neutron sources to be used in BNCT treatment

    Science.gov (United States)

    Cerullo, N.; Esposito, J.; Daquino, G. G.

    2004-01-01

    Monte Carlo modelling of an irradiation facility, for boron neutron capture therapy (BNCT) application, using a set of advanced type, accelerator based, 3H(d,n) 4He (D-T) fusion neutron source device is presented. Some general issues concerning the design of a proper irradiation beam shaping assembly, based on very hard energy neutron source spectrum, are reviewed. The facility here proposed, which represents an interesting solution compared to the much more investigated Li or Be based accelerator driven neutron source could fulfil all the medical and safety requirements to be used by an hospital environment.

  19. Clinical requirements and accelerator concepts for BNCT

    International Nuclear Information System (INIS)

    Ludewigt, B.A.; Bleuel, D.L.; Chu, W.T.; Donahue, R.J.; Kwan, J.; Leung, K.N.; Reginato, L.L.; Wells, R.P.

    1997-05-01

    Accelerator-based neutron sources are an attractive alternative to nuclear reactors for providing epithermal neutron beams for Boron Neutron Capture Therapy. Based on clinical requirements and neutronics modeling the use of proton and deuteron induced reactions in 7 Li and 9 Be targets has been compared. Excellent epithermal neutron beams can be produced via the 7 Li(p,n) 7 Be reaction at proton energies of ∼2.5 MeV. An electrostatic quadrupole accelerator and a lithium target, which can deliver and handle 2.5 MeV protons at beam currents up to 50 mA, are under development for an accelerator-based BNCT facility at the Lawrence Berkeley National Laboratory

  20. An Accelerator Neutron Source for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Blue, Thomas, E

    2006-03-14

    The overall goal of this project was to develop an accelerator-based neutron source (ABNS) for Boron Neutron Capture Therapy (BNCT). Specifically, our goals were to design, and confirm by measurement, a target assembly and a moderator assembly that would fulfill the design requirements of the ABNS. These design requirements were 1) that the neutron field quality be as good as the neutron field quality for the reactor-based neutron sources for BNCT, 2) that the patient treatment time be reasonable, 3) that the proton current required to treat patients in reasonable times be technologially achievable at reasonable cost with good reliability, and accelerator space requirements which can be met in a hospital, and finally 4) that the treatment be safe for the patients.

  1. An Accelerator Neutron Source for BNCT

    International Nuclear Information System (INIS)

    Blue, Thomas E.

    2006-01-01

    The overall goal of this project was to develop an accelerator-based neutron source (ABNS) for Boron Neutron Capture Therapy (BNCT). Specifically, our goals were to design, and confirm by measurement, a target assembly and a moderator assembly that would fulfill the design requirements of the ABNS. These design requirements were (1) that the neutron field quality be as good as the neutron field quality for the reactor-based neutron sources for BNCT, (2) that the patient treatment time be reasonable, (3) that the proton current required to treat patients in reasonable times be technologically achievable at reasonable cost with good reliability, and accelerator space requirements which can be met in a hospital, and finally (4) that the treatment be safe for the patients

  2. Electrostatic design and beam transport for a folded tandem electrostatic quadrupole accelerator facility for accelerator-based boron neutron capture therapy

    International Nuclear Information System (INIS)

    Thatar Vento, V.; Bergueiro, J.; Cartelli, D.; Valda, A.A.; Kreiner, A.J.

    2011-01-01

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT), we discuss here the electrostatic design of the machine, including the accelerator tubes with electrostatic quadrupoles and the simulations for the transport and acceleration of a high intensity beam.

  3. Accelerator based-boron neutron capture therapy (BNCT)-clinical QA and QC

    International Nuclear Information System (INIS)

    Suzuki, Minoru; Tanaka, Hiroki; Sakurai, Yoshinori; Yong, Liu; Kashino, Genro; Kinashi, Yuko; Masunaga, Shinichiro; Ono, Koji; Maruhashi, Akira

    2009-01-01

    Alpha-particle and recoil Li atom yielded by the reaction ( 10 B, n), due to their high LET properties, efficiently and specifically kill the cancer cell that has incorporated the boron. Efficacy of this boron neutron capture therapy (BNCT) has been demonstrated mainly in the treatment of recurrent head/neck and malignant brain cancers in Kyoto University Research Reactor Institute (KUR). As the clinical trial of BNCT is to start from 2009 based on an accelerator (not on the Reactor), this paper describes the tentative outline of the standard operation procedure of BNCT for its quality assurance (QA) and quality control (QC) along the flow of its clinical practice. Personnel concerned in the practice involve the attending physician, multiple physicians in charge of BNCT, medical physicists, nurses and reactor stuff. The flow order of the actual BNCT is as follows: Pre-therapeutic evaluation mainly including informed consent and confirmation of the prescription; Therapeutic planning including setting of therapy volume, and of irradiation axes followed by meeting for stuffs' agreement, decision of irradiating field in the irradiation room leading to final decision of the axis, CT for the planning, decision of the final therapeutic plan according to Japan Atomic Energy Agency-Computational Dosimetry System (JCDS) and meeting of all related personnel for the final confirmation of therapeutic plan; and BNCT including the transport of patient to KUR, dripping of boronophenylalanine, setting up of the patient on the machine, blood sampling for pharmacokinetics, boron level measurement for decision of irradiating time, switch on/off of the accelerator, confirmation of patient's movement in the irradiated field after the neutron irradiation, blood sampling for confirmation of the boron level, and patient's leave from the room. The QA/QC check is principally to be conducted with the two-person rule. The purpose of the clinical trial is to establish the usefulness of BNCT

  4. Analysis of accelerator based neutron spectra for BNCT using proton recoil spectroscopy

    International Nuclear Information System (INIS)

    Wielopolski, L.; Ludewig, H.; Powell, J.R.; Raparia, D.; Alessi, J.G.; Lowenstein, D.I.

    1998-01-01

    Boron Neutron Capture Therapy (BNCT) is a promising binary treatment modality for high-grade primary brain tumors (glioblastoma multiforme, GM) and other cancers. BNCT employs a boron-10 containing compound that preferentially accumulates in the cancer cells in the brain. Upon neutron capture by 10 B energetic alpha particles and triton released at the absorption site kill the cancer cell. In order to gain penetration depth in the brain Fairchild proposed, for this purpose, the use of energetic epithermal neutrons at about 10 keV. Phase I/II clinical trials of BNCT for GM are underway at the Brookhaven Medical Research Reactor (BMRR) and at the MIT Reactor, using these nuclear reactors as the source for epithermal neutrons. In light of the limitations of new reactor installations, e.g. cost, safety and licensing, and limited capability for modulating the reactor based neutron beam energy spectra alternative neutron sources are being contemplated for wider implementation of this modality in a hospital environment. For example, accelerator based neutron sources offer the possibility of tailoring the neutron beams, in terms of improved depth-dose distributions, to the individual and offer, with relative ease, the capability of modifying the neutron beam energy and port size. In previous work new concepts for compact accelerator/target configuration were published. In this work, using the Van de Graaff accelerator the authors have explored different materials for filtering and reflecting neutron beams produced by irradiating a thick Li target with 1.8 to 2.5 MeV proton beams. However, since the yield and the maximum neutron energy emerging from the Li-7(p,n)Be-7 reaction increase with increase in the proton beam energy, there is a need for optimization of the proton energy versus filter and shielding requirements to obtain the desired epithermal neutron beam. The MCNP-4A computer code was used for the initial design studies that were verified with benchmark experiments

  5. Electrostatic design and beam transport for a folded tandem electrostatic quadrupole accelerator facility for accelerator-based boron neutron capture therapy.

    Science.gov (United States)

    Vento, V Thatar; Bergueiro, J; Cartelli, D; Valda, A A; Kreiner, A J

    2011-12-01

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT), we discuss here the electrostatic design of the machine, including the accelerator tubes with electrostatic quadrupoles and the simulations for the transport and acceleration of a high intensity beam. Copyright © 2011 Elsevier Ltd. All rights reserved.

  6. An accelerator neutron source for BNCT. Technical progress report, 1 June 1993--31 May 1994

    International Nuclear Information System (INIS)

    Blue, T.E.; Vafai, K.

    1994-02-01

    This is the progress report for the project entitled, ''An Accelerator Neutron Source for BNCT.'' The progress report is for the period from July 1, 1993 to date. The overall objective of our research project is to develop an Accelerator Epithermal Neutron Irradiation Facility (AENIF) for Boron Neutron Capture Therapy (BNCT). The AENIF consists of a 2.5 MeV high current proton accelerator, a lithium target to produce source neutrons, and a moderator/reflector assembly to obtain from the energetic source neutrons an epithermal neutron field suitable for BNCT treatments. Our project goals are to develop the non-accelerator components of the AENIF, and to specifically include in our development: (1) design, numerical simulation, and experimental verification of a target assembly which is capable of removing 75 kW of beam power; (2) re-optimization of the moderator assembly design based on in-phantom dose assessments using neutron spectra calculated in phantom and an energy-dependent neutron Relative Biological Effectiveness (RBE); (3) construction of a prototype moderator assembly and confirmation of its design by measurements; (4) design of the shielding of the accelerator and treatment rooms for an AENIF; and (5) design of a high energy beam transport system which is compatible with the shielding design and the thermal-hydraulic design

  7. Characterisation of an accelerator-based neutron source for BNCT versus beam energy

    CERN Document Server

    Agosteo, S; D'Errico, F; Nath, R; Tinti, R

    2002-01-01

    Neutron capture in sup 1 sup 0 B produces energetic alpha particles that have a high linear energy transfer in tissue. This results in higher cell killing and a higher relative biological effectiveness compared to photons. Using suitably designed boron compounds which preferentially localize in cancerous cells instead of healthy tissues, boron neutron capture therapy (BNCT) has the potential of providing a higher tumor cure rate within minimal toxicity to normal tissues. This clinical approach requires a thermal neutron source, generally a nuclear reactor, with a fluence rate sufficient to deliver tumorcidal doses within a reasonable treatment time (minutes). Thermal neutrons do not penetrate deeply in tissue, therefore BNCT is limited to lesions which are either superficial or otherwise accessible. In this work, we investigate the feasibility of an accelerator-based thermal neutron source for the BNCT of skin melanomas. The source was designed via MCNP Monte Carlo simulations of the thermalization of a fast ...

  8. Beam shaping assembly optimization for (7)Li(p,n)(7)Be accelerator based BNCT.

    Science.gov (United States)

    Minsky, D M; Kreiner, A J

    2014-06-01

    Within the framework of accelerator-based BNCT, a project to develop a folded Tandem-ElectroStatic-Quadrupole accelerator is under way at the Atomic Energy Commission of Argentina. The proposed accelerator is conceived to deliver a proton beam of 30mA at about 2.5MeV. In this work we explore a Beam Shaping Assembly (BSA) design based on the (7)Li(p,n)(7)Be neutron production reaction to obtain neutron beams to treat deep seated tumors. © 2013 Elsevier Ltd. All rights reserved.

  9. High neutronic efficiency, low current targets for accelerator-based BNCT applications

    International Nuclear Information System (INIS)

    Powell, J.R.; Ludewig, H.; Todosow, M.

    1998-01-01

    The neutronic efficiency of target/filters for accelerator-based BNCT applications is measured by the proton current required to achieve a desirable neutron current at the treatment port (10 9 n/cm 2 /s). In this paper the authors describe two possible targeyt/filter concepts wihch minimize the required current. Both concepts are based on the Li-7 (p,n)Be-7 reaction. Targets that operate near the threshold energy generate neutrons that are close tothe desired energy for BNCT treatment. Thus, the filter can be extremely thin (∼ 5 cm iron). However, this approach has an extremely low neutron yield (n/p ∼ 1.0(-6)), thus requiring a high proton current. The proposed solutino is to design a target consisting of multiple extremely thin targets (proton energy loss per target ∼ 10 keV), and re-accelerate the protons between each target. Targets operating at ihgher proton energies (∼ 2.5 MeV) have a much higher yield (n/p ∼ 1.0(-4)). However, at these energies the maximum neutron energy is approximately 800 keV, and thus a neutron filter is required to degrade the average neutron energy to the range of interest for BNCT (10--20 keV). A neutron filter consisting of fluorine compounds and iron has been investigated for this case. Typically a proton current of approximately 5 mA is required to generate the desired neutron current at the treatment port. The efficiency of these filter designs can be further increased by incorporating neutron reflectors that are co-axial with the neutron source. These reflectors are made of materials which have high scattering cross sections in the range 0.1--1.0 MeV

  10. Commissioning of accelerator based boron neutron capture therapy system

    International Nuclear Information System (INIS)

    Nakamura, S.; Wakita, A.; Okamoto, H.; Igaki, H.; Itami, J.; Ito, M.; Abe, Y.; Imahori, Y.

    2017-01-01

    Boron neutron capture therapy (BNCT) is a treatment method using a nuclear reaction of 10 B(n, α) 7 Li. BNCT can be deposited the energy to a tumor since the 10 B which has a higher cross-section to a neutron is high is concentrated on the tumor. It is different from conventional radiation therapies that BNCT expects higher treatment effect to radiation resistant tumors since the generated alpha and lithium particles have higher radiological biological effectiveness. In general, BNCT has been performed in research nuclear reactor. Thus, BNCT is not widely applied in a clinical use. According to recent development of accelerator-based boron neutron capture therapy system, the system has an adequate flux of neutrons. Therefore, National Cancer Canter Hospital, Tokyo, Japan is planning to install accelerator based BNCT system. Protons with 2.5 MeV are irradiated to a lithium target system to generate neutrons. As a result, thermal load of the target is 50 kW since current of the protons is 20.0 mA. Additionally, when the accelerator-based BNCT system is installed in a hospital, the facility size is disadvantage in term of neutron measurements. Therefore, the commissioning of the BNCT system is being performed carefully. In this article, we report about the commissioning. (author)

  11. Development of a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Castell, W.; Di Paolo, H.; Baldo, M.; Bergueiro, J.

    2011-01-01

    We describe the present status of an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction. The machine currently being constructed is a folded TESQ with a high-voltage terminal at 0.6 MV. We report here on the progress achieved in a number of different areas.

  12. Characterisation of an accelerator-based neutron source for BNCT versus beam energy

    Science.gov (United States)

    Agosteo, S.; Curzio, G.; d'Errico, F.; Nath, R.; Tinti, R.

    2002-01-01

    Neutron capture in 10B produces energetic alpha particles that have a high linear energy transfer in tissue. This results in higher cell killing and a higher relative biological effectiveness compared to photons. Using suitably designed boron compounds which preferentially localize in cancerous cells instead of healthy tissues, boron neutron capture therapy (BNCT) has the potential of providing a higher tumor cure rate within minimal toxicity to normal tissues. This clinical approach requires a thermal neutron source, generally a nuclear reactor, with a fluence rate sufficient to deliver tumorcidal doses within a reasonable treatment time (minutes). Thermal neutrons do not penetrate deeply in tissue, therefore BNCT is limited to lesions which are either superficial or otherwise accessible. In this work, we investigate the feasibility of an accelerator-based thermal neutron source for the BNCT of skin melanomas. The source was designed via MCNP Monte Carlo simulations of the thermalization of a fast neutron beam, generated by 7 MeV deuterons impinging on a thick target of beryllium. The neutron field was characterized at several deuteron energies (3.0-6.5 MeV) in an experimental structure installed at the Van De Graaff accelerator of the Laboratori Nazionali di Legnaro, in Italy. Thermal and epithermal neutron fluences were measured with activation techniques and fast neutron spectra were determined with superheated drop detectors (SDD). These neutron spectrometry and dosimetry studies indicated that the fast neutron dose is unacceptably high in the current design. Modifications to the current design to overcome this problem are presented.

  13. Development of a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy.

    Science.gov (United States)

    Kreiner, A J; Castell, W; Di Paolo, H; Baldo, M; Bergueiro, J; Burlon, A A; Cartelli, D; Vento, V Thatar; Kesque, J M; Erhardt, J; Ilardo, J C; Valda, A A; Debray, M E; Somacal, H R; Sandin, J C Suarez; Igarzabal, M; Huck, H; Estrada, L; Repetto, M; Obligado, M; Padulo, J; Minsky, D M; Herrera, M; Gonzalez, S J; Capoulat, M E

    2011-12-01

    We describe the present status of an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the (7)Li(p,n)(7)Be reaction. The machine currently being constructed is a folded TESQ with a high-voltage terminal at 0.6 MV. We report here on the progress achieved in a number of different areas. Copyright © 2011 Elsevier Ltd. All rights reserved.

  14. Feasibility study to develop BNCT facility at the Indonesian research reactor

    International Nuclear Information System (INIS)

    Hastowo, H.

    2001-01-01

    A survey on the Indonesian research reactors and its supporting facilities has been done in order to check the possibility to install BNCT facility. Oncologists from several hospitals have been informing about the BNCT treatment for tumours and they give a positive response to support utilisation of the BNCT facility. Several aspects required to support the BNCT treatment have also been identified and related activities on that matter soon will be initiated. The interim result in our survey indicated that utilisation of the 30 MW Multipurpose reactor would not be possible from the technical point of view. Further study will be concentrated on the TRIGA reactor and an epithermal neutron beam facility at the thermal column of this reactor will be designed for further work. (author)

  15. Demonstration of the importance of a dedicated neutron beam monitoring system for BNCT facility

    International Nuclear Information System (INIS)

    Chao, Der-Sheng; Liu, Yuan-Hao; Jiang, Shiang-Huei

    2016-01-01

    The neutron beam monitoring system is indispensable to BNCT facility in order to achieve an accurate patient dose delivery. The neutron beam monitoring of a reactor-based BNCT (RB-BNCT) facility can be implemented through the instrumentation and control system of a reactor provided that the reactor power level remains constant during reactor operation. However, since the neutron flux in reactor core is highly correlative to complicated reactor kinetics resulting from such as fuel depletion, poison production, and control blade movement, some extent of variation may occur in the spatial distribution of neutron flux in reactor core. Therefore, a dedicated neutron beam monitoring system is needed to be installed in the vicinity of the beam path close to the beam exit of the RB-BNCT facility, where it can measure the BNCT beam intensity as closely as possible and be free from the influence of the objects present around the beam exit. In this study, in order to demonstrate the importance of a dedicated BNCT neutron beam monitoring system, the signals originating from the two in-core neutron detectors installed at THOR were extracted and compared with the three dedicated neutron beam monitors of the THOR BNCT facility. The correlation of the readings between the in-core neutron detectors and the BNCT neutron beam monitors was established to evaluate the improvable quality of the beam intensity measurement inferred by the in-core neutron detectors. In 29 sampled intervals within 16 days of measurement, the fluctuations in the mean value of the normalized ratios between readings of the three BNCT neutron beam monitors lay within 0.2%. However, the normalized ratios of readings of the two in-core neutron detectors to one of the BNCT neutron beam monitors show great fluctuations of 5.9% and 17.5%, respectively. - Highlights: • Two in-core neutron detectors and three BNCT neutron beam monitors were compared. • BNCT neutron beam monitors improve the stability in neutron

  16. Development of breast cancer irradiation technique for BNCT at JRR-4

    International Nuclear Information System (INIS)

    Nakamura, Takemi; Horiguchi, Hironori; Arai, Masaji; Yanagie, Hironobu

    2014-06-01

    In the Department of Research Reactor and Tandem Accelerator, developments of irradiation technique with application enlargement for breast cancer on BNCT have been performed in the second medium term plans. We compiled this report about the technological development to solve several problems with the irradiation of breast cancer in the medical irradiation facility of JRR-4. In the present study, design fabrication of a collimator for breast cancer, dose evaluation analysis by clinical model, investigation of dose enhancement at deeper region and investigation of fixing method for breast cancer irradiation were studied. By these evaluation results, we verified that the developed breast cancer irradiation technique can be applied to BNCT medical irradiation of JRR-4. These results are expected to be able to contribute to breast cancer irradiation techniques of other reactor-based BNCT and future accelerator-based BNCT. (author)

  17. Design of a BNCT facility at HANARO

    International Nuclear Information System (INIS)

    Jun, Byung Jin; Lee, Byung Chul

    1998-01-01

    Based on the feasibility study of the BNCT at HANARO, it was confirmed that only thermal BNCT is possible at the IR beam tube if appropriate filtering system be installed. Medical doctors in Korea Cancer Center Hospital agreed that the thermal BNCT facility would be worthwhile for the BNCT technology development in Korea as well as superficial cancer treatment. For the thermal BNCT to be effective, the thermal neutron flux should be high enough for patient treatment during relatively short time and also the fast neutron and gamma-ray fluxes should be as low as possible. In this point of view, the following design requirements are set up: 1) thermal neutron flux at the irradiation position should be higher than 3x10 9 n/cm 2 -sec, 2) ratio of the fast neutrons and gamma-rays to the thermal neutrons should be minimized, and 3) patient treatment should be possible without interrupt to the reactor operation. To minimize the fast neutrons and gamma-rays with the required thermal neutrons at the irradiation position, a radiation filter consisting of single crystals of silicon and bismuth at liquid nitrogen temperature is designed. For the shielding purpose around the irradiation position, polyethylene, lead, LiF, etc., are appropriately arranged around the radiation filter. A water shutter in front of the radiation filter is adopted so as to avoid interrupt to the reactor operation. At present, detail design of the radiation filter is ongoing. Cooling capabilities of the filter will be tested through a mockup experiment. Dose rate distributions around the radiation filter and a prompt gamma-ray activation analysis system for the analyses of boron content in the biological samples are under design. The construction of this facility will be started from next year if it is permitted from the regulatory body this year. Some other future works exist and are described in the paper. (author)

  18. Design of a beam shaping assembly for an accelerator-based BNCT system

    International Nuclear Information System (INIS)

    Stichelbaut, F.; Forton, E.; Jongen, Y.

    2006-01-01

    A complete BNCT system based on a high-intensity proton accelerator is developed by the IBA company. The neutron beam is produced via the 7 Li(p,n) 7 Be reaction using a solid lithium target. The neutron energy spectrum is tailored with a beam shaping assembly surrounding the target. This device is the object of an extensive R and D project and is fully designed with the Monte Carlo simulation code MCNPX. The emphasis is put on the treatment quality, notably the radiation dose at the skin level, and the achievable neutron flux. (author)

  19. Proceedings of neutron irradiation technical meeting on BNCT

    International Nuclear Information System (INIS)

    2000-10-01

    The 'Neutron Irradiation Technical Meeting for Boron Neutron Capture Therapy (BNCT)' was held on March 13, 2000 at Tokai Research Establishment. The Meeting is aimed to introduce the neutron beam facility for medical irradiation at JRR-4 to Japanese researchers widely, as well as providing an opportunity for young researchers, engineers, medical representatives such surgeons and doctors of pharmacology to present their research activities and to exchange valuable information. JAERI researcher presented the performance and the irradiation technology in the JRR-4 neutron beam facility, while external researchers made various and beneficial presentations containing such accelerator-based BNCT, spectrum-shifter, biological effect, pharmacological development and so on. In this meeting, a special lecture titled 'The Dawn of BNCT and Its Development.' was given by MD, Prof. Takashi Minobe, an executive director of Japan Foundation for Emergency Medicine. The 11 of the presented papers are indexed individually. (J.P.N.)

  20. Proceedings of neutron irradiation technical meeting on BNCT

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2000-10-01

    The 'Neutron Irradiation Technical Meeting for Boron Neutron Capture Therapy (BNCT)' was held on March 13, 2000 at Tokai Research Establishment. The Meeting is aimed to introduce the neutron beam facility for medical irradiation at JRR-4 to Japanese researchers widely, as well as providing an opportunity for young researchers, engineers, medical representatives such surgeons and doctors of pharmacology to present their research activities and to exchange valuable information. JAERI researcher presented the performance and the irradiation technology in the JRR-4 neutron beam facility, while external researchers made various and beneficial presentations containing such accelerator-based BNCT, spectrum-shifter, biological effect, pharmacological development and so on. In this meeting, a special lecture titled 'The Dawn of BNCT and Its Development.' was given by MD, Prof. Takashi Minobe, an executive director of Japan Foundation for Emergency Medicine. The 11 of the presented papers are indexed individually. (J.P.N.)

  1. Design of thermal neutron beam based on an electron linear accelerator for BNCT.

    Science.gov (United States)

    Zolfaghari, Mona; Sedaghatizadeh, Mahmood

    2016-12-01

    An electron linear accelerator (Linac) can be used for boron neutron capture therapy (BNCT) by producing thermal neutron flux. In this study, we used a Varian 2300 C/D Linac and MCNPX.2.6.0 code to simulate an electron-photoneutron source for use in BNCT. In order to decelerate the produced fast neutrons from the photoneutron source, which optimize the thermal neutron flux, a beam-shaping assembly (BSA) was simulated. After simulations, a thermal neutron flux with sharp peak at the beam exit was obtained in the order of 3.09×10 8 n/cm 2 s and 6.19×10 8 n/cm 2 s for uranium and enriched uranium (10%) as electron-photoneutron sources respectively. Also, in-phantom dose analysis indicates that the simulated thermal neutron beam can be used for treatment of shallow skin melanoma in time of about 85.4 and 43.6min for uranium and enriched uranium (10%) respectively. Copyright © 2016. Published by Elsevier Ltd.

  2. Demonstration of a high-intensity neutron source based on a liquid-lithium target for Accelerator based Boron Neutron Capture Therapy.

    Science.gov (United States)

    Halfon, S; Arenshtam, A; Kijel, D; Paul, M; Weissman, L; Berkovits, D; Eliyahu, I; Feinberg, G; Kreisel, A; Mardor, I; Shimel, G; Shor, A; Silverman, I; Tessler, M

    2015-12-01

    A free surface liquid-lithium jet target is operating routinely at Soreq Applied Research Accelerator Facility (SARAF), bombarded with a ~1.91 MeV, ~1.2 mA continuous-wave narrow proton beam. The experiments demonstrate the liquid lithium target (LiLiT) capability to constitute an intense source of epithermal neutrons, for Accelerator based Boron Neutron Capture Therapy (BNCT). The target dissipates extremely high ion beam power densities (>3 kW/cm(2), >0.5 MW/cm(3)) for long periods of time, while maintaining stable conditions and localized residual activity. LiLiT generates ~3×10(10) n/s, which is more than one order of magnitude larger than conventional (7)Li(p,n)-based near threshold neutron sources. A shield and moderator assembly for BNCT, with LiLiT irradiated with protons at 1.91 MeV, was designed based on Monte Carlo (MCNP) simulations of BNCT-doses produced in a phantom. According to these simulations it was found that a ~15 mA near threshold proton current will apply the therapeutic doses in ~1h treatment duration. According to our present results, such high current beams can be dissipated in a liquid-lithium target, hence the target design is readily applicable for accelerator-based BNCT. Copyright © 2015 Elsevier Ltd. All rights reserved.

  3. Investigation of development and management of treatment planning systems for BNCT at foreign facilities

    International Nuclear Information System (INIS)

    2001-03-01

    A new computational dosimetry system for BNCT: JCDS is developed by JAERI in order to carry out BNCT with epithermal neutron beam at present. The development and management situation of computational dosimetry system, which are developed and are used in BNCT facilities in foreign countries, were investigated in order to accurately grasp functions necessary for preparation of the treatment planning and its future subjects. In present state, 'SERA', which are developed by Idaho National Engineering and Environmental Laboratory (INEEL), is used in many BNCT facilities. Followings are necessary for development and management of the treatment planning system. (1) Reliability confirmation of system performance by verification as comparison examination of calculated value with actual experimental measured value. (2) Confirmation systems such as periodic maintenance for retention of the system quality. (3) The improvement system, which always considered relative merits and demerits with other computational dosimetry system. (4) The development of integrated system with patient setting. (author)

  4. The Idaho Power Burst Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program overview

    International Nuclear Information System (INIS)

    Dorn, R.V. III; Griebenow, M.L.; Ackermann, A.L.; Miller, L.G.; Miller, D.L.; Wheeler, F.J.; Bradshaw, K.M.; Wessol, D.E.; Harker, Y.D.; Nigg, D.W.; Randolph, P.D.; Bauer, W.F.; Gavin, P.R.; Richards, T.L.

    1992-01-01

    The Power Burst Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program has been funded since 1988 to evaluate brain tumor treatment using Na 2 B 12 H 11 SH (borocaptate sodium or BSH) and epithermal neutrons. The PBF/BNCT Program pursues this goal as a comprehensive, multidisciplinary, multiorganizational endeavor applying modern program management techniques. The initial focus was to: (1) establish a representative large animal model and (2) develop the generic analytical and measurement capabilities require to control treatment repeatability and determine critical treatment parameters independent of tumor type and body location. This paper will identify the PBF/BNCT Program elements and summarize the status of some of the developed capabilities

  5. Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors.

    Science.gov (United States)

    Blue, Thomas E; Yanch, Jacquelyn C

    2003-01-01

    This paper reviews the development of low-energy light ion accelerator-based neutron sources (ABNSs) for the treatment of brain tumors through an intact scalp and skull using boron neutron capture therapy (BNCT). A major advantage of an ABNS for BNCT over reactor-based neutron sources is the potential for siting within a hospital. Consequently, light-ion accelerators that are injectors to larger machines in high-energy physics facilities are not considered. An ABNS for BNCT is composed of: (1) the accelerator hardware for producing a high current charged particle beam, (2) an appropriate neutron-producing target and target heat removal system (HRS), and (3) a moderator/reflector assembly to render the flux energy spectrum of neutrons produced in the target suitable for patient irradiation. As a consequence of the efforts of researchers throughout the world, progress has been made on the design, manufacture, and testing of these three major components. Although an ABNS facility has not yet been built that has optimally assembled these three components, the feasibility of clinically useful ABNSs has been clearly established. Both electrostatic and radio frequency linear accelerators of reasonable cost (approximately 1.5 M dollars) appear to be capable of producing charged particle beams, with combinations of accelerated particle energy (a few MeV) and beam currents (approximately 10 mA) that are suitable for a hospital-based ABNS for BNCT. The specific accelerator performance requirements depend upon the charged particle reaction by which neutrons are produced in the target and the clinical requirements for neutron field quality and intensity. The accelerator performance requirements are more demanding for beryllium than for lithium as a target. However, beryllium targets are more easily cooled. The accelerator performance requirements are also more demanding for greater neutron field quality and intensity. Target HRSs that are based on submerged-jet impingement and

  6. Shielding design of a treatment room for an accelerator-based epithermal neutron irradiation facility for BNCT

    International Nuclear Information System (INIS)

    Evans, J.F.; Blue, T.E.

    1996-01-01

    Protecting the facility personnel and the general public from radiation exposure is a primary safety concern of an accelerator-based epithermal neutron irradiation facility. This work makes an attempt at answering the questions open-quotes How much?close quotes and open-quotes What kind?close quotes of shielding will meet the occupational limits of such a facility. Shielding effectiveness is compared for ordinary and barytes concretes in combination with and without borated polyethylene. A calculational model was developed of a treatment room, patient open-quotes scatterer,close quotes and the epithermal neutron beam. The Monte Carlo code, MCNP, was used to compute the total effective dose equivalent rates at specific points of interest outside of the treatment room. A conservative occupational effective dose rate limit of 0.01 mSv h -1 was the guideline for this study. Conservative Monte Carlo calculations show that constructing the treatment room walls with 1.5 m of ordinary concrete, 1.2 m of barytes concrete, 1.0 m of ordinary concrete preceded by 10 cm of 5% boron-polyethylene, or 0.8 m of barytes concrete preceded by 10 cm of 5% boron-polyethylene will adequately protect facility personnel. 20 refs., 8 figs., 2 tabs

  7. Optimization of the irradiation beam in the BNCT research facility at IEA-R1 reactor

    International Nuclear Information System (INIS)

    Castro, Vinicius Alexandre de

    2014-01-01

    Boron Neutron Capture Therapy (BNCT) is a radiotherapeutic technique for the treatment of some types of cancer whose useful energy comes from a nuclear reaction that occurs when thermal neutron impinges upon a Boron-10 atom. In Brazil there is a research facility built along the beam hole number 3 of the IEA-R1 research reactor at IPEN, which was designed to perform BNCT research experiments. For a good performance of the technique, the irradiation beam should be mostly composed of thermal neutrons with a minimum as possible gamma and above thermal neutron components. This work aims to monitor and evaluate the irradiation beam on the sample irradiation position through the use of activation detectors (activation foils) and also to propose, through simulation using the radiation transport code, MCNP, new sets of moderators and filters which shall deliver better irradiation fields at the irradiation sample position In this work, a simulation methodology, based on a MCNP card, known as wwg (weight window generation) was studied, and the neutron energy spectrum has been experimentally discriminated at 5 energy ranges by using a new set o activation foils. It also has been concluded that the BNCT research facility has the required thermal neutron flux to perform studies in the area and it has a great potential for improvement for tailoring the irradiation field. (author)

  8. High power accelerator-based boron neutron capture with a liquid lithium target and new applications to treatment of infectious diseases

    Energy Technology Data Exchange (ETDEWEB)

    Halfon, S. [Soreq NRC, Yavne 81800 (Israel); Racah Institute of Physics, Hebrew University, Jerusalem 91904 (Israel)], E-mail: halfon@phys.huji.ac.il; Paul, M. [Racah Institute of Physics, Hebrew University, Jerusalem 91904 (Israel); Steinberg, D. [Biofilm Laboratory, Institute of Dental Sciences, Faculty of Dentistry, Hebrew University-Hadassah (Israel); Nagler, A.; Arenshtam, A.; Kijel, D. [Soreq NRC, Yavne 81800 (Israel); Polacheck, I. [Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center (Israel); Srebnik, M. [Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Hebrew University, Jerusalem 91120 (Israel)

    2009-07-15

    A new conceptual design for an accelerator-based boron neutron capture therapy (ABNCT) facility based on the high-current low-energy proton beam driven by the linear accelerator at SARAF (Soreq Applied Research Accelerator Facility) incident on a windowless forced-flow liquid-lithium target, is described. The liquid-lithium target, currently in construction at Soreq NRC, will produce a neutron field suitable for the BNCT treatment of deep-seated tumor tissues, through the reaction {sup 7}Li(p,n){sup 7}Be. The liquid-lithium target is designed to overcome the major problem of solid lithium targets, namely to sustain and dissipate the power deposited by the high-intensity proton beam. Together with diseases conventionally targeted by BNCT, we propose to study the application of our setup to a novel approach in treatment of diseases associated with bacterial infections and biofilms, e.g. inflammations on implants and prosthetic devices, cystic fibrosis, infectious kidney stones. Feasibility experiments evaluating the boron neutron capture effectiveness on bacteria annihilation are taking place at the Soreq nuclear reactor.

  9. INEL BNCT research program: Annual report, 1995

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1996-04-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1995. Contributions from the principal investigators about their individual projects are included, specifically, physics (treatment planning software, real-time neutron beam measurement dosimetry), and radiation biology (large animal models efficacy studies). Design of a reactor based epithermal neutron extraction facility is discussed in detail. Final results of boron magnetic resonance imagining is included for both borocaptate sodium (BSH) and boronophenylalanine (BPA) in rats, and BSH in humans. Design of an epithermal neutron facility using electron linear accelerators is presented, including a treatise on energy removal from the beam target. Information on the multiple fraction injection of BSH in rats is presented.

  10. INEL BNCT research program: Annual report, 1995

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1996-04-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1995. Contributions from the principal investigators about their individual projects are included, specifically, physics (treatment planning software, real-time neutron beam measurement dosimetry), and radiation biology (large animal models efficacy studies). Design of a reactor based epithermal neutron extraction facility is discussed in detail. Final results of boron magnetic resonance imagining is included for both borocaptate sodium (BSH) and boronophenylalanine (BPA) in rats, and BSH in humans. Design of an epithermal neutron facility using electron linear accelerators is presented, including a treatise on energy removal from the beam target. Information on the multiple fraction injection of BSH in rats is presented

  11. Current status of accelerator-based boron neutron capture therapy

    International Nuclear Information System (INIS)

    Kreiner, A. J.; Bergueiro, J.; Di Paolo, H.; Castell, W.; Vento, V. Thatar; Cartelli, D.; Kesque, J.M.; Valda, A.A.; Ilardo, J.C.; Baldo, M.; Erhardt, J.; Debray, M.E.; Somacal, H.R.; Estrada, L.; Sandin, J.C. Suarez; Igarzabal, M.; Huck, H.; Padulo, J.; Minsky, D.M.

    2011-01-01

    The direct use of proton and heavy ion beams for radiotherapy is a well established cancer treatment modality, which is becoming increasingly widespread due to its clear advantages over conventional photon-based treatments. This strategy is suitable when the tumor is spatially well localized. Also the use of neutrons has a long tradition. Here Boron Neutron Capture Therapy (BNCT) stands out, though on a much smaller scale, being a second-generation promising alternative for tumors which are diffuse and infiltrating. On this sector, so far only nuclear reactors have been used as neutron sources. In this paper we describe the current situation worldwide as far as the use of accelerator-based neutron sources for BNCT is concerned (so-called Accelerator-Based (AB)-BNCT). In particular we discuss the present status of an ongoing project to develop a folded Tandem-ElectroStatic-Quadrupole (TESQ) accelerator at the Atomic Energy Commission of Argentina. The project goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams to perform BNCT for deep-seated tumors in less than an hour. (author)

  12. A shielding design for an accelerator-based neutron source for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Hawk, A.E.; Blue, T.E. E-mail: blue.1@osu.edu; Woollard, J.E

    2004-11-01

    Research in boron neutron capture therapy (BNCT) at The Ohio State University Nuclear Engineering Department has been primarily focused on delivering a high quality neutron field for use in BNCT using an accelerator-based neutron source (ABNS). An ABNS for BNCT is composed of a proton accelerator, a high-energy beam transport system, a {sup 7}Li target, a target heat removal system (HRS), a moderator assembly, and a treatment room. The intent of this paper is to demonstrate the advantages of a shielded moderator assembly design, in terms of material requirements necessary to adequately protect radiation personnel located outside a treatment room for BNCT, over an unshielded moderator assembly design.

  13. Accelerator Based Neutron Beams for Neutron Capture Therapy

    International Nuclear Information System (INIS)

    Yanch, Jacquelyn C.

    2003-01-01

    The DOE-funded accelerator BNCT program at the Massachusetts Institute of Technology has resulted in the only operating accelerator-based epithermal neutron beam facility capable of generating significant dose rates in the world. With five separate beamlines and two different epithermal neutron beam assemblies installed, we are currently capable of treating patients with rheumatoid arthritis in less than 15 minutes (knee joints) or 4 minutes (finger joints) or irradiating patients with shallow brain tumors to a healthy tissue dose of 12.6 Gy in 3.6 hours. The accelerator, designed by Newton scientific Incorporated, is located in dedicated laboratory space that MIT renovated specifically for this project. The Laboratory for Accelerator Beam Applications consists of an accelerator room, a control room, a shielded radiation vault, and additional laboratory space nearby. In addition to the design, construction and characterization of the tandem electrostatic accelerator, this program also resulted in other significant accomplishments. Assemblies for generating epithermal neutron beams were designed, constructed and experimentally evaluated using mixed-field dosimetry techniques. Strategies for target construction and target cooling were implemented and tested. We demonstrated that the method of submerged jet impingement using water as the coolant is capable of handling power densities of up to 6 x 10(sup 7) W/m(sup 2) with heat transfer coefficients of 10(sup 6)W/m(sup 2)-K. Experiments with the liquid metal gallium demonstrated its superiority compared with water with little effect on the neutronic properties of the epithermal beam. Monoenergetic proton beams generated using the accelerator were used to evaluate proton RBE as a function of LET and demonstrated a maximum RBE at approximately 30-40 keV/um, a finding consistent with results published by other researchers. We also developed an experimental approach to biological intercomparison of epithermal beams and

  14. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

    Energy Technology Data Exchange (ETDEWEB)

    Pozzi, E. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)], E-mail: epozzi@cnea.gov.ar; Nigg, D.W. [Idaho National Laboratory, Idaho Falls (United States); Miller, M.; Thorp, S.I. [Instrumentation and Control Department, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Zarza, L.; Estryk, G. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Monti Hughes, A.; Molinari, A.J.; Garabalino, M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Quintana, J. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Trivillin, V.A.; Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)

    2009-07-15

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x10{sup 9} n cm{sup -2} s{sup -1} and the fast neutron flux was 2.5x10{sup 6} n cm{sup -2} s{sup -1}, indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in {sup 6}Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  15. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

    International Nuclear Information System (INIS)

    Pozzi, E.; Nigg, D.W.; Miller, M.; Thorp, S.I.; Heber, E.M.; Zarza, L.; Estryk, G.; Monti Hughes, A.; Molinari, A.J.; Garabalino, M.; Itoiz, M.E.; Aromando, R.F.; Quintana, J.; Trivillin, V.A.; Schwint, A.E.

    2009-01-01

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x10 9 n cm -2 s -1 and the fast neutron flux was 2.5x10 6 n cm -2 s -1 , indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in 6 Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  16. Radiation field characterization of a BNCT research facility using Monte Carlo Method - Code MCNP-4B

    International Nuclear Information System (INIS)

    Hernandes, Antonio Carlos

    2002-01-01

    Boron Neutron Capture Therapy - BNCT- is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an AmBe neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these BNCT studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluency Ν Τ = 1,35x10 8 n/cm 2 , a fast neutron dose of 5,86x -1 0 Gy/Ν Τ and a gamma ray dose of 8,30x -14 Gy/Ν Τ . (author)

  17. Physical and biological dosimetry at the RA-3 facility for small animal irradiation: preliminary BNCT studies in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    Pozzi, Emiliano; Miller, Marcelo; Thorp, Silvia I.; Heber, Elisa M.; Trivillin, Veronica A.; Zarza, Leandro; Estryk, Guillermo; Schwint, Amanda E.; Nigg, David W.

    2007-01-01

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality based on the capture reaction that occurs between thermal neutrons and boron-10 atoms that accumulate selectively in tumor tissue, emitting high linear energy transfer (LET), short range (5-9 microns) particles (alpha y 7 Li). Thus, BNCT would potentially target tumor tissue selectively, sparing normal tissue. Herein we evaluated the feasibility of treating experimental oral mucosa tumors with BNCT at RA-3 (CAE) employing the hamster cheek pouch oral cancer model and characterized the irradiation field at the RA-3 facility. We evaluated the therapeutic effect on tumor of BNCT mediated by BPA in the hamster cheek pouch oral cancer model and the potential radio toxic effects in normal tissue. We evidenced a moderate biological response in tumor, with no radio toxic effects in normal tissue following irradiations with no shielding for the animal body. Given the sub-optimal therapeutic response, we designed and built a 6 Li 2 CO 3 shielding for the body of the animal to increase the irradiation dose to tumor, without exceeding normal tissue radio tolerance. The measured absolute magnitude of thermal neutron flux and the characterization of the beam with and without the shielding in place, suggest that the irradiation facility in the thermal column of RA-3 would afford an excellent platform to perform BNCT studies in vitro and in vivo in small experimental animals. The present findings must be confirmed and extended by performing in vivo BNCT radiobiological studies in small experimental animals, employing the shielding device for the animal body. (author) [es

  18. Characterisation of the TAPIRO BNCT epithermal facility

    Energy Technology Data Exchange (ETDEWEB)

    Burn, K. W. [FIS-NUC, ENEA, Via Martiri di Montesole 4, Bologna (Italy); Colli, V. [Dept. of Physics of Univ., INFN, Via Celoria 16, I-20133 Milano (Italy); Curzio, G.; D' Errico, F. [DIMNP, Univ. of Pisa, Via Diotisalvi 2, I-56126 Pisa (Italy); Gambarini, G. [Dept. of Physics of Univ., INFN, Via Celoria 16, I-20133 Milano (Italy); Rosi, G. [FIS-ION, ENEA, Casaccia, Via Anguillarese 301, I-00060 Santa Maria di Galeria, Roma (Italy); Scolari, L. [Dept. of Physics of Univ., INFN, Via Celoria 16, I-20133 Milano (Italy)

    2004-07-01

    A collimated epithermal beam for boron neutron capture therapy (BNCT) research has been designed and built at the TAPIRO fast research reactor. A complete experimental characterisation of the radiation field in the irradiation chamber has been performed, to verify agreement with IAEA requirements. Slow neutron fluxes have been measured by means of an activation technique and with thermoluminescent detectors (TLDs). The fast neutron dose has been determined with gel dosemeters, while the fast neutron spectrum has been acquired by means of a neutron spectrometer based on superheated drop detectors. The gamma-dose has been measured with gel dosemeters and TLDs. For an independent verification of the experimental results, fluxes, doses and neutron spectra have been calculated with Monte Carlo simulations using the codes MCNP4B and MCNPX 2.1.5 with the direct statistical approach (DSA). The results obtained confirm that the epithermal beams achievable at TAPIRO are of suitable quality for BNCT purposes. (authors)

  19. Requirements for BNCT at a nuclear research reactor. Results from a BNCT workshop organized by the European Commission in Prague, November 2005

    International Nuclear Information System (INIS)

    Moss, Ray; Sauerwein, Wolfgang; Wittig, Andrea; Burian, Jiri

    2006-01-01

    As part of the European Commission's Enlargement and Integration Action (E and IA), which is intended to improve exchange and relationship within the extended European Union (EU), a Workshop was organized in Prague in November 2005. The purpose of the workshop was to present and discuss technical and organisational requirements in setting up a BNCT facility at a research reactor. Topics included: treatment of a patient by BNCT; organisational aspects and regulatory affairs; BNCT from the nuclear perspective and BNCT from the clinician's perspective. Presentations were given by BNCT experts in their particular field, whilst eleven different national nuclear research centres from the New Member States and Accession Countries, interested in developing a BNCT programme, presented the status of their preparations. The conclusions of the Workshop were that an early and close collaboration between nuclear and medical groups is the basis for BNCT, that a local effort to build a BNCT facility should be supported by a national research programme including basic and clinical science and that the JRC and its partners are ready to support national initiatives within the EU and candidate countries. (author)

  20. BNCT with linac, feasibility study

    International Nuclear Information System (INIS)

    Alfuraih, A.; Ma, A.; Spyrou, N.M.; Awotwi-Pratt, Joseph

    2006-01-01

    High energy photon beams from Medical Linear Accelerators (linacs) which are used in radiotherapy produce undesirable neutrons, beside the clinically useful electron and photon beams. Neutrons are produced from the photonuclear reaction (γ,n) of high energy photons with high Z-materials which compose the accelerator head. In this paper the possible use of these undesirable neutrons for BNCT is investigated, making use of high energy linacs already installed in hospitals, primarily for high energy electron and photon therapy and applying them in the context of BNCT. The photoneutron components emitted by the accelerator is the source for Monte Carlo simulations of the interactions that take place within the head of a voxel-based phantom. The neutron flux across the phantom head is calculated using different moderator arrangements and different techniques in the aim of increasing the thermal neutron flux at the targeted site. Also, we shall test different configurations of the linac head to maximize the exposure of high-Z materials to the photon beam, including the removal of the flattening filter, so as to boost the photoneutron production in the linac head. Experimental work will be conducted in hospitals to validate the Monte Carlo simulations. To make use of linacs for BNCT will be advantageous in the sense that the setting in a hospital department is much more acceptable by the public than a reactor installation. This will mean less complications regarding patient positioning and movement with respect to the beams, additional patient transportation and management will be more cost effective. (author)

  1. BNCT Technology Development on HANARO Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Chun, Ki Jung; Park, Kyung Bae; Whang, Seung Ryul; Kim, Myong Seop

    2007-06-15

    So as to establish the biological effects of BNCT in the HANARO Reactor, biological damages in cells and animals with treatment of boron/neutron were investigated. And 124I-BPA animal PET image, analysis technology of the boron contents in the mouse tissues by ICP-AES was established. A Standard clinical protocol, a toxicity evaluation report and an efficacy investigation report of BNCT has been developed. Based on these data, the primary permission of clinical application was acquired through IRB of our hospital. Three cases of pre-clinical experiment for boron distribution and two cases of medium-sized animal simulation experiment using cat with verifying for 2 months after BNCT was performed and so the clinical demonstration with a patient was prepared. Also neutron flux, fast neutron flux and gamma ray dose of BNCT facility were calculated and these data will be utilized good informations for clinical trials and further BNCT research. For the new synthesis of a boron compound, o-carboranyl ethylamine, o-carboranylenepiperidine, o-carboranyl-THIQ and o-carboranyl-s-triazine derivatives were synthesized. Among them, boron uptake in the cancer cell of the triazine derivative was about 25 times than that of BPA and so these three synthesized methods of new boron compounds were patented.

  2. BNCT Technology Development on HANARO Reactor

    International Nuclear Information System (INIS)

    Chun, Ki Jung; Park, Kyung Bae; Whang, Seung Ryul; Kim, Myong Seop

    2007-06-01

    So as to establish the biological effects of BNCT in the HANARO Reactor, biological damages in cells and animals with treatment of boron/neutron were investigated. And 124I-BPA animal PET image, analysis technology of the boron contents in the mouse tissues by ICP-AES was established. A Standard clinical protocol, a toxicity evaluation report and an efficacy investigation report of BNCT has been developed. Based on these data, the primary permission of clinical application was acquired through IRB of our hospital. Three cases of pre-clinical experiment for boron distribution and two cases of medium-sized animal simulation experiment using cat with verifying for 2 months after BNCT was performed and so the clinical demonstration with a patient was prepared. Also neutron flux, fast neutron flux and gamma ray dose of BNCT facility were calculated and these data will be utilized good informations for clinical trials and further BNCT research. For the new synthesis of a boron compound, o-carboranyl ethylamine, o-carboranylenepiperidine, o-carboranyl-THIQ and o-carboranyl-s-triazine derivatives were synthesized. Among them, boron uptake in the cancer cell of the triazine derivative was about 25 times than that of BPA and so these three synthesized methods of new boron compounds were patented

  3. Research of accelerator-based neutron source for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Li Changkai; Ma Yingjie; Tang Xiaobin; Xie Qin; Geng Changran; Chen Da

    2013-01-01

    Background: 7 Li (p, n) reaction of high neutron yield and low threshold energy has become one of the most important neutron generating reactions for Accelerator-based Boron Neutron Capture Therapy (BNCT). Purpose Focuses on neutron yield and spectrum characteristics of this kind of neutron generating reaction which serves as an accelerator-based neutron source and moderates the high energy neutron beams to meet BNCT requirements. Methods: The yield and energy spectrum of neutrons generated by accelerator-based 7 Li(p, n) reaction with incident proton energy from 1.9 MeV to 3.0 MeV are researched using the Monte Carlo code-MCNPX2.5.0. And the energy and angular distribution of differential neutron yield by 2.5-MeV incident proton are also given in this part. In the following part, the character of epithermal neutron beam generated by 2.5-MeV incident protons is moderated by a new-designed moderator. Results: Energy spectra of neutrons generated by accelerator-based 7 Li(p, n) reaction with incident proton energy from 1.9 MeV to 3.0 MeV are got through the simulation and calculation. The best moderator thickness is got through comparison. Conclusions: Neutron beam produced by accelerator-based 7 Li(p, n) reaction, with the bombarding beam of 10 mA and the energy of 2.5 MeV, can meet the requirement of BNCT well after being moderated. (authors)

  4. INEL BNCT Research Program annual report 1994

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1995-11-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1994. Contributions from the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (treatment planning software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of BSH and BPA is presented and results of 21 spontaneous tumor bearing dogs that have been treated with BNCT at Brookhaven National Laboratory (BNL) are discussed. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Highlights from the First International Workshop on Accelerator-Based Neutron Sources for BNCT are included

  5. BNCT-RTPE: BNCT radiation treatment planning environment

    International Nuclear Information System (INIS)

    Wessol, D.E.; Wheeler, F.J.; Babcock, R.S.

    1995-01-01

    Several improvements have been developed for the BNCT radiation treatment planning environment (BNCT-Rtpe) during 1994. These improvements have been incorporated into Version 1.0 of BNCT-Rtpe which is currently installed at the INEL, BNL, Japanese Research Center (JRC), and Finland's Technical Research Center. Platforms supported by this software include Hewlett-Packard (HP), SUN, International Business Machines (IBM), and Silicon Graphics Incorporated (SGI). A draft version of the BNCT-Rtpe user manual is available. Version 1.1 of BNCT-Rtpe is scheduled for release in March 1995. It is anticipated that Version 2.x of BNCT-Rtpe, which includes the nonproprietary NURBS library and data structures, will be released in September 1995

  6. 9Be(d,n)10B-based neutron sources for BNCT

    International Nuclear Information System (INIS)

    Capoulat, M.E.; Herrera, M.S.; Minsky, D.M.; González, S.J.; Kreiner, A.J.

    2014-01-01

    In the frame of accelerator-based BNCT, the 9 Be(d,n) 10 B reaction was investigated as a possible source of epithermal neutrons. In order to determine the configuration in terms of bombarding energy, target thickness and Beam Shaping Assembly (BSA) design that results in the best possible beam quality, a systematic optimization study was carried out. From this study, the optimal configuration resulted in tumor doses ≥40 Gy-Eq, with a maximum value of 51 Gy-Eq at a depth of about 2.7 cm, in a 60 min treatment. The optimal configuration was considered for the treatment planning assessment of a real Glioblastoma Multiforme case. From this, the resulted dose performances were comparable to those obtained with an optimized 7 Li(p,n)-based neutron source, under identical conditions and subjected to the same clinical protocol. - Highlights: • Study of the 9 Be(d,n) 10 B reaction as a source of epithermal neutrons for BNCT. • Evaluation of the optimal configuration of target thickness, deuteron energy and BSA design. • Computational dose assessment for brain tumor treatments using the MCNP code. • Treatment planning assessment of a particular clinical Glioblastoma Multiforme case. • Dose performances were comparable to those obtained with an optimized 7 Li(p,n)-based source

  7. Calculation of fluence rate distributions in a pre design clinical facility for BNCT at the LFR

    International Nuclear Information System (INIS)

    Peeters, T.T.J.M.; Freudenreich, W.E.

    1995-12-01

    In a previous study [1], it was demonstrated that the creation of a thermal neutron facility for clinical BNCT in the LFR is feasible. Monte Carlo calculations had shown that the neutron fluence rates and gamma dose rates at the detector position of a model representing a first outline of a clinical facility met all requirements that are necessary for clinical BNCT. In order to gain more information about the neutron fluence rates at several positions, a second step is required. Calculations have been performed for the free beam and for a tumour bearing phantom at 5 cm and 10 cm distance from the irradiation window. Due to thermalization and back scattering, the thermal fluence rates in the tumour at 5 and 10 cm distance from the bismuth shield appeared to be approximately twice as high as the thermal fluence rates in the free beam at the corresponding positions of 5 to 6 cm and 10 to 11 cm from the irradiation window. (orig.)

  8. Accelerator-Based Boron Neutron Capture Therapy and the Development of a Dedicated Tandem-Electrostatic-Quadrupole

    International Nuclear Information System (INIS)

    Kreiner, A. J.; Di Paolo, H.; Burlon, A. A.; Valda, A. A.; Debray, M. E.; Somacal, H. R.; Minsky, D. M.; Kesque, J. M.; Giboudot, Y.; Levinas, P.; Fraiman, M.; Romeo, V.

    2007-01-01

    There is a generalized perception that the availability of suitable particle accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of Boron Neutron Capture Therapy (BNCT). Progress on an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator for Accelerator-Based (AB)-BNCT is described here. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. A folded tandem, with 1.25 MV terminal voltage, combined with an ESQ chain is being designed and constructed. A 30 mA proton beam of 2.5 MeV are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. The first design and construction of an ESQ module is discussed and its electrostatic fields are investigated theoretically and experimentally. Also new beam transport calculations through the accelerator are presented

  9. An accelerator-based epithermal photoneutron source for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Mitchell, H.E.

    1996-04-01

    Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 10 7 neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF 3 composite and a stacked Al/Teflon design) at various incident electron energies

  10. An accelerator-based epithermal photoneutron source for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Mitchell, Hannah E. [Georgia Inst. of Technology, Atlanta, GA (United States)

    1996-04-01

    Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 107 neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF3 composite and a stacked Al/Teflon design) at various incident electron energies.

  11. INEL BNCT Research Program annual report 1994

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1995-11-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1994. Contributions from the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (treatment planning software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of BSH and BPA is presented and results of 21 spontaneous tumor bearing dogs that have been treated with BNCT at Brookhaven National Laboratory (BNL) are discussed. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Highlights from the First International Workshop on Accelerator-Based Neutron Sources for BNCT are included. Selected papers have been indexed separately for inclusion in the Energy Science and Technology Database.

  12. 2.5 MeV CW 4-vane RFQ accelerator design for BNCT applications

    Science.gov (United States)

    Zhu, Xiaowen; Wang, Hu; Lu, Yuanrong; Wang, Zhi; Zhu, Kun; Zou, Yubin; Guo, Zhiyu

    2018-03-01

    Boron Neutron Capture Therapy (BNCT) promises a bright future in cancer therapy for its highly selective destruction of cancer cells, using the 10B +n→7Li +4 He reaction. It offers a more satisfactory therapeutic effect than traditional methods for the treatment of malignant brain tumors, head and neck cancer, melanoma, liver cancer and so on. A CW 4-vane RFQ, operating at 162.5 MHz, provides acceleration of a 20 mA proton beam to 2.5 MeV, bombarding a liquid lithium target for neutron production with a soft neutron energy spectrum. The fast neutron yield is about 1.73×1013 n/s. We preliminarily develop and optimize a beam shaping assembly design for the 7Li(p, n)7Be reaction with a 2.5 MeV proton beam. The epithermal neutron flux simulated at the beam port will reach up to 1 . 575 ×109 n/s/cm2. The beam dynamics design, simulation and benchmark for 2.5 MeV BNCT RFQ have been performed with both ParmteqM (V3.05) and Toutatis, with a transmission efficiency higher than 99.6% at 20 mA. To ease the thermal management in the CW RFQ operation, we adopt a modest inter-vane voltage design (U = 65 kV), though this does increase the accelerator length (reaching 5.2 m). Using the well-developed 3D electromagnetic codes, CST MWS and ANSYS HFSS, we are able to deal with the complexity of the BNCT RFQ, taking the contribution of each component in the RF volume into consideration. This allows us to optimize the longitudinal field distribution in a full-length model. Also, the parametric modeling technique is of great benefit to extensive modifications and simulations. In addition, the resonant frequency tuning of this RFQ is studied, giving the tuning sensitivities of vane channel and wall channel as -16.3 kHz/°C and 12.4 kHz/°C, respectively. Finally, both the multipacting level of this RFQ and multipacting suppressing in the coaxial coupler are investigated.

  13. Dosimetric performance evaluation regarding proton beam incident angles of a lithium-based AB-BNCT design

    International Nuclear Information System (INIS)

    Lee, Pei-Yi; Jiang, Shiang-Huei; Liu, Yuan-Hao

    2014-01-01

    The 7 Li(p,xn) 7 Be nuclear reaction, based on the low-energy protons, could produce soft neutrons for accelerator-based boron neutron capture therapy (AB-BNCT). Based on the fact that the induced neutron field is relatively divergent, the relationship between the incident angle of proton beam and the neutron beam quality was evaluated in this study. To provide an intense epithermal neutron beam, a beam-shaping assembly (BSA) was designed. And a modified Snyder head phantom was used in the calculations for evaluating the dosimetric performance. From the calculated results, the intensity of epithermal neutrons increased with the increase in proton incident angle. Hence, either the irradiation time or the required proton current can be reduced. When the incident angle of 2.5-MeV proton beam is 120 deg., the required proton current is ∼13.3 mA for an irradiation time of half an hour. The results of this study show that the BSA designs can generate neutron beams with good intensity and penetrability. Using a 20-mA, 2.5-MeV proton beam as the source, the required irradiation time, to induce 60 RBE-Gy of maximum tumour dose, is less than half an hour in any proton beam alignments. On the premise that the dosimetric performances are similar, the intensity of epithermal neutrons can be increased by using non-collinear (e.g. 90 deg., 120 deg.) incident protons. Thus, either the irradiation time or the required proton current can be reduced. The use of 120 deg. BSA model shows the possibility to reduce the required proton current to ∼13.3 mA when the goal of irradiation time is 30 min. The decrease of required proton beam current certainly will make the use of lithium target much easier. In June 2013, a 5-MeV, 30-mA radio frequency quadruple (RFQ) accelerator for BNCT was built at INFN-LNL (Legnaro National Laboratories, Italy), which shows a possibility to build a suitable RFQ accelerator for the authors' design. In addition, a 2.5-MeV, 30-mA Tandem accelerator was

  14. Optimization of beam shaping assembly based on D-T neutron generator and dose evaluation for BNCT

    Science.gov (United States)

    Naeem, Hamza; Chen, Chaobin; Zheng, Huaqing; Song, Jing

    2017-04-01

    The feasibility of developing an epithermal neutron beam for a boron neutron capture therapy (BNCT) facility based on a high intensity D-T fusion neutron generator (HINEG) and using the Monte Carlo code SuperMC (Super Monte Carlo simulation program for nuclear and radiation process) is proposed in this study. The Monte Carlo code SuperMC is used to determine and optimize the final configuration of the beam shaping assembly (BSA). The optimal BSA design in a cylindrical geometry which consists of a natural uranium sphere (14 cm) as a neutron multiplier, AlF3 and TiF3 as moderators (20 cm each), Cd (1 mm) as a thermal neutron filter, Bi (5 cm) as a gamma shield, and Pb as a reflector and collimator to guide neutrons towards the exit window. The epithermal neutron beam flux of the proposed model is 5.73 × 109 n/cm2s, and other dosimetric parameters for the BNCT reported by IAEA-TECDOC-1223 have been verified. The phantom dose analysis shows that the designed BSA is accurate, efficient and suitable for BNCT applications. Thus, the Monte Carlo code SuperMC is concluded to be capable of simulating the BSA and the dose calculation for BNCT, and high epithermal flux can be achieved using proposed BSA.

  15. Cyclotron-based neutron source for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Mitsumoto, T.; Yajima, S.; Tsutsui, H.; Ogasawara, T.; Fujita, K. [Sumitomo Heavy Industries, Ltd (Japan); Tanaka, H.; Sakurai, Y.; Maruhashi, A. [Kyoto University Research Reactor Institute (Japan)

    2013-04-19

    Kyoto University Research Reactor Institute (KURRI) and Sumitomo Heavy Industries, Ltd. (SHI) have developed a cyclotron-based neutron source for Boron Neutron Capture Therapy (BNCT). It was installed at KURRI in Osaka prefecture. The neutron source consists of a proton cyclotron named HM-30, a beam transport system and an irradiation and treatment system. In the cyclotron, H- ions are accelerated and extracted as 30 MeV proton beams of 1 mA. The proton beams is transported to the neutron production target made by a beryllium plate. Emitted neutrons are moderated by lead, iron, aluminum and calcium fluoride. The aperture diameter of neutron collimator is in the range from 100 mm to 250 mm. The peak neutron flux in the water phantom is 1.8 Multiplication-Sign 109 neutrons/cm{sup 2}/sec at 20 mm from the surface at 1 mA proton beam. The neutron source have been stably operated for 3 years with 30 kW proton beam. Various pre-clinical tests including animal tests have been done by using the cyclotron-based neutron source with {sup 10}B-p-Borono-phenylalanine. Clinical trials of malignant brain tumors will be started in this year.

  16. New EORTC clinical trials for BNCT

    International Nuclear Information System (INIS)

    Hideghety, K.; Moss, R.; Vries, M. de

    2000-01-01

    Due to ethical reasons, a separated optimization of the two components of BNCT in the frame of clinical investigations can only be performed applying the whole binary system. The ongoing trial at HFR (High Flux Reactor Petten) has proven the feasibility of BNCT under defined conditions. On that basis the European Commission supported a comprehensive research project on boron imaging including three further clinical studies. In the first trial the boron uptake related to the blood boron concentration and surrounding normal tissue in various solid tumours will be examined using BSH (Sodiumborocaptate), BPA (Boronophenylalanine) or both in order to explore tumour entities, which may gain benefit from BNCT. The major objectives of the second trial are to define the maximum tolerated single and cumulative dose, and the dose limiting toxicity of BSH. The third clinical trial, a phase II study is designed to evaluate the anti-tumour effect of fractionated BNCT at the Petten treatment facility against cerebral metastasis of malignant melanoma using BPA. (author)

  17. Radiation field characterization of a BNCT research facility using Monte Carlo method - code MCNP-4B

    International Nuclear Information System (INIS)

    Hernandez, Antonio Carlos

    2002-01-01

    Boron Neutron Capture Therapy - BNCT - is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an Am Be neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these Becton studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluencyN T = 1,35x10 8 n/cm , a fast neutron dose of 5,86x10 -10 Gy/N T and a gamma ray dose of 8,30x10 -14 Gy/N T . (author)

  18. INEL BNCT Program

    International Nuclear Information System (INIS)

    Ackermann, A.L.; Dorn, R.V. III.

    1991-03-01

    This Bulletin presents a summary of accomplishments and highlights in the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program for March 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, a milestone summary, and animal data charts

  19. Quality assurance for BNCT at nuclear facilities. A necessary burden or the unavoidable seal of approval

    International Nuclear Information System (INIS)

    Moss, R.; Morrissey, J.; Sauerwein, W.; Hideghety, K.; Rassow, J.; Stecher-Rasmussen, F.

    2000-01-01

    The BNCT clinical trial at the HFR Petten is performed on a completely multi-national basis. The irradiation facility is located in one country (The Netherlands), is operated by an international team of experts under the leadership of a radiotherapist from another country (Germany) and treats patients coming from different European countries. In gaining the necessary approval, it became apparent, especially in the many discussions with the (Dutch) Health authorities that Quality Assurance (QA) would be and is a critical aspect. This is even more so, in the case of BNCT, where it was not only a (relatively) new experimental treatment (in 1996/97) about to be performed for the first time in Europe, but it was to be performed in a non-hospital environment and furthermore in a nuclear research reactor. It was necessary therefore to comply, as closely as possible, with similarly accepted practices in conventional radiotherapy. Despite QA being a sometimes burdensome task, this paper nevertheless raises the issue as to whether it is necessary or whether it is the seal of approval for BNCT as an acceptable mode of treatment in mainstream radiotherapy. (author)

  20. Introducing BNCT treatment in new treatment facilities

    International Nuclear Information System (INIS)

    Gabel, D.

    2001-01-01

    The physical and radiobiological studies that should be performed before the initiation of BNCT are discussed. The need for dose-escalation versus response studies in large animal models is questioned. These studies are time consuming, expensive and legally difficult in some countries and may be dispensable. (author)

  1. The studsvik BNCT project: structure and the proposed protocols

    International Nuclear Information System (INIS)

    Capala, J.; Stenstam, B.H.; Skoeld, K.; Henriksson, R.; Salford, L.; Carlsson, J.

    2000-01-01

    The BNCT facility at Studsvik is now ready for clinical trials. Scientific operations of the Studsvik BNCT project are overseen by the Scientific Advisory Board comprised of representatives of all major universities in Sweden. Furthermore, special task groups for clinical and preclinical studies have been formed to facilitate collaboration with academia and to assure the quality of the research. Proposed clinical Phase II trials for glioblastoma are sponsored by the Swedish National Neuro-Oncology Group and, initially, will involve two protocols: Protocol no.1. BNCT for glioblastoma patients who have not received any therapy other than surgery (including stereotactic biopsy only). Protocol no.2. BNCT as a palliative treatment for patients with recurrent glioblastoma following conventional therapies or BNCT. In both protocols, BPA, administered by a 6 hour i.v. infusion, will be used as the boron delivery agent. (author)

  2. INEL BNCT Program

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1991-08-01

    This Bulletin presents a summary of accomplishments and highlights in the Idaho National Engineering Laboratory's (INEL) Boron Neutron Capture Therapy (BNCT) Program for August 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  3. Dose estimation of the THOR BNCT treatment room

    International Nuclear Information System (INIS)

    Hsu, F.Y.; Liu, H.M.; Yu, C.C.; Huang, Y.H.; Tsai, H.N.

    2006-01-01

    BNCT beam of Tsing Hua Open-pool Reactor (THOR) was designed and constructed since 1998. A treatment room for the newly modified THOR BNCT beam was constructed for the next clinical-stage trials in 2004. Dose distribution in a patient (or a phantom) is important as irradiated with the BNCT beam. The dose distributions for different type of radiations such as neutron and photons in the treatment room are strongly becoming the index or reference of success for a BNCT facility. An ART head phantom was placed in front of the THOR BNCT beam port and was irradiated. In each section of the head phantom, numbers of small holes are inside and separated uniformly. Dual detector: TLD-600 and TLD-700 chips were placed inside these holes within the phantom to distinct doses of neutron and photon. Besides, Dual-TLD chips were latticed placed in the horizontal plane of beam central axis, in the treatment room to estimate the spatial dose distribution of neutron and photon. Gold foils were assisted in TLD dose calibrations. Neutron and photon dose distributions in phantom and spatial dose distributions in the THOR BNCT treatment room were both estimated in this work. Testing and improvement in THOR BNCT beam were continuative during these years. Results of this work could be the reference and be helpful for the further clinical trials in nearly future. (author)

  4. Development of an anthropomorfic simulator for simulation and measurements of neutron dose and flux the facility for BNCT studies

    International Nuclear Information System (INIS)

    Muniz, Rafael Oliveira Rondon

    2010-01-01

    IPEN facility for researches in BNCT (Boron Neutron Capture Therapy) uses IEA-R1 reactor's irradiation channel number 3, where there is a mixed radiation field - neutrons and gamma. The researches in progress require the radiation fields, in the position of the irradiation of sample, to have in its composition maximized thermal neutrons component and minimized, fast and epithermal neutron flux and gamma radiation. This work was developed with the objective of evaluating whether the present radiation field in the facility is suitable for BNCT researches. In order to achieve this objective, a methodology for the dosimetry of thermal neutrons and gamma radiation in mixed fields of high doses, which was not available in IPEN, was implemented in the Center of Nuclear Engineering of IPEN, by using thermoluminescent dosimeters - TLDs 400, 600 and 700. For the measurements of thermal and epithermal neutron flux, activation detectors of gold were used applying the cadmium ratio technique. A cylindrical phantom composed by acrylic discs was developed and tested in the facility and the DOT 3.5. computational code was used in order to obtain theoretical values of neutron flux and the dose along phantom. In the position corresponding to about half the length of the cylinder of the phantom, the following values were obtained: thermal neutron flux (2,52 ± 0,06).10 8 n/cm 2 s, epithermal neutron flux (6,17 ± 0,26).10 7 .10 6 n/cm 2 s, absorbed dose due to thermal neutrons (4,2 ± 1,8)Gy and (10,1 ± 1,3)Gy due to gamma radiation. The obtained values show that the fluxes of thermal and epithermal neutrons flux are appropriate for studies in BNCT, however, the dose due to gamma radiation is high, indicating that the facility should be improved. (author)

  5. Comparison of quality assurance for performance and safety characteristics of the facility for Boron Neutron Capture therapy in Petten/NL with medical electron accelerators

    International Nuclear Information System (INIS)

    Rassow, Juergen; Stecher-Rasmussen, Finn; Voorbraak, Wim; Moss, Ray; Vroegindeweij, Corine; Hideghety, Katalin; Sauerwein, Wolfgang

    2001-01-01

    Background and purpose: The European Council Directive on health protection 97/43/EURATOM requires radiotherapy quality assurance programmes for performance and safety characteristics including acceptance and repeated tests. For Boron Neutron Capture therapy (BNCT) at the High Flux Reactor (HFR) in Petten/NL such a programme has been developed on the basis of IEC publications for medical electron accelerators. Results: The fundamental differences of clinical dosimetry for medical electron accelerators and BNCT are presented and the order of magnitude of dose components and their stability and that of the main other influencing parameter 10 B concentration for BNCT patient treatments. A comparison is given for requirements for accelerators and BNCT units indicating items which are not transferable, equal or additional. Preliminary results of in vivo measurements done with a set of 55 Mn, 63 Cu and 197 Au activation foils for all single fields for the four fractions at all 15 treated patients show with <±4% up to now a worse reproducibility than the used dose monitoring systems (±1.5%) caused by influence of hair position on the foil-skull distance. Conclusions: Despite the more complex clinical dosimetry (because of four relevant dose components, partly of different linear energy transfer (LET)) BNCT can be regulated following the principles of quality assurance procedures for therapy with medical electron accelerators. The reproducibility of applied neutron fluence (proportional to absorbed doses) and the main safety aspects are equal for all teletherapy methods including BNCT

  6. SPES-BNCT Project Beam Shaping Assembly. State of the Art

    International Nuclear Information System (INIS)

    Ceballos Sanchez, Cesar

    2007-01-01

    The SPES-BNCT project will exploit the intense proton beam provided by the RFQ (30mA, 5MeV), currently under construction at LNL, to yield a neutron source using the 9 Be(p,xn) nuclear reaction. The goal is to setup an accelerator-driven, thermal neutron beam facility, aimed at the Boron Neutron Capture experimental treatment of extended shallow skin melanoma. The neutron energy spectrum is shifted with a beam shaping assembly (BSA) surrounding the target. This device is fully designed with the Monte Carlo simulation code MCNPX, with the purpose of maximizing the thermal neutron component of the beam and focusing it on the irradiation area. (Author)

  7. Novel applications of particle accelerators to radiotherapy

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Burlon, A.A.; Universidad Nacional de San Martin, Villa Ballester

    2002-01-01

    Charged hadrons (protons and heavier ions) have very definite advantages over photons as far as radiotherapy applications are concerned. They allow for much better spatial dose localization due to their charge, relatively high mass and nature of the energy deposition process. In the frame of an attempt to promote the introduction of hadrontherapy in Argentina an external beam facility has been installed at our tandem accelerator TANDAR. The advantages of heavy ions can only be fully exploited for tumors of well defined localization. In certain types of malignancies, however, the region infiltrated by tumor cells is diffuse, with no sharp boundaries and with microscopic ramifications. In such cases (particularly in certain brain cancers) a more sophisticated scheme has been suggested called boron neutron capture therapy (BNCT). In this work, the use of the Tandar accelerator to produce neutrons for feasibility studies for BNCT through low-energy proton beams on a thick LiF target is being briefly described. Studies on the 13 C(d,n) reaction and a comparison with other neutron-producing reactions are also mentioned. Simulation work to optimize an accelerator-based neutron production target is discussed. A project is being prepared to develop a small proton accelerator in Argentina. Technical specifications of this machine are briefly discussed. (author)

  8. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma

    International Nuclear Information System (INIS)

    Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, H.

    2011-01-01

    The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT). We have treated 23 glioblastoma patients with BNCT without any additional chemotherapy since 1998. The median survival time (MST) of BNCT was 19.5 months, and 2-year, 3-year and 5-year survival rates were 26.1%, 17.4% and 5.8%, respectively. This clinical result of BNCT in patients with GBM is superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment. - Highlights: ► In this study, we evaluate the clinical outcome of boron neutron capture therapy (BNCT) for malignant brain tumors. ► We have treated 23 glioblastoma (GBM) patients with BNCT without any additional chemotherapy. ► Clinical results of BNCT in patients with GBM are superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment.

  9. Study of a neutron producing target via the 7Li(p,n)7Be reaction near its energy threshold for BNCT (boron neutron capture therapy)

    International Nuclear Information System (INIS)

    Burlon, Alejandro; Kreiner, Andres J.; Debray, Mario E.; Stoliar, Pablo; Kesque, Jose M.; Naab, Fabian; Ozafran, Mabel J.; Schuff, Juan; Vazquez, Monica; Caraballo, Maria E.; Valda, Alejandro; Somacal, Hector; Davidson, Miguel; Davidson, Jorge

    2000-01-01

    In the framework of Accelerator Based BNCT (AB-BNCT) the 7 Li(p,n) 7 Be reaction near its energy threshold is one of the most promising. In this work a thick LiF target irradiated with a proton beam was studied as a neutron source. The 1.88-2.0 MeV proton beam was produced by the tandem accelerator TANDAR at CNEA's facilities in Buenos Aires. A water-filled phantom, containing a boron sample was irradiated with the resulting neutron beam. The boron neutron capture reaction produces a 0.478 MeV gamma ray in 94 % of the cases. The neutron yield was monitored by detecting this gamma ray using a germanium detector with an 'anti-Compton' shield. Moreover, the thermal neutron flux was evaluated at different depths inside the phantom using bare and Cd-covered gold foils. A maximum neutron thermal flux of 1.4 x 10 8 1/(cm 2 -s-mA) was obtained at 4.2 cm from the phantom surface. (author)

  10. Development of cancer therapy facility of HANARO and medical research in BNCT; development of the technique for boron concentration analysis

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Hee Dong; Byun, Soo Hyun; Sun, Gwang Min; Kim, Suk Kwon; Kim, In Jung; Park, Chang Su [Seoul National University, Seoul (Korea)

    2002-03-01

    Objective and Necessity of the Project- Development of a boron concentration analysis facility used for BNCT. - Development of the technique for boron concentration analysis. Contents and Scopes of the Project - Construction of the boron concentration analysis facility based on PGAA. Estimation of the neutron beam characteristics. -Establishment of the technique for the boron concentration analysis. - Estimation of the reliability for the boron analysis. Results of the Project -Installation of the boron concentration analysis facility at Hanaro. - Neutron beam characteristics are the sample position (neutron flux : 7.9 x 10{sup 7} n/cm{sup 2}s, Cd-ratio : 266) Technique for the boron concentration analysis. - Boron detection sensitivity and limit (detection sensitivity : 2, 131 cps/mg-B, detection limit : 67 ng for 10,000 sec). 63 refs., 37 figs., 13 tabs. (Author)

  11. PBF/BNCT [power burst facility/boron neutron capture therapy] program for cancer treatment

    International Nuclear Information System (INIS)

    Dorn, R.V. III.

    1989-06-01

    Highlights of the PBF/BNCT Program during June include progress within the areas of gross boron analysis in tissue, blood, and urine; analytical methodologies development for BSH (sodium borocaptate) purity determination; boron microscopic (subcellular) analytical development; noninvasive boron quantification determination; dosimetry; and analytical radiation transport and interaction modeling for BNCT

  12. Radiological Research Accelerator Facility

    International Nuclear Information System (INIS)

    Goldhagen, P.; Marino, S.A.; Randers-Pehrson, G.; Hall, E.J.

    1986-01-01

    The Radiological Research Accelerator Facility (RARAF) is based on a 4-MV Van de Graaff accelerator, which can be used to generate a variety of well-characterized radiation beams for research in radiobiology and radiological physics. It is part of the Radiological Research Laboratory (RRL), and its operation is supported as a National Facility by the US Department of Energy. RARAF is available to all potential users on an equal basis, with priorities based on the recommendations of a Scientific Advisory Committee. Facilities and services are provided to users, but the research projects themselves must be supported separately. This chapter presents a brief description of current experiments being carried out at RARAF and of the operation of the Facility from January through June, 1986. Operation of the Facility for all of 1985 was described in the 1985 Progress Report for RARAF. The experiments described here were supported by various Grants and Contracts from NIH and DOE and by the Statens Stralskyddsinstitut of Sweden

  13. Evaluation of radioactivity in the bodies of mice induced by neutron exposure from an epi-thermal neutron source of an accelerator-based boron neutron capture therapy system

    Science.gov (United States)

    NAKAMURA, Satoshi; IMAMICHI, Shoji; MASUMOTO, Kazuyoshi; ITO, Masashi; WAKITA, Akihisa; OKAMOTO, Hiroyuki; NISHIOKA, Shie; IIJIMA, Kotaro; KOBAYASHI, Kazuma; ABE, Yoshihisa; IGAKI, Hiroshi; KURITA, Kazuyoshi; NISHIO, Teiji; MASUTANI, Mitsuko; ITAMI, Jun

    2017-01-01

    This study aimed to evaluate the residual radioactivity in mice induced by neutron irradiation with an accelerator-based boron neutron capture therapy (BNCT) system using a solid Li target. The radionuclides and their activities were evaluated using a high-purity germanium (HP-Ge) detector. The saturated radioactivity of the irradiated mouse was estimated to assess the radiation protection needs for using the accelerator-based BNCT system. 24Na, 38Cl, 80mBr, 82Br, 56Mn, and 42K were identified, and their saturated radioactivities were (1.4 ± 0.1) × 102, (2.2 ± 0.1) × 101, (3.4 ± 0.4) × 102, 2.8 ± 0.1, 8.0 ± 0.1, and (3.8 ± 0.1) × 101 Bq/g/mA, respectively. The 24Na activation rate at a given neutron fluence was found to be consistent with the value reported from nuclear-reactor-based BNCT experiments. The induced activity of each nuclide can be estimated by entering the saturated activity of each nuclide, sample mass, irradiation time, and proton current into the derived activation equation in our accelerator-based BNCT system. PMID:29225308

  14. Radiation safety training for accelerator facilities

    International Nuclear Information System (INIS)

    Trinoskey, P.A.

    1997-02-01

    In November 1992, a working group was formed within the U.S. Department of Energy's (DOE's) accelerator facilities to develop a generic safety training program to meet the basic requirements for individuals working in accelerator facilities. This training, by necessity, includes sections for inserting facility-specific information. The resulting course materials were issued by DOE as a handbook under its technical standards in 1996. Because experimenters may be at a facility for only a short time and often at odd times during the day, the working group felt that computer-based training would be useful. To that end, Lawrence Livermore National Laboratory (LLNL) and Argonne National Laboratory (ANL) together have developed a computer-based safety training program for accelerator facilities. This interactive course not only enables trainees to receive facility- specific information, but time the training to their schedule and tailor it to their level of expertise

  15. BNCT Project at the J. Stefan TRIGA Reactor

    International Nuclear Information System (INIS)

    Glumac, B.; Maucec, M.; Jeraj, R.; Kodeli, I.

    1994-01-01

    Contribution presents condensed description of the BNCT method, as one of the most promising methods of cancer radio therapy in the future. Certain planned research activities considering realization of BNCT project in Slovenia are also shown. Modelling of irradiation facility as well as mathematical simulation of neutron and photon transport are completely performed by Monte Carlo computer simulation, and for that reason some basic characteristics and capabilities of MCNP4A computer code are also presented. Finally, some results obtained up to this time are presented. (author)

  16. INEEL BNCT Research Program Annual Report, CY-2000

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, James Robert

    2001-03-01

    This report is a summary of the activities conducted in conjunction with the Idaho National Engineering and Environmental Laboratory (INEEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 2000. Applications of supportive research and development, as well as technology deployment in the fields of chemistry, radiation physics and dosimetry, neutron source design and demonstration, and support the Department of Energy’s (DOE) National BNCT Program goals are the goals of this Program. Contributions from the individual contributors about their projects are included, specifically described are the following, chemistry: analysis of biological samples and an infrared blood-boron analyzer, and physics: progress in the patient treatment planning software, measurement of neutron spectra for the Argentina RA-6 reactor, and recalculation of the Finnish research reactor FiR 1 neutron spectra, BNCT accelerator technology, and modification to the research reactor at Washington State University for an epithermal-neutron beam.

  17. SERA -- An advanced treatment planning system for neutron therapy and BNCT

    International Nuclear Information System (INIS)

    Nigg, D.W.; Wemple, C.A.; Wessol, D.E.; Wheeler, F.J.; Albright, C.; Cohen, M.; Frandsen, M.; Harkin, G.; Rossmeier, M.

    1999-01-01

    Detailed treatment planning calculations on a patient-specific basis are required for boron neutron capture therapy (BNCT). Two integrated treatment planning systems developed specifically for BNCT have been in clinical use in the United States over the past few years. The MacNCTPLAN BNCT treatment planning system is used in the clinical BNCT trials that are underway at the Massachusetts Institute of Technology. A second system, BNCT rtpe (BNCT radiation therapy planning environment), developed independently by the Idaho national Engineering and Environmental Laboratory (INEEL) in collaboration with Montana State University (MSU), is used for treatment planning in the current series of BNCT clinical trials for glioblastoma at Brookhaven National Laboratory (BNL). This latter system is also licensed for use at several other BNCT research facilities worldwide. Although the currently available BNCT planning systems have served their purpose well, they suffer from somewhat long computation times (2 to 3 CPU-hours or more per field) relative to standard photon therapy planning software. This is largely due to the need for explicit three-dimensional solutions to the relevant transport equations. The simplifying approximations that work well for photon transport computations are not generally applicable to neutron transport computations. Greater computational speeds for BNCT treatment planning must therefore generally be achieved through the application of improved numerical techniques rather than by simplification of the governing equations. Recent efforts at INEEL and MSU have been directed toward this goal. This has resulted in a new paradigm for this type of calculation and the subsequent creation of the new simulation environment for radiotherapy applications (SERA) treatment planning system for BNCT. SERA is currently in initial clinical testing in connection with the trials at BNL, and it is expected to replace the present BNCT rtpe system upon general release

  18. Improvements at the biological shielding of BNCT research facility in the IEA-R1 reactor

    International Nuclear Information System (INIS)

    Souza, Gregorio Soares de

    2011-01-01

    The technique of neutron capture in boron is a promising technique in cancer treatment, it uses the high LET particles from the reaction 10 B (n, α) 7 Li to destroy cancer cells.The development of this technique began in the mid-'50s and even today it is the object of study and research in various centers around the world, Brazil has built a facility that aims to conduct research in BNCT, this facility is located next to irradiation channel number three at the research nuclear reactor IEA-R1 and has a biological shielding designed to meet the radiation protection standards. This biological shielding was developed to allow them to conduct experiments with the reactor at maximum power, so it is not necessary to turn on and off the reactor to irradiate samples. However, when the channel is opened for experiments the background radiation in the experiments salon increases and this background variation makes it impossible to perform measurements in a neutron diffraction research that utilizes the irradiation channel number six. This study aims to further improve the shielding in order to minimize the variation of background making it possible to perform the research facility in BNCT without interfering with the action of the research group of the irradiation channel number six. To reach this purpose, the code MCNP5, dosimeters and activation detectors were used to plan improvements in the biological shielding. It was calculated with the help of the code an improvement that can reduce the average heat flow in 71.2% ± 13 and verified experimentally a mean reduce of 70 ± 9% in dose due to thermal neutrons. (author)

  19. Nuclear physics accelerator facilities

    International Nuclear Information System (INIS)

    1988-12-01

    This paper describes many of the nuclear physics heavy-ion accelerator facilities in the US and the research programs being conducted. The accelerators described are: Argonne National Laboratory--ATLAS; Brookhaven National Laboratory--Tandem/AGS Heavy Ion Facility; Brookhaven National Laboratory--Relativistic Heavy Ion Collider (RHIC) (Proposed); Continuous Electron Beam Accelerator Facility; Lawrence Berkeley Laboratory--Bevalac; Lawrence Berkeley Laboratory--88-Inch Cyclotron; Los Alamos National Laboratory--Clinton P. Anderson Meson Physics Facility (LAMPF); Massachusetts Institute of Technology--Bates Linear Accelerator Center; Oak Ridge National Laboratory--Holifield Heavy Ion Research Facility; Oak Ridge National Laboratory--Oak Ridge Electron Linear Accelerator; Stanford Linear Accelerator Center--Nuclear Physics Injector; Texas AandM University--Texas AandM Cyclotron; Triangle Universities Nuclear Laboratory (TUNL); University of Washington--Tandem/Superconducting Booster; and Yale University--Tandem Van de Graaff

  20. The BNCT facility at the HFR Petten: Quality assurance for reactor facilities in clinical trials

    International Nuclear Information System (INIS)

    Moss, R.; Watkins, P.; Vroegindeweij, C.; Stecher-Rasmussen, F.; Huiskamp, R.; Ravensberg, K.; Appelman, K.; Sauerwein, W.; Hideghety, K.; Gabel, D.

    2001-01-01

    The first clinical trial in Europe of Boron Neutron Capture Therapy (BNCT) for the treatment of glioblastoma was opened in July 1997. The trial is a Phase I study with the principal aim to establish the maximum tolerated radiation dose and the dose limiting toxicity under defined conditions. It is the first time that a clinical application could be realised on a completely multi-national scale. The treatment takes place at the High Flux Reactor (HFR) in Petten, the Netherlands, is operated by an international team of experts under the leadership of a German radiotherapist, and treats patients coming from different European countries. It has therefore been necessary to create a very specialised organisation and contractual structure with the support of administrations from different countries, who had to find and adapt solutions within existing laws that had never foreseen such a situation. Furthermore, the treatment does not take place in an hospital environment and even more so, the facility is at a nuclear research reactor. Hence, special efforts were made on quality assurance, in order that the set-up at the facility and the personnel involved complied, as closely as possible, with similar practices in conventional radiotherapy departments. (author)

  1. Additive effect of BPA and Gd-DTPA for application in accelerator-based neutron source

    International Nuclear Information System (INIS)

    Yoshida, F.; Yamamoto, T.; Nakai, K.; Zaboronok, A.; Matsumura, A.

    2015-01-01

    Because of its fast metabolism gadolinium as a commercial drug was not considered to be suitable for neutron capture therapy. We studied additive effect of gadolinium and boron co-administration using colony forming assay. As a result, the survival of tumor cells with additional 5 ppm of Gd-DTPA decreased to 1/10 compared to the cells with boron only. Using gadolinium to increase the effect of BNCT instead of additional X-ray irradiation might be beneficial, as such combination complies with the short-time irradiation regimen at the accelerator-based neutron source. - Highlights: • Gd-DTPA is widely clinically used as a contrast medium for MRI. • Shift to an accelerator-based neutron source is advantageous for gadolinium NCT. • Boron–gadolinium NCT effects on tumor cell lines were significant. • Additional administration of Gd-DTPA might enhance the effect of BPA–BNCT.

  2. Accelerator development for a radioactive beam facility based on ATLAS

    International Nuclear Information System (INIS)

    Shepard, K. W.

    1998-01-01

    The existing superconducting linac ATLAS is in many respects an ideal secondary beam accelerator for an ISOL (Isotope separator on-line) type radioactive beam facility. Such a facility would require the addition of two major accelerator elements: a low charge state injector for the existing heavy ion linac, and a primary beam accelerator providing 220 MV of acceleration for protons and light ions. Development work for both of these elements, including the option of superconducting cavities for the primary beam accelerator is discussed

  3. Accelerator development for a radioactive beam facility based on ATLAS.

    Energy Technology Data Exchange (ETDEWEB)

    Shepard, K. W.

    1998-01-08

    The existing superconducting linac ATLAS is in many respects an ideal secondary beam accelerator for an ISOL (Isotope separator on-line) type radioactive beam facility. Such a facility would require the addition of two major accelerator elements: a low charge state injector for the existing heavy ion linac, and a primary beam accelerator providing 220 MV of acceleration for protons and light ions. Development work for both of these elements, including the option of superconducting cavities for the primary beam accelerator is discussed.

  4. Ion Beam Facilities at the National Centre for Accelerator based Research using a 3 MV Pelletron Accelerator

    Science.gov (United States)

    Trivedi, T.; Patel, Shiv P.; Chandra, P.; Bajpai, P. K.

    A 3.0 MV (Pelletron 9 SDH 4, NEC, USA) low energy ion accelerator has been recently installed as the National Centre for Accelerator based Research (NCAR) at the Department of Pure & Applied Physics, Guru Ghasidas Vishwavidyalaya, Bilaspur, India. The facility is aimed to carried out interdisciplinary researches using ion beams with high current TORVIS (for H, He ions) and SNICS (for heavy ions) ion sources. The facility includes two dedicated beam lines, one for ion beam analysis (IBA) and other for ion implantation/ irradiation corresponding to switching magnet at +20 and -10 degree, respectively. Ions with 60 kV energy are injected into the accelerator tank where after stripping positively charged ions are accelerated up to 29 MeV for Au. The installed ion beam analysis techniques include RBS, PIXE, ERDA and channelling.

  5. Experimental and Simulated Characterization of a Beam Shaping Assembly for Accelerator- Based Boron Neutron Capture Therapy (AB-BNCT)

    International Nuclear Information System (INIS)

    Burlon, Alejandro A.; Valda, Alejandro A.; Girola, Santiago; Minsky, Daniel M.; Kreiner, Andres J.

    2010-01-01

    In the frame of the construction of a Tandem Electrostatic Quadrupole Accelerator facility devoted to the Accelerator-Based Boron Neutron Capture Therapy, a Beam Shaping Assembly has been characterized by means of Monte-Carlo simulations and measurements. The neutrons were generated via the 7 Li(p, n) 7 Be reaction by irradiating a thick LiF target with a 2.3 MeV proton beam delivered by the TANDAR accelerator at CNEA. The emerging neutron flux was measured by means of activation foils while the beam quality and directionality was evaluated by means of Monte Carlo simulations. The parameters show compliance with those suggested by IAEA. Finally, an improvement adding a beam collimator has been evaluated.

  6. Qt based control system software for Low Energy Accelerator Facility

    International Nuclear Information System (INIS)

    Basu, A.; Singh, S.; Nagraju, S.B.V.; Gupta, S.; Singh, P.

    2012-01-01

    Qt based control system software for Low Energy Accelerating Facility (LEAF) is operational at Bhabha Atomic Research Centre (BARC), Trombay, Mumbai. LEAF is a 50 keV negative ion electrostatic accelerator based on SNICS ion source. Control system uses Nokia Trolltech's QT 4.x API for control system software. Ni 6008 USB based multifunction cards has been used for control and read back field equipments such as power supplies, pumps, valves etc. Control system architecture is designed to be client server. Qt is chosen for its excellent GUI capability and platform independent nature. Control system follows client server architecture. The paper will describe the control system. (author)

  7. INEEL BNCT research program. Annual report, January 1, 1996--December 31, 1996

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1997-04-01

    This report is a summary of the progress and research produced for the Idaho National Engineering and Environmental Laboratory (INEEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1996. Contributions from the individual investigators about their projects are included, specifically, physics: treatment planning software, real-time neutron beam measurement dosimetry, measurement of the Finnish research reactor epithermal neutron spectrum, BNCT accelerator technology; and chemistry: analysis of biological samples and preparation of 10 B enriched decaborane

  8. Characterisation of the TAPIRO BNCT thermal facility

    Energy Technology Data Exchange (ETDEWEB)

    Rosi, G. [ENEA FIS-ION, CR Casaccia, Via Anguillarese 301, I-00060 Roma (Italy); Gambarini, G.; Colli, V.; Gay, S.; Scolari, L. [Dept. of Physics, Univ. of Milan, INFN, Via Celoria 16, I-20133 Milano (Italy); Fiorani, O.; Perrone, A. [ENEA FIS-ION, CR Casaccia, Via Anguillarese 301, I-00060 Roma (Italy); Nava, E. [ENEA FIS-NUC, Via Martiri di Monte Sole 4, I-40129 Bologna (Italy); Fasolo, F.; Visca, L.; Zanini, A. [INFN, Via Pietro Giuria 1, I-10125 Torino (Italy)

    2004-07-01

    Dosimetry and spectrometry measurements have been carried out in the thermal column of the research fast reactor RSV-TAPIRO (ENEA-Casaccia, Rome) in order to investigate its suitability for irradiation of cells or mice, with a view to research in the interests of boron neutron capture therapy (BNCT). The thermal column consists of a graphite moderator (40 cm thick) containing a lead shield (13 cm thick) in order to shield reactor background. The irradiation volume, inside this structure, has cubic shape (18 x 18 x 18 cm{sup 3}). Besides measurements of fluence and dose rates in air or in phantom performed with thermoluminescence dosemeters (TLDs) and using the activation technique, dose and fluence profiles have been generated using a method based on gel dosemeters analysed with optical imaging. To check the consistency of the results, spectrometry measurements in the same irradiation volume have been performed by means of bubble detectors. (authors)

  9. A D-D/D-T fusion reaction based neutron generator system for liver tumor BNCT

    International Nuclear Information System (INIS)

    Koivunoro, H.; Lou, T.P.; Leung, K. N.; Reijonen, J.

    2003-01-01

    Boron-neutron capture therapy (BNCT) is an experimental radiation treatment modality used for highly malignant tumor treatments. Prior to irradiation with low energetic neutrons, a 10B compound is located selectively in the tumor cells. The effect of the treatment is based on the high LET radiation released in the 10 B(n,α) 7 Li reaction with thermal neutrons. BNCT has been used experimentally for brain tumor and melanoma treatments. Lately applications of other severe tumor type treatments have been introduced. Results have shown that liver tumors can also be treated by BNCT. At Lawrence Berkeley National Laboratory, various compact neutron generators based on D-D or D-T fusion reactions are being developed. The earlier theoretical studies of the D-D or D-T fusion reaction based neutron generators have shown that the optimal moderator and reflector configuration for brain tumor BNCT can be created. In this work, the applicability of 2.5 MeV neutrons for liver tumor BNCT application was studied. The optimal neutron energy for external liver treatments is not known. Neutron beams of different energies (1eV < E < 100 keV) were simulated and the dose distribution in the liver was calculated with the MCNP simulation code. In order to obtain the optimal neutron energy spectrum with the D-D neutrons, various moderator designs were performed using MCNP simulations. In this article the neutron spectrum and the optimized beam shaping assembly for liver tumor treatments is presented

  10. Neutron generator for BNCT based on high current ECR ion source with gyrotron plasma heating.

    Science.gov (United States)

    Skalyga, V; Izotov, I; Golubev, S; Razin, S; Sidorov, A; Maslennikova, A; Volovecky, A; Kalvas, T; Koivisto, H; Tarvainen, O

    2015-12-01

    BNCT development nowadays is constrained by a progress in neutron sources design. Creation of a cheap and compact intense neutron source would significantly simplify trial treatments avoiding use of expensive and complicated nuclear reactors and accelerators. D-D or D-T neutron generator is one of alternative types of such sources for. A so-called high current quasi-gasdynamic ECR ion source with plasma heating by millimeter wave gyrotron radiation is suggested to be used in a scheme of D-D neutron generator in the present work. Ion source of that type was developed in the Institute of Applied Physics of Russian Academy of Sciences (Nizhny Novgorod, Russia). It can produce deuteron ion beams with current density up to 700-800 mA/cm(2). Generation of the neutron flux with density at the level of 7-8·10(10) s(-1) cm(-2) at the target surface could be obtained in case of TiD2 target bombardment with deuteron beam accelerated to 100 keV. Estimations show that it is enough for formation of epithermal neutron flux with density higher than 10(9) s(-1) cm(-2) suitable for BNCT. Important advantage of described approach is absence of Tritium in the scheme. First experiments performed in pulsed regime with 300 mA, 45 kV deuteron beam directed to D2O target demonstrated 10(9) s(-1) neutron flux. This value corresponds to theoretical estimations and proofs prospects of neutron generator development based on high current quasi-gasdynamic ECR ion source. Copyright © 2015 Elsevier Ltd. All rights reserved.

  11. The Radiological Research Accelerator Facility

    International Nuclear Information System (INIS)

    Hall, E.J.; Marino, S.A.

    1990-07-01

    The Radiological Research Accelerator Facility (RARAF) is based on a 4-MV Van de Graaff accelerator, which is used to generate a variety of well-characterized radiation beams for research in radiobiology, radiological physics, and radiation chemistry. It is part of the Center for Radiological Research (CRR) -- formerly the Radiological Research Laboratory (RRL) -- of Columbia University, and its operation is supported as a National Facility by the US Department of Energy (DOE). Fifteen different experiments were run during these 12 months, approximately the same as the previous two years. Brief summaries of each experiment are included. Accelerator usage is summarized and development activities are discussed. 7 refs., 4 tabs

  12. Mock-up experiment at Birmingham University for BNCT project of Osaka University – Neutron flux measurement with gold foil

    International Nuclear Information System (INIS)

    Tamaki, S.; Sakai, M.; Yoshihashi, S.; Manabe, M.; Zushi, N.; Murata, I.; Hoashi, E.; Kato, I.; Kuri, S.; Oshiro, S.; Nagasaki, M.; Horiike, H.

    2015-01-01

    Mock-up experiment for development of accelerator based neutron source for Osaka University BNCT project was carried out at Birmingham University, UK. In this paper, spatial distribution of neutron flux intensity was evaluated by foil activation method. Validity of the design code system was confirmed by comparing measured gold foil activities with calculations. As a result, it was found that the epi-thermal neutron beam was well collimated by our neutron moderator assembly. Also, the design accuracy was evaluated to have less than 20% error. - Highlights: • Accelerator based neutron source for BNCT is being developed in Osaka University. • Mock-up experiment was carried out at Birmingham University, UK. • Neutronics performance of our assembly was evaluated from gold foil activation. • Gold foil activation was determined by using HPGe detectors. • Validity of the neutronics design code system was confirmed.

  13. Monte Carlo simulation to study the doses in an accelerator BNCT treatment

    International Nuclear Information System (INIS)

    Burlon, Alejandro A.; Valda, Alejandro A.; Somacal, Hector R.; Kreiner, Andres J.; Minsky, Daniel M.

    2003-01-01

    In this work the 7 Li(p, n) 7 Be reaction has been studied as a neutron source for accelerator-based BNCT (Boron Neutron Capture Therapy). In order to optimize the design of the neutron production target and the beam shaping assembly, extensive MCNP simulations have been performed. These simulations include a thick Li metal target, a whole-body phantom, a moderator-reflector assembly (Al/AlF 3 as moderator and graphite as reflector) and the treatment room. The doses were evaluated for two proton bombarding energies of 1.92 MeV (near to the threshold of the reaction) and 2.3 MeV (near to the resonance of the reaction) and for three Al/ALF 3 moderator thicknesses (18, 26 and 34 cm). To assess the doses, a comparison using a Tumor Control Probability (TCP) model was done. In a second instance, the effect of the specific skin radiosensitivity (an RBE of 2.5 for the 10 B(n,α) 7 Li reaction) and a 10 B uptake of 17 ppm was considered for the scalp. Finally, the simulations show the advantage of irradiating with near-resonance-energy protons (2.3 MeV) because of the high neutron yield at this energy, leading to the lowest treatment times. Moreover, the 26 cm Al/AlF 3 moderator has shown the best performance among the studied cases. (author)

  14. Accelerator based research facility as an inter university centre

    International Nuclear Information System (INIS)

    Mehta, G.K.

    1995-01-01

    15 UD pelletron has been operating as a user facility from July 1991. It is being utilised by a large number of universities and other institutions for research in basic Nuclear Physics, Materials Science, Atomic Physics, Radiobiology and Radiation Chemistry. There is an on-going programme for augmenting the accelerator facilities by injecting Pelletron beams into superconducting linear accelerator modules. Superconducting niobium resonator is being developed in Argonne National Laboratory as a joint collaborative effort. All other things such as cryostats, rf instrumentation, cryogenic distribution system, computer control etc are being done indigenously. Research facilities, augmentation plans and the research being conducted by the universities in various disciplines are described. (author)

  15. Reprint of Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina

    International Nuclear Information System (INIS)

    Gadan, M.A.; González, S.J.; Batalla, M.; Olivera, M.S.; Policastro, L.; Sztejnberg, M.L.

    2015-01-01

    In the frame of the Argentine BNCT Project a new research line has been started to study the application of BNCT to the treatment of locoregional recurrences of HER2+ breast cancer subtype. Based on former studies, the strategy considers the use of immunoliposomes as boron carriers nanovehicles to target HER2 overexpressing cells. The essential concerns of the current stage of this proposal are the development of carriers that can improve the efficiency of delivery of boron compounds and the dosimetric assessment of treatment feasibility. For this purpose, an specific pool of clinical cases that can benefit from this application was determined. In this work, we present the proposal and the advances related to the different stages of current research. - Highlights: • A new proposal of BNCT for HER2+ breast cancer treatment is introduced. • The proposal considers development of immunoliposomes as boron carrier nanovehicles. • Locoregional recurrences after treatment were identified as candidates for initial BNCT studies. • First analysis show acceptable neutron flux distributions provided by RA-6 BNCT facility.

  16. The Brookhaven Accelerator Test Facility

    International Nuclear Information System (INIS)

    Batchelor, K.; Ben-Zvi, I.; Fernow, R.C.; Fischer, J.; Fisher, A.S.; Gallardo, J.; Jialin, Xie; Kirk, H.G.; Parsa, Z.; Palmer, R.B.; Rao, T.; Rogers, J.; Sheehan, J.; Tsang, T.Y.F.; Ulc, S.; Van Steenbergen, A.; Woodle, M.; Zhang, R.S.; McDonald, K.T.; Russell, D.P.; Jiang, Z.Y.; Pellegrini, C.; Wang, X.J.

    1990-01-01

    The Accelerator Test Facility (ATF), presently under construction at Brookhaven National laboratory, is described. It consists of a 50-MeV electron beam synchronizable to a high-peak power CO 2 laser. The interaction of electrons with the laser field will be probed, with some emphasis on exploring laser-based acceleration techniques. 5 refs., 2 figs

  17. Quality control procedure of the BNCT patient dose determination

    International Nuclear Information System (INIS)

    Bjugg, H.; Kortesniemi, M.; Seppaelae, T.; Karila, J.; Perkioe, J.; Ryynaenen, P.; Savolainen, S.; Auterinen, I.; Kotiluoto, P.; Seren, T.

    2000-01-01

    The concepts used at the Finnish BNCT facility for the patient dose quality assurance are introduced here. Dose planning images are obtained using a MR scanner with MRI sensitive markers. The dose distribution is computed with BNCT Rtpe. The program and the beam (DORT) model used have been verified with measurements and validated with MCNP calculations in phantoms. Dosimetric intercomparison has been done between FiR 1 and BMRR BNCT beams. The FiR 1 beam has been characterised also by visiting teams. Before every patient irradiation the relationship between beam monitor pulse rate and neutron fluence rate in the beam is checked by activation measurements. Cross-hair lasers used in the patient positioning are checked for spatial drift prior to each treatment. Kinetic models used to estimate the time-behaviour of blood boron concentration have been verified using independent patient sample data to assess and verify the performance of the applications. Quality control guides have been developed for each step in the patient irradiation. (author)

  18. INEL BNCT Program: Volume 5, No. 9

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1991-01-01

    This Bulletin presents a summary of accomplishments and highlights of the Idaho National Engineering Laboratory's (INEL) Boron Neutron Capture Therapy (BNCT) Program for September 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  19. Development of beryllium-based neutron target system with three-layer structure for accelerator-based neutron source for boron neutron capture therapy.

    Science.gov (United States)

    Kumada, Hiroaki; Kurihara, Toshikazu; Yoshioka, Masakazu; Kobayashi, Hitoshi; Matsumoto, Hiroshi; Sugano, Tomei; Sakurai, Hideyuki; Sakae, Takeji; Matsumura, Akira

    2015-12-01

    The iBNCT project team with University of Tsukuba is developing an accelerator-based neutron source. Regarding neutron target material, our project has applied beryllium. To deal with large heat load and blistering of the target system, we developed a three-layer structure for the target system that includes a blistering mitigation material between the beryllium used as the neutron generator and the copper heat sink. The three materials were bonded through diffusion bonding using a hot isostatic pressing method. Based on several verifications, our project chose palladium as the intermediate layer. A prototype of the neutron target system was produced. We will verify that sufficient neutrons for BNCT treatment are generated by the device in the near future. Copyright © 2015 Elsevier Ltd. All rights reserved.

  20. Gene transfer-applied BNCT (g-BNCT) for amelanotic melanoma in brain. Further upregulation of 10B uptake by cell modulation

    International Nuclear Information System (INIS)

    Iwakura, M.; Tamaki, N.; Hiratsuka, J.

    2000-01-01

    Our success in eradicating melanoma by single BNCT with BPA led to the next urgent theme, i.e. application of such BNCT for currently uncurable melanoma metastasis in brain. In order to establish 10 B-BPA-BNCT for melanoma in brain, we have investigated the pharmacokinetics of BPA which is most critical factor for successful BNCT, in melanotic and amelanotic and further tyrosinase gene-transfected amelanotic melanoma proliferating in brain having blood-brain-barrier, as compared to melanoma proliferating in skin. We have established three implanted models for melanoma in brain: 1) A1059 cells, amelanotic melanoma, 2) B16B15b cells, melanotic melanoma cells, highly metastatic to brain, and 3) TA1059 cells, with active melanogenesis induced by tyrosinase gene transfection. We would like to report the results of comparative analysis of the BPA uptake ability in these melanoma cells in both brain and skin. Based on these findings, we are further investigating to enhance 10 B-BPA uptake by not only g-BNCT but also by additional melanogenesis upregulating cell modulation. (author)

  1. Accelerator technical design report for high-intensity proton accelerator facility project, J-PARC

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2003-03-01

    This report presents the detail of the technical design of the accelerators for the High-Intensity Proton Accelerator Facility Project, J-PARC. The accelerator complex comprises a 400-MeV room-temperature linac (600-MeV superconducting linac), 3-GeV rapid-cycling synchrotron (RCS), and a 50-GeV synchrotron (MR). The 400-MeV beam is injected to the RCS, being accelerated to 3 GEV. The 1-MW beam thus produced is guided to the Materials Life Science Experimental Facility, with both the pulsed spallation neutron source and muon source. A part of the beam is transported to the MR, which provides the 0.75-MW beam to either the Nuclear and Fundamental Particle Experimental Facility or the Neutrino Production Target. On the other hand, the beam accelerated to 600 MeV by the superconducting linac is used for the Nuclear Waster Transmutation Experiment. In this way, this facility is unique, being multipurpose one, including many new inventions and Research and Development Results. This report is based upon the accomplishments made by the Accelerator Group and others of the Project Team, which is organized on the basis of the Agreement between JAERI and KEK on the Construction and Research and Development of the High-Intensity Proton Accelerator Facility. (author)

  2. The Radiological Research Accelerator Facility

    International Nuclear Information System (INIS)

    Hall, E.J.; Marino, S.A.

    1991-05-01

    The Radiological Research Accelerator Facility (RARAF) is based on 4-MV Van de Graaff accelerator, which is used to generate a variety of well-characterized radiation beams for research in radiobiology, radiological physics, and radiation chemistry. It is part of the Center for Radiological Research (CRR) -- formerly the Radiological Research Laboratory (RRL) -- of Columbia University, and its operation is supported as a National Facility by the US Department of Energy (DOE). As such, RARAF is available to all potential users on an equal basis, and scientists outside the CRR are encouraged to submit proposals for experiments at RARAF. The operation of the Van de Graaff is supported by the DOE, but the research projects themselves must be supported separately. Brief summaries of research experiments are included. Accelerator usage is summarized and development activities are discussed. 8 refs., 8 tabs

  3. Radiobiology studies for the evaluation of epithermal neutron beams used for BNCT

    International Nuclear Information System (INIS)

    Green, S.; Jones, B.; Mill, A.J.

    2006-01-01

    This paper outlines our plans for a study to establish the radiobiological effectiveness of the various mixes of radiation components present in an epithermal neutron beam designed for BNCT and to incorporate these data into clinical protocols for the treatment of malignant glioma. This is a description of work which is funded and just now beginning in Birmingham so no results can be presented. Our project will involve a combination of experimental measurements carried out in Birmingham and in Boston and mathematical modelling carried out in Birmingham. Despite all the extant in-vitro and in-vivo work, there is no widely accepted method to determine biological effect by accounting for variations in beam component mix, dose rate and treatment fractionation for disparate from the various BNCT centres. The objectives of this study are: To develop a cell-based radiobiology protocol to provide essential data on safety and efficacy of beams for Boron Neutron Capture Therapy (BNCT) in advance of clinical trials. To exploit the facilities at Massachusetts Institute of Technology for variable dose-rate epithermal irradiations to validate the above protocol. To develop mathematical models of this radiobiological system that can be used to inform decisions on dose selection, fractionation schedules, BNCT use as supplementary boosts or for re-treatment of recurrent cancers. To provide fundamental data relevant to the understanding of the radiobiology of simultaneous mixed high-and low-LET radiations over a clinically relevant dose-range. (author)

  4. Liquid Li based neutron source for BNCT and science application

    International Nuclear Information System (INIS)

    Horiike, H.; Murata, I.; Iida, T.; Yoshihashi, S.; Hoashi, E.; Kato, I.; Hashimoto, N.; Kuri, S.; Oshiro, S.

    2015-01-01

    Liquid lithium (Li) is a candidate material for a target of intense neutron source, heat transfer medium in space engines and charges stripper. For a medical application of BNCT, epithermal neutrons with least energetic neutrons and γ-ray are required so as to avoid unnecessary doses to a patient. This is enabled by lithium target irradiated by protons at 2.5 MeV range, with utilizing the threshold reaction of "7Li(p,n)"7Be at 1.88 MeV. In the system, protons at 2.5 MeV penetrate into Li layer by 0.25 mm with dissipating heat load near the surface. To handle it, thin film flow of high velocity is important for stable operation. For the proton accelerator, electrostatic type of the Schnkel or the tandem is planned to be employed. Neutrons generated at 0.6 MeV are gently moderated to epithermal energy while suppressing accompanying γ-ray minimum by the dedicated moderator assembly. - Highlights: • Liquid lithium (Li) is a candidate material for a target of intense neutron source. • An accelerator based neutron source with p-liquid Li target for boron neutron capture therapy is under development in Osaka University, Japan. • In our system, the harmful radiation dose due to rays and fast neutrons will be suppressed very low. • The system performance are very promising as a state of art cancer treatment system. • The project is planned as a joint undertaking between industries and Osaka University.

  5. A new AMS facility at Inter University Accelerator Centre, New Delhi

    Science.gov (United States)

    Kumar, Pankaj; Chopra, S.; Pattanaik, J. K.; Ojha, S.; Gargari, S.; Joshi, R.; Kanjilal, D.

    2015-10-01

    Inter University Accelerator Centre (IUAC), a national facility of government of India, is having a 15UD Pelletron accelerator for multidisciplinary ion beam based research programs. Recently, a new accelerator mass spectrometry (AMS) facility has been developed after incorporating many changes in the existing 15UD Pelletron accelerator. A clean chemistry laboratory for 10Be and 26Al with all the modern facilities has also been developed for the chemical processing of samples. 10Be measurements on sediment samples, inter laboratory comparison results and 26Al measurements on standard samples are presented in this paper. In addition to the 10Be and 26Al AMS facilities, a new 14C AMS facility based on a dedicated 500 kV tandem ion accelerator with two cesium sputter ion sources, is also being setup at IUAC.

  6. Future directions of accelerator-based NP and HEP facilities

    Energy Technology Data Exchange (ETDEWEB)

    Roser, T.

    2011-07-24

    Progress in particle and nuclear physics has been closely connected to the progress in accelerator technologies - a connection that is highly beneficial to both fields. This paper presents a review of the present and future facilities and accelerator technologies that will push the frontiers of high-energy particle interactions and high intensity secondary particle beams.

  7. Operation of the Brookhaven National Laboratory Accelerator Test Facility

    International Nuclear Information System (INIS)

    Batchelor, K.; Ben-Zvi, I.; Botke, I.; Chou, T.S.; Fernow, R.; Fischer, J.; Fisher, A.; Gallardo, J.; Ingold, G.; Malone, R.; Palmer, R.; Parsa, Z.; Pogorelsky, I.; Rogers, J.; Sheehan, J.; Srinivasan-Rao, T.; Tsang, T.; Ulc, S.; van Steenbergen, A.; Wang, X.J.; Woodle, M.; Yu, L.H.

    1992-01-01

    Early operation of the 50 MeV high brightness electron linac of the Accelerator Test Facility is described along with experimental data. This facility is designed to study new linear acceleration techniques and new radiation sources based on linacs in combination with free electron lasers. The accelerator utilizes a photo-excited, metal cathode, radio frequency electron gun followed by two travelling wave accelerating sections and an Experimental Hall for the study program

  8. 'Sequential' Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    International Nuclear Information System (INIS)

    Molinari, Ana J.; Pozzi, Emiliano C.C.; Hughes, Andrea Monti; Heber, Elisa M.; Garabalino, Marcela A.; Thorp, Silvia I.; Miller, Marcelo; Itoiz, Maria E.; Aromando, Romina F.; Nigg, David W.; Quintana, Jorge; Santa Cruz, Gustavo A.; Trivillin, Veronica A.; Schwint, Amanda E.

    2011-01-01

    In the present study we evaluated the therapeutic effect and/or potential radiotoxicity of the novel 'Tandem' Boron Neutron Capture Therapy (T-BNCT) for the treatment of oral cancer in the hamster cheek pouch model at RA-3 Nuclear Reactor. Two groups of animals were treated with 'Tandem BNCT', i.e. BNCT mediated by boronophenylalanine (BPA) followed by BNCT mediated by sodium decahydrodecaborate (GB-10) either 24 h (T-24h-BNCT) or 48 h (T-48h-BNCT) later. A total tumor dose-matched single application of BNCT mediated by BPA and GB-10 administered jointly ((BPA + GB-10)-BNCT) was administered to an additional group of animals. At 28 days post-treatment, T-24h-BNCT and T-48h-BNCT induced, respectively, overall tumor control (OTC) of 95% and 91%, with no statistically significant differences between protocols. Tumor response for the single application of (BPA + GB-10)-BNCT was 75%, significantly lower than for T-BNCT. The T-BNCT protocols and (BPA + GB-10)-BNCT induced reversible mucositis in dose-limiting precancerous tissue around treated tumors, reaching Grade 3/4 mucositis in 47% and 60% of the animals respectively. No normal tissue radiotoxicity was associated to tumor control for any of the protocols. 'Tandem' BNCT enhances tumor control in oral cancer and reduces or, at worst, does not increase, mucositis in dose-limiting precancerous tissue.

  9. Operation of the Brookhaven national laboratory accelerator test facility

    International Nuclear Information System (INIS)

    Batchelor, K.; Ben-Zvi, I.; Botke, I.; Chou, T.S.; Fernow, R.; Fischer, J.; Fisher, A.; Gallardo, J.; Ingold, G.; Malone, R.; Palmer, R.; Parsa, Z.; Pogorelsky, I.; Rogers, J.; Sheehan, J.; Srinivasan-Rao, T.; Tsang, T.; Ulc, S.; Van Steenbergen, A.; Wang, X.J.; Woodle, M.; Yu, L.H.

    1992-01-01

    Early operation of the 50 MeV high brightness electron linac of the Accelerator Test Facility is described along with experimental data. This facility is designed to study new linear acceleration techniques and new radiation sources based on linacs in combination with free electron lasers. The accelerator utilizes a photo-excited, metal cathode, radio frequency electron gun followed by two travelling wave accelerating sections and an Experimental Hall for the study program. (Author) 5 refs., 4 figs., tab

  10. A new AMS facility at Inter University Accelerator Centre, New Delhi

    Energy Technology Data Exchange (ETDEWEB)

    Kumar, Pankaj, E-mail: pkb@iuac.res.in [Inter-University Accelerator Center (IUAC), New Delhi (India); Chopra, S. [Inter-University Accelerator Center (IUAC), New Delhi (India); Pattanaik, J.K. [Department of Earth Sciences, Indian Institute of Science Education and Research Kolkata, Nadia, WB (India); Ojha, S.; Gargari, S.; Joshi, R.; Kanjilal, D. [Inter-University Accelerator Center (IUAC), New Delhi (India)

    2015-10-15

    Inter University Accelerator Centre (IUAC), a national facility of government of India, is having a 15UD Pelletron accelerator for multidisciplinary ion beam based research programs. Recently, a new accelerator mass spectrometry (AMS) facility has been developed after incorporating many changes in the existing 15UD Pelletron accelerator. A clean chemistry laboratory for {sup 10}Be and {sup 26}Al with all the modern facilities has also been developed for the chemical processing of samples. {sup 10}Be measurements on sediment samples, inter laboratory comparison results and {sup 26}Al measurements on standard samples are presented in this paper. In addition to the {sup 10}Be and {sup 26}Al AMS facilities, a new {sup 14}C AMS facility based on a dedicated 500 kV tandem ion accelerator with two cesium sputter ion sources, is also being setup at IUAC.

  11. Proposal for an Accelerator R&D User Facility at Fermilab's Advanced Superconducting Test Accelerator (ASTA)

    Energy Technology Data Exchange (ETDEWEB)

    Church, M. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Edwards, H. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Harms, E. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Henderson, S. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Holmes, S. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Lumpkin, A. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Kephart, R. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Levedev, V. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Leibfritz, J. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Nagaitsev, S. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Piot, P. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Northern Illinois Univ., DeKalb, IL (United States); Prokop, C. [Northern Illinois Univ., DeKalb, IL (United States); Shiltsev, V. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Sun, Y. E. [Argonne National Lab. (ANL), Argonne, IL (United States); Valishev, A. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States)

    2013-10-01

    Fermilab is the nation’s particle physics laboratory, supported by the DOE Office of High Energy Physics (OHEP). Fermilab is a world leader in accelerators, with a demonstrated track-record— spanning four decades—of excellence in accelerator science and technology. We describe the significant opportunity to complete, in a highly leveraged manner, a unique accelerator research facility that supports the broad strategic goals in accelerator science and technology within the OHEP. While the US accelerator-based HEP program is oriented toward the Intensity Frontier, which requires modern superconducting linear accelerators and advanced highintensity storage rings, there are no accelerator test facilities that support the accelerator science of the Intensity Frontier. Further, nearly all proposed future accelerators for Discovery Science will rely on superconducting radiofrequency (SRF) acceleration, yet there are no dedicated test facilities to study SRF capabilities for beam acceleration and manipulation in prototypic conditions. Finally, there are a wide range of experiments and research programs beyond particle physics that require the unique beam parameters that will only be available at Fermilab’s Advanced Superconducting Test Accelerator (ASTA). To address these needs we submit this proposal for an Accelerator R&D User Facility at ASTA. The ASTA program is based on the capability provided by an SRF linac (which provides electron beams from 50 MeV to nearly 1 GeV) and a small storage ring (with the ability to store either electrons or protons) to enable a broad range of beam-based experiments to study fundamental limitations to beam intensity and to develop transformative approaches to particle-beam generation, acceleration and manipulation which cannot be done elsewhere. It will also establish a unique resource for R&D towards Energy Frontier facilities and a test-bed for SRF accelerators and high brightness beam applications in support of the OHEP

  12. Clearance of materials from accelerator facilities

    Directory of Open Access Journals (Sweden)

    Rokni Sayed H.

    2017-01-01

    Full Text Available A new Technical Standard that supports the clearance of materials and equipment (personal property from U.S. Department of Energy (DOE accelerator facilities has been developed. The Standard focuses on personal property that has the potential to be radiologically impacted by accelerator operations. It addresses material clearance programs and protocols for off-site releases without restriction on use. Common metals with potential volumetric activation are of main interest with technical bases provided in Appendices of the Standard. The clearance protocols in the Standard include three elements: 1 clearance criteria, 2 process knowledge, and 3 measurement methods. This paper presents the technical aspects of the new Standard, discusses operational experience gained in clearance of materials and equipment from several accelerator facilities at SLAC and examples as to how this Standard can be applied to benefit the entirety of the DOE Accelerator Complex.

  13. TIARA electrostatic accelerator facility

    International Nuclear Information System (INIS)

    Tajima, Satoshi; Takada, Isao; Mizuhashi, Kiyoshi; Uno, Sadanori; Ohkoshi, Kiyonori; Nakajima, Yoshinori; Saitoh, Yuichi; Ishii, Yasuyuki; Kamiya, Tomihiro

    1996-07-01

    In order to promote the Advanced Radiation Technology Project, Japan Atomic Energy Research Institute constructed TIARA facility composed of four ion accelerators at Takasaki Radiation Chemistry Research Establishment for the period from 1988 to 1993. A 3MV tandem accelerator and an AVF cycrotron were completed in 1991 as the first phase of the construction, and a 3MV single-ended accelerator and a 400kV ion implanter were completed in 1993 as the second phase. Three electrostatic accelerators, the tandem, the single-ended and the implanter, were installed in the Multiple-beam facility of TIARA and have been operated for various experiments with using single, dual and triple beams without any serious trouble. This report describes the constructive works, machine performances, control systems, safety systems and accessory equipments of the electrostatic accelerators. (author)

  14. Pelletron ion accelerator facilities at Inter University Accelerator Centre

    International Nuclear Information System (INIS)

    Chopra, S.

    2011-01-01

    Inter University Accelerator Centre has two tandem ion accelerators, 15UD Pelletron and 5SDH-2 Pelletron, for use in different areas of research. Recently Accelerator Mass Spectrometry facility has also been added to to the existing experimental facilities of 15UD Pelletron. In these years many modifications and up gradations have been performed to 15UD Pelletron facility. A new MCSNICS ion source has been procured to produce high currents for AMS program. Two foils stripper assemblies ,one each before and after analyzing magnet, have also been added for producing higher charge state beams for LINAC and for experiments requiring higher charge states of accelerated beams. A new 1.7 MV Pelletron facility has also been recently installed at IUAC and it is equipped with RBS and Channelling experimental facility. There are two beam lines installed in the system and five more beam lines can be added to the system. A clean chemistry laboratory with all the modern facilities has also been developed at IUAC for the chemical processing of samples prior to the AMS measurements. The operational description of the Pelletron facilities, chemical processing of samples, methods of measurements and results of AMS measurements are being presented. (author)

  15. First clinical results on the finnish study on BPA-mediated BNCT in glioblastoma

    International Nuclear Information System (INIS)

    Kankaanranta, L.; Seppaelae, T.; Kallio, M.

    2000-01-01

    An open phase I dose-escalation boron neutron capture therapy (BNCT) study on glioblastoma multiforme (GBM) was initiated at the BNCT facility FiR 1, Espoo, Finland, in May 1999. The aim of the study is to investigate the safety of boronophenylalanine (BPA)-mediated BNCT. Ten GBM patients were treated with a 2-field treatment plan using one fraction. BPA-F was used as the 10 B carrier infused as a fructose solution 290 mg BPA/kg over 2-hours prior to irradiation with epithermal neutrons. Average doses to the normal brain, contrast enhancing tumour, and the target ranged from 3.0 to 5.6 Gy (W), from 35.1 to 66.7 Gy (W), and from 29.6 to 53.6 Gy (W), respectively. BNCT was associated with acceptable toxicity. The median follow-up is 9 months (range, 3 to 16 months) post diagnosis in July 2000. Seven of the 10 patients have recurrent or persistent GBM, and the median time to progression is 8 months. Only one patient has died, and the estimated 1-year overall survival is 86%. Five of the recurrent tumours were treated with external beam photon radiation therapy to the total dose of 30-40 Gy with few acute side-effects. These preliminary findings suggest that acute toxicity of BPA-mediated BNCT is acceptable when average brain doses of 5.6 Gy (W) or less are used. The followup time is too short to evaluate survival, but the estimated 1-year survival of 86% achieved with BNCT followed by conventional photon irradiation at the time of tumour progression is encouraging and emphasises the need of further investigation of BPA-mediated BNCT. (author)

  16. “Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    Energy Technology Data Exchange (ETDEWEB)

    Ana J. Molinari; Emiliano C. C. Pozzi; Andrea Monti Hughes; Elisa M. Heber; Marcela A. Garabalino; Silvia I. Thorp; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; David W. Nigg; Jorge Quintana; Gustavo A. Santa Cruz; Veronica A. Trivillin; Amanda E. Schwint

    2011-04-01

    In the present study we evaluated the therapeutic effect and/or potential radiotoxicity of the novel “Tandem” Boron Neutron Capture Therapy (T-BNCT) for the treatment of oral cancer in the hamster cheek pouch model at RA-3 Nuclear Reactor. Two groups of animals were treated with “Tandem BNCT”, i.e. BNCT mediated by boronophenylalanine (BPA) followed by BNCT mediated by sodium decahydrodecaborate (GB-10) either 24 h (T-24h-BNCT) or 48 h (T-48h-BNCT) later. A total tumor dose-matched single application of BNCT mediated by BPA and GB-10 administered jointly [(BPA + GB-10)-BNCT] was administered to an additional group of animals. At 28 days post-treatment, T-24h-BNCT and T-48h-BNCT induced, respectively, overall tumor control (OTC) of 95% and 91%, with no statistically significant differences between protocols. Tumor response for the single application of (BPA + GB-10)-BNCT was 75%, significantly lower than for T-BNCT. The T-BNCT protocols and (BPA + GB-10)-BNCT induced reversible mucositis in dose-limiting precancerous tissue around treated tumors, reaching Grade 3/4 mucositis in 47% and 60% of the animals respectively. No normal tissue radiotoxicity was associated to tumor control for any of the protocols. “Tandem” BNCT enhances tumor control in oral cancer and reduces or, at worst, does not increase, mucositis in dose-limiting precancerous tissue.

  17. The Radiological Research Accelerator Facility

    International Nuclear Information System (INIS)

    Hall, E.J.

    1992-05-01

    The Radiological Research Accelerator Facility (RARAF) is based on a 4-MV Van de Graaff accelerator, which is used to generate a variety of well-characterized radiation beams for research in radiobiology, radiological physics, and radiation chemistry. It is part of the Center for Radiological Research (CRR) -- formerly the Radiological Research Laboratory (RRL) -- of Columbia University, and its operation is supported as a National Facility by the US Department of Energy (DOE). As such, RARAF is available to all potential users on an equal basis, and scientists outside the CRR are encouraged to submit proposals for experiments at RARAF. The operation of the Van de Graaff is supported by the DOE, but the research projects themselves must be supported separately. Experiments performed from May 1991--April 1992 are described

  18. The BNCT project in the Czech Republic

    International Nuclear Information System (INIS)

    Burian, J.; Marek, M.; Rataj, J.; Honova, H.; Petruzelka, L.; Prokes, K.; Tovarys, F.; Dbaly, V.; Honzatko, J.; Tomandl, I.

    2000-01-01

    The start of clinical trials is expected before NCT Osaka 2000. The experiences from different part of project are presented. The BNCT facility at LVR-15 reactor of NRI consists of epithermal neutron beam with improved construction (6.98 x 10 8 /cm 2 s with acceptable background of fast neutrons and gammas) and irradiation and control rooms equipped by appropriate devices. Internationally-recognized software MacNCTPLAN is utilized for computational dosimetry and treatment planning. In the part of protocol the following parameters have been assessed: patient selection, BSH dosage, fractionation, starting dose, dose escalation steps. At the LVR-15, at horizontal channel, a prompt gamma ray analysis (PGRA) system has been developed and is operated for BNCT purposes. Some human blood samples were analyzed and compared with classical ICP method. During the process of licensing the experience was obtained, some notes are discussed in the paper. The first results were received for the study of biological effect of the LVR source for small animal model. (author)

  19. BNCT for malignant brain tumors in children

    International Nuclear Information System (INIS)

    Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, Hiroaki

    2006-01-01

    BSH-based intra-operative BNCT as an initial treatment underwent in 4 children with malignant brain tumors since 1998. There were 2 glioblastomas, one primitive neuroectodermal tumor (PNET) and one anaplastic ependymoma patient. They included two children under 3-year-old. All GBM patients were died of CSF dissemination without tumor regrowth in the primary site. Another PNET and anaplastic ependymoma patients are still alive without tumor recurrence. We can consider BNCT is optimal treatment modality for malignant brain tumor in children. (author)

  20. Beta Beams: an accelerator based facility to explore Neutrino oscillation physics

    CERN Document Server

    Wildner, E; Hansen, C; De Melo Mendonca, T; Stora, T; Payet, J; Chance, A; Zorin, V; Izotov, I; Rasin, S; Sidorov, A; Skalyga, V; De Angelis, G; Prete, G; Cinausero, M; Kravchuk, VL; Gramegna, F; Marchi, T; Collazuol, G; De Rosa, G; Delbar, T; Loiselet, M; Keutgen, T; Mitrofanov, S; Lamy, T; Latrasse, L; Marie-Jeanne, M; Sortais, P; Thuillier, T; Debray, F; Trophime, C; Hass, M; Hirsh, T; Berkovits, D; Stahl, A

    2011-01-01

    The discovery that the neutrino changes flavor as it travels through space has implications for the Standard Model of particle physics (SM)[1]. To know the contribution of neutrinos to the SM, needs precise measurements of the parameters governing the neutrino oscillations. This will require a high intensity beam-based neutrino oscillation facility. The EURONu Design Study will review three currently accepted methods of realizing this facility (the so-called Super-Beams, Beta Beams and Neutrino Factories) and perform a cost assessment that, coupled with the physics performance, will give means to the European research authorities to make a decision on the layout and construction of the future European neutrino oscillation facility. ”Beta Beams” produce collimated pure electron neutrino and antineutrino beams by accelerating beta active ions to high energies and letting them decay in a race-track shaped storage ring. EURONu Beta Beams are based on CERNs infrastructure and the fact that some of the already ...

  1. High-power liquid-lithium target prototype for accelerator-based boron neutron capture therapy.

    Science.gov (United States)

    Halfon, S; Paul, M; Arenshtam, A; Berkovits, D; Bisyakoev, M; Eliyahu, I; Feinberg, G; Hazenshprung, N; Kijel, D; Nagler, A; Silverman, I

    2011-12-01

    A prototype of a compact Liquid-Lithium Target (LiLiT), which will possibly constitute an accelerator-based intense neutron source for Boron Neutron Capture Therapy (BNCT) in hospitals, was built. The LiLiT setup is presently being commissioned at Soreq Nuclear Research Center (SNRC). The liquid-lithium target will produce neutrons through the (7)Li(p,n)(7)Be reaction and it will overcome the major problem of removing the thermal power generated using a high-intensity proton beam (>10 kW), necessary for sufficient neutron flux. In off-line circulation tests, the liquid-lithium loop generated a stable lithium jet at high velocity, on a concave supporting wall; the concept will first be tested using a high-power electron beam impinging on the lithium jet. High intensity proton beam irradiation (1.91-2.5 MeV, 2-4 mA) will take place at Soreq Applied Research Accelerator Facility (SARAF) superconducting linear accelerator currently in construction at SNRC. Radiological risks due to the (7)Be produced in the reaction were studied and will be handled through a proper design, including a cold trap and appropriate shielding. A moderator/reflector assembly is planned according to a Monte Carlo simulation, to create a neutron spectrum and intensity maximally effective to the treatment and to reduce prompt gamma radiation dose risks. Copyright © 2011 Elsevier Ltd. All rights reserved.

  2. Protocols for BNCT of glioblastoma multiforme at Brookhaven: Practical considerations

    Energy Technology Data Exchange (ETDEWEB)

    Chanana, A.D.; Coderre, J.A.; Joel, D.D.; Slatkin, D.N.

    1996-12-31

    In this report we discuss some issues considered in selecting initial protocols for boron neutron capture therapy (BNCT) of human glioblastoma multiforme. First the tolerance of normal tissues, especially the brain, to the radiation field. Radiation doses limits were based on results with human and animal exposures. Estimates of tumor control doses were based on the results of single-fraction photon therapy and single fraction BNCT both in humans and experimental animals. Of the two boron compounds (BSH and BPA), BPA was chosen since a FDA-sanctioned protocol for distribution in humans was in effect at the time the first BNCT protocols were written and therapy studies in experimental animals had shown it to be more effective than BSH.

  3. The Radiological Research Accelerator Facility

    International Nuclear Information System (INIS)

    Hall, E.J.; Marino, S.A.

    1993-05-01

    The Radiological Research Accelerator Facility (RARAF) is based on a 4-MV Van de Graaff accelerator, which is used to generate a variety of well-characterized radiation beams for research in radiobiology, radiological physics, and radiation chemistry. It is part of the Center for Radiological Research (CRR) - formerly the Radiological Research Laboratory of Columbia University, and its operation is supported as a National Facility by the US Department of Energy (DOE). As such, RARAF is available to all potential users on an equal basis and scientists outside the CRR are encouraged to submit proposals for experiments at RARAF. The operation of the Van de Graaff is supported by the DOE, but the research projects themselves must be supported separately. This report provides a listing and brief description of experiments performed at RARAF during the May 1, 1992 through April 30, 1993

  4. A conceptual design of neutron tumor therapy reactor facility with a YAYOI based fast neutron source reactor

    International Nuclear Information System (INIS)

    Wakabayashi, Hiroaki; An, Shigehiro.

    1983-01-01

    Fast neutron is known as one of useful radiations for radiation therapy of tumors. Boron neutron capture therapy (BNCT) of tumors which makes use of 10 B(n, α) 7 Li reaction of 10 B compounds selectively attached to tumor cells with thermal and intermediate neutrons is another way of neutron based radiation therapy which is, above all, attractive enough to kill tumor cells selectively sparing normal tissue. In Japan, BNCT has already been applied and leaned to be effective. After more than a decade operational experiences and the specific experiments designed for therapeutical purposes, in this paper, a conceptual design of a special neutron therapy reactor facility based on YAYOI - fast neutron source reactor of Nuclear Engineering Research Laboratory, Faculty of Engineering, the University of Tokyo - modified to provide an upward beam of fast and intermediate neutrons is presented. Emphasis is placed on the in-house nature of facility and on the coordinating capability of biological and physical researches as well as maintenances of the facility. (author)

  5. Radiation transport calculation methods in BNCT

    International Nuclear Information System (INIS)

    Koivunoro, H.; Seppaelae, T.; Savolainen, S.

    2000-01-01

    Boron neutron capture therapy (BNCT) is used as a radiotherapy for malignant brain tumours. Radiation dose distribution is necessary to determine individually for each patient. Radiation transport and dose distribution calculations in BNCT are more complicated than in conventional radiotherapy. Total dose in BNCT consists of several different dose components. The most important dose component for tumour control is therapeutic boron dose D B . The other dose components are gamma dose D g , incident fast neutron dose D f ast n and nitrogen dose D N . Total dose is a weighted sum of the dose components. Calculation of neutron and photon flux is a complex problem and requires numerical methods, i.e. deterministic or stochastic simulation methods. Deterministic methods are based on the numerical solution of Boltzmann transport equation. Such are discrete ordinates (SN) and spherical harmonics (PN) methods. The stochastic simulation method for calculation of radiation transport is known as Monte Carlo method. In the deterministic methods the spatial geometry is partitioned into mesh elements. In SN method angular integrals of the transport equation are replaced with weighted sums over a set of discrete angular directions. Flux is calculated iteratively for all these mesh elements and for each discrete direction. Discrete ordinates transport codes used in the dosimetric calculations are ANISN, DORT and TORT. In PN method a Legendre expansion for angular flux is used instead of discrete direction fluxes, land the angular dependency comes a property of vector function space itself. Thus, only spatial iterations are required for resulting equations. A novel radiation transport code based on PN method and tree-multigrid technique (TMG) has been developed at VTT (Technical Research Centre of Finland). Monte Carlo method solves the radiation transport by randomly selecting neutrons and photons from a prespecified boundary source and following the histories of selected particles

  6. INEL BNCT Program: Volume 5, No. 9. Bulletin, September 1991

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. [ed.

    1991-12-31

    This Bulletin presents a summary of accomplishments and highlights of the Idaho National Engineering Laboratory`s (INEL) Boron Neutron Capture Therapy (BNCT) Program for September 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  7. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: An experimental study that supports a potential new application of BNCT

    International Nuclear Information System (INIS)

    Monti Hughes, A.; Heber, E.M.; Pozzi, E.; Nigg, D.W.; Calzetta, O.; Blaumann, H.; Longhino, J.; Nievas, S.I.; Aromando, R.F.; Itoiz, M.E.; Trivillin, V.A.; Schwint, A.E.

    2009-01-01

    We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na 2 10 B 10 H 10 ) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences.

  8. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: An experimental study that supports a potential new application of BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Monti Hughes, A.; Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Pozzi, E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Department of Research and Production Reactors, Ezeiza Atomic Center, CNEA, Buenos Aires (Argentina); Nigg, D.W. [Idaho National Laboratory, Idaho Falls, Idaho (United States); Calzetta, O.; Blaumann, H.; Longhino, J. [Department of Nuclear Engineering, Bariloche Atomic Center, CNEA, Rio Negro (Argentina); Nievas, S.I. [Department of Chemistry, CNEA, Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Trivillin, V.A. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina)], E-mail: schwint@cnea.gov.ar

    2009-07-15

    We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na{sub 2}{sup 10}B{sub 10}H{sub 10}) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences.

  9. A beamline systems model for Accelerator-Driven Transmutation Technology (ADTT) facilities

    Energy Technology Data Exchange (ETDEWEB)

    Todd, A.M.M.; Paulson, C.C.; Peacock, M.A. [Grumman Research and Development Center, Princeton, NJ (United States)] [and others

    1995-10-01

    A beamline systems code, that is being developed for Accelerator-Driven Transmutation Technology (ADTT) facility trade studies, is described. The overall program is a joint Grumman, G.H. Gillespie Associates (GHGA) and Los Alamos National Laboratory effort. The GHGA Accelerator Systems Model (ASM) has been adopted as the framework on which this effort is based. Relevant accelerator and beam transport models from earlier Grumman systems codes are being adapted to this framework. Preliminary physics and engineering models for each ADTT beamline component have been constructed. Examples noted include a Bridge Coupled Drift Tube Linac (BCDTL) and the accelerator thermal system. A decision has been made to confine the ASM framework principally to beamline modeling, while detailed target/blanket, balance-of-plant and facility costing analysis will be performed externally. An interfacing external balance-of-plant and facility costing model, which will permit the performance of iterative facility trade studies, is under separate development. An ABC (Accelerator Based Conversion) example is used to highlight the present models and capabilities.

  10. A beamline systems model for Accelerator-Driven Transmutation Technology (ADTT) facilities

    International Nuclear Information System (INIS)

    Todd, Alan M. M.; Paulson, C. C.; Peacock, M. A.; Reusch, M. F.

    1995-01-01

    A beamline systems code, that is being developed for Accelerator-Driven Transmutation Technology (ADTT) facility trade studies, is described. The overall program is a joint Grumman, G. H. Gillespie Associates (GHGA) and Los Alamos National Laboratory effort. The GHGA Accelerator Systems Model (ASM) has been adopted as the framework on which this effort is based. Relevant accelerator and beam transport models from earlier Grumman systems codes are being adapted to this framework. Preliminary physics and engineering models for each ADTT beamline component have been constructed. Examples noted include a Bridge Coupled Drift Tube Linac (BCDTL) and the accelerator thermal system. A decision has been made to confine the ASM framework principally to beamline modeling, while detailed target/blanket, balance-of-plant and facility costing analysis will be performed externally. An interfacing external balance-of-plant and facility costing model, which will permit the performance of iterative facility trade studies, is under separate development. An ABC (Accelerator Based Conversion) example is used to highlight the present models and capabilities

  11. Design and simulation of an optimized e-linac based neutron source for BNCT research

    International Nuclear Information System (INIS)

    Durisi, E.; Alikaniotis, K.; Borla, O.; Bragato, F.; Costa, M.; Giannini, G.; Monti, V.; Visca, L.; Vivaldo, G.; Zanini, A.

    2015-01-01

    The paper is focused on the study of a novel photo-neutron source for BNCT preclinical research based on medical electron Linacs. Previous studies by the authors already demonstrated the possibility to obtain a mixed thermal and epithermal neutron flux of the order of 10"7 cm"−"2 s"−"1. This paper investigates possible Linac’s modifications and a new photo-converter design to rise the neutron flux above 5 10"7 cm"−"2 s"−"1, also reducing the gamma contamination. - Highlights: • Proposal of a mixed thermal and epithermal (named hyperthermal) neutron source based on medical high energy electron Linac. • Photo-neutron production via Giant Dipole Resonance on high Z materials. • MCNP4B-GN simulations to design the photo-converter geometry maximizing the hyperthermal neutron flux and minimizing the fast neutron and gamma contaminations. Hyperthermal neutron field suitable for BNCT preclinical research.

  12. Accelerator-based research facility of UGC as an inter-university centre

    International Nuclear Information System (INIS)

    Mehta, G.K.

    1994-01-01

    A 15-UD Pelletron has been operating as a users facility from July 1991. It is being utilised by a large number of universities and other institutions for research in basic nuclear physics, materials science, atomic physics, radiobiology and radiation chemistry. There is an on-going programme for augmenting the accelerator facilities by injecting Pelletron beams into superconducting linear accelerator modules. Superconducting niobium resonators are being developed at Argonne National Laboratory as a joint collaborative effort. All other things such as cryostat, rf-instrumentation, cryogene distribution system, computer control etc. are being done indigenously. Research possibilities are described. (author). 6 refs., 4 figs

  13. Beam based alignment at the KEK accelerator test facility

    International Nuclear Information System (INIS)

    Ross, M.; Nelson, J.; Woodley, M.; Wolski, A.

    2002-01-01

    The KEK Accelerator Test Facility (ATF) damping ring is a prototype low emittance source for the NLC/JLC linear collider. To achieve the goal normalized vertical emittance gey = 20 nm-rad, magnet placement accuracy better than 30 mm must be achieved. Accurate beam-based alignment (BBA) is required. The ATF arc optics uses a FOBO cell with two horizontally focusing quadrupoles, two sextupoles and a horizontally defocusing gradient dipole, all of which must be aligned with BBA. BBA at ATF uses the quadrupole and sextupole trim windings to find the trajectory through the center of each magnet. The results can be interpreted to assess the accuracy of the mechanical alignment and the beam position monitor offsets

  14. Clinical results of BNCT for malignant meningiomas

    International Nuclear Information System (INIS)

    Miyatake, Shin-ichi; Tamura, Yoji; Kawabata, Shinji

    2006-01-01

    Malignant meningiomas is difficult pathology to be controlled as well as GBM. Since June of 2005, we applied BNCT for 7 cases of malignancy related meningiomas with 13 times neutron irradiation. Five were anaplastic, one was atypical meningiomas and one was sarcoma transformed from meningioma with cervical lymph node metastasis. All cases were introduced after repetitive surgeries and XRT or SRS. Follow-up images were available for 6 cases with observation duration between 2 to 9 months. We applied F-BPA-PET before BNCT in 6 out of 7 cases. One case was received methionine-PET. Five out of 6 cases who received BPA-PET study showed good BPA uptake more than 3 of T/N ratio. One atypical meningiomas cases showed 2.0 of T/N ratio. Original tumor sizes were between 9.2 to 92.7 ml. Two out of 5 anaplastic meningiomas showed CR and all six cases showed radiographic improvements. Clinical symptoms before BNCT such as hemiparesis and facial pain were improved after BNCT, except one case. An huge atypical meningiomas which arisen from tentorium and extended bilateral occipital lobes and brain stem, visual problems were worsened after repetitive BNCT with increase of peritumoral edema. Malignant meningiomas are seemed to be good candidate for BNCT. (author)

  15. Radiological Research Accelerator Facility. Progress report, April 1-November 30, 1986

    International Nuclear Information System (INIS)

    1986-07-01

    The Radiological Research Accelerator Facility (RARAF) is based on a 4-MV Van de Graaff accelerator, which is used to generate a variety of well-characterized radiation beams for research in radiobiology and radiological physics. The experiments run at RARAF are described, and center on neutron dosimetry, mutagenesis, and neutron-induced oncogenic transformations as well as survival of exposed cells. Accelerator utilization, operation, and development of facilities are reviewed

  16. High-power electron beam tests of a liquid-lithium target and characterization study of (7)Li(p,n) near-threshold neutrons for accelerator-based boron neutron capture therapy.

    Science.gov (United States)

    Halfon, S; Paul, M; Arenshtam, A; Berkovits, D; Cohen, D; Eliyahu, I; Kijel, D; Mardor, I; Silverman, I

    2014-06-01

    A compact Liquid-Lithium Target (LiLiT) was built and tested with a high-power electron gun at Soreq Nuclear Research Center (SNRC). The target is intended to demonstrate liquid-lithium target capabilities to constitute an accelerator-based intense neutron source for Boron Neutron Capture Therapy (BNCT) in hospitals. The lithium target will produce neutrons through the (7)Li(p,n)(7)Be reaction and it will overcome the major problem of removing the thermal power >5kW generated by high-intensity proton beams, necessary for sufficient therapeutic neutron flux. In preliminary experiments liquid lithium was flown through the target loop and generated a stable jet on the concave supporting wall. Electron beam irradiation demonstrated that the liquid-lithium target can dissipate electron power densities of more than 4kW/cm(2) and volumetric power density around 2MW/cm(3) at a lithium flow of ~4m/s, while maintaining stable temperature and vacuum conditions. These power densities correspond to a narrow (σ=~2mm) 1.91MeV, 3mA proton beam. A high-intensity proton beam irradiation (1.91-2.5MeV, 2mA) is being commissioned at the SARAF (Soreq Applied Research Accelerator Facility) superconducting linear accelerator. In order to determine the conditions of LiLiT proton irradiation for BNCT and to tailor the neutron energy spectrum, a characterization of near threshold (~1.91MeV) (7)Li(p,n) neutrons is in progress based on Monte-Carlo (MCNP and Geant4) simulation and on low-intensity experiments with solid LiF targets. In-phantom dosimetry measurements are performed using special designed dosimeters based on CR-39 track detectors. © 2013 Elsevier Ltd. All rights reserved.

  17. The BNL Accelerator Test Facility control system

    International Nuclear Information System (INIS)

    Malone, R.; Bottke, I.; Fernow, R.; Ben-Zvi, I.

    1993-01-01

    Described is the VAX/CAMAC-based control system for Brookhaven National Laboratory's Accelerator Test Facility, a laser/linac research complex. Details of hardware and software configurations are presented along with experiences of using Vsystem, a commercial control system package

  18. First clinical results from the EORTC phase I Trial ''postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility''

    International Nuclear Information System (INIS)

    Sauerwein, W.; Hideghety, K.; Rassow, J.; Devries, M.J.; Goetz, C.; Paquis, P.; Grochulla, F.; Wolbers, J.G.; Haselsberger, K.; Turowski, B.; Moss, R.L.; Stecher-Rasmussen, F.; Touw, D.; Wiestler, O.D.; Frankhauser, H.; Gabel, D.

    2001-01-01

    Based on the pre-clinical work of the European Collaboration on Boron Neutron Capture Therapy a study protocol was prepared in 1995 to initiate Boron Neutron Capture Therapy (BNCT) in patients at the High Flux Reactor (HFR) in Petten. Bio-distribution and pharmacokinetics data of the boron drug Na 2 B 12 H 11 SH (BSH) as well as the radiobiological effects of BNCT with BSH in healthy brain tissue of dogs were considered in designing the strategy for this clinical Phase I trial. The primary goal of the radiation dose escalation study is the investigation of possible adverse events due to BNCT; i.e. to establish the dose limiting toxicity and the maximal tolerated dose. The treatment is delivered in 4 fractions at a defined average boron concentration in blood. Cohorts of 10 patients are treated per dose group. The starting dose was set at 80% of the dose at which neurological symptoms occurred in preclinical dog experiments following a single fraction. After an observation period of at least 6 months, the dose is increased by 10% for the next cohort if less then three severe side effects related to the treatment occurred. The results of the first cohort are presented here. The evaluated dose level can be considered safe. (author)

  19. First clinical results from the EORTC phase I Trial ''postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility''

    Energy Technology Data Exchange (ETDEWEB)

    Sauerwein, W; Hideghety, K; Rassow, J [Department of Radiotherapy, University of Essen (Germany); Devries, M J [NDDO Oncology, Amsterdam (Netherlands); Goetz, C [Neurochirurgische Klinik, Klinikum Grosshadern Muenchen, Munich (Germany); Paquis, P [Dept. de Neurochirurgie, Hopital Pasteur, Nice (France); Grochulla, F [Klinik fuer Neurochirurgie, Zentralkrankenhaus Bremen (Germany); Wolbers, J G [Department of Neurosurgery, University Hospital ' ' Vrije Universiteit' ' , Amsterdam (Netherlands); Haselsberger, K [Klinik fuer Neurochirurgie, Karl-Franzens-Universitaet, Graz (Austria); Turowski, B [Institut fuer Neuroradiologie, Johann-Wolfgang-von-Goethe-Universitaet, Frankfurt (Germany); Moss, R L [HFR Unit, Joint Research Centre, European Commission, Petten (Netherlands); Stecher-Rasmussen, F [Nuclear Research and Consultancy Group NRG, Petten (Netherlands); Touw, D [Pharmacy, University/Academic Hospital ' ' Vrije Universiteit' ' , Amsterdam (Netherlands); Wiestler, O D [Department of Neuropathology, German Brain Tumour Reference Centre, Universitaetsklinikum Bonn (Germany); Frankhauser, H [Service de Neurochirurgie CHUV, Lausanne (Switzerland); Gabel, D [Chemistry Department, University of Bremen (Germany)

    2001-05-01

    Based on the pre-clinical work of the European Collaboration on Boron Neutron Capture Therapy a study protocol was prepared in 1995 to initiate Boron Neutron Capture Therapy (BNCT) in patients at the High Flux Reactor (HFR) in Petten. Bio-distribution and pharmacokinetics data of the boron drug Na{sub 2}B{sub 12}H{sub 11}SH (BSH) as well as the radiobiological effects of BNCT with BSH in healthy brain tissue of dogs were considered in designing the strategy for this clinical Phase I trial. The primary goal of the radiation dose escalation study is the investigation of possible adverse events due to BNCT; i.e. to establish the dose limiting toxicity and the maximal tolerated dose. The treatment is delivered in 4 fractions at a defined average boron concentration in blood. Cohorts of 10 patients are treated per dose group. The starting dose was set at 80% of the dose at which neurological symptoms occurred in preclinical dog experiments following a single fraction. After an observation period of at least 6 months, the dose is increased by 10% for the next cohort if less then three severe side effects related to the treatment occurred. The results of the first cohort are presented here. The evaluated dose level can be considered safe. (author)

  20. Liquid Li based neutron source for BNCT and science application.

    Science.gov (United States)

    Horiike, H; Murata, I; Iida, T; Yoshihashi, S; Hoashi, E; Kato, I; Hashimoto, N; Kuri, S; Oshiro, S

    2015-12-01

    Liquid lithium (Li) is a candidate material for a target of intense neutron source, heat transfer medium in space engines and charges stripper. For a medical application of BNCT, epithermal neutrons with least energetic neutrons and γ-ray are required so as to avoid unnecessary doses to a patient. This is enabled by lithium target irradiated by protons at 2.5 MeV range, with utilizing the threshold reaction of (7)Li(p,n)(7)Be at 1.88 MeV. In the system, protons at 2.5 MeV penetrate into Li layer by 0.25 mm with dissipating heat load near the surface. To handle it, thin film flow of high velocity is important for stable operation. For the proton accelerator, electrostatic type of the Schnkel or the tandem is planned to be employed. Neutrons generated at 0.6 MeV are gently moderated to epithermal energy while suppressing accompanying γ-ray minimum by the dedicated moderator assembly. Copyright © 2015 Elsevier Ltd. All rights reserved.

  1. Alpha-amino alcohol of para-boronophenylalanine, BPAol, as a potential boron carrier for BNCT

    International Nuclear Information System (INIS)

    Takagaki, M.; Ono, K.; Masunaga, S.; Kinashi, Y.

    2000-01-01

    α amino alcohol of boronophenylalanine BPAol in which -COOH group is replaced with hydrophilic group of -OH of p-boronophenylalanine (BPA) has been synthesized and its BNCT effect on experimental tumor models have been investigated. Tumor cell killing effect of BPAol on C6 gliosarcoma cells was very high 4.4 times as that of BPA, since it was actively accumulated into tumor cells in 4-5 times as that of BPA. Carboxylic group of BPA might not play as an essential role in uptake of BPA into tumor cells. BPAol-based BNCT strongly inhibited the tumor growth of Green's melanotic melanoma hamsters even under therapeutic dose of BPA-based BNCT. These preliminary findings strongly warrant further extensive pre-clinical study for BPAol as a boron carrier for BNCT. (author)

  2. The Radiological Research Accelerator Facility:

    International Nuclear Information System (INIS)

    Hall, E.J.; Goldhagen, P.

    1988-07-01

    The Radiological Research Accelerator Facility (RARAF) is based on a 4-MV Van de Graaff accelerator, which is used to generated a variety of well-characterized radiation beams for research in radiobiology, radiological physics, and radiation chemistry. It is part of the Radiological Research Laboratory (RRL) of Columbia University, and its operation is supported as a National Facility by the U.S. Department of Energy. As such, RARAF is available to all potential users on an equal basis, and scientists outside the RRL are encouraged to submit proposals for experiments at RARAF. Facilities and services are provided to users, but the research projects themselves must be supported separately. RARAF was located at BNL from 1967 until 1980, when it was dismantled and moved to the Nevis Laboratories of Columbia University, where it was then reassembled and put back into operation. Data obtained from experiment using RARAF have been of pragmatic value to radiation protection and to neutron therapy. At a more fundamental level, the research at RARAF has provided insight into the biological action of radiation and especially its relation to energy distribution in the cell. High-LET radiations are an agent of special importance because they can cause measurable cellular effects by single particles, eliminating some of the complexities of multievent action and more clearly disclosing basic features. This applies particularly to radiation carcinogenesis. Facilities are available at RARAF for exposing objects to different radiations having a wide range of linear energy transfers (LETs)

  3. An update on the clinical trial of BNCT at the BMRR

    International Nuclear Information System (INIS)

    Ma, R.; Capala, J.; Chanana, A.D.; Coderre, J.A.; Diaz, A.Z.

    1999-01-01

    Boron neutron capture therapy (BNCT) was proposed more than six decades ago. It is a binary treatment modality that requires selective delivery of a 10 B-labeled compound to a tumor and slow neutron irradiation of the tumor-bearing tissues. In order to improve the penetration of the neutron beam, an epithermal neutron beam was developed at the Brookhaven Medical Research Reactor (BMRR). This epithermal neutron beam can deliver relatively high thermal neutron fluence at depth without severe skin damage. Boronophenylalanine-fructose (BPA-F), a nontoxic boron carrier, was found to preferentially accumulate in tumor cells following intravenous infusion in patients with GBM. In preclinical BNCT studies in rats bearing 9L gliosarcoma, BPA-mediated BNCT was shown to be more efficacious than photon irradiation. In 1994, improvements in the neutron beam and in the understanding of the radiobiology of BPA-mediated BNCT led to the initiation of BNCT trials for human GBM at BMRR using BPA-F and epithermal neutrons. The primary objective of the phase I/II clinical trial of BPA-mediated BNCT at BMRR is to evaluate the safety of the BPA-F-mediated BNCT using epithermal neutrons in patients with GBM at a series of escalating BNCT doses. An incidental objective is to evaluate the therapeutic effectiveness of BNCT at each dose level. For each dose escalation group, the average brain dose (ABD) is escalated, as well as the minimum tumor dose. In summary, the BNCT procedure employed in the phase I/II clinical trial of BPA-F-mediated BNCT for GBM at BNL was found to be safe in all patients. The palliation afforded by a single session of BNCT compares favorably with palliation provided by fractionated photon therapy and adjuvant chemotherapy. If no evidence of radiation-induced brain toxicity is found in the current protocol, BNCT radiation dose will be further escalated

  4. Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats

    International Nuclear Information System (INIS)

    Trivillin, V.A.; Garabalino, M.A.; Colombo, L.L.

    2013-01-01

    Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats Introduction: Boron Neutron Capture Therapy (BNCT) is based on selective tumor uptake of boron compounds, followed by neutron irradiation. BNCT was proposed for the treatment of unresectable, diffuse lung metastases. The aim of the present study was to perform BNCT studies in an experimental model of lung metastases. Materials and Methods: 3 x 106/0.5 ml colon carcinoma cells (DHD/K12/TRb) were injected iv in syngeneic BDIX rats. Three weeks post-inoculation, rats with diffuse lung metastases were used for in vivo BNCT studies in the RA-3 Nuclear Reactor. Based on previous biodistribution studies and computational dosimetry with Monte Carlo simulation, 2 doses were prescribed, i.e. 4 Gy and 8 Gy minimum absorbed dose to tumor. The animals were assigned to 5 experimental groups (n= 4 to 8) at each dose level: T0 (euthanized pre-treatment), BPA-BNCT, Comb-BNCT (BPA+GB-10), Beam only (background dose) and Sham (same manipulation, no treatment). Boron concentration was measured in a blood sample taken pre-irradiation to verify that the value was in the range established in previous biodistribution studies. The animals were followed clinically for 2 weeks after neutron irradiation and then euthanized to assess the response of tumor and normal lung, macroscopically and histologically. To date we have evaluated the end-point weight of lung (normal lung + metastases) and % lung weight/body weight as an indicator of tumor growth. Results: The statistical analysis (ANOVA) of % lung weight/body weight showed statistically significant differences (p<0.05) between groups T0 (0.79 ± 0.38) and Sham (1.87 ± 0.91). No statistically significant differences were observed between the Beam only groups (at both dose levels) and Sham. Similar and statistically significant tumor control was induced in the groups BPA-BNCT Low dose (LD) (0.56 ± 0.11), BPA-BNCT High dose (HD) (0.80 ± 0.16), Comb-BNCT

  5. Berkeley Lab Laser Accelerator (BELLA) facility

    Data.gov (United States)

    Federal Laboratory Consortium — The Berkeley Lab Laser Accelerator (BELLA) facility (formerly LOASIS) develops advanced accelerators and radiation sources. High gradient (1-100 GV/m) laser-plasma...

  6. Implementation of BNCT treatment planning procedures

    International Nuclear Information System (INIS)

    Capala, J.; Ma, R.; Diaz, A.Z.; Chanana, A.D.; Coderre, J.A.

    2001-01-01

    Estimation of radiation doses delivered during boron neutron capture therapy (BNCT) requires combining data on spatial distribution of both the thermal neutron fluence and the 10 B concentration, as well as the relative biological effectiveness of various radiation dose components in the tumor and normal tissues. Using the treatment planning system created at Idaho National Engineering and Environmental Laboratory and the procedures we had developed for clinical trials, we were able to optimize the treatment position, safely deliver the prescribed BNCT doses, and carry out retrospective analyses and reviews. In this paper we describe the BNCT treatment planning process and its implementation in the ongoing dose escalation trials at Brookhaven National Laboratory. (author)

  7. MCNP study for epithermal neutron irradiation of an isolated liver at the Finnish BNCT facility.

    Science.gov (United States)

    Kotiluoto, P; Auterinen, I

    2004-11-01

    A successful boron neutron capture treatment (BNCT) of a patient with multiple liver metastases has been first given in Italy, by placing the removed organ into the thermal neutron column of the Triga research reactor of the University of Pavia. In Finland, FiR 1 Triga reactor with an epithermal neutron beam well suited for BNCT has been extensively used to irradiate patients with brain tumors such as glioblastoma and recently also head and neck tumors. In this work we have studied by MCNP Monte Carlo simulations, whether it would be beneficial to treat an isolated liver with epithermal neutrons instead of thermal ones. The results show, that the epithermal field penetrates deeper into the liver and creates a build-up distribution of the boron dose. Our results strongly encourage further studying of irradiation arrangement of an isolated liver with epithermal neutron fields.

  8. Improvement of neutron irradiation field of research reactors for BNCT

    International Nuclear Information System (INIS)

    Aizawa, Otohiko

    1992-01-01

    The modification of research reactors for an improvement of the irradiation field for BNCT has been investigated in comparison with the field characteristics of the 'old' configuration at the Musashi reactor. The new point of this study is that the evaluation has been done by using an arrangement including both the facility structure and a whole-body phantom, and also by considering the whole-body absorbed dose. (author)

  9. Boron Neutron Capture Therapty (BNCT) in an Oral Precancer Model: Therapeutic Benefits and Potential Toxicity of a Double Application of BNCT with a Six-Week Interval

    Energy Technology Data Exchange (ETDEWEB)

    Andrea Monti Hughes; Emiliano C.C. Pozzi; Elisa M. Heber; Silvia Thorp; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; Ana J. Molinari; Marcela A. Garabalino; David W. Nigg; Veronica A. Trivillin; Amanda E. Schwint

    2011-11-01

    Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA [(GB-10 + BPA)-BNCT] or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB- 10 + BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10 + BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.

  10. BRAHMMA - accelerator driven subcritical facility

    International Nuclear Information System (INIS)

    Roy, Tushar; Shukla, Shefali; Shukla, M.; Ray, N.K.; Kashyap, Y.S.; Patel, T.; Gadkari, S.C.

    2017-01-01

    Accelerator Driven Subcritical systems are being studied worldwide for their potential in burning minor actinides and reducing long term radiotoxicity of spent nuclear fuels. In order to pursue the physics studies of Accelerator Driven Subcritical systems, a thermal subcritical assembly BRAHMMA (BeOReflectedAndHDPeModeratedMultiplying Assembly) has been developed at Purnima Labs, BARC. The facility consists of two major components: Subcritical core and Accelerator (DT/ DD Purnima Neutron Generator)

  11. Performance of the Argonne Wakefield Accelerator facility and initial experimental results

    International Nuclear Information System (INIS)

    Gai, W.; Conde, M.; Cox, G.; Konecny, R.; Power, J.; Schoessow, P.; Simpson, J.; Barov, N.

    1996-01-01

    The Argonne Wakefield Accelerator (AWA) facility has begun its experimental program. This unique facility is designed to address advanced acceleration research which requires very short, intense electron bunches. The facility incorporates two photo-cathode based electron sources. One produces up to 100 nC, multi-kiloamp 'drive' bunches which are used to excite wakefields in dielectric loaded structures and in plasma. The second source produces much lower intensity 'witness' pulses which are used to probe the fields produced by the drive. The drive and witness pulses can be precisely timed as well as laterally positioned with respect to each other. We discuss commissioning, initial experiments, and outline plans for a proposed 1 GeV demonstration accelerator. (author)

  12. Physics of epi-thermal boron neutron capture therapy (epi-thermal BNCT).

    Science.gov (United States)

    Seki, Ryoichi; Wakisaka, Yushi; Morimoto, Nami; Takashina, Masaaki; Koizumi, Masahiko; Toki, Hiroshi; Fukuda, Mitsuhiro

    2017-12-01

    The physics of epi-thermal neutrons in the human body is discussed in the effort to clarify the nature of the unique radiologic properties of boron neutron capture therapy (BNCT). This discussion leads to the computational method of Monte Carlo simulation in BNCT. The method is discussed through two examples based on model phantoms. The physics is kept at an introductory level in the discussion in this tutorial review.

  13. Shielding experiments for accelerator facilities

    Energy Technology Data Exchange (ETDEWEB)

    Nakashima, Hiroshi; Tanaka, Susumu; Sakamoto, Yukio [Japan Atomic Energy Research Inst., Tokai, Ibaraki (Japan). Tokai Research Establishment] [and others

    2000-06-01

    A series of shielding experiments was carried out by using AVF cyclotron accelerator of TIARA at JAERI in order to validate shielding design methods for accelerator facilities in intermediate energy region. In this paper neutron transmission experiment through thick shields and radiation streaming experiment through a labyrinth are reported. (author)

  14. Shielding experiments for accelerator facilities

    International Nuclear Information System (INIS)

    Nakashima, Hiroshi; Tanaka, Susumu; Sakamoto, Yukio

    2000-01-01

    A series of shielding experiments was carried out by using AVF cyclotron accelerator of TIARA at JAERI in order to validate shielding design methods for accelerator facilities in intermediate energy region. In this paper neutron transmission experiment through thick shields and radiation streaming experiment through a labyrinth are reported. (author)

  15. IFMIF [International Fusion Materials Irradiation Facility], an accelerator-based neutron source for fusion components irradiation testing: Materials testing capabilities

    International Nuclear Information System (INIS)

    Mann, F.M.

    1988-08-01

    The International Fusion Materials Irradiation Facility (IFMIF) is proposed as an advanced accelerator-based neutron source for high-flux irradiation testing of large-sized fusion reactor components. The facility would require only small extensions to existing accelerator and target technology originally developed for the Fusion Materials Irradiation Test (FMIT) facility. At the extended facility, neutrons would be produced by a 0.1-A beam of 35-MeV deuterons incident upon a liquid lithium target. The volume available for high-flux (>10/sup 15/ n/cm/sup 2/-s) testing in IFMITF would be over a liter, a factor of about three larger than in the FMIT facility. This is because the effective beam current of 35-MeV deuterons on target can be increased by a factor of ten to 1A or more. Such an increase can be accomplished by funneling beams of deuterium ions from the radio-frequency quadruple into a linear accelerator and by taking advantage of recent developments in accelerator technology. Multiple beams and large total current allow great variety in available testing. For example, multiple simultaneous experiments, and great flexibility in tailoring spatial distributions of flux and spectra can be achieved. 5 refs., 2 figs., 1 tab

  16. Qualitative safety analysis in accelerator based systems

    International Nuclear Information System (INIS)

    Sarkar, P.K.; Chowdhury, Lekha M.

    2006-01-01

    In recent developments connected to high energy and high current accelerators, the accelerator driven systems (ADS) and the Radioactive Ion Beam (RIB) facilities come in the forefront of application. For medical and industrial applications high current accelerators often need to be located in populated areas. These facilities pose significant radiological hazard during their operation and accidental situations. We have done a qualitative evaluation of radiological safety analysis using the probabilistic safety analysis (PSA) methods for accelerator-based systems. The major contribution to hazard comes from a target rupture scenario in both ADS and RIB facilities. Other significant contributors to hazard in the facilities are also discussed using fault tree and event tree methodologies. (author)

  17. Accelerator-driven subcritical facility:Conceptual design development

    Science.gov (United States)

    Gohar, Yousry; Bolshinsky, Igor; Naberezhnev, Dmitry; Duo, Jose; Belch, Henry; Bailey, James

    2006-06-01

    A conceptual design development of an accelerator-driven subcritical facility has been carried out in the preparation of a joint activity with Kharkov Institute of Physics and Technology of Ukraine. The main functions of the facility are the medical isotope production and the support of the Ukraine nuclear industry. An electron accelerator is considered to drive the subcritical assembly. The neutron source intensity and spectrum have been studied. The energy deposition, spatial neutron generation, neutron utilization fraction, and target dimensions have been quantified to define the main target performance parameters, and to select the target material and beam parameters. Different target conceptual designs have been developed based the engineering requirements including heat transfer, thermal hydraulics, structure, and material issues. The subcritical assembly is designed to obtain the highest possible neutron flux level with a Keff of 0.98. Different fuel materials, uranium enrichments, and reflector materials are considered in the design process. The possibility of using low enrichment uranium without penalizing the facility performance is carefully evaluated. The mechanical design of the facility has been developed to maximize its utility and minimize the time for replacing the target and the fuel assemblies. Safety, reliability, and environmental considerations are included in the facility conceptual design. The facility is configured to accommodate future design improvements, upgrades, and new missions. In addition, it has large design margins to accommodate different operating conditions and parameters. In this paper, the conceptual design and the design analyses of the facility will be presented.

  18. In vitro biological models in order to study BNCT

    International Nuclear Information System (INIS)

    Dagrosa, Maria A.; Kreimann, Erica L.; Schwint, Amanda E.; Juvenal, Guillermo J.; Pisarev, Mario A.; Farias, Silvia S.; Garavaglia, Ricardo N.; Batistoni, Daniel A.

    1999-01-01

    Undifferentiated thyroid carcinoma (UTC) lacks an effective treatment. Boron neutron capture therapy (BNCT) is based on the selective uptake of 10 B-boronated compounds by some tumours, followed by irradiation with an appropriate neutron beam. The radioactive boron originated ( 11 B) decays releasing 7 Li, gamma rays and alpha particles, and these latter will destroy the tumour. In order to explore the possibility of applying BNCT to UTC we have studied the biodistribution of BPA. In vitro studies: the uptake of p- 10 borophenylalanine (BPA) by the UTC cell line ARO, primary cultures of normal bovine thyroid cells (BT) and human follicular adenoma (FA) thyroid was studied. No difference in BPA uptake was observed between proliferating and quiescent ARO cells. The uptake by quiescent ARO, BT and FA showed that the ARO/BT and ARO/FA ratios were 4 and 5, respectively (p< 0.001). The present experimental results open the possibility of applying BNCT for the treatment of UTC. (author)

  19. A treatment planning comparison of BPA- or BSH-based BNCT of malignant gliomas

    International Nuclear Information System (INIS)

    Capala, J.; Coderre, J.A.; Chanana, A.D.

    1996-01-01

    Accurate delivery of the prescribed dose during clinical BNCT requires knowledge (or reasonably valid assumptions) about the boron concentrations in tumor and normal tissues. For conversion of physical dose (Gy) into photon-equivalent dose (Gy-Eq), relative biological effectiveness (RBE) and/or compound-adjusted biological effectiveness (CBE) factors are required for each tissue. The BNCT treatment planning software requires input of the following values: the boron concentration in blood and tumor, RBEs in brain, tumor and skin for the high-LET beam components, the CBE factors for brain, tumor, and skin, and the RBE for the gamma component

  20. Might iodomethyl-α-tyrosine be a surrogate for BPA in BNCT?

    International Nuclear Information System (INIS)

    Miura, Michiko; Micca, P.L.; Nawrocky, M.M.; Slatkin, D.N.

    1996-01-01

    A single-photon emission computed tomography [SPECT] imaging agent that is an analogue of a boron carrier for boron neutron-capture therapy [BNCT] of cerebral gliomas would be useful for assessing the kinetics of boron uptake in tumors and in the surrounding brain tissues noninvasively. BNCT is based on the interaction of thermalized neutrons with 10 B nuclei in the targeted tumor. For BNCT of brain tumors, it is crucial that 10 B concentrations in radiosensitive regions of the brain be minimal since malignant cells and vital brain tissues are often inter-mingled at the margins of the tumor. Currently, boronophenylalanine [BPA]-mediated BNCT is undergoing preliminary clinical study for postoperative radiotherapy of glioblastorna multiforme at Brookhaven National Laboratory. Investigators in Japan are developing 18 F-fluoroboronophenylaianine [FBPA] as a positron 18 F (T 1/2 = 110 min), which is usually emission tomography [PET] surrogate for BPA. generated at a cyclotron dedicated to PET, is generally a minimally perturbing substitute for the 2-H on the aromatic ring because of its small size and the strong covalent bond it forms with carbon. However, SPECT has potential advantages over PET: (1) SPECT is clinically more widely available at lower cost; (2) most radioisotopes for the synthesis of SPECT agents can be purchased; (3) SPECT is less difficult to implement. It is thought that the quality of images derived from the two techniques would each be sufficiently informative for BNCT treatment planning purposes, provided that the SPECT and PET agents being considered were both pharmacokinetic surrogates for BPA. This study evaluated the use of 123 I alpha methyltyrosine as a surrogate for BPA in BNCT

  1. Might iodomethyl-{alpha}-tyrosine be a surrogate for BPA in BNCT?

    Energy Technology Data Exchange (ETDEWEB)

    Miura, Michiko; Micca, P.L.; Nawrocky, M.M.; Slatkin, D.N.

    1996-12-31

    A single-photon emission computed tomography [SPECT] imaging agent that is an analogue of a boron carrier for boron neutron-capture therapy [BNCT] of cerebral gliomas would be useful for assessing the kinetics of boron uptake in tumors and in the surrounding brain tissues noninvasively. BNCT is based on the interaction of thermalized neutrons with {sup 10}B nuclei in the targeted tumor. For BNCT of brain tumors, it is crucial that {sup 10}B concentrations in radiosensitive regions of the brain be minimal since malignant cells and vital brain tissues are often inter-mingled at the margins of the tumor. Currently, boronophenylalanine [BPA]-mediated BNCT is undergoing preliminary clinical study for postoperative radiotherapy of glioblastorna multiforme at Brookhaven National Laboratory. Investigators in Japan are developing {sup 18}F-fluoroboronophenylaianine [FBPA] as a positron {sup 18}F (T{sub 1/2} = 110 min), which is usually emission tomography [PET] surrogate for BPA. generated at a cyclotron dedicated to PET, is generally a minimally perturbing substitute for the 2-H on the aromatic ring because of its small size and the strong covalent bond it forms with carbon. However, SPECT has potential advantages over PET: (1) SPECT is clinically more widely available at lower cost; (2) most radioisotopes for the synthesis of SPECT agents can be purchased; (3) SPECT is less difficult to implement. It is thought that the quality of images derived from the two techniques would each be sufficiently informative for BNCT treatment planning purposes, provided that the SPECT and PET agents being considered were both pharmacokinetic surrogates for BPA. This study evaluated the use of {sup 123}I alpha methyltyrosine as a surrogate for BPA in BNCT.

  2. Quality management in BNCT at a nuclear research reactor

    Energy Technology Data Exchange (ETDEWEB)

    Sauerwein, Wolfgang, E-mail: w.sauerwein@uni-due.de [NCTeam, Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45122 Essen (Germany); Moss, Raymond [ESE Unit, Institute for Energy, Joint Research Centre, European Commission, Westerduinweg 3, P.O. Box 2 NL-1755ZG Petten (Netherlands); Stecher-Rasmussen, Finn [NCT Physics, Nassaulaan 12, 1815GK Alkmaar (Netherlands); Rassow, Juergen [NCTeam, Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45122 Essen (Germany); Wittig, Andrea [Department of Radiotherapy and Radiation Oncology, University Hospital Marburg, Philipps-University Marburg, Baldingerstrasse, 35043 Marburg (Germany)

    2011-12-15

    Each medical intervention must be performed respecting Health Protection directives, with special attention to Quality Assurance (QA) and Quality Control (QC). This is the basis of safe and reliable treatments. BNCT must apply QA programs as required for performance and safety in (conventional) radiotherapy facilities, including regular testing of performance characteristics (QC). Furthermore, the well-established Quality Management (QM) system of the nuclear reactor used has to be followed. Organization of these complex QM procedures is offered by the international standard ISO 9001:2008.

  3. Hot target assembly at 14 UD Pelletron Accelerator Facility, BARC- TIFR, Mumbai

    International Nuclear Information System (INIS)

    Sharma, S.C.; Ramjilal; Ninawe, N.G.; Bhagwat, P.V.; Ahmeabadhai, P.; Kain, V.

    2005-01-01

    BARC-TIFR 14 UD Pelletron Accelerator Facility at Mumbai is operational since 1989 with progressively increased efficiency. The accelerator has been serving as major facility for heavy ion based research in India. There is an increased demand for high current proton beam, especially on heated targets for reactor physics based experiments. A proton beam setup is commissioned in the tower area of the existing facility itself, which provide proton beam of energy 2 MeV to 26 MeV with maximum 3 μA current. This setup is being used to produce radioisotopes and tracer packets. Proton beam of few MeV in μA current range is also needed to study radiation effects on metals at higher temperature, for use in reactors. For this purpose a hot target assembly has been designed and is being currently used at the Pelletron Accelerator

  4. In vivo BNCT in experimental and spontaneous tumors at RA-1 reactor

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Schwint, Amanda E.; Nigg, David W.

    2003-01-01

    Within the search for new applications of Boron Neutron Capture Therapy (BNCT) and the basic research oriented towards the study of BNCT radiobiology to optimize its therapeutic gain, we previously proposed and validated the hamster cheek pouch oral cancer model and showed, for the first time, the success of BNCT to treat oral cancer in an experimental model. The staff of the Ra-1 Reactor (Constituyentes Atomic Center) adapted the thermal beam and physical set-up to perform in vivo BNCT of superficial tumors in small animals. We preformed a preliminary characterization of the thermal beam, performed beam only irradiation of normal and tumor bearing hamsters and in vivo BNCT of experimental oral squamous cell carcinomas in hamsters mediated by boron phenylalanine (BPA) and GB-10 (Na 2 10 B 10 H 10 ). Having demonstrated the absence of radio toxic effects in healthy tissue and a therapeutic effect of in vivo BNCT in hamster cheek pouch tumors employing the Ra-1 thermal beam, we performed a feasibility study of the treatment by BNCT of 3 terminal cases of spontaneous head and neck squamous cell carcinoma in cats following the corresponding biodistribution studies. This was the first treatment of spontaneous tumors by BNCT in our country and the first treatment by BNCT in cats worldwide. This preclinical study in terminal cases showed significant tumor control by BNCT with no damage to normal tissue. (author)

  5. CEBAF [Continuous Electron Beam Accelerator Facility] design report

    International Nuclear Information System (INIS)

    1986-05-01

    This book describes the conceptual design of, and the planning for, the Continuous Electron Beam Accelerator Facility (CEBAF), which will be a high-intensity, continuous-wave electron linear accelerator (linac) for nuclear physics. Its principal scientific goal is to understand the quark structure, behavior, and clustering of individual nucleons in the nuclear medium, and simultaneously to understand the forces governing this behavior. The linac will consist of 1 GeV of accelerating structure, split into two antiparallel 0.5-GeV segments. The segments will be connected by a beam transport system to circulate the electron beams from one segment to the other for up to four complete passes of acceleration. The maximum beam energy will be 4 GeV at a design current of 200 microamperes. The accelerator complex will also include systems to extract three continuous beams from the linac and to deliver them to three experimental halls equipped with detectors and instrumentation for nuclear physics research. The accelerating structure will be kept superconducting within insulated cryostats filled with liquid helium produced at a central helium refrigerator and distributed to the cryostats via insulated transfer lines. An injector, instrumentation and controls for the accelerator, radio-frequency power systems, and several support facilities will also be provided. A cost estimate based on the Work Breakdown Structure has been completed. Assuming a five-year construction schedule starting early in FY 1987, the total estimated cost is $236 million (actual year dollars), including contingency

  6. Present status of TIARA electrostatic accelerator facility

    Energy Technology Data Exchange (ETDEWEB)

    Tajima, Satoshi; Takada, Isao; Mizuhashi, Kiyoshi; Saito, Yuichi; Uno, Sadanori; Okoshi, Kiyonori; Ishii, Yasuyuki; Nakajima, Yoshinori; Sakai, Takuro [Japan Atomic Energy Research Inst., Takasaki, Gunma (Japan). Takasaki Radiation Chemistry Research Establishment

    1996-12-01

    The electrostatic accelerator, 3 MV tandem accelerator, 3 MV single end accelerator and 400 kV ion implantation equipment, which were installed in Takasaki Ion Irradiation Research Facility (TIARA) of Japan Atomic Energy Research Institute, have been used for the research on the advanced utilization of radiation mainly in material science by ion beam. The utilization is open to other researchers, and in fiscal year 1995, about 40% was the utilization by outsiders. The number of the experimental subjects adopted in fiscal year 1995 was 47, and the fields of research were space and environment materials, nuclear fusion reactor materials, new functional materials, biotechnology and base technology. The operation time in fiscal year 1995 was 1201, 1705 and 1505 hours for the tandem accelerator, single end accelerator and ion implantation equipment, respectively. The methods of experiment are reported. The troubles occurred in the tandem accelerator and single end accelerator are reported. As the diversification of beam utilization in the tandem accelerator, the utilizations of high energy molecular ions, low energy negative ions, multivalent ions by post stripper and low intensity ions by mesh attenuator have been attempted. These utilizations are described. (K.I.)

  7. Dosimetric study of varying aperture-surface distance at the Finnish BNCT facility

    International Nuclear Information System (INIS)

    Uusi-Simola, Jouni; Seppaelae, Tiina; Nieminen, Katja; Kotiluoto, Petri; Seren, Tom; Auterinen, Iiro; Kortesniemi, Mika; Savolainen, Sauli

    2006-01-01

    Comparison of experimental and calculated dosimetric values in a water phantom was performed at the Finnish BNCT facility at the FiR 1 research reactor. The purpose was to study the effect of changing aperture to surface distance (ASD) to radiation dose and to verify the accuracy of the treatment planning and to provide data for comparison of the methods. A magnesium ionisation chamber flushed with argon gas was used to measure absorbed photon dose rate. Diluted manganese (Mn) and gold (Au) foils and Mn wires were used to determine Mn and Au activation reaction rates. Computer simulations with both SERA and MCNP programs were used to independently calculate the corresponding values. Photon dose and activation reaction rate depth profiles at beam central axis an axial profiles at 2.5 and 6 cm depths were measured and calculated for 11 and 14 and 17 cm diameter apertures. Depth profiles for activation reaction rates were determined for the clinically used 11 and 14 cm diameter apertures for 0, 5, and 10 cm ASD. In addition, the optional 17 cm beam was characterised at 0 and 5 cm ASD. The beam intensity decreases by approximately 20% and 40% when ASD is increased to 5 cm or 10 cm, respectively. The shape of the 55 Mn activation reaction rate depth profile and photon depth radial profile did not vary more than 5% for the 14 cm beam when the ASD was increased from 0 cm to 10 cm. (author)

  8. The CSU Accelerator and FEL Facility

    NARCIS (Netherlands)

    Milton, S.V.; Biedron, S.G.; Burleson, T.; Carrico, C.; Edelenbos, J.; Hall, C.; Horovitz, K.; Morin, A.; Rand, L.; Sipahi, N.; Sipahi, T.; van der Slot, P.; Yehudah, H.; Dong, A.; Tanaka, T.; Schaa, V.R.W.

    2013-01-01

    The Colorado State University (CSU) Accelerator Facility will include a 6-MeV L-Band electron linear accelerator (linac) with a free-electron laser (FEL) system capable of producing Terahertz (THz) radiation, a laser laboratory, a microwave test stand, and a magnetic test stand. The photocathode

  9. Medical set-up of boron neutron capture therapy (BNCT) for malignant glioma at the Japan research reactor (JRR)-4

    International Nuclear Information System (INIS)

    Yamamoto, T.; Matsumura, A.; Nose, T.; Shibata, Y.; Nakai, K.; Sakurai, F.; Kishi, T.; Kumada, H.; Yamamoto, K.; Torii, Y.

    2001-01-01

    The University of Tsukuba project for boron neutron capture therapy (BNCT) was initiated at the Japan Atomic Energy Research Institute (JAERI) in 1992. The clinical study for BNCT began at the Japan Research Reactor (JRR)-2 of the JAERI in November 1995. By the end of 1998, a new medical irradiation facility had been installed in JRR-4 of that included a new medical treatment room and patient-monitoring area adjacent to the irradiation room. The medical treatment room was built to reflect a hospital-type operation room that includes an operating table with a carbon head frame, anesthesia apparatus with several cardiopulmonary monitors, etc. Following craniotomy in the treatment room, a patient under anesthesia is transported into the irradiation room for BNCT. The boron concentration in tissue is measured with prompt gamma ray analysis (PGA) and simultaneously by inductively coupled plasma atomic emission spectroscopy (ICP-AES) methods. For the immediate pre- and post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of the JAERI. The long term follow-up is done at the University of Tsukuba Hospital. Epithermal neutron beam also became available at the new JRR-4. By changing the thickness and/or the configuration of heavy water, a cadmium plate, and a graphite reflector, the JRR-4 provides a variety of neutron beams, including three typical beams (Epithermal mode and Thermal modes I and II). Intraoperative BNCT using the thermal beam is planned to study at the beginning of the clinical trial. The ongoing development of the JAERI Computational Dosimetry System (JCDS) and radiobiological studies have focused in the application of the epithermal beam for BNCT. After obtaining these basic data, we are planning to use the epithermal beam for intraoperative BNCT. (author)

  10. The Berkeley Accelerator Space Effects (BASE) Facility - A new mission for the 88-Inch Cyclotron at LBNL

    International Nuclear Information System (INIS)

    McMahan, M.A.

    2005-01-01

    In FY04, the 88-Inch Cyclotron began a new operating mode that supports a local research program in nuclear science, R and D in accelerator technology and a test facility for the National Security Space (NSS) community (the US Air Force and NRO). The NSS community (and others on a cost recovery basis) can take advantage of both the light- and heavy-ion capabilities of the cyclotron to simulate the space radiation environment. A significant portion of this work involves the testing of microcircuits for single event effects. The experimental areas within the building that are used for the radiation effects testing are now called the Berkeley Accelerator Space Effects (BASE) Facility. Improvements to the facility to provide increased reliability, quality assurance and new capabilities are underway and will be discussed. These include a 16 A MeV 'cocktail' of beams for heavy ion testing, a neutron beam, more robust dosimetry, and other upgrades

  11. Accelerator complex for a radioactive ion beam facility at ATLAS

    International Nuclear Information System (INIS)

    Nolen, J.A.

    1995-01-01

    Since the superconducting heavy ion linac ATLAS is an ideal post-accelerator for radioactive beams, plans are being developed for expansion of the facility with the addition of a driver accelerator, a production target/ion source combination, and a low q/m pre-accelerator for radioactive ions. A working group including staff from the ANL Physics Division and current ATLAS users are preparing a radioactive beam facility proposal. The present paper reviews the specifications of the accelerators required for the facility

  12. The Brookhaven National Laboratory Accelerator Test Facility

    International Nuclear Information System (INIS)

    Batchelor, K.

    1992-01-01

    The Brookhaven National Laboratory Accelerator Test Facility comprises a 50 MeV traveling wave electron linear accelerator utilizing a high gradient, photo-excited, raidofrequency electron gun as an injector and an experimental area for study of new acceleration methods or advanced radiation sources using free electron lasers. Early operation of the linear accelerator system including calculated and measured beam parameters are presented together with the experimental program for accelerator physics and free electron laser studies

  13. Accelerator mass spectrometry and associated facilities at Inter-University Accelerator Centre, New Delhi, India

    International Nuclear Information System (INIS)

    Kumar, Pankaj; Bohra, Archna; Ojha, S.; Gargari, S.; Joshi, R.; Roonwal, G.S.; Chopra, S.; Pattanaik, J.K.; Balakrishnan, S.

    2011-01-01

    Accelerator Mass Spectrometry (AMS) facility at Inter-University Accelerator Centre (IUAC) is developed by upgrading its existing 15UD Pelletron accelerator. Since last two decades Pelletron is mainly used for nuclear physics, materials science, atomic physics, radiation biology and accelerator mass spectrometry is recent development. In addition, a chemistry laboratory in clean room for the chemical processing of samples for AMS studies has also been established. At present the AMS facility is used for 10 Be, 26 Al measurements and soon other long lived radio-isotopes will also be used

  14. Biodistribution of Boron compounds in an experimental model of liver metastases for Boron Neutron Capture (BNCT) Studies

    International Nuclear Information System (INIS)

    Garabalino, Marcela A.; Monti Hughes, Andrea; Molinari, Ana J.; Heber, Elisa M.; Pozzi, Emiliano C.C.; Itoiz, Maria E.; Trivillin, Veronica A.; Schwint, Amanda E.; Nievas, Susana; Aromando, Romina F.

    2009-01-01

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10 B carriers in tumors followed by irradiation with thermal or epithermal neutrons. The high linear energy transfer alpha particles and recoiling 7 Li nuclei emitted during the capture of a thermal neutron by a 10 B nucleus have a short range and a high biological effectiveness. Thus, BNCT would potentially target neoplastic tissue selectively. In previous studies we demonstrated the therapeutic efficacy of different BNCT protocols in an experimental model of oral cancer. More recently we performed experimental studies in normal rat liver that evidenced the feasibility of treating liver metastases employing a novel BNCT protocol proposed by JEC based on ex-situ treatment and partial liver auto-transplant. The aim of the present study was to perform biodistribution studies with different boron compounds and different administration protocols to determine the protocols that would be therapeutically useful in 'in vivo' BNCT studies at the RA-3 Nuclear Reactor in an experimental model of liver metastases in rats. Materials and Methods. A total of 70 BDIX rats (Charles River Lab., MA, USA) were inoculated in the liver with syngeneic colon cancer cells DH/DK12/TRb (ECACC, UK) to induce the development of subcapsular metastatic nodules. 15 days post-inoculation the animals were used for biodistribution studies. A total of 11 protocols were evaluated employing the boron compounds boronophenylalanine (BPA) and GB-10 (Na 2 10 B 1 -0H 10 ), alone or combined employing different doses and administration routes. Tumor, normal tissue and blood samples were processed for boron measurement by ICP-OES. Results. Several protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue, i.e. BPA 15.5 mg 10 B/kg iv + GB-10 50 mg 10 B/kg iv; BPA 46.5 mg 10 B/kg ip; BPA 46.5 mg 10 B/kg ip

  15. Employment of MCNP in the study of TLDS 600 and 700 seeking the implementation of radiation beam characterization of BNCT facility at IEA-R1

    International Nuclear Information System (INIS)

    Cavalieri, Tassio Antonio

    2013-01-01

    Boron Neutron Capture Therapy, BNCT, is a bimodal radiotherapy procedure for cancer treatment. Its useful energy comes from a nuclear reaction driven by impinging thermal neutron upon Boron 10 atoms. A BNCT research facility has been constructed in IPEN at the IEA-R1 reactor, to develop studies in this area. One of its prime experimental parameter is the beam dosimetry which is nowadays made by using activation foils, for neutron measurements, and TLD 400, for gamma dosimetry. For mixed field dosimetry, the International Commission on Radiation Units and Measurements, ICRU, recommends the use of pair of detectors with distinct responses to the field components. The TLD 600/ TLD 700 pair meets this criteria, as the amount of 6 Li, a nuclide with high thermal neutron cross section, greatly differs in their composition. This work presents a series of experiments and simulations performed in order to implement the mixed field dosimetry based on the use of TLD 600/TLD 700 pair. It also intended to compare this mixed field dosimetric methodology to the one so far used by the BNCT research group of IPEN. The response of all TLDs were studied under irradiations in different irradiation fields and simulations, underwent by MCNP, were run in order to evaluate the dose contribution from each field component. Series of repeated irradiations under pure gamma field and mixed field neutron/gamma field showed differences in the TLD individual responses which led to the adoption of a Normalization Factor. It has allowed to overcome TLD selection. TLD responses due to different field components and spectra were studied. It has shown to be possible to evaluate the relative gamma/neutron fluxes from the relative responses observed in the two Regions of Interest, ROIs, from TLD 600 and TLD 700. It has also been possible to observe the TLD 700 response to neutron, which leads to a gamma dose overestimation when one follows the ICRU recommended mixed field dosimetric procedure. Dose

  16. Towards a new therapy protocol for liver metastases. Effect of boron compounds and BNCT on normal liver regeneration

    International Nuclear Information System (INIS)

    Cardoso, Jorge E.; Heber, Elisa M.; Trivillin, Veronica A.

    2006-01-01

    The Taormina project developed a new method for BNCT treatment of multifocal unresectable liver metastases based on whole liver autograft. The Roffo Institute liver surgeons propose a new technique based on partial liver autograft that would pose less risk to the patient but would require significant healthy liver regeneration following BNCT. The aim of the present study was to assess the effect of BPA, GB-10 (Na 2 10 B 10 H 10 ) and (GB-10 + BPA) and of BNCT mediated by these boron compounds on normal liver regeneration in the Wistar rat. Normal liver regeneration, body weight, hemogram, liver and kidney function were assessed following partial hepatectomy post administration of BPA, GB-10 or (GB-10 + BPA) and post in vivo BNCT at the RA-6 Reactor. These end-points were evaluated 9 days following partial hepatectomy, the time at which complete liver regeneration occurs in untreated controls. The corresponding biodistribution studies were conducted to perform dosimetric calculations. BPA, GB-10 and (GB-10 + PBA) and in vivo BNCT mediated by these boron compounds in dose ranges compatible with therapy did not cause alterations in the outcome of normal liver regeneration, and did not induce alterations in body weight, hemogram, liver or kidney function. The experimental data available to date support the development of a new BNCT protocol for the treatment of liver metastases that requires the regeneration of normal liver past-BNCT. (author)

  17. Accelerator facilities and development of physics in Kazakhstan (1992-2002)

    International Nuclear Information System (INIS)

    Shkol'nik, V.S.; Arzumanov, A.A.; Borisenko, A.N.; Gorlachev, I.D.; Kadyrzhanov, K.K.; Kuterbekov, K.A.; Lysukhin, S.N.; Tuleushev, A.Zh.

    2003-01-01

    The monograph is devoted to the use both the isochronous cyclotron U-150M and the accelerator of the heavy ions UKP-2-1, which are the base facilitates of the Institute of Nuclear Physics of the National Nuclear Center of the Republic of Kazakhstan (INP NNC RK) for scientific researches in the field of nuclear physics of low and middle energies, radiation solid state physics and applied nuclear physics. The history of creation of facilities, some archival documents are given The use of the accelerators of INP NNC RK for the last ten years (1992-2002) is described in detail. The parameters of facilities, photos of the main functional units of the accelerators as well as nuclear and physical methods realized on these basic facilities have been presented. The appendixes present copies of some important historical documents as well as the following materials: a list of on accelerator themes, a list of dissertation works, a list of publications of the Nuclear Physics Department within the period of 1972-2002 and the Solid State Department within the period of 1995-2002 carried out using the accelerators of INP NNC RK. The book is intended for scientists studying actual problems of nuclear physics of low and middle energies, radiation solid state physics as well as students specializing in this field (author)

  18. Fatal carotid blowout syndrome after BNCT for head and neck cancers

    International Nuclear Information System (INIS)

    Aihara, T.; Hiratsuka, J.; Ishikawa, H.; Kumada, H.; Ohnishi, K.; Kamitani, N.; Suzuki, M.; Sakurai, H.; Harada, T.

    2015-01-01

    Boron neutron capture therapy (BNCT) is high linear energy transfer (LET) radiation and tumor-selective radiation that does not cause serious damage to the surrounding normal tissues. BNCT might be effective and safe in patients with inoperable, locally advanced head and neck cancers, even those that recur at previously irradiated sites. However, carotid blowout syndrome (CBS) is a lethal complication resulting from malignant invasion of the carotid artery (CA); thus, the risk of CBS should be carefully assessed in patients with risk factors for CBS after BNCT. Thirty-three patients in our institution who underwent BNCT were analyzed. Two patients developed CBS and experienced widespread skin invasion and recurrence close to the carotid artery after irradiation. Careful attention should be paid to the occurrence of CBS if the tumor is located adjacent to the carotid artery. The presence of skin invasion from recurrent lesions after irradiation is an ominous sign of CBS onset and lethal consequences. - Highlights: • This study is fatal carotid blowout syndrome after BNCT for head and neck cancers. • Thirty-three patients in our institution who underwent BNCT were analyzed. • Two patients (2/33) developed CBS. • The presence of skin invasion from recurrent lesions after irradiation is an ominous sign of CBS. • We must be aware of these signs to perform BNCT safely.

  19. Conceptual Design of a Clinical BNCT Beam in an Adjacent Dry Cell of the Jozef Stefan Institute TRIGA Reactor

    International Nuclear Information System (INIS)

    Maucec, Marko

    2000-01-01

    The MCNP4B Monte Carlo transport code is used in a feasibility study of the epithermal neutron boron neutron capture therapy facility in the thermalizing column of the 250-kW TRIGA Mark II reactor at the Jozef Stefan Institute (JSI). To boost the epithermal neutron flux at the reference irradiation point, the efficiency of a fission plate with almost 1.5 kg of 20% enriched uranium and 2.3 kW of thermal power is investigated. With the same purpose in mind, the TRIGA reactor core setup is optimized, and standard fresh fuel elements are concentrated partly in the outermost ring of the core. Further, a detailed parametric study of the materials and dimensions for all the relevant parts of the irradiation facility is carried out. Some of the standard epithermal neutron filter/moderator materials, as well as 'pressed-only' low-density Al 2 O 3 and AlF 3 , are considered. The proposed version of the BNCT facility, with PbF 2 as the epithermal neutron filter/moderator, provides an epithermal neutron flux of ∼1.1 x 10 9 n/cm 2 .s, thus enabling patient irradiation times of nfast /φ epi -13 Gy.cm 2 /n and [overdot]D γ /φ epi -13 Gy.cm 2 /n), the in-air performances of the proposed beam are comparable to all existing epithermal BNCT facilities. The design presents an equally efficient alternative to the BNCT beams in TRIGA reactor thermal columns that are more commonly applied. The cavity of the dry cell, a former JSI TRIGA reactor spent-fuel storage facility, adjacent to the thermalizing column, could rather easily be rearranged into a suitable patient treatment room, which would substantially decrease the overall developmental costs

  20. Indian participation in FAIR accelerator facility

    International Nuclear Information System (INIS)

    Sur, Amitava

    2015-01-01

    India is a founder member of the FAIR-GmbH, the upcoming International Accelerator Facility at Darmstadt, Germany. Indian participation at FAIR is being funded jointly by the Department of Science and Technology (DST) and the Department of Atomic Energy (DAE). Indo- FAIR Coordination Centre at Bose Institute (BI-IFCC) is coordinating the Indian efforts of both in-kind contribution as well as experimental programmes at FAIR. FAIR aims for beams of stable and unstable nuclei as well as antiprotons in a wide range of intensities and energies. A superconducting double-synchrotron SIS100/300 with a circumference of 1,100 meters and with magnetic rigidities of 100 and 300 Tm, respectively, is at the heart of the FAIR accelerator facility. The existing GSI accelerators UNILAC and SIS18 will serve as an injector. Adjacent to the large double- synchrotron is a complex system of storage- cooler rings and experiment stations, including a superconducting nuclear fragment separator (Super-FRS) and an antiproton production target. FAIR will supply rare isotope beams (RIBs) and antiproton beams. In FAIR accelerator facility up to four research programs can be run in a parallel mode. The multidisciplinary research program covers the fields of QCD studies with cooled beams of antiprotons, nucleus nucleus collisions at highest baryon density, nuclear structure and nuclear astrophysics investigations with nuclei far off stability, high density plasma physics, atomic and material science studies, radio-biological and other application-oriented studies will contribute in providing in-kind items both for the accelerator and the experiments. As per current plans Indian in kind contributions include: Power Converters, Superconducting Magnets, Beam Stopper, Vacuum Chamber. A short sample from an Indian Industry has been tested successfully at FAIR. Indian participation in building the accelerator components for FAIR is presented

  1. Conceptual design of 30 MeV magnet system used for BNCT epithermal neutron source

    International Nuclear Information System (INIS)

    Slamet Santosa; Taufik

    2015-01-01

    Conceptual design of 30 MeV Magnet System Used for BNCT Epithermal Neutron Source has been done based on methods of empirical model of basic equation, experiences of 13 MeV cyclotron magnet design and personal communications. In the field of health, cyclotron can be used as an epithermal neutron source for Boron Neutron Capture Therapy (BNCT). The development of cyclotron producing epithermal neutrons for BNCT has been performed at Kyoto University, of which it produces a proton beam current of 1.1 mA with energy of 30 MeV. With some experiences on 13 MeV cyclotron magnet design, to support BNCT research and development we performed the design studies of 30 MeV cyclotron magnet system, which is one of the main components of the cyclotron for deflecting proton beam into circular trajectory and serves as beam focusing. Results of this study are expected to define the parameters of particular cyclotron magnet. The scope of this study includes the study of the parameters component of the 30 MeV cyclotron and magnet initial parameters. The empirical method of basic equation model is then corroborated by a simulation using Superfish software. Based on the results, a 30 MeV cyclotron magnet for BNCT neutron source enables to be realized with the parameters of B 0 = 1.06 T, frequency RF = 64.733938 ≈ 65 MHz, the external radius of 0.73 m, the radius of the polar = 0.85 m, BH = 1.95 T and a gap hill of 4 cm. Because proton beam current that be needed for BNCT application is very large, then in the calculation it is chosen a great focusing axial νz = 0.630361 which can generate B V = 0.44 T. (author)

  2. OPTIMIZATION OF A NEUTRON BEAM SHAPING ASSEMBLY DESIGN FOR BNCT AND ITS DOSIMETRY SIMULATION BASED ON MCNPX

    Directory of Open Access Journals (Sweden)

    I Made Ardana

    2017-10-01

    OPTIMASI DESAIN KOLIMATOR NEUTRON UNTUK SISTEM BNCT DAN UJI DOSIMETRINYA MENGGUNAKAN PROGRAM MCNPX. Telah dilakukan penelitian tentang sistem BNCT yang meliputi dua tahapan simulasi dengan menggunakan program MCNPX yaitu uji simulasi untuk optimasi desain kolimator neutron untuk sistem BNCT berbasis Siklotron 30 MeV dan uji simulasi untuk menghitung fluks neutron dan dosimetri radiasi pada kanker sarkoma jaringan lunak pada leher dan kepala. Tujuan simulasi untuk mendapatkan desain kolimator yang paling optimal dalam memoderasi fluks neutron cepat yang dihasilkan dari sistem target berilium sehingga dapat dihasilkan fluks neutron yang sesuai untuk sistem BNCT. Uji optimasi dilakukan dengan cara memvariasikan bahan dan ketebalan masing-masing komponen dalam kolimator seperi reflektor, moderator, filter neutron cepat, filter neutron thermal, filter radiasi gamma dan lubang keluaran. Desain kolimator yang diperoleh dari hasil optimasi tersusun atas moderator berbahan Al dengan ketebalan 39 cm, filter neutron cepat berbahan LiF2 setebal 8,2 cm, dan filter neutron thermal berbahan B4C setebal 0,5 cm. Untuk reflektor, filter radiasi gamma dan lubang keluaran masing-masing menggunakan bahan PbF2, Pb dan Bi. Fluks neutron epithermal yang dihasilkan dari kolimator yang didesain adalah sebesar 2,83 x 109 n/s cm-2 dan telah memenuhi seluruh parameter fluks neutron yang sesuai untuk sistem BNCT. Selanjutnya uji simulasi dosimetri pada kanker sarkoma jaringan lunak pada leher dan kepala dilakukan dengan cara memvariasikan konsentrasi senyawa boron pada model phantom leher manusia (ORNL. Selanjutnya model phantom tersebut diiradiasi dengan fluks neutron yang berasal dari kolimator yang telah didesain sebelumnya. Hasilnya, fluks neutron thermal mencapai nilai tertinggi pada kedalaman 4,8 cm di dalam model phantom leher ORNL dengan laju dosis tertinggi terletak pada area jaringan kanker. Untuk masing-masing variasi konsentrasi senyawa boron pada model phantom leher ORNL supaya

  3. Required performance to the concrete structure of the accelerator facilities

    International Nuclear Information System (INIS)

    Irie, Masaaki; Yoshioka, Masakazu; Miyahara, Masanobu

    2006-01-01

    As for the accelerator facility, there is many a thing which is constructed as underground concrete structure from viewpoint such as cover of radiation and stability of the structure. Required performance to the concrete structure of the accelerator facility is the same as the general social infrastructure, but it has been possessed the feature where target performance differs largely. As for the body sentence, expressing the difference of the performance which is required from the concrete structure of the social infrastructure and the accelerator facility, construction management of the concrete structure which it plans from order of the accelerator engineering works facility, reaches to the design, supervision and operation it is something which expresses the method of thinking. In addition, in the future of material structural analysis of the concrete which uses the neutron accelerator concerning view it showed. (author)

  4. American brain tumor patients treated with BNCT in Japan

    International Nuclear Information System (INIS)

    Laramore, G.E.; Griffin, B.R.; Spence, A.

    1995-01-01

    The purpose of this work is to establish and maintain a database for patients from the United States who have received BNCT in Japan for malignant gliomas of the brain. This database will serve as a resource for the DOE to aid in decisions relating to BNCT research in the United States, as well as assisting the design and implementation of clinical trials of BNCT for brain cancer patients in this country. The database will also serve as an information resource for patients with brain tumors and their families who are considering this form of therapy

  5. The Continuous Electron Beam Accelerator Facility

    International Nuclear Information System (INIS)

    Grunder, H.A.; Bisognano, J.J.; Diamond, W.I.; Hartline, B.K.; Leemann, C.W.; Mougey, J.; Sundelin, R.M.; York, R.C.

    1987-01-01

    On February 13, 1987, construction started on the Continuous Electron Beam Accelerator Facility - a 4-GeV, 200-μA, continuous beam, electron accelerator facility designed for nuclear physics research. The machine has a racetrack configuration with two antiparallel, 500-MeV, superconducting linac segments connected by beam lines to allow four passes of recirculation. The accelerating structure consists of 1500-MHz, five-cell niobium cavities developed at Cornell University. A liquid helium cryogenic system cools the cavities to an operating temperature of 2 K. Beam extraction after any three of the four passes allows simultaneous delivery of up to three beams of independently variable currents and different, but correlated, energies to the three experimental areas. Beam breakup thresholds exceed the design current by nearly two orders of magnitude. Project completion and the start of physics operations are scheduled for 1993. The total estimated cost is $255 million

  6. Compact X-ray source at STF (Super Conducting Accelerator Test Facility)

    International Nuclear Information System (INIS)

    Urakawa, J

    2012-01-01

    KEK-STF is a super conducting linear accelerator test facility for developing accelerator technologies for the ILC (International Linear Collider). We are supported in developing advanced accelerator technologies using STF by Japanese Ministry (MEXT) for Compact high brightness X-ray source development. Since we are required to demonstrate the generation of high brightness X-ray based on inverse Compton scattering using super conducting linear accelerator and laser storage cavity technologies by October of next year (2012), the design has been fixed and the installation of accelerator components is under way. The necessary technology developments and the planned experiment are explained.

  7. "Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    Energy Technology Data Exchange (ETDEWEB)

    Ana J. Molinari; Andrea Monti Hughes; Elisa M. Heber; Marcela A. Garabalino; Veronica A. Trivillin; Amanda E. Schwint; Emiliano C. C. Pozzi; Maria E. Itoiz; Silvia I. Thorp; Romina F. Aromando; David W. Nigg; Jorge Quintana; Gustavo A. Santa Cruz

    2011-04-01

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10B carriers in tumors followed by irradiation with a thermal or epithermal neutron beam. The minor abundance stable isotope of boron, 10B, interacts with low energy (thermal) neutrons to produce high linear energy transfer (LET) a-particles and 7Li ions. These disintegration products are known to have a high relative biological effectiveness (RBE). Their short range (<10 {micro}m) would limit the damage to cells containing 10B (1,2). Thus, BNCT would target tumor tissue selectively, sparing normal tissue. Clinical trials of BNCT for the treatment of glioblastoma multiforme and/or melanoma and, more recently, head and neck tumors and liver metastases, using boronophenylalanine (BPA) or sodium mercaptoundecahydrododecaborane (BSH) as the 10B carriers, have been performed or are underway in Argentina, Japan, the US and Europe (e.g. 3-8). To date, the clinical results have shown a potential, albeit inconclusive, therapeutic advantage for this technique. Contributory translational studies have been carried out employing a variety of experimental models based on the implantation of tumor cells in normal tissue (e.g. 5).

  8. The SARAF Project - Soreq Applied Research Accelerator Facility

    International Nuclear Information System (INIS)

    Nagler, A.; Mardor, I.; Berkovits, D.; Piel, C.

    2004-01-01

    The relevance of particle accelerators to society, in the use of their primary and secondary beams for the analysis of physical, chemical and biological samples and for modification of properties of materials, is well recognized and documented. Nevertheless, apart of the construction of small accelerators for nuclear research in the 1960's and 70's, Israel has so far neglected this important and growing field. Furthermore, there is an urgent need in Israel for a state of the art research facility to attract and introduce students to current advanced physics techniques and technologies and to train the next generation of experimental scientists in various branches and disciplines. Therefore, Soreq NRC recently initiated the establishment of a new accelerator facility, named SARAF Soreq Applied Research Accelerator Facility. SARAF will be a continuous wave (CW), proton and deuteron RF superconducting linear accelerator with variable energy (5 - 40 MeV) and current (0.04 -2 mA). SARAF is designed to enable hands-on maintenance, which means that its beam loss will be below 10 -5 for the entire accelerator. These specifications will place SARAF in line with the next generation of accelerators world wide. Soreq expects that this fact will attract the Israeli and international research communities to use this facility extensively. Soreq NRC intends to use SARAF for basic, medical and biological research, and non-destructive testing (NDT). Another major activity will be the research and development of radio-isotopes production techniques. Given the availability of high current (up to 2 mA) protons and deuterons, a major activity will be research and development of high power density (up to 80 kW on a few cm 2 ) irradiation targets

  9. Radiation protection of the operation of accelerator facilities. On high energy proton and electron accelerators

    International Nuclear Information System (INIS)

    Kondo, Kenjiro

    1997-01-01

    Problems in the radiation protection raised by accelerated particles with energy higher than several hundreds MeV in strong accelerator facilities were discussed in comparison with those with lower energy in middle- and small-scale facilities. The characteristics in the protection in such strong accelerator facilities are derived from the qualitative changes in the interaction between the high energy particles and materials and from quantitative one due to the beam strength. In the former which is dependent on the emitting mechanism of the radiation, neutron with broad energy spectrum and muon are important in the protection, and in the latter, levels of radiation and radioactivity which are proportional to the beam strength are important. The author described details of the interaction between high energy particles and materials: leading to the conclusion that in the electron accelerator facilities, shielding against high energy-blemsstrahlung radiation and -neutron is important and in the proton acceleration, shielding against neutron is important. The characteristics of the radiation field in the strong accelerator facilities: among neutron, ionized particles and electromagnetic wave, neutron is most important in shielding since it has small cross sections relative to other two. Considerations for neutron are necessary in the management of exposure. Multiplicity of radionuclides produced: which is a result of nuclear spallation reaction due to high energy particles, especially to proton. Radioactivation of the accelerator equipment is a serious problem. Other problems: the interlock systems, radiation protection for experimenters and maintenance of the equipment by remote systems. (K.H.). 11 refs

  10. Nuclear physics accelerator facilities of the world

    International Nuclear Information System (INIS)

    1991-12-01

    this report is intended to provide a convenient summary of the world's major nuclear physics accelerator facility with emphasis on those facilities supported by the US Department of Energy (DOE). Previous editions of this report have contained only DOE facilities. However, as the extent of global collaborations in nuclear physics grows, gathering summary information on the world's nuclear physics accelerator facilities in one place is useful. Therefore, the present report adds facilities operated by the National Science Foundation (NSF) as well as the leading foreign facilities, with emphasis on foreign facilities that have significant outside user programs. The principal motivation for building and operating these facilities is, of course, basic research in nuclear physics. The scientific objectives for this research were recently reviewed by the DOE/NSF Nuclear Science Advisory Committee, who developed a long range plan, Nuclei, Nucleons, and Quarks -- Nuclear Science in the 1990's. Their report begins as follows: The central thrust of nuclear science is the study of strongly interacting matter and of the forces that govern its structure and dynamics; this agenda ranges from large- scale collective nuclear behavior through the motions of individual nucleons and mesons, atomic nuclei, to the underlying distribution of quarks and gluons. It extends to conditions at the extremes of temperature and density which are of significance to astrophysics and cosmology and are conducive to the creation of new forms of strongly interacting matter; and another important focus is on the study of the electroweak force, which plays an important role in nuclear stability, and on precision tests of fundamental interactions. The present report provides brief descriptions of the accelerator facilities available for carrying out this agenda and their research programs

  11. Status report of pelletron accelerator and ECR based heavy ion accelerator programme

    International Nuclear Information System (INIS)

    Gupta, A.K.

    2015-01-01

    The BARC-TIFR Pelletron Accelerator is completing twenty seven years of round-the-clock operation, serving diverse users from institutions within and outside DAE. Over the years, various developmental activities and application oriented programs have been initiated at Pelletron Accelerator Facility, resulting into enhanced utilization of the accelerator. We have also been pursuing an ECR based heavy ion accelerator programme under XII th Plan, consisting of an 18 GHz superconducting ECR (Electron Cyclotron Resonance) ion source and a room temperature RFQ (Radio Frequency Quadrupole) followed by low and high beta superconducting niobium resonator cavities. This talk will provide the current status of Pelletron Accelerator and the progress made towards the ECR based heavy ion accelerator program at BARC. (author)

  12. Radiation shielding design of BNCT treatment room for D-T neutron source.

    Science.gov (United States)

    Pouryavi, Mehdi; Farhad Masoudi, S; Rahmani, Faezeh

    2015-05-01

    Recent studies have shown that D-T neutron generator can be used as a proper neutron source for Boron Neutron Capture Therapy (BNCT) of deep-seated brain tumors. In this paper, radiation shielding calculations have been conducted based on the computational method for designing a BNCT treatment room for a recent proposed D-T neutron source. By using the MCNP-4C code, the geometry of the treatment room has been designed and optimized in such a way that the equivalent dose rate out of the treatment room to be less than 0.5μSv/h for uncontrolled areas. The treatment room contains walls, monitoring window, maze and entrance door. According to the radiation protection viewpoint, dose rate results of out of the proposed room showed that using D-T neutron source for BNCT is safe. Copyright © 2015 Elsevier Ltd. All rights reserved.

  13. Accelerator based neutron source for neutron capture therapy

    International Nuclear Information System (INIS)

    Salimov, R.; Bayanov, B.; Belchenko, Yu.; Belov, V.; Davydenko, V.; Donin, A.; Dranichnikov, A.; Ivanov, A.; Kandaurov, I; Kraynov, G.; Krivenko, A.; Kudryavtsev, A.; Kursanov, N.; Savkin, V.; Shirokov, V.; Sorokin, I.; Taskaev, S.; Tiunov, M.

    2004-01-01

    Full text: The Budker Institute of Nuclear Physics (Novosibirsk) and the Institute of Physics and Power Engineering (Obninsk) have proposed an accelerator based neutron source for neutron capture and fast neutron therapy for hospital. Innovative approach is based upon vacuum insulation tandem accelerator (VITA) and near threshold 7 Li(p,n) 7 Be neutron generation. Pilot accelerator based neutron source for neutron capture therapy is under construction now at the Budker Institute of Nuclear Physics, Novosibirsk, Russia. In the present report, the pilot facility design is presented and discussed. Design features of facility components are discussed. Results of experiments and simulations are presented. Complete experimental tests are planned by the end of the year 2005

  14. Los Alamos High-Brightness Accelerator FEL (HIBAF) facility

    Energy Technology Data Exchange (ETDEWEB)

    Cornelius, W.D.; Bender, S.; Meier, K.; Thode, L.E.; Watson, J.M.

    1989-01-01

    The 10-/mu/m Los Alamos free-electron laser (FEL) facility is being upgraded. The conventional electron gun and bunchers have been replaced with a much more compact 6-MeV photoinjector accelerator. By adding existing parts from previous experiments, the primary beam energy will be doubled to 40 MeV. With the existing 1-m wiggler (/lambda//sub w/ = 2.7 cm) and resonator, the facility can produce photons with wavelengths from 3 to 100 /mu/m when lasing on the fundamental mode and produce photons in the visible spectrum with short-period wigglers or harmonic operation. After installation of a 150/degree/ bend, a second wiggler will be added as an amplifier. The installation of laser transport tubes between the accelerator vault and an upstairs laboratory will provide experimenters with a radiation-free environment for experiments. Although the initial experimental program of the upgraded facility will be to test the single accelerator-master oscillator/power amplifier configuration, some portion of the operational time of the facility can be dedicated to user experiments. 13 refs., 5 figs., 6 tabs.

  15. Change in operating parameters of the Continuous Electron Beam Accelerator Facility and Free Electron Laser, Thomas Jefferson National Accelerator Facility, Newport News, Virginia

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1997-10-01

    In this environmental assessment (EA), the US Department of Energy (DOE) reports the results of an analysis of the potential environmental impacts from a proposed change in operating parameters of the Continuous Electron Beam Accelerator Facility (CEBAF), and operation of the Free Electron Laser (FEL) facility beyond the initial demonstration period. With this proposal, DOE intends to increase CEBAF operating range from its current operating maximum beam energy of 4.0 GeV [giga-(billion) electron volts] to 8.0 GeV at a beam power of no greater than 1,000 kW [1 megawatt (MW)], its maximum attainable level, based on current technology and knowledge, without significant, costly equipment modifications. DOE has prepared an EA for this action to determine the potential for adverse impacts from operation of CEBAF and the FEL at the proposed levels. Changing the operating parameters of CEBAF would require no new major construction and minor modifications to the accelerator, its support systems, the FEL, and onsite utility systems. Modifications and performance improvements would be made to (1) the accelerator housed in the underground tunnels, (2) its support systems located in the above ground service buildings, and (3) the water and equipment cooling systems both in the tunnel and at the ground surface. All work would be performed on previously disturbed land and in, on, or adjacent to existing buildings, structures, and equipment. With the proposed action, the recently constructed FEL facility at the Jefferson Lab would operate in concert with CEBAF beyond its demonstration period and up to its maximum effective electron beam power level of 210 kW. In this EA, DOE evaluates the impacts of the no-action alternative and the proposed action alternative. Alternatives considered, but dismissed from further evaluation, were the use of another accelerator facility and the use of another technology.

  16. Change in operating parameters of the Continuous Electron Beam Accelerator Facility and Free Electron Laser, Thomas Jefferson National Accelerator Facility, Newport News, Virginia

    International Nuclear Information System (INIS)

    1997-10-01

    In this environmental assessment (EA), the US Department of Energy (DOE) reports the results of an analysis of the potential environmental impacts from a proposed change in operating parameters of the Continuous Electron Beam Accelerator Facility (CEBAF), and operation of the Free Electron Laser (FEL) facility beyond the initial demonstration period. With this proposal, DOE intends to increase CEBAF operating range from its current operating maximum beam energy of 4.0 GeV [giga-(billion) electron volts] to 8.0 GeV at a beam power of no greater than 1,000 kW [1 megawatt (MW)], its maximum attainable level, based on current technology and knowledge, without significant, costly equipment modifications. DOE has prepared an EA for this action to determine the potential for adverse impacts from operation of CEBAF and the FEL at the proposed levels. Changing the operating parameters of CEBAF would require no new major construction and minor modifications to the accelerator, its support systems, the FEL, and onsite utility systems. Modifications and performance improvements would be made to (1) the accelerator housed in the underground tunnels, (2) its support systems located in the above ground service buildings, and (3) the water and equipment cooling systems both in the tunnel and at the ground surface. All work would be performed on previously disturbed land and in, on, or adjacent to existing buildings, structures, and equipment. With the proposed action, the recently constructed FEL facility at the Jefferson Lab would operate in concert with CEBAF beyond its demonstration period and up to its maximum effective electron beam power level of 210 kW. In this EA, DOE evaluates the impacts of the no-action alternative and the proposed action alternative. Alternatives considered, but dismissed from further evaluation, were the use of another accelerator facility and the use of another technology

  17. Accelerator-based pulsed cold neutron source

    International Nuclear Information System (INIS)

    Inoue, Kazuhiko; Iwasa, Hirokatsu; Kiyanagi, Yoshiaki

    1979-01-01

    An accelerator-based pulsed cold neutron source was constructed. The accelerator is a 35 MeV electron linear accelerator with 1 kW average beam power. The cold neutron beam intensity at a specimen is equivalent to that of a research reactor of 10 14 n/cm 2 .s thermal flux in the case of the quasi-elastic neutron scattering measurements. In spite of some limitations to the universal uses, it has been demonstrated by this facility that the modest capacity accelerator-based pulsed cold neutron source is a highly efficient cold neutron source with low capital investment. Design philosophy, construction details, performance and some operational experiences are described. (author)

  18. Clinical results of BNCT for malignant brain tumors in children

    International Nuclear Information System (INIS)

    Nakagawa, Yoshinobu; Kageji, Teruyoshi; Mizobuchi, Yoshifumi; Kumada, Hiroaki; Nakagawa, Yoshiaki

    2009-01-01

    It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue. However, boron neutron capture therapy (BNCT) has tumor selectivity such that it can make damage only in tumor cells. We evaluated the clinical results and courses in patients with malignant glioma under 15 years. Among 183 patients with brain tumors treated by our group using BSH-based intra-operative BNCT, 23 patients were under 15 years. They included 4 patients under 3 years. There were 3 glioblastomas (GBM), 6 anaplastic astrocytomas(AAS), 7 primitive neuroectodermal tumors (PNET), 6 pontine gliomas and 1 anaplastic ependymoma. All GBM and PNET patients died due to CSF and/or CNS dissemination without local tumor regrowth. All pontine glioma patients died due to regrowth of the tumor. Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence. BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation. Although it can achieve the local control in the primary site, it cannot prevent CSF dissemination in patients with glioblastoma.

  19. The BNL Accelerator Test Facility and experimental program

    International Nuclear Information System (INIS)

    Ben-Zvi, I.; State Univ. of New York, Stony Brook, NY

    1992-01-01

    The Accelerator Test Facility (ATF) at BNL is a users' facility for experiments in Accelerator and Beam Physics. The ATF provides high brightness electron beams and high-power laser pulses synchronized to the electron beam, suitable for studies of new methods of high-gradient acceleration and state-of-the-art Free-Electron Lasers. The electrons are produced by a laser photocathode rf gun and accelerated to 50 MeV by two traveling wave accelerator sections. The lasers include a 10 mJ, 10 ps ND:YAG laser and a 500 mJ, 10 to 100 ps C0 2 laser. A number of users from National Laboratories, universities and industry take part in experiments at the ATF. The experimental program includes various laser acceleration schemes, Free-Electron Laser experiments and a program on the development of high-brightness electron beams. The ATF's experimental program commenced in early 1991 at an energy of about 4 MeV. The full program, with 50 MeV and the high-power laser will begin operation this year

  20. The BNL Accelerator Test Facility and experimental program

    International Nuclear Information System (INIS)

    Ben-Zvi, I.; State Univ. of New York, Stony Brook, NY

    1991-01-01

    The Accelerator Test Facility (ATF) at BNL is a users' facility for experiments in Accelerator and Beam Physics. The ATF provides high brightness electron beams and high power laser pulses synchronized to the electron beam, suitable for studies of new methods of high gradient acceleration and state of the art free electron lasers. The electrons are produced by a laser photocathode rf gun and accelerated to 50 to 100 MeV by two traveling wave accelerator sections. The lasers include a 10 mJ, 10 ps Nd:YAG laser and a 100 mJ, 10 ps CO 2 laser. A number of users from National Laboratories, universities and industry take part in experiments at the ATF. The experimental program includes various acceleration schemes, Free-Electron Laser experiments and a program on the development of high brightness electron beams. The AFT's experimental program commenced in early 1991 at an energy of about 4 MeV. The full program, with 50 MeV and the High power laser will begin operation this year. 28 refs., 4 figs

  1. The ANTARES accelerator: a facility for environmental monitoring and materials characterisation

    International Nuclear Information System (INIS)

    Tuniz, C.

    1997-01-01

    An analytical facility for Accelerator Mass Spectrometry (AMS) and Ion Beam Analysis (IBA) has been under development since 1989 on the 8-MV tandem accelerator ANTARES at the Lucas Heights Science and Technology Centre. Three beamlines are presently dedicated to the AMS analysis of long-lived radionuclides and one is used for the study of multilayered semiconductor structures by heavy ion recoil spectrometry. Having accomplished the task of transforming the old nuclear physics accelerator from Rutgers University into a world-class analytical facility, ANSTO scientists are now promoting research projects based on the capability of the ANTARES instruments. New instruments are being constructed on the ANTARES accelerator for future programs in environmental monitoring, safeguards, nuclear waste disposal and applications in advanced materials. A new AMS beamline has been designed that is expected to be capable of measuring rare heavy radionuclides, such as 236 U, 229 , 230T h and 244 Pu, in natural samples with ultra-high sensitivity. A novel, heavy ion microprobe will allow IBA of surfaces with a spatial resolution of 10 μm for high-energy ions (20-100 MeV) from chlorine to iodine. These instruments are complementary to other advanced analytical tools developed by ANSTO, such as the synchrotron radiation beamline at the Australian National Beamline Facility

  2. Development of a distributed control system for the JAERI tandem accelerator facility

    International Nuclear Information System (INIS)

    Hanashima, Susumu

    2005-01-01

    In the JAERI tandem accelerator facility, we are building accelerator complex aiming generation and acceleration of radio nuclear beam. Several accelerators, ion sources and a charge breeder are installed in the facility. We are developing a distributed control system enabling smooth operation of the facility. We report basic concepts of the control system in this article. We also describe about a control hardware using plastic optical fiber, which is developed for the control system. (author)

  3. Status and Plans for a Superconducting RF Accelerator Test Facility at Fermilab

    International Nuclear Information System (INIS)

    Andrews, R.; Baffes, C.M.; Carlson, K.; Chase, B.; Church, M.D.; Harms, E.R.; Klebaner, A.L.; Leibfritz, J.R.; Martinez, A.; Nagaitsev, S.; Nobrega, L.E.

    2012-01-01

    The Advanced Superconducting Test Accelerator (ASTA) is being constructed at Fermilab. The existing New Muon Lab (NML) building is being converted for this facility. The accelerator will consist of an electron gun, injector, beam acceleration section consisting of 3 TTF-type or ILC-type cryomodules, multiple downstream beam lines for testing diagnostics and conducting various beam tests, and a high power beam dump. When completed, it is envisioned that this facility will initially be capable of generating a 750 MeV electron beam with ILC beam intensity. An expansion of this facility was recently completed that will provide the capability to upgrade the accelerator to a total beam energy of 1.5 GeV. Two new buildings were also constructed adjacent to the ASTA facility to house a new cryogenic plant and multiple superconducting RF (SRF) cryomodule test stands. In addition to testing accelerator components, this facility will be used to test RF power systems, instrumentation, and control systems for future SRF accelerators such as the ILC and Project-X. This paper describes the current status and overall plans for this facility.

  4. Research on accelerator-driven transmutation and studies of experimental facilities

    Energy Technology Data Exchange (ETDEWEB)

    Takizuka, Takakazu [Japan Atomic Energy Research Inst., Tokai, Ibaraki (Japan). Tokai Research Establishment

    1997-11-01

    JAERI is carrying out R and Ds on accelerator-driven transmutation systems under the national OMEGA Program that aims at development of the technology to improve efficiency and safety in the final disposal of radioactive waste. Research facilities for accelerator-driven transmutation experiments are proposed to construct within the framework of the planned JAERI Neutron Science Project. This paper describes the features of the proposed accelerator-driven transmutation systems and their technical issues to be solved. A research facility plan under examination is presented. The plan is divided in two phases. In the second phase, technical feasibility of accelerator-driven systems will be demonstrated with a 30-60 MW experimental integrated system and with a 7 MW high-power target facility. (author)

  5. Biological dosimetry studies for boron neutron capture therapy at the RA-1 research reactor facility

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Schwint, Amanda E.; Castillo, Jorge

    2004-01-01

    Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminescent dosimeters to characterize the BNCT facility developed at the RA-1 research reactor operated by the National Atomic Energy Commission in Buenos Aires. Biological dosimetry was performed employing the hamster cheek pouch oral cancer model previously validated for BNCT studies by our group. Results indicate that the RA-1 neutron source produces useful dose rates for BNCT studies but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications. (author)

  6. European accelerator facilities for single event effects testing

    Energy Technology Data Exchange (ETDEWEB)

    Adams, L; Nickson, R; Harboe-Sorensen, R [ESA-ESTEC, Noordwijk (Netherlands); Hajdas, W; Berger, G

    1997-03-01

    Single event effects are an important hazard to spacecraft and payloads. The advances in component technology, with shrinking dimensions and increasing complexity will give even more importance to single event effects in the future. The ground test facilities are complex and expensive and the complexities of installing a facility are compounded by the requirement that maximum control is to be exercised by users largely unfamiliar with accelerator technology. The PIF and the HIF are the result of experience gained in the field of single event effects testing and represent a unique collaboration between space technology and accelerator experts. Both facilities form an essential part of the European infrastructure supporting space projects. (J.P.N.)

  7. Proposed Brookhaven accelerator-based neutron generator

    International Nuclear Information System (INIS)

    Grand, P.; Batchelor, K.; Chasman, R.; Rheaume, R.

    1976-01-01

    The d-Li Neutron Source concept, which includes a high-current dueteron linac, is an outgrowth of attempts made to use the BNL, 200-MeV proton linac BLIP facility to do radiation damage studies. It included a 100 mA, 30-MeV deuteron linear accelerator and a fast-flowing liquid lithium jet as the target. The latest design is not very different, except that the current is now 200 mA and the linac energy has been raised to 35 MeV. Both parameters, were changed to optimize the effectiveness of the facility with respect to flux, experimental volume and match to 14 MeV neutron-radiation-damage effects. The proposed Brookhaven Accelerator-based Neutron Generator is described with particular emphasis on the linear accelerator. The proposed facility is a practical and efficient way of producing the intense, high energy neutron beams needed for CTR material studies. The accelerator and liquid-metal technologies are well proven, state-of-the-art technologies. The fact that no new technology is required guarantees the possibility of meeting construction schedules, and more importantly, guarantees a high level of operational reliability

  8. Comparison and analysis of BNCT radiation dose between gold wire and JCDS measurement

    International Nuclear Information System (INIS)

    Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, Hiroaki

    2006-01-01

    We compared and evaluated boron neutron capture therapy (BNCT) radiation dose between gold wire measurement and JAERI Computational Dosimetry System (JCDS). Gold wire analysis demonstrates the actual BNCT dose though it dose not reflect the real the maximum and minimum dose in tumor tissue. We can conclude that JCDS is precise and high-reliable dose planning system for BNCT. (author)

  9. Treatment Planning Systems for BNCT Requirements and Peculiarities

    CERN Document Server

    Daquino, G G

    2003-01-01

    The main requirements and peculiarities expected from the BNCT-oriented treatment planning system (TPS) are summarized in this paper. The TPS is a software, which can be integrated or composed by several auxiliary programs. It plays important roles inside the whole treatment planning of the patient's organ in BNCT. However, the main goal is the simulation of the irradiation, in order to obtain the optimal configuration, in terms of neutron spectrum, patient positioning and dose distribution in the tumour and healthy tissues. The presence of neutrons increases the level of complexity, because much more nuclear reactions need to be monitored and properly calculated during the simulation of the patient's treatment. To this purposes several 3D geometry reconstruction techniques, generally based on the CT scanning data, are implemented and Monte Carlo codes are normally used. The TPSs are expected to show also the results (basically doses and fluences) in a proper format, such as isocurves (or isosurfaces) along t...

  10. Development of high intensity ion sources for a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

    International Nuclear Information System (INIS)

    Bergueiro, J.; Igarzabal, M.; Suarez Sandin, J.C.; Somacal, H.R.; Thatar Vento, V.; Huck, H.; Valda, A.A.; Repetto, M.

    2011-01-01

    Several ion sources have been developed and an ion source test stand has been mounted for the first stage of a Tandem-Electrostatic-Quadrupole facility For Accelerator-Based Boron Neutron Capture Therapy. A first source, designed, fabricated and tested is a dual chamber, filament driven and magnetically compressed volume plasma proton ion source. A 4 mA beam has been accelerated and transported into the suppressed Faraday cup. Extensive simulations of the sources have been performed using both 2D and 3D self-consistent codes.

  11. Development of high intensity ion sources for a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Bergueiro, J. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [CONICET, Buenos Aires (Argentina); Igarzabal, M.; Suarez Sandin, J.C. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina); Somacal, H.R. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina); Thatar Vento, V. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [CONICET, Buenos Aires (Argentina); Huck, H.; Valda, A.A. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina); Repetto, M. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)

    2011-12-15

    Several ion sources have been developed and an ion source test stand has been mounted for the first stage of a Tandem-Electrostatic-Quadrupole facility For Accelerator-Based Boron Neutron Capture Therapy. A first source, designed, fabricated and tested is a dual chamber, filament driven and magnetically compressed volume plasma proton ion source. A 4 mA beam has been accelerated and transported into the suppressed Faraday cup. Extensive simulations of the sources have been performed using both 2D and 3D self-consistent codes.

  12. Effective flow-accelerated corrosion programs in nuclear facilities

    International Nuclear Information System (INIS)

    Esselman, Thomas C.; McBrine, William J.

    2004-01-01

    Piping Flow-Accelerated Corrosion Programs in nuclear power generation facilities are classically comprised of the selection of inspection locations with the assistance of a predictive methodology such as the Electric Power Research Institute computer codes CHECMATE or CHECWORKS, performing inspections, conducting structural evaluations on the inspected components, and implementing the appropriate sample expansion and corrective actions. Performing such a sequence of steps can be effective in identifying thinned components and implementing appropriate short term and long term actions necessary to resolve flow-accelerated corrosion related problems. A maximally effective flow-accelerated corrosion (FAC) program requires an understanding of many programmatic details. These include the procedural control of the program, effective use of historical information, managing the activities performed during a limited duration outage, allocating resources based on risk allocation, having an acute awareness of how the plant is operated, investigating components removed from the plant, and several others. This paper will describe such details and methods that will lead to a flow-accelerated corrosion program that effectively minimizes the risk of failure due to flow-accelerated corrosion and provide full and complete documentation of the program. (author)

  13. New heavy-ion accelerator facility at Oak Ridge

    International Nuclear Information System (INIS)

    Stelson, P.H.

    1974-01-01

    Funds were obtained to establish a new national heavy-ion facility to be located at Oak Ridge. The principal component of this facility is a 25-MW tandem designed specifically for good heavy-ion acceleration, which will provide high quality beams of medium weight ions for nuclear research by itself. The tandem beams will also be injected into ORIC for additional energy gain, so that usable beams for nuclear physics research can be extended to about A = 160. A notable feature of the tandem is that it will be of the ''folded'' type, in which both the negative and positive accelerating tubes are contained in the same column. The accelerator system, the experimental lay-out, and the time schedule for the project are discussed

  14. Desain Beam Shaping Assembly (BSA berbasis D-D Neutron Generator 2,45 MeV untuk Uji Fasilitas BNCT

    Directory of Open Access Journals (Sweden)

    Desman P. Gulo

    2015-12-01

    Full Text Available Boron Neutron Capture Therapy (BNCT is one of the cancer treatments that are being developed in nowadays. In order to support BNCT treatment for cancer that exists in underneath skin like breast cancer, the facility needs a generator that is able to produce epithermal neutron. One of the generator that is able to produce neutron is D-D neutron generator with 2.45 MeV energy. Based on the calculation of this paper, we found that the total production of neutron per second (neutron yield from Neutron Generator (NG by PSTA-BATAN Yogyakarta is 2.55×1011 n/s. The energy and flux that we found is in the range of quick neutron. Thus, it needs to be moderated to the level of epithermal neutron which is located in the interval energy of 1 eV to 10 KeV with 109 n/cm2s flux. This number is the recommendation standard from IAEA. Beam Shaping Assembly (BSA is needed in order to moderate the quick neutron to the level of epithermal neutron. One part of BSA that has the responsibility in moderating the quick neutron to epithermal neutron is the moderator. The substance of moderator used in this paper is MgF2 and A1F3. The thickness of moderator has been set in in such a way by using MCNPX software in order to fulfill the standard of IAEA. As the result of optimizing BSA moderator, the data obtain epithermal flux with the total number of 4.64×108 n/cm2/s for both of moderators with the thickness of moderator up to 15 cm. At the end of this research, the number of epithermal flux does not follow the standard of IAEA. This is because the flux neutron that is being produced by NG is relatively small. In conclusion, the NG from PSTA-BATAN Yogyakarta is not ready to be used for the BNCT treatment facility for the underneath skin cancer like breast cancer.

  15. Establishment of nuclear data system - Feasibility study for neutron-beam= facility at pohang accelerator laboratory

    Energy Technology Data Exchange (ETDEWEB)

    Nam Kung, Won; Koh, In Soo; Cho, Moo Hyun; Kim, Kui Nyun; Kwang, Hung Sik; Park, Sung Joo [Pohang Accelerator Laboratory, Pohang (Korea, Republic of)

    1996-12-01

    Nuclear data which have been produced by a few developed countries in the= past are essential elements to many disciplines, especially to nuclear engineering. As we promote our nuclear industry further to the level of advanced countries, we also have to establish the Nuclear Data System to produce and evaluate nuclear data independently. We have studied the possibility to build a neutron-beam facility utilizing accelerator facilities, technologies and man powers at pohang Accelerator Laboratory. We found specific parameters for the PAL 100-MeV electron linac based on the existing klystron, modulator, accelerating tubes and other facilities in the PAL; the beam energy is 60-100 MeV, the beam current for the short pulse (10 ns) is 2 A and for the long pulse is 500 mA and the pulse repetition rate is 60 Hz. We propose a neutron-beam facility using PAL 100-MeV electron linac where we can use a Ta-target for the neutron generation and three different time-of-flight beam lines (10 m, 20 m, and 100 m). One may find that the proposed neutron-beam facility is comparable with other operating neutron facilities in the world. We conclude that the proposed neutron-beam facility utilizing the existing accelerator facility in the PAL would be an excellent facility for neutron data production in combination with the ` Hanaro` facility in KAERI. 8 refs., 11 tabs., 12 figs. (author)

  16. Colorado State University (CSU) accelerator and FEL facility

    NARCIS (Netherlands)

    Milton, S.; Biedron, S.; Harris, J.; Martinez, J.; D'Audney, A.; Edelen, J.; Einstein, J.; Hall, C.; Horovitz, K.; Morin, A.; Sipahi, N.; Sipahi, T.; Williams, J.; Carrico, C.; Van Der Slot, P. J M

    2014-01-01

    The Colorado State University (CSU) Accelerator Facility will include a 6-MeV L-Band (1.3 GHz) electron linear accelerator (linac) with a free-electron laser (FEL) system capable of producing Terahertz (THz) radiation, a laser laboratory, a microwave test laboratory, and a magnetic test laboratory.

  17. Development of high intensity ion sources for a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy.

    Science.gov (United States)

    Bergueiro, J; Igarzabal, M; Sandin, J C Suarez; Somacal, H R; Vento, V Thatar; Huck, H; Valda, A A; Repetto, M; Kreiner, A J

    2011-12-01

    Several ion sources have been developed and an ion source test stand has been mounted for the first stage of a Tandem-Electrostatic-Quadrupole facility For Accelerator-Based Boron Neutron Capture Therapy. A first source, designed, fabricated and tested is a dual chamber, filament driven and magnetically compressed volume plasma proton ion source. A 4 mA beam has been accelerated and transported into the suppressed Faraday cup. Extensive simulations of the sources have been performed using both 2D and 3D self-consistent codes. Copyright © 2011 Elsevier Ltd. All rights reserved.

  18. The continuous electron beam accelerator facility

    International Nuclear Information System (INIS)

    Grunder, H.A.

    1989-01-01

    Tunnel construction and accelerator component development, assembly, and testing are under way at the Continuous Electron Beam Accelerator Facility. CEBAF's 4-GeV, 200-μA superconducting recirculating accelerator will provide cw beam to simultaneous experiments in three end stations for studies of the nuclear many-body system, its quark substructure, and the strong and electroweak interactions governing this form of matter. Prototype accelerating cavities, assembled in cryostats and tested on site, continue to exceed performance specifications. An on-site liquid helium capability supports cryostat development and cavity testing. Major elements of the accelerator instrumentation and control hardware and software are in use in cryogenics, rf, and injector tests. Prototype rf systems have been operated and prototype klystrons have been ordered. The initial, 100-keV, room-temperature region of the 45-MeV injector is operational and meets specifications. CEBAF's end stations have been conceptually designed; experimental equipment conceptual designs will be completed in 1989. 2 refs., 5 figs., 2 tabs

  19. Status of Thomas Jefferson National Accelerator Facility (Jefferson Lab)

    International Nuclear Information System (INIS)

    H.A. Grunder

    1997-01-01

    When first beam was delivered on target in July 1994, the Continuous Electron Beam Accelerator Facility (CEBAF), in Newport News, Virginia realized the return on years of planning and work to create a laboratory devoted to exploration of matter that interacts through the strong force, which holds the quarks inside the proton and binds protons and neutrons into the nucleus. Dedicated this year as the Thomas Jefferson National Accelerator Facility (Jefferson Lab), the completion of construction and beginning of its experimental program has culminated a process that began more than a decade ago with the convening of the Bromley Panel to look at research possibilities for such an electron accelerator

  20. The accelerator facility of the Heidelberg Ion-Beam Therapy Centre (HIT)

    Science.gov (United States)

    Peters, Andreas

    The following sections are included: * Introduction * Beam parameters * General layout of the HIT facility * The accelerator chain in detail * Operational aspects of a particle therapy facility * 24/7 accelerator operation at 335 days per year * Safety and regulatory aspects * Status and perspectives * References

  1. Reliability Considerations for the Operation of Large Accelerator User Facilities

    CERN Document Server

    Willeke, F.J.

    2016-01-01

    The lecture provides an overview of considerations relevant for achieving highly reliable operation of accelerator based user facilities. The article starts with an overview of statistical reliability formalism which is followed by high reliability design considerations with examples. The article closes with operational aspects of high reliability such as preventive maintenance and spares inventory.

  2. A case of astrocytoma, 19 year history after BNCT

    International Nuclear Information System (INIS)

    Kamano, Shuji

    2006-01-01

    A 39-year-old man had received Boron Neutron Capture Therapy (BNCT) in 1987 for a Grade II Astrocytoma. He gradually exacerbated and received a second operation in 1994. The mass taken in the second operation is almost competent with radiation necrosis. Following that, he shows no signs of recurrence. Currently, he has returned to full time employment in physical labor. This case suggests effectiveness of BNCT for rather low-grade astrocytomas. (author)

  3. Initial Experimental Verification of the Neutron Beam Modeling for the LBNL BNCT Facility

    International Nuclear Information System (INIS)

    Bleuel, D.L.; Chu, W.T.; Donahue, R.J.; Ludewigt, B.A.; McDonald, R.J.; Smith, A.R.; Stone, N.A.; Vuji, J.

    1999-01-01

    In preparation for future clinical BNCT trials, neutron production via the 7Li(p,n) reaction as well as subsequent moderation to produce epithermal neutrons have been studied. Proper design of a moderator and filter assembly is crucial in producing an optimal epithermal neutron spectrum for brain tumor treatments. Based on in-phantom figures-of-merit,desirable assemblies have been identified. Experiments were performed at the Lawrence Berkeley National Laboratory's 88-inch cyclotron to characterize epithermal neutron beams created using several microampere of 2.5 MeV protons on a lithium target. The neutron moderating assembly consisted of Al/AlF3 and Teflon, with a lead reflector to produce an epithermal spectrum strongly peaked at 10-20 keV. The thermal neutron fluence was measured as a function of depth in a cubic lucite head phantom by neutron activation in gold foils. Portions of the neutron spectrum were measured by in-air activation of six cadmium-covered materials (Au, Mn, In, Cu, Co, W) with high epithermal neutron absorption resonances. The results are reasonably reproduced in Monte Carlo computational models, confirming their validity

  4. Primary study for boron neutron capture therapy uses the RSG-GAS beam tube facility

    International Nuclear Information System (INIS)

    Suroso

    2000-01-01

    The minimum epithermal neutron flux as one of the prerequisite of Boron Neutron Capture Therapy (BNCT) is 1.0 x 10 9 n/(cm 2 s) RSG-GAS have 6 beam tube facilities for neutron source, which is one of the beam tube S-2 has a possibility to utilization for BNCT facility. The totally flux neutron measurement in the front of S-2 beam tube is 1.8 x 10 7 n/(cm 2 s). The neutron flux measurement was less than for BNCT minimum prerequisite. Concerning to the flux neutron production in the reactor, which is reach to 2.5 x 10 14 n/(cm 2 s), there for the S-2 beam tube could be used beside collimator modification

  5. Beam Position Monitoring in the CSU Accelerator Facility

    Science.gov (United States)

    Einstein, Joshua; Vankeuren, Max; Watras, Stephen

    2014-03-01

    A Beam Position Monitoring (BPM) system is an integral part of an accelerator beamline, and modern accelerators can take advantage of newer technologies and designs when creating a BPM system. The Colorado State University (CSU) Accelerator Facility will include four stripline detectors mounted around the beamline, a low-noise analog front-end, and digitization and interface circuitry. The design will support a sampling rate greater than 10 Hz and sub-100 μm accuracy.

  6. Performance of the Argonne Wakefield Accelerator Facility and initial experimental results

    International Nuclear Information System (INIS)

    Gai, W.; Conde, M.; Cox, G.; Konecny, R.; Power, J.; Schoessow, P.; Simpson, J.; Barov, N.

    1996-01-01

    The Argonne Wakefield Accelerator facility has begun its experimental program. It is designed to address advanced acceleration research requiring very short, intense electron bunches. It incorporates two photocathode based electron sources. One produces up to 100 nC, multi-kiloamp 'drive' bunches which are used to excite wakefields in dielectric loaded structures and in plasma. The second source produces much lower intensity 'witness' pulses which are used to probe the fields produced by the drive. The drive and witness pulses can be precisely timed as well as laterally positioned with respect to each other. This paper discusses commissioning, initial experiments, and outline plans for a proposed 1 GeV demonstration accelerator

  7. Boron Neutron Capture Therapy at the TRIGA Mark II of Pavia, Italy - The BNCT of the diffuse tumours

    Energy Technology Data Exchange (ETDEWEB)

    Altieri, S.; Bortolussi, S.; Stella, S.; Bruschi, P.; Gadan, M.A. [University of Pavia (Italy); INFN - National Institute for Nuclear Physics, of Pavia (Italy)

    2008-10-29

    The selectivity based on the B distribution rather than on the irradiation field makes Boron neutron Capture Therapy (BNCT) a valid option for the treatment of the disseminated tumours. As the range of the high LET particles is shorter than a cell diameter, the normal cells around the tumour are not damaged by the reactions occurring in the tumoral cells. PAVIA 2001: first treatment of multiple hepatic metastases from colon ca by BNCT and auto-transplantation technique: TAOrMINA project. The liver was extracted after BPA infusion, irradiated in the Thermal Column of the Pavia TRIGA Mark II reactor, and re-implanted in the patient. Two patients were treated, demonstrating the feasibility of the therapy and the efficacy in destroying the tumoral nodules sparing the healthy tissues. In the last years, the possibility of applying BNCT to the lung tumours using epithermal collimated neutron beams and without explanting the organ, is being explored. The principal obtained results of the BNCT research are presented, with particular emphasis on the following aspects: a) the project of a new thermal column configuration to make the thermal neutron flux more uniform inside the explanted liver, b) the Monte Carlo study by means of the MCNP code of the thermal neutron flux distribution inside a patient's thorax irradiated with epithermal neutrons, and c) the measurement of the boron concentration in tissues by (n,{alpha}) spectroscopy and neutron autoradiography. The dose distribution in the thorax are simulated using MCNP and the anthropomorphic model ADAM. To have a good thermal flux distribution inside the lung epithermal neutrons must be used, which thermalize crossing the first tissue layers. Thermal neutrons do not penetrate and the obtained uniformity is poor. In the future, the construction of a PGNAA facility using a horizontal channel of the TRIGA Mark II is planned. With this method the B concentration can be measured also in liquid samples (blood, urine) and

  8. Subcellular boron and fluorine distributions with SIMS ion microscopy in BNCT and cancer research

    Energy Technology Data Exchange (ETDEWEB)

    Subhash Chandra

    2008-05-30

    The development of a secondary ion mass spectrometry (SIMS) based technique of Ion Microscopy in boron neutron capture therapy (BNCT) was the main goal of this project, so that one can study the subcellular location of boron-10 atoms and their partitioning between the normal and cancerous tissue. This information is fundamental for the screening of boronated drugs appropriate for neutron capture therapy of cancer. Our studies at Cornell concentrated mainly on studies of glioblastoma multiforme (GBM). The early years of the grant were dedicated to the development of cryogenic methods and correlative microscopic approaches so that a reliable subcellular analysis of boron-10 atoms can be made with SIMS. In later years SIMS was applied to animal models and human tissues of GBM for studying the efficacy of potential boronated agents in BNCT. Under this grant the SIMS program at Cornell attained a new level of excellence and collaborative SIMS studies were published with leading BNCT researchers in the U.S.

  9. Subcellular boron and fluorine distributions with SIMS ion microscopy in BNCT and cancer research

    International Nuclear Information System (INIS)

    Subhash, Chandra

    2008-01-01

    The development of a secondary ion mass spectrometry (SIMS) based technique of Ion Microscopy in boron neutron capture therapy (BNCT) was the main goal of this project, so that one can study the subcellular location of boron-10 atoms and their partitioning between the normal and cancerous tissue. This information is fundamental for the screening of boronated drugs appropriate for neutron capture therapy of cancer. Our studies at Cornell concentrated mainly on studies of glioblastoma multiforme (GBM). The early years of the grant were dedicated to the development of cryogenic methods and correlative microscopic approaches so that a reliable subcellular analysis of boron-10 atoms can be made with SIMS. In later years SIMS was applied to animal models and human tissues of GBM for studying the efficacy of potential boronated agents in BNCT. Under this grant the SIMS program at Cornell attained a new level of excellence and collaborative SIMS studies were published with leading BNCT researchers in the U.S.

  10. Feasibility of the utilization of BNCT in the fast neutron therapy beam at Fermilab

    International Nuclear Information System (INIS)

    Langen, Katja; Lennox, Arlene J.; Kroc, Thomas K.; DeLuca, Paul M. Jr.

    2000-01-01

    The Neutron Therapy Facility at Fermilab has treated cancer patients since 1976. Since then more than 2,300 patients have been treated and a wealth of clinical information accumulated. The therapeutic neutron beam at Fermilab is produced by bombarding a beryllium target with 66 MeV protons. The resulting continuous neutron spectrum ranges from thermal to 66 MeV in neutron energy. It is clear that this spectrum is not well suited for the treatment of tumors with boron neutron capture therapy (BNCT) only However, since this spectrum contains thermal and epithermal components the authors are investigating whether BNCT can be used in this beam to boost the tumor dose. There are clinical scenarios in which a selective tumor dose boost of 10 - 15% could be clinically significant. For these cases the principal treatment would still be fast neutron therapy but a tumor boost could be used either to deliver a higher dose to the tumor tissue or to reduce the dose to the normal healthy tissue while maintaining the absorbed dose level in the tumor tissue

  11. 6 MV Folded Tandem Ion Accelerator facility at BARC

    International Nuclear Information System (INIS)

    Gupta, S.K.

    2010-01-01

    The 6 MV Folded Tandem Ion Accelerator (FOTIA) facility is operational round the clock and accelerated beams of both light and heavy ions are being used extensively by various divisions of BARC, Universities, lIT Bombay and other R and D labs across the country. The FOTIA is an upgraded version of the old 5.5 MV single stage Van-de-Graaff accelerator (1962-1992). Since its commissioning in the year 2000, the poor beam transmission through the 180 deg folding magnet was a matter of concern. A systematic study for beam transmission through the accelerator was carried out and progressive modifications in folding magnet chamber, foil stripper holder and improvement in average vacuum level through the accelerator have resulted in large improvement of beam transmission leading to up to 2.0 micro-amp analyzed proton beams on target. Now the utilization of the beams from the accelerator has increased many folds for basic and applied research in the fields of atomic and nuclear physics, material science and radiation biology etc. Few new beam lines after the indigenously developed 5-port switching magnet are added and the experimental setup for PIXE, PIGE, External PIXE, 4 neutron detector, Proton Induced Positron Annihilation Spectroscopy (PIPAS) setup and the general purpose scattering chamber etc have been commissioned in the beam hall. The same team has developed a Low Energy Accelerator Facility (LEAF) which delivers negative ions of light and heavy ions for application in implantation, irradiation damage studies in semiconductor devices and testing of new beam line components being developed for Low Energy High Intensity Proton Accelerator (LEHIPA) programme at BARC. The LEAF has been developed as stand alone facility and can deliver beam quickly with minimum intervention of the operator. Few more features are being planned to deliver uniform scanned beams on large targets. (author)

  12. Neutron flux and gamma dose measurement in the BNCT irradiation facility at the TRIGA reactor of the University of Pavia

    Science.gov (United States)

    Bortolussi, S.; Protti, N.; Ferrari, M.; Postuma, I.; Fatemi, S.; Prata, M.; Ballarini, F.; Carante, M. P.; Farias, R.; González, S. J.; Marrale, M.; Gallo, S.; Bartolotta, A.; Iacoviello, G.; Nigg, D.; Altieri, S.

    2018-01-01

    University of Pavia is equipped with a TRIGA Mark II research nuclear reactor, operating at a maximum steady state power of 250 kW. It has been used for many years to support Boron Neutron Capture Therapy (BNCT) research. An irradiation facility was constructed inside the thermal column of the reactor to produce a sufficient thermal neutron flux with low epithermal and fast neutron components, and low gamma dose. In this irradiation position, the liver of two patients affected by hepatic metastases from colon carcinoma were irradiated after borated drug administration. The facility is currently used for cell cultures and small animal irradiation. Measurements campaigns have been carried out, aimed at characterizing the neutron spectrum and the gamma dose component. The neutron spectrum has been measured by means of multifoil neutron activation spectrometry and a least squares unfolding algorithm; gamma dose was measured using alanine dosimeters. Results show that in a reference position the thermal neutron flux is (1.20 ± 0.03) ×1010 cm-2 s-1 when the reactor is working at the maximum power of 250 kW, with the epithermal and fast components, respectively, 2 and 3 orders of magnitude lower than the thermal component. The ratio of the gamma dose with respect to the thermal neutron fluence is 1.2 ×10-13 Gy/(n/cm2).

  13. Tumor development in field-cancerized tissue is inhibited by a double application of Boron neutron capture therapy (BNCT) without exceeding radio-tolerance

    International Nuclear Information System (INIS)

    Monti Hughes, Andrea; Heber, Elisa M.; Itoiz, Maria E.; Molinari, Ana J.; Garabalino, Marcela A.; Trivillin, Veronica A.; Schwint, Amanda E.; Aromando, Romina F.

    2009-01-01

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of a 'single' application of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-1(Na 2 10 B 10 H 10 ) or (GB-10+BPA) to treat hamster cheek pouch tumors with no normal tissue radiotoxicity. Based on these results, we developed a model of precancerous tissue in the hamster cheek pouch for long-term studies. Employing this model we evaluated the long-term potential inhibitory effect on the development of second primary tumors from precancerous tissue and eventual radiotoxicity of a single application of BNCT mediated by BPA, GB-10 or (GB-10+BPA), in the RA-6. The clinical rationale of this study was to search for a BNCT protocol that is therapeutic for tumor, not radio-toxic for the normal tissue that lies in the neutron beam path, and exerts the desired inhibitory effect on the development of second primary tumors, without exceeding the radio-tolerance of precancerous tissue, the dose limiting tissue in this case. Second primary tumors that arise in precancerous tissue (also called locoregional recurrences) are a frequent cause of therapeutic failure in head and neck tumors. Aim: Evaluate the radiotoxicity and inhibitory effect of a 'double' application of the same BNCT protocols that were proved therapeutically successful for tumor and precancerous tissue, with a long term follow up (8 months). A 'double' application of BNCT is a potentially useful strategy for the treatment of tumors, in particular the larger ones, but the cost in terms of side-effects in dose-limiting tissues might preclude its application and requires cautious evaluation. Materials and methods: We performed a double application of 1) BPA-BNCT; 2) (GB

  14. SINBAD—The accelerator R&D facility under construction at DESY

    Energy Technology Data Exchange (ETDEWEB)

    Dorda, U., E-mail: ulrich.dorda@desy.de [DESY, Hamburg & Zeuthen (Germany); Assmann, R.; Brinkmann, R.; Flöttmann, K.; Hartl, I.; Hüning, M.; Kärtner, F.; Fallahi, A.; Marchetti, B.; Nie, Y.; Osterhoff, J.; Schlarb, H.; Zhu, J. [DESY, Hamburg & Zeuthen (Germany); Maier, A.R. [University Hamburg (Germany)

    2016-09-01

    The SINBAD facility (Short INnovative Bunches and Accelerators at DESY) is a long-term dedicated accelerator research and development facility currently under construction at DESY. It will be located in the premises of the old DORIS accelerator complex and host multiple independent experiments cost-effectively accessing the same central infrastructure like a central high power laser. With the removal of the old DORIS accelerator being completed, the refurbishment of the technical infrastructure is currently starting up. The presently ongoing conversion of the area into the SINBAD facility and the currently foreseen layout is described. The first experiment will use a compact S-band linac for the production of ultra-short bunches at hundred MeV. Once established, one of the main usages will be to externally inject electrons into a laser-driven plasma wakefield accelerator to boost the energy to GeV-level while maintaining a usable beam quality, ultimately aiming to drive an FEL. The second experiment already under planning is the setup of an attosecond radiation source with advanced technology. Further usage of the available space and infrastructure is revised and national and international collaborations are being established.

  15. FiR 1 reactor in service for boron neutron capture therapy (BNCT) and isotope production

    International Nuclear Information System (INIS)

    Auterinen, I.; Salmenhaara, S.E.J. . Author

    2004-01-01

    The FiR 1 reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose for the existence of the reactor is now the Boron Neutron Capture Therapy (BNCT), but FiR 1 has also an important national role in providing local enterprises and research institutions in the fields of industrial measurements, pharmaceuticals, electronics etc. with isotope production and activation analysis services. In the 1990's a BNCT treatment facility was built at the FiR 1 reactor located at Technical Research Centre of Finland. A special new neutron moderator material Fluental TM (Al+AlF3+Li) developed at VTT ensures the superior quality of the neutron beam. Also the treatment environment is of world top quality after a major renovation of the whole reactor building in 1997. Recently the lithiated polyethylene neutron shielding of the beam aperture was modified to ease the positioning of the patient close to the beam aperture. Increasing the reactor power to 500 kW would allow positioning of the patient further away from the beam aperture. Possibilities to accomplish a safety analysis for this is currently under considerations. Over thirty patients have been treated at FiR 1 since May 1999, when the license for patient treatment was granted to the responsible BNCT treatment organization, Boneca Corporation. Currently three clinical trial protocols for tumours in the brain as well as in the head and neck region are recruiting patients. (author)

  16. Design concept of radiation control system for the high intensity proton accelerator facility

    Energy Technology Data Exchange (ETDEWEB)

    Miyamoto, Yukihiro; Ikeno, Koichi; Akiyama, Shigenori; Harada, Yasunori [Japan Atomic Energy Research Inst., Tokai, Ibaraki (Japan). Tokai Research Establishment

    2002-11-01

    Description is given for the characteristic radiation environment for the High Intensity Proton Accelerator Facility and the design concept of the radiation control system of it. The facility is a large scale accelerator complex consisting of high energy proton accelerators carrying the highest beam intensity in the world and the related experimental facilities and therefore provides various issues relevant to the radiation environment. The present report describes the specifications for the radiation control system for the facility, determined in consideration of these characteristics. (author)

  17. Stability of high-speed lithium sheet jets for the neutron source in Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    Nakagawa, Masamichi; Takahashi, Minoru; Aritomi, Masanori; Kobayashi, Toru

    2014-01-01

    The stability of high-speed liquid lithium sheet jets was analytically studied for the neutron source in Boron Neutron Capture Therapy (BNCT), which makes cancers and tumors curable with cell-level selections and hence high QOL. The object of our research is to realize the thin and high-speed plane sheet jets of liquid lithium in a high-vacuum as an accelerator target. Linear analysis approach is made to the stability on thin plane sheet jets of liquid lithium in a high-vacuum, and then our analytical results were compared with the previous experimental ones. We proved that the waves of surface tension on thin lithium sheet jets in a high-vacuum are of supercritical flows and neutral stable under about 17.4 m/s in flow velocity and that the fast non-dispersive anti-symmetric waves are more significant than the very slow dispersive symmetric waves. We also formulated the equation of shrinking angle in isosceles-triangularly or isosceles-trapezoidal shrinking sheet jets corresponding to the Mach angle of supersonic gas flows. This formula states universally the physical meaning of Weber number of sheet jets on the wave of surface tension in supercritical flows. We obtained satisfactory prospects (making choice of larger flow velocity U and larger thickness of sheet a) to materialize a liquid target of accelerator in BNCT. (author)

  18. The Design of HVAC System in the Conventional Facility of Proton Accelerator Research Center

    International Nuclear Information System (INIS)

    Jeon, G. P.; Kim, J. Y.; Choi, B. H.

    2007-01-01

    The HVAC systems for conventional facility of Proton Accelerator Research Center consist of 3 systems : accelerator building HVAC system, beam application building HVAC system and miscellaneous HVAC system. We designed accelerator building HVAC system and beam application research area HVAC system in the conventional facilities of Proton Accelerator research center. Accelerator building HVAC system is divided into accelerator tunnel area, klystron area, klystron gallery area, accelerator assembly area. Also, Beam application research area HVAC system is divided into those of beam experimental hall, accelerator control area, beam application research area and Ion beam application building. In this paper, We described system design requirements and explained system configuration for each systems. We presented operation scenario of HVAC system in the Conventional Facility of Proton Accelerator Research Center

  19. Design of experiment existing parameter physics for supporting of Boron Neutron Capture Therapy (BNCT) method a t the piercing radial beam port of Kartini research reactor

    International Nuclear Information System (INIS)

    Indry Septiana Novitasari; Yosaphat Sumardi; Widarto

    2014-01-01

    The experiment existing parameters physics for supporting of in vivo and in vitro test facility of Boron Neutron Capture Therapy (BNCT) preliminary study at the piercing radial beam port has been done. The existing experiments is needed for determining that the parameter physics is fulfill the BNCT method requirement. To realize the existing experiment have been done by design analysis, methodology, calculation method and some procedure related with radiation safety analysis and environment. Preparation for existing experiment physics such as foil detector of Gold (Au) should be irradiated for 30 minute, irradiation instrument and procedure related with the experiment for radiation safety. (author)

  20. Employment of MCNP in the study of TLDS 600 and 700 seeking the implementation of radiation beam characterization of BNCT facility at IEA-R1; Emprego do MCNP no estudo dos TLDS 600 e 700 visando a implementacao da caracterizacao do feixe de irradiacao da instalacao de BNCT do IEA-R1

    Energy Technology Data Exchange (ETDEWEB)

    Cavalieri, Tassio Antonio

    2013-07-01

    Boron Neutron Capture Therapy, BNCT, is a bimodal radiotherapy procedure for cancer treatment. Its useful energy comes from a nuclear reaction driven by impinging thermal neutron upon Boron 10 atoms. A BNCT research facility has been constructed in IPEN at the IEA-R1 reactor, to develop studies in this area. One of its prime experimental parameter is the beam dosimetry which is nowadays made by using activation foils, for neutron measurements, and TLD 400, for gamma dosimetry. For mixed field dosimetry, the International Commission on Radiation Units and Measurements, ICRU, recommends the use of pair of detectors with distinct responses to the field components. The TLD 600/ TLD 700 pair meets this criteria, as the amount of {sup 6}Li, a nuclide with high thermal neutron cross section, greatly differs in their composition. This work presents a series of experiments and simulations performed in order to implement the mixed field dosimetry based on the use of TLD 600/TLD 700 pair. It also intended to compare this mixed field dosimetric methodology to the one so far used by the BNCT research group of IPEN. The response of all TLDs were studied under irradiations in different irradiation fields and simulations, underwent by MCNP, were run in order to evaluate the dose contribution from each field component. Series of repeated irradiations under pure gamma field and mixed field neutron/gamma field showed differences in the TLD individual responses which led to the adoption of a Normalization Factor. It has allowed to overcome TLD selection. TLD responses due to different field components and spectra were studied. It has shown to be possible to evaluate the relative gamma/neutron fluxes from the relative responses observed in the two Regions of Interest, ROIs, from TLD 600 and TLD 700. It has also been possible to observe the TLD 700 response to neutron, which leads to a gamma dose overestimation when one follows the ICRU recommended mixed field dosimetric procedure. Dose

  1. Cell death following BNCT: A theoretical approach based on Monte Carlo simulations

    Energy Technology Data Exchange (ETDEWEB)

    Ballarini, F., E-mail: francesca.ballarini@pv.infn.it [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Bakeine, J. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy); Bortolussi, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Bruschi, P. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy); Cansolino, L.; Clerici, A.M.; Ferrari, C. [University of Pavia, Department of Surgery, Experimental Surgery Laboratory, Pavia (Italy); Protti, N.; Stella, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Zonta, A.; Zonta, C. [University of Pavia, Department of Surgery, Experimental Surgery Laboratory, Pavia (Italy); Altieri, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy)

    2011-12-15

    In parallel to boron measurements and animal studies, investigations on radiation-induced cell death are also in progress in Pavia, with the aim of better characterisation of the effects of a BNCT treatment down to the cellular level. Such studies are being carried out not only experimentally but also theoretically, based on a mechanistic model and a Monte Carlo code. Such model assumes that: (1) only clustered DNA strand breaks can lead to chromosome aberrations; (2) only chromosome fragments within a certain threshold distance can undergo misrejoining; (3) the so-called 'lethal aberrations' (dicentrics, rings and large deletions) lead to cell death. After applying the model to normal cells exposed to monochromatic fields of different radiation types, the irradiation section of the code was purposely extended to mimic the cell exposure to a mixed radiation field produced by the {sup 10}B(n,{alpha}) {sup 7}Li reaction, which gives rise to alpha particles and Li ions of short range and high biological effectiveness, and by the {sup 14}N(n,p){sup 14}C reaction, which produces 0.58 MeV protons. Very good agreement between model predictions and literature data was found for human and animal cells exposed to X- or gamma-rays, protons and alpha particles, thus allowing to validate the model for cell death induced by monochromatic radiation fields. The model predictions showed good agreement also with experimental data obtained by our group exposing DHD cells to thermal neutrons in the TRIGA Mark II reactor of University of Pavia; this allowed to validate the model also for a BNCT exposure scenario, providing a useful predictive tool to bridge the gap between irradiation and cell death.

  2. SINP MSU accelerator facility and applied research

    International Nuclear Information System (INIS)

    Chechenin, N.G.; Ishkhanov, B.S.; Kulikauskas, V.S.; Novikov, L.S.; Pokhil, G.P.; Romanovskii, E.A.; Shvedunov, V.I.; Spasskii, A.V.

    2004-01-01

    Full text: SINP accelerator facility includes 120 cm cyclotron, electrostatic generator with the upper voltage 3.0 MeV, electrostatic generator with the upper voltage 2.5 MeV, Cocroft -Walton generator with the upper voltage 500 keV, 150 keV accelerator for solid microparticles. A new generation of electron beam accelerators has been developed during the last decade. The SINP accelerator facility will be shortly described in the report. A wide range of basic research in nuclear and atomic physics, physics of ion-beam interactions with condensed matter is currently carried out. SINP activity in the applied research is concentrated in the following areas of materials science: - Materials diagnostics with the Rutherford backscattering techniques (RBS) and channeling of ions (RBS/C). A large number of surface ad-layers and multilayer systems for advanced micro- and nano-electronic technology have been investigated. A selected series of examples will be illustrated. - Concentration depth profiles of hydrogen by the elastic recoils detection techniques (ERD). Primarily, the hydrogen depth profiles in perspective materials for thermonuclear reactors have been investigated. - Lattice site locations of hydrogen by a combination of ERD and channeling techniques. This is a new technique which was successfully applied for investigation of hydrogen and hydrogen-defect complexes in silicon for the smart-cut technology. - Light element diagnostics by RBS and nuclear backscattering techniques (NBS). The technique is illustrated by applications for nitrogen concentration profiling in steels. Nitrogen take-up and release, nitrides precipitate formation will be illustrated. - New medium energy ion scattering (MEIS) facility and applications. Ultra-high vacuum and superior energy resolution electrostatic toroidal analyzer is designed to be applied for characterization of composition and structure of several upper atomic layers of materials

  3. Successful BNCT for patients with cutaneous and mucosal melanomas. Report of 4 cases

    International Nuclear Information System (INIS)

    Morita, Norimasa; Hiratsuka, Junichi; Kuwabara, Chiaki; Aihara, Teruhito; Harada, Tamotsu; Imajo, Yoshinari; Ono, Koji; Fukuda, Hiroshi; Kumada, Hiroaki

    2006-01-01

    Since 2003 we have conducted BNCT clinical trials on melanomas at the Kyoto University Research Reactor (KUR) and Japan Research Reactor No.4 (JRR-4). We report 4 patients given BNCT for malignant melanomas: 2 with superficial spreading types on the heel, 1 with mucosal melanoma in the nasal cavity, and 1 with a melanoma on the vulva and in the vagina. The two cutaneous melanomas and the nasal cavity mucosal melanoma showed a complete response (CR) by 6 months after BNCT. The residual melanoma showed a partial response (PR) by 3 months after treatment and no regrowth since then. Although two patients experienced normal-tissue damage that exceeded the tolerance level, all the participants were cured within a few months of treatment. BNCT was shown to be a promising treatment for mucosal, as well as for cutaneous, melanomas. (author)

  4. Medical setup of intraoperative BNCT at JRR-4

    International Nuclear Information System (INIS)

    Akutsu, H.; Yamamoto, T.; Matsumura, A.

    2000-01-01

    Since October 1999, we have been performing clinical trials of intraoperative boron neutron capture therapy (IOBNCT) using a mixed thermal-epithermal beam at the Japan Research Reactor No. 4 (JRR-4). For immediate pre-BNCT care, including administration of a boron compound as well as post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of JRR-4. Following craniotomy in the treatment room, anesthetized patients were transported into the irradiation room for BNCT. The boron concentration in tissue was measured by the PGA and ICP-AES methods. The long-term follow-up was done at the University of Tsukuba Hospital. IOBNCT is a complex clinical procedure, which requires sophisticated operating team and co-medical staffs and also cooperation with physicist team. IOBNCT is a complex clinical procedure requiring a high level of cooperation among the operating team, co-medical staff, and physicists. For the safe and successful performance of IOBNCT, we have made the program including critical pathway and prepared various equipments for IOBNCT. To ensure the safe and successful performance of IOBNCT, we developed a critical pathway for use during the procedure, and prepared various apparatus for IOBNCT. (author)

  5. The MIT HEDP Accelerator Facility for Diagnostic Development for OMEGA, Z, and the NIF

    Science.gov (United States)

    Sio, H.; Gatu Johnson, M.; Birkel, A.; Doeg, E.; Frankel, R.; Kabadi, N. V.; Lahmann, B.; Manzin, M.; Simpson, R. A.; Parker, C. E.; Sutcliffe, G. D.; Wink, C.; Frenje, J. A.; Li, C. K.; Seguin, F. H.; Petrasso, R. D.; Leeper, R.; Hahn, K.; Ruiz, C. L.; Sangster, T. C.; Hilsabeck, T.

    2017-10-01

    The MIT HEDP Accelerator Facility utilizes a 135-keV, linear electrostatic ion accelerator; DT and DD neutron sources; and two x-ray sources for development and characterization of nuclear diagnostics for OMEGA, Z, and the NIF. The accelerator generates DD and D3He fusion products through the acceleration of D+ ions onto a 3He-doped Erbium-Deuteride target. Accurately characterized fusion product rates of around 106 s- 1 are routinely achieved. The DT and DD neutron sources generate up to 6×108 and 1×107 neutrons/s, respectively. One x-ray generator is a thick-target W source with a peak energy of 225 keV and a maximum dose rate of 12 Gy/min; the other uses Cu, Mo, or Ti elemental tubes to generate x-rays with a maximum energy of 40 keV. Diagnostics developed and calibrated at this facility include CR-39-based charged-particle spectrometers, neutron detectors, and the particle Time-Of-Flight (pTOF) and Magnetic PTOF CVD-diamond-based bang time detectors. The accelerator is also a valuable hands-on tool for graduate and undergraduate education at MIT. This work was supported in part by the U.S. DoE, SNL, LLE and LLNL.

  6. Construction Management for Conventional Facilities of Proton Accelerator

    International Nuclear Information System (INIS)

    Kim, Jun Yeon; Cho, Jang Hyung; Cho, Sung Won

    2013-01-01

    Proton Engineering Frontier Project, puts its aim to building 100MeV 20mA linear proton accelerator which is national facility for NT, BT, IT, and future technologies, expected to boost up the national industry competitiveness. This R and D, Construction Management is in charge of the supportive works such as site selection, architecture and engineering of conventional facilities, and overall construction management. The major goals of this work are as follows: At first, architecture and engineering of conventional facilities. Second, construction management, supervision and inspection on construction of conventional facilities. Lastly, cooperation with the project host organization, Gyeongju city, for adjusting technically interrelated work during construction. In this research, We completed the basic, detail, and field changed design of conventional facilities. Acquisition of necessary construction and atomic license, radiation safety analysis, site improvement, access road construction were successfully done as well. Also, we participated in the project host related work as follows: Project host organization and site selection, construction technical work for project host organization and procedure management, etc. Consequently, we so fulfilled all of the own goals which were set up in the beginning of this construction project that we could made contribution for installing and running PEFP's developed 100MeV 20mA linear accelerator

  7. Carborane-containing metalloporphyrins for BNCT

    International Nuclear Information System (INIS)

    Miura, Michiko; Joel, D.D.; Nawrocky, M.M.; Micca, P.L.

    1996-01-01

    For BNCT of malignant brain tumors, it is crucial that there be relatively high boron concentrations in tumor compared with normal tissues within the neutron-irradiated treatment volume. Fairchild and Bond estimated that major advances in BNCT should be possible if ratios of 10 B concentrations in tumor to those in normal tissue (e.g. brain and blood) were at least 5: 1. Given that the only current boron carrier being tested clinically in the U.S., p-boronophenyl-alanine[BPA], yields tumor blood and tumor brain ratios of about 3:1, the criteria for new boronated compounds should be to at least match these ratios and maintain tumor boron concentrations greater than 30 μg B/g. Although previously tested boronated porphyrins have not only matched but surpassed these ratios, it was at a cost of greater toxicity. Chemical and hematological assays of blood analytes; showed marked thrombocytopenia, a decrease to about one-tenth the normal concentration of platelets circulating in the blood, in addition to abnormalities in concentrations of circulating enzymes, that indicated liver toxicity. The physical appearance and behavior of the affected mice were different from those of mice injected with solvent only. Although thrombocytopenia and other toxic effects had disappeared after a few days, previously tested porphyrins would not be safe to infuse into patients for BNCT of potentially hemorrhagic malignant tumors in the brain such as glioblastoma multiforme and metastatic melanoma. We synthesized a different boronated porphyrin, tetracarboranylphenylporphyrin, [TCP] and inserted nickel, copper, or manganese into its coordination center. Biological studies of NiTCP in mice and of CuTCP in rats show that these compounds elicit little or no toxicity when given at potentially therapeutic doses

  8. Carborane-containing metalloporphyrins for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Miura, Michiko; Joel, D.D.; Nawrocky, M.M.; Micca, P.L. [and others

    1996-12-31

    For BNCT of malignant brain tumors, it is crucial that there be relatively high boron concentrations in tumor compared with normal tissues within the neutron-irradiated treatment volume. Fairchild and Bond estimated that major advances in BNCT should be possible if ratios of {sup 10}B concentrations in tumor to those in normal tissue (e.g. brain and blood) were at least 5: 1. Given that the only current boron carrier being tested clinically in the U.S., p-boronophenyl-alanine[BPA], yields tumor blood and tumor brain ratios of about 3:1, the criteria for new boronated compounds should be to at least match these ratios and maintain tumor boron concentrations greater than 30 {mu}g B/g. Although previously tested boronated porphyrins have not only matched but surpassed these ratios, it was at a cost of greater toxicity. Chemical and hematological assays of blood analytes; showed marked thrombocytopenia, a decrease to about one-tenth the normal concentration of platelets circulating in the blood, in addition to abnormalities in concentrations of circulating enzymes, that indicated liver toxicity. The physical appearance and behavior of the affected mice were different from those of mice injected with solvent only. Although thrombocytopenia and other toxic effects had disappeared after a few days, previously tested porphyrins would not be safe to infuse into patients for BNCT of potentially hemorrhagic malignant tumors in the brain such as glioblastoma multiforme and metastatic melanoma. We synthesized a different boronated porphyrin, tetracarboranylphenylporphyrin, [TCP] and inserted nickel, copper, or manganese into its coordination center. Biological studies of NiTCP in mice and of CuTCP in rats show that these compounds elicit little or no toxicity when given at potentially therapeutic doses.

  9. Epithermal neutron beam for BNCT research at the Washington State University TRIGA research reactor

    International Nuclear Information System (INIS)

    Nigg, D.W.; Venhuizen, J.R.; Wheeler, F.J.; Wemple, C.A.; Tripard, G.E.; Gavin, P.R.

    2000-01-01

    A new epithermal-neutron beam facility for BNCT (Boron Neutron Capture Therapy) research and boronated agent screening in animal models is in the final stages of construction at Washington State University (WSU). A key distinguishing feature of the design is the incorporation of a new, high-efficiency, neutron moderating and filtering material, Fluental, developed by the Technical Research Centre of Finland. An additional key feature is the provision for adjustable filter-moderator thickness to systematically explore the radiobiological consequences of increasing the fast-neutron contamination above the nominal value associated with the baseline system. (author)

  10. Medium energy heavy ion accelerator 14 UD Pelletron- a BARC-TIFR facility: a 5 year progress report 1989-1994

    International Nuclear Information System (INIS)

    Chatterjee, A.; Tandon, P.N.

    1995-01-01

    The medium energy heavy ion accelerator (MEHIA) facility based on 14 UD Pelletron set up under the collaborative project of Bhabha Atomic Research Centre (BARC) and Tata Institute of Fundamental Research (TIFR) at the TIFR campus at Bombay has been serving as a joint BARC-TIFR facility for heavy-ion accelerator based research. As this accelerator has just completed five years of its successful operations, it has been thought to be an appropriate time to bring out a report of the research work carried out with the accelerator facility over these last five years. To put the research work in proper perspective, the present report is formatted to provide a short write-up highlighting the work carried out in each area of activity along with a list of the publications which have resulted from these investigations. Some theoretical work related to the experimental activities with the pelletron accelerator has also been included in the list of publications. The research work in the area of nuclear physics, which forms the main thrust of the research activities with the accelerator, covers areas of high spin states, high energy photons, resonances in heavy ion reactions, heavy ion elastic and transfer reactions, heavy ion fusion-fission reactions and radiochemical studies in heavy ion reactions. The interdisciplinary areas of research include condensed matter physics and accelerator based atomic physics. In addition to the above topics the present report also describes the work related to the pelletron accelerator and associated experimental facilities, gas detector development work, data acquisition systems and spectrometer for heavy recoil ions under development. The present status of the superconducting Linac booster project is also briefly described. (author). refs., tabs

  11. Boron neutron capture therapy (BNCT) for glioblastoma multiforme (GBM), using the epithermal neutron beam at the Brookhaven National Laboratory

    International Nuclear Information System (INIS)

    Chadha, Manjeet; Capala, Jacek; Coderre, Jeffrey A.; Elowitz, Eric H.; Joel, Darrel D.; Hungyuan, B. Liu; Slatkin, Daniel N.; Chanana, Arjun D.

    1996-01-01

    Objective: BNCT is a binary treatment modality based on the nuclear reactions that occur when boron ( 10 B) is exposed to thermal neutrons. Preclinical studies have demonstrated the therapeutic efficacy of p-boronophenylalanine (BPA)-based BNCT. The objective of the Phase I/II trial was to evaluate BPA-fructose (BPA-F) as a boron delivery agent for GBM and to study the feasibility and safety of a single-fraction of BNCT. Materials and Methods: The trial design required i) a BPA-F biodistribution study performed at the time of craniotomy; and ii) BNCT within 4 weeks of the craniotomy. From September 94 to July 95, 10 patients with biopsy proven GBM were treated. All but 1 patient underwent a biodistribution study receiving IV BPA-F at the time of craniotomy. Multiple tissue samples and concurrent blood and urine samples were collected for evaluation of the boron concentration and clearance kinetics. For BNCT all patients received 250 mg/kgm of BPA-F (IV infusion over 2 hrs) followed by neutron irradiation. The blood 10 B concentration during irradiation was used to calculate the time of neutron exposure. The 3D treatment planning was done using the BNCT treatment planning software developed at the Idaho National Engineering Laboratory. The BNCT dose is expressed as the sum of the physical dose components corrected for both the RBE and the 10 B localization factor with the unit Gy-Eq. The photon-equivalent dose, where the thermal neutron fluence reaches a maximum, is the peak-dose equivalent. A single-fraction of BNCT was delivered prescribing 10.5 Gy-Eq (9 patients) and 13.8 Gy-Eq (1 patient) as the peak dose-equivalent to the normal brain. The peak dose rate was kept below 27 cGy-Eq/min. Results: Biodistribution data: The maximum blood 10 B concentration was observed at the end of the infusion and scaled as a linear function of the administered dose. The 10 B concentration in the scalp and in the GBM tissue was higher than in blood by 1.5 x and at least 3.5 x

  12. Monitoring total boron in blood for BNCT by a novel atomic emission method

    International Nuclear Information System (INIS)

    Laakso, J.; Kulvik, M.; Ruokonen, I.; Vaehaetalo, J.; Faerkkilae, M.; Kallio, M.; Zilliacus, R.

    2000-01-01

    In BNCT the duration and timing of the is adjusted by 10 B concentrations in whole blood. Time-frame for determinations is less than 20 minutes. Therefore fast and accurate boron determinations are a prerequisite for BNCT. We present a method based on ICP-AES instrument for whole blood and plasma boron determinations with protein precipitation with trichloroacetic acid as sample pre-treatment and beryllium as an internal standard. The method was compared to established but tedious ICP-mass spectrometric method with wet ashing as a sample pre-treatment. The ICP-AES method is in good agreement (correlation coefficient 0.99) the ICP-MS. Within-day and between-day imprecisions were less than 3,5% CV for whole blood samples. Samples taken during and after BPA-F infusion (290 mg/kg) revealed an uneven distribution between plasma and erythrocytes. The present method is feasible and one of the fastest currently available for BNCT. Our results indicate that BPA-F or its metabolites do not seem to be tightly bound to plasma proteins. It also seems that determination of boron in plasma sample may be preferable than measuring boron in whole blood. (author)

  13. A new target concept for proton accelerator driven boron neutron capture therapy applications

    International Nuclear Information System (INIS)

    Powell, J.R.; Ludewig, H.; Todosow, M.; Reich, M.

    1998-01-01

    A new target concept termed Discs Incorporating Sector Configured Orbiting Sources (DISCOS), is proposed for spallation applications, including BNCT (Boron Neutron Capture Therapy). In the BNCT application a proton beam impacts a sequence of ultra thin lithium DISCOS targets to generate neutrons by the 7 Li(p,n) 7 Be reaction. The proton beam loses only a few keV of its ∼MeV energy as it passes through a given target, and is re-accelerated to its initial energy, by a DC electric field between the targets

  14. Development of a 20 MeV Dielectric-Loaded Accelerator Test Facility

    International Nuclear Information System (INIS)

    Gold, Steven H.; Fliflet, Arne W.; Kinkead, Allen K.; Gai Wei; Power, John G.; Konecny, Richard; Jing Chunguang; Tantawi, Sami G.; Nantista, Christopher D.; Hu, Y.; Chen, H.; Tang, C.; Lin, Y.; Bruce, Ralph W.; Bruce, Robert L.; Lewis, David III

    2004-01-01

    This paper describes a joint project by the Naval Research Laboratory (NRL) and Argonne National Laboratory (ANL), in collaboration with the StanFord Linear Accelerator Center (SLAC), to develop a dielectric-loaded accelerator (DLA) test facility powered by a high-power 11.424-GHz magnicon amplifier. The magnicon can presently produce 25 MW of output power in a 250-ns pulse at 10 Hz, and efforts are in progress to increase this to 50 MW. The facility will include a 5 MeV electron injector being developed by the Accelerator Laboratory of Tsinghua University in Beijing, China. The DLA test structures are being developed by ANL, and some have undergone testing at NRL at gradients up to ∼8 MV/m. SLAC is developing a means to combine the two magnicon output arms, and to drive an injector and accelerator with separate control of the power ratio and relative phase. RWBruce Associates, Inc., working with NRL, is developing a means to join short ceramic sections into a continuous accelerator tube by ceramic brazing using an intense millimeter-wave beam. The installation and testing of the first dielectric-loaded test accelerator, including injector, DLA structure, and spectrometer, should take place within the next year. The facility will be used for testing DLA structures using a variety of materials and configurations, and also for testing other X-band accelerator concepts. The initial goal is to produce a compact 20 MeV dielectric-loaded test accelerator

  15. BNL ACCELERATOR-BASED RADIOBIOLOGY FACILITIES

    International Nuclear Information System (INIS)

    LOWENSTEIN, D.I.

    2000-01-01

    For the past several years, the Alternating Gradient Synchrotron (AGS) at Brookhaven National Laboratory (USA) has provided ions of iron, silicon and gold, at energies from 600 MeV/nucleon to 10 GeV/nucleon, for the US National Aeronautics and Space Administration (NASA) radiobiology research program. NASA has recently funded the construction of a new dedicated ion facility, the Booster Applications Facility (BAF). The Booster synchrotron will supply ion beams ranging from protons to gold, in an energy range from 40--3,000 MeV/nucleon with maximum beam intensities of 10 10 to 10 11 ions per pulse. The BAF Project is described and the future AGS and BAF operation plans are presented

  16. Measurement and simulation of the TRR BNCT beam parameters

    Energy Technology Data Exchange (ETDEWEB)

    Bavarnegin, Elham [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Department of Physics, University of Guilan, Rasht (Iran, Islamic Republic of); Sadremomtaz, Alireza [Department of Physics, University of Guilan, Rasht (Iran, Islamic Republic of); Khalafi, Hossein [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Kasesaz, Yaser, E-mail: ykasesaz@aeoi.org.ir [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Golshanian, Mohadeseh; Ghods, Hossein; Ezzati, Arsalan; Keyvani, Mehdi; Haddadi, Mohammad [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of)

    2016-09-11

    Recently, the configuration of the Tehran Research Reactor (TRR) thermal column has been modified and a proper thermal neutron beam for preclinical Boron Neutron Capture Therapy (BNCT) has been obtained. In this study, simulations and experimental measurements have been carried out to identify the BNCT beam parameters including the beam uniformity, the distribution of the thermal neutron dose, boron dose, gamma dose in a phantom and also the Therapeutic Gain (TG). To do this, the entire TRR structure including the reactor core, pool, the thermal column and beam tubes have been modeled using MCNPX Monte Carlo code. To measure in-phantom dose distribution a special head phantom has been constructed and foil activation techniques and TLD700 dosimeter have been used. The results show that there is enough uniformity in TRR thermal BNCT beam. TG parameter has the maximum value of 5.7 at the depth of 1 cm from the surface of the phantom, confirming that TRR thermal neutron beam has potential for being used in treatment of superficial brain tumors. For the purpose of a clinical trial, more modifications need to be done at the reactor, as, for example design, and construction of a treatment room at the beam exit which is our plan for future. To date, this beam is usable for biological studies and animal trials. There is a relatively good agreement between simulation and measurement especially within a diameter of 10 cm which is the dimension of usual BNCT beam ports. This relatively good agreement enables a more precise prediction of the irradiation conditions needed for future experiments.

  17. External radiation exposure control system in accelerator facilities

    International Nuclear Information System (INIS)

    Ogawa, Tatsuhiko; Iimoto, Takeshi; Kosako, Toshiso

    2011-01-01

    The external exposure control systems in KEK and CERN are discussed to find out good practices and unreasonableness of radiation control in accelerator facilities, which plays an important role in optimizing national and/or site specific radiological regulations, referring to relevant ICRP publications. Personal dose limits and radiation area classifications were analyzed and their reasonableness were explored. Good example of supervised areas, area classification based on realistic assumptions on working time etc are found. On the other hand, unreasonable systems, that are often attributed to the national regulation or ideas presented in the old publications are also found. (author)

  18. Radioprotective agents to reduce BNCT (Boron Neutron Capture Therapy) induced mucositis in the hamster cheek pouch

    International Nuclear Information System (INIS)

    Monti Hughes, A.; Pozzi, E.C.C.; Thorp, S.

    2013-01-01

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of BNCT mediated by boronophenylalanine (BPA) in the hamster cheek pouch oral cancer and pre cancer model. Despite therapeutic efficacy, mucositis induced in premalignant tissue was dose limiting and favored, in some cases, tumor development. In a clinical scenario, oral mucositis limits the dose administered to head and neck tumors. Aim: Our aim was to evaluate the effect of the administration of different radioprotective agents, seeking to reduce BNCT-induced mucositis to acceptable levels in dose-limiting premalignant tissue; without compromising therapeutic effect evaluated as inhibition on tumor development in premalignant tissue; without systemic or local side effects; and without negative effects on the biodistribution of the boron compound used for treatment. Materials and methods: Cancerized hamsters with DMBA (dimethylbenzanthracene) were treated with BPA-BNCT 5 Gy total absorbed dose to premalignant tissue, at the RA-3 Nuclear Reactor, divided into different groups: 1-treated with FLUNIXIN; 2- ATORVASTATIN; 3-THALIDOMIDE; 4-HISTAMINE (two concentrations: Low -1 mg/ml- and High -5 mg/ml-); 5-JNJ7777120; 6-JNJ10191584; 7-SALINE (vehicle). Cancerized animals without any treatment (neither BNCT nor radioprotective therapy) were also analyzed. We followed the animals during one month and evaluated the percentage of animals with unacceptable/severe mucositis, clinical status and percentage of animals with new tumors post treatment. We also performed a preliminary biodistribution study of BPA + Histamine “low” concentration to evaluate the potential effect of the radioprotector on BPA biodistribution. Results: Histamine

  19. Brookhaven National Laboratory's Accelerator Test Facility: research highlights and plans

    Science.gov (United States)

    Pogorelsky, I. V.; Ben-Zvi, I.

    2014-08-01

    The Accelerator Test Facility (ATF) at Brookhaven National Laboratory has served as a user facility for accelerator science for over a quarter of a century. In fulfilling this mission, the ATF offers the unique combination of a high-brightness 80 MeV electron beam that is synchronized to a 1 TW picosecond CO2 laser. We unveil herein our plan to considerably expand the ATF's floor space with an upgrade of the electron beam's energy to 300 MeV and the CO2 laser's peak power to 100 TW. This upgrade will propel the ATF even further to the forefront of research on advanced accelerators and radiation sources, supporting the most innovative ideas in this field. We discuss emerging opportunities for scientific breakthroughs, including the following: plasma wakefield acceleration studies in research directions already active at the ATF; laser wakefield acceleration (LWFA), where the longer laser wavelengths are expected to engender a proportional increase in the beam's charge while our linac will assure, for the first time, the opportunity to undertake detailed studies of seeding and staging of the LWFA; proton acceleration to the 100-200 MeV level, which is essential for medical applications; and others.

  20. 50 Years of the Radiological Research Accelerator Facility (RARAF)

    OpenAIRE

    Marino, Stephen A.

    2017-01-01

    The Radiological Research Accelerator Facility (RARAF) is in its 50th year of operation. It was commissioned on April 1, 1967 as a collaboration between the Radiological Research Laboratory (RRL) of Columbia University, and members of the Medical Research Center of Brookhaven National Laboratory (BNL). It was initially funded as a user facility for radiobiology and radiological physics, concentrating on monoenergetic neutrons. Facilities for irradiation with MeV light charged particles were d...

  1. The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

    Energy Technology Data Exchange (ETDEWEB)

    Yamamoto, T., E-mail: tetsu_tsukuba@yahoo.co.jp [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nakai, K. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo (Japan); Kumada, H.; Okumura, T.; Mizumoto, M.; Tsuboi, K. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Zaboronok, A.; Ishikawa, E.; Aiyama, H.; Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)

    2011-12-15

    The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m{sup 2}) for the treatment of newly diagnosed GBM. BPA uptake is determined by {sup 18}F-BPA-PET and/or {sup 11}C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival.

  2. Micro-controller based fiber optic data telemetry system for the ion source of low energy accelerator facility at BARC

    International Nuclear Information System (INIS)

    Padmakumar, Sapna; Ware, Shailaja V.; Subrahmanyam, N.B.V.; Bhatt, J.P.; Singh, S.K.; Gupta, S.K.; Singh, P.; Choudhury, R.K.

    2009-01-01

    The Low Energy Accelerator Facility (LEAF) is a 50 keV, high intensity, negative ion accelerator facility that has been set up indigenously at Nuclear Physics Division, BARC. This facility is capable of delivering a wide range of negative ion beams of both light and heavy ions across the periodic table using a SNICS II (Source of Negative Ion by Caesium Sputtering) source. A micro-controller based control and monitoring system has been developed exclusively for the ion source parameters of LEAF. The data control and monitoring system mainly targets acquiring the data from the field in the terms of parameters such as voltages and currents. There are processes which need to be monitored continuously in order to keep certain parameters under check. The microcontroller based fiber optic data telemetry system allows us to perform the aforesaid task. The voltages can be controlled and monitored by providing the inputs and receiving the feedback through a user friendly graphic user interface. With this system one can control the status as well as analog value of the high voltage power supplies like extractor, cathode, filament, focus line heater and oven. This system consists of Fiber optic transceiver, which is connected on serial port (RS 232C) of microcontroller as well as RS232 port of PC. The whole control system is reliable even in noisy environments including RF and worse EMI conditions. This compact modular design is implemented using low cost devices and allows easy and fast maintainability. In the paper, the details of the system are presented. (author)

  3. Collimator and shielding design for boron neutron capture therapy (BNCT) facility at TRIGA MARK II reactor

    International Nuclear Information System (INIS)

    Mohd Rafi Mohd Solleh; Abdul Aziz Tajuddin; Abdul Aziz Mohamed; Eid Mahmoud Eid Abdel Munem; Mohamad Hairie Rabir; Julia Abdul Karim; Yoshiaki, Kiyanagi

    2011-01-01

    The geometry of reactor core, thermal column, collimator and shielding system for BNCT application of TRIGA MARK II Reactor were simulated with MCNP5 code. Neutron particle lethargy and dose were calculated with MCNPX code. Neutron flux in a sample located at the end of collimator after normalized to measured value (Eid Mahmoud Eid Abdel Munem, 2007) at 1 MW power was 1.06 x 10 8 n/ cm 2 / s. According to IAEA (2001) flux of 1.00 x 10 9 n/ cm 2 / s requires three hours of treatment. Few modifications were needed to get higher flux. (Author)

  4. A 1MeV, 1A negative ion accelerator test facility

    International Nuclear Information System (INIS)

    Hanada, M.; Dairaku, M.; Inoue, T.; Miyamoto, K.; Ohara, Y.; Okumura, Y.; Watanabe, K.; Yokoyama, K.

    1995-01-01

    For the Proof-of-Principle test of negative ion acceleration up to 1 MeV, the beam energy required for ITER, a negative ion test facility named MeV Test Facility (MTF) and an ion source/accelerator have been designed and constructed. They are designed to produce a 1 MeV H- beam at a low source pressure of 0.13Pa. The MTF has a power supply system, which constituts of a 1MV, 1A, 60 s Cockcroft-Walton type dc high energy generator and power supplies for negative ion generation and extraction (ion source power supplies). The negative ion source/accelerator is composed of a cesiated volume source and a 5-stage, multi-aperture, electrostatic accelerator. The MTF and the ion source/accelerator have been completed, and the accelertion test up to 1 MeV of the H- ions has started. (orig.)

  5. A core laboratory offering full evaluation of new boron compounds. A service to the BNCT community

    International Nuclear Information System (INIS)

    Zamenhof, R.G.; Patel, H.; Palmer, M.R.; Lin, H.C.; Busse, P.M.; Harling, O.; Binns, P.J.; Riley, K.J.; Bernard, J.

    2000-01-01

    A joint project by the Beth Israel Deaconess Medical Center at Harvard Medical School and The Nuclear Reactor Laboratory of the Massachusetts Institute of Technology is proposed which would provide a core laboratory for the evaluation of new boron compounds. Federal agency funding has been applied for to support such a facility. The facility's evaluation of candidate boron compounds will include: quantitative cellular boron uptake; cell survival curve analysis (using a thermal neutron beam); small or large animal pharmacokinetic analysis; macro- and micro boron distribution analysis using high-resolution autoradiography, prompt gamma analysis and ICP-AES; small or large animal in vivo tumor control studies (using thermal or epithermal neutron beams); and pharmacological in vivo toxicity evaluation. The laboratory will include small and large animal surgical facilities and resources for additional boron compound chemistry as required by the evaluation procedure. This facility will be open to the BNCT research community. (author)

  6. A post-accelerator for the US rare isotope accelerator facility

    CERN Document Server

    Ostroumov, P N; Kolomiets, A A; Nolen, J A; Portillo, M; Shepard, K W; Vinogradov, N E

    2003-01-01

    The proposed rare isotope accelerator (RIA) facility includes a post-accelerator for rare isotopes (RIB linac) which must produce high-quality beams of radioactive ions over the full mass range, including uranium, at energies above the Coulomb barrier, and have high transmission and efficiency. The latter requires the RIB linac to accept at injection ions in the 1+ charge state. A concept for such a post accelerator suitable for ions up to mass 132 has been previously described . This paper presents a modified concept which extends the mass range to uranium. A high resolution separator for purifying beams at the isobaric level precedes the RIB linac. The mass filtering process will provide high purity beams while preserving transmission. For most cases a resolution of about m/DELTA m=20 000 is adequate at mass A=100 to obtain a separation between isobars of mass excess difference of 5 MeV. The design for a device capable of purifying beams at the isobaric level includes calculations up to fifth order. The RIB...

  7. Study of electron beam energy conversion at gyrocon-linear accelerator facility

    International Nuclear Information System (INIS)

    Karliner, M.M.; Makarov, I.G.; Ostreiko, G.N.

    2004-01-01

    A gyrocon together with the high-voltage 1.5 MeV accelerator ELIT-3A represents a power generator at 430 MHz serving for linear electron accelerator pulse driving. The facility description and results of calorimetric measurements of ELIT-3A electron beam power and accelerated beam at the end of accelerator are presented in the paper. The achieved energy conversion efficiency is about 55%

  8. Microdosimetric measurements in the thermal neutron irradiation facility of LENA reactor

    International Nuclear Information System (INIS)

    Colautti, P.; Moro, D.; Chiriotti, S.; Conte, V.; Evangelista, L.; Altieri, S.; Bortolussi, S.; Protti, N.; Postuma, I.

    2014-01-01

    A twin TEPC with electric-field guard tubes has been constructed to be used to characterize the BNCT field of the irradiation facility of LENA reactor. One of the two mini TEPC was doped with 50 ppm of 10 B in order to simulate the BNC events occurring in BNCT. By properly processing the two microdosimetric spectra, the gamma, neutron and BNC spectral components can be derived with good precision (∼6%). However, direct measurements of 10 B in some doped plastic samples, which were used for constructing the cathode walls, point out the scarce accuracy of the nominal 10 B concentration value. The influence of the Boral ® door, which closes the irradiation channel, has been measured. The gamma dose increases significantly (+51%) when the Boral ® door is closed. The crypt-cell-regeneration weighting function has been used to measure the quality, namely the RBE µ value, of the radiation field in different conditions. The measured RBE µ values are only partially consistent with the RBE values of other BNCT facilities. - Highlights: • A counter with two mini TEPCs, both equipped with electrical-field guard tubes, has been constructed. • The microdosimetric spectrum of the LENA-reactor irradiation vane has been studied. • The radiation-field quality (RBE) assessment confirms that the D n /D tot ratio is not an accurate parameter to characterize the BNCT radiation field

  9. Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, H.

    2011-01-01

    The purpose of this study was to compare the radiation dose between long-survivors and non-long-survivors in patients with glioblatoma (GBM) treated with boron neutron capture therapy (BNCT). Among 23 GBM patients treated with BNCT, there were five patients who survived more than three years after diagnosis. The physical and weighted dose of the minimum gross tumor volume (GTV) of long-survivors was much higher than that of non-long survivors with significant statistical differences.

  10. Correlation of clinical outcome to the estimated radiation dose from Boron Neutron Capture Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Chadha, M. [Beth Israel Medical Center, NY (United States). Dept. of Radiation Oncology; Coderre, J.A.; Chanana, A.D. [Brookhaven National Lab., Upton, NY (United States)] [and others

    1996-12-31

    A phase I/II trial delivering a single fraction of BNCT using p-Boronophenylalanine-Fructose and epithermal neutrons at the the Brookhaven Medical Research Reactor was initiated in September 1994. The primary endpiont of the study was to evaluate the feasibility and safety of a given BNCT dose. The clinical outcome of the disease was a secondary endpoint of the study. The objective of this paper is to evaluate the correlation of the clinical outcome of patients to the estimated radiation dose from BNCT.

  11. Correlation of clinical outcome to the estimated radiation dose from Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    Chadha, M.

    1996-01-01

    A phase I/II trial delivering a single fraction of BNCT using p-Boronophenylalanine-Fructose and epithermal neutrons at the the Brookhaven Medical Research Reactor was initiated in September 1994. The primary endpiont of the study was to evaluate the feasibility and safety of a given BNCT dose. The clinical outcome of the disease was a secondary endpoint of the study. The objective of this paper is to evaluate the correlation of the clinical outcome of patients to the estimated radiation dose from BNCT

  12. Hardware availability calculations and results of the IFMIF accelerator facility

    International Nuclear Information System (INIS)

    Bargalló, Enric; Arroyo, Jose Manuel; Abal, Javier; Beauvais, Pierre-Yves; Gobin, Raphael; Orsini, Fabienne; Weber, Moisés; Podadera, Ivan; Grespan, Francesco; Fagotti, Enrico; De Blas, Alfredo; Dies, Javier; Tapia, Carlos; Mollá, Joaquín; Ibarra, Ángel

    2014-01-01

    Highlights: • IFMIF accelerator facility hardware availability analyses methodology is described. • Results of the individual hardware availability analyses are shown for the reference design. • Accelerator design improvements are proposed for each system. • Availability results are evaluated and compared with the requirements. - Abstract: Hardware availability calculations have been done individually for each system of the deuteron accelerators of the International Fusion Materials Irradiation Facility (IFMIF). The principal goal of these analyses is to estimate the availability of the systems, compare it with the challenging IFMIF requirements and find new paths to improve availability performances. Major unavailability contributors are highlighted and possible design changes are proposed in order to achieve the hardware availability requirements established for each system. In this paper, such possible improvements are implemented in fault tree models and the availability results are evaluated. The parallel activity on the design and construction of the linear IFMIF prototype accelerator (LIPAc) provides detailed design information for the RAMI (reliability, availability, maintainability and inspectability) analyses and allows finding out the improvements that the final accelerator could have. Because of the R and D behavior of the LIPAc, RAMI improvements could be the major differences between the prototype and the IFMIF accelerator design

  13. Hardware availability calculations and results of the IFMIF accelerator facility

    Energy Technology Data Exchange (ETDEWEB)

    Bargalló, Enric, E-mail: enric.bargallo-font@upc.edu [Fusion Energy Engineering Laboratory (FEEL), Technical University of Catalonia (UPC), Barcelona (Spain); Arroyo, Jose Manuel [Laboratorio Nacional de Fusión por Confinamiento Magnético – CIEMAT, Madrid (Spain); Abal, Javier [Fusion Energy Engineering Laboratory (FEEL), Technical University of Catalonia (UPC), Barcelona (Spain); Beauvais, Pierre-Yves; Gobin, Raphael; Orsini, Fabienne [Commissariat à l’Energie Atomique, Saclay (France); Weber, Moisés; Podadera, Ivan [Laboratorio Nacional de Fusión por Confinamiento Magnético – CIEMAT, Madrid (Spain); Grespan, Francesco; Fagotti, Enrico [Istituto Nazionale di Fisica Nucleare, Legnaro (Italy); De Blas, Alfredo; Dies, Javier; Tapia, Carlos [Fusion Energy Engineering Laboratory (FEEL), Technical University of Catalonia (UPC), Barcelona (Spain); Mollá, Joaquín; Ibarra, Ángel [Laboratorio Nacional de Fusión por Confinamiento Magnético – CIEMAT, Madrid (Spain)

    2014-10-15

    Highlights: • IFMIF accelerator facility hardware availability analyses methodology is described. • Results of the individual hardware availability analyses are shown for the reference design. • Accelerator design improvements are proposed for each system. • Availability results are evaluated and compared with the requirements. - Abstract: Hardware availability calculations have been done individually for each system of the deuteron accelerators of the International Fusion Materials Irradiation Facility (IFMIF). The principal goal of these analyses is to estimate the availability of the systems, compare it with the challenging IFMIF requirements and find new paths to improve availability performances. Major unavailability contributors are highlighted and possible design changes are proposed in order to achieve the hardware availability requirements established for each system. In this paper, such possible improvements are implemented in fault tree models and the availability results are evaluated. The parallel activity on the design and construction of the linear IFMIF prototype accelerator (LIPAc) provides detailed design information for the RAMI (reliability, availability, maintainability and inspectability) analyses and allows finding out the improvements that the final accelerator could have. Because of the R and D behavior of the LIPAc, RAMI improvements could be the major differences between the prototype and the IFMIF accelerator design.

  14. Availability simulation software adaptation to the IFMIF accelerator facility RAMI analyses

    Energy Technology Data Exchange (ETDEWEB)

    Bargalló, Enric, E-mail: enric.bargallo-font@upc.edu [Fusion Energy Engineering Laboratory (FEEL), Technical University of Catalonia (UPC) Barcelona-Tech, Barcelona (Spain); Sureda, Pere Joan [Fusion Energy Engineering Laboratory (FEEL), Technical University of Catalonia (UPC) Barcelona-Tech, Barcelona (Spain); Arroyo, Jose Manuel [Laboratorio Nacional de Fusión por Confinamiento Magnético – CIEMAT, Madrid (Spain); Abal, Javier; De Blas, Alfredo; Dies, Javier; Tapia, Carlos [Fusion Energy Engineering Laboratory (FEEL), Technical University of Catalonia (UPC) Barcelona-Tech, Barcelona (Spain); Mollá, Joaquín; Ibarra, Ángel [Laboratorio Nacional de Fusión por Confinamiento Magnético – CIEMAT, Madrid (Spain)

    2014-10-15

    Highlights: • The reason why IFMIF RAMI analyses needs a simulation is explained. • Changes, modifications and software validations done to AvailSim are described. • First IFMIF RAMI results obtained with AvailSim 2.0 are shown. • Implications of AvailSim 2.0 in IFMIF RAMI analyses are evaluated. - Abstract: Several problems were found when using generic reliability tools to perform RAMI (Reliability Availability Maintainability Inspectability) studies for the IFMIF (International Fusion Materials Irradiation Facility) accelerator. A dedicated simulation tool was necessary to model properly the complexity of the accelerator facility. AvailSim, the availability simulation software used for the International Linear Collider (ILC) became an excellent option to fulfill RAMI analyses needs. Nevertheless, this software needed to be adapted and modified to simulate the IFMIF accelerator facility in a useful way for the RAMI analyses in the current design phase. Furthermore, some improvements and new features have been added to the software. This software has become a great tool to simulate the peculiarities of the IFMIF accelerator facility allowing obtaining a realistic availability simulation. Degraded operation simulation and maintenance strategies are the main relevant features. In this paper, the necessity of this software, main modifications to improve it and its adaptation to IFMIF RAMI analysis are described. Moreover, first results obtained with AvailSim 2.0 and a comparison with previous results is shown.

  15. Availability simulation software adaptation to the IFMIF accelerator facility RAMI analyses

    International Nuclear Information System (INIS)

    Bargalló, Enric; Sureda, Pere Joan; Arroyo, Jose Manuel; Abal, Javier; De Blas, Alfredo; Dies, Javier; Tapia, Carlos; Mollá, Joaquín; Ibarra, Ángel

    2014-01-01

    Highlights: • The reason why IFMIF RAMI analyses needs a simulation is explained. • Changes, modifications and software validations done to AvailSim are described. • First IFMIF RAMI results obtained with AvailSim 2.0 are shown. • Implications of AvailSim 2.0 in IFMIF RAMI analyses are evaluated. - Abstract: Several problems were found when using generic reliability tools to perform RAMI (Reliability Availability Maintainability Inspectability) studies for the IFMIF (International Fusion Materials Irradiation Facility) accelerator. A dedicated simulation tool was necessary to model properly the complexity of the accelerator facility. AvailSim, the availability simulation software used for the International Linear Collider (ILC) became an excellent option to fulfill RAMI analyses needs. Nevertheless, this software needed to be adapted and modified to simulate the IFMIF accelerator facility in a useful way for the RAMI analyses in the current design phase. Furthermore, some improvements and new features have been added to the software. This software has become a great tool to simulate the peculiarities of the IFMIF accelerator facility allowing obtaining a realistic availability simulation. Degraded operation simulation and maintenance strategies are the main relevant features. In this paper, the necessity of this software, main modifications to improve it and its adaptation to IFMIF RAMI analysis are described. Moreover, first results obtained with AvailSim 2.0 and a comparison with previous results is shown

  16. Abscopal effect of boron neutron capture therapy (BNCT). Proof of principle in an experimental model of colon cancer

    Energy Technology Data Exchange (ETDEWEB)

    Trivillin, Veronica A.; Monti Hughes, Andrea; Schwint, Amanda E. [Comision Nacional de Energia Atomica (CNEA), Department of Radiobiology, B1650KNA San Martin, Provincia Buenos Aires (Argentina); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Pozzi, Emiliano C.C.; Curotto, Paula [Centro Atomico Ezeiza, Comision Nacional de Energia Atomica (CNEA), Department of Research and Production Reactors, Provincia Buenos Aires (Argentina); Colombo, Lucas L. [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Instituto de Oncologia Angel H. Roffo, Ciudad Autonoma de Buenos Aires (Argentina); Thorp, Silvia I.; Farias, Ruben O. [Comision Nacional de Energia Atomica (CNEA), Department of Instrumentation and Control, Provincia Buenos Aires (Argentina); Garabalino, Marcela A. [Comision Nacional de Energia Atomica (CNEA), Department of Radiobiology, B1650KNA San Martin, Provincia Buenos Aires (Argentina); Gonzalez, Sara J. [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Comision Nacional de Energia Atomica (CNEA), Department of Instrumentation and Control, Provincia Buenos Aires (Argentina); Santa Cruz, Gustavo A. [Comision Nacional de Energia Atomica (CNEA), Department of Boron Neutron Capture Therapy, Provincia Buenos Aires (Argentina); Carando, Daniel G. [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Universidad de Buenos Aires, Faculty of Exact and Natural Sciences, Ciudad Autonoma de Buenos Aires (Argentina)

    2017-11-15

    The aim of the present study was to evaluate, for the first time, the abscopal effect of boron neutron capture therapy (BNCT). Twenty-six BDIX rats were inoculated subcutaneously with 1 x 10{sup 6} DHD/K12/TRb syngeneic colon cancer cells in the right hind flank. Three weeks post-inoculation, the right leg of 12 rats bearing the tumor nodule was treated with BPA-BNCT (BPA-Boronophenylalanine) at the RA-3 nuclear reactor located in Buenos Aires, Argentina, at an absorbed dose of 7.5 Gy to skin as the dose-limiting tissue. The remaining group of 14 tumor-bearing rats were left untreated and used as control. Two weeks post-BNCT, 1 x 10{sup 6} DHD/K12/TRb cells were injected subcutaneously in the contralateral left hind flank of each of the 26 BDIX rats. Tumor volume in both legs was measured weekly for 7 weeks to determine response to BNCT in the right leg and to assess a potential influence of BNCT in the right leg on tumor development in the left leg. Within the BNCT group, a statistically significant reduction was observed in contralateral left tumor volume in animals whose right leg tumor responded to BNCT (post-treatment/pre-treatment tumor volume <1) versus animals who failed to respond (post/pre ≥1), i.e., 13 ± 15 vs 271 ± 128 mm{sup 3}. In addition, a statistically significant reduction in contralateral left leg tumor volume was observed in BNCT-responsive animals (post/pre <1) vs untreated animals, i.e., 13 ± 15 vs 254 ± 251 mm{sup 3}. The present study performed in a simple animal model provides proof of principle that the positive response of a tumor to BNCT is capable of inducing an abscopal effect. (orig.)

  17. Abscopal effect of boron neutron capture therapy (BNCT). Proof of principle in an experimental model of colon cancer

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Monti Hughes, Andrea; Schwint, Amanda E.; Pozzi, Emiliano C.C.; Curotto, Paula; Colombo, Lucas L.; Thorp, Silvia I.; Farias, Ruben O.; Garabalino, Marcela A.; Gonzalez, Sara J.; Santa Cruz, Gustavo A.; Carando, Daniel G.

    2017-01-01

    The aim of the present study was to evaluate, for the first time, the abscopal effect of boron neutron capture therapy (BNCT). Twenty-six BDIX rats were inoculated subcutaneously with 1 x 10 6 DHD/K12/TRb syngeneic colon cancer cells in the right hind flank. Three weeks post-inoculation, the right leg of 12 rats bearing the tumor nodule was treated with BPA-BNCT (BPA-Boronophenylalanine) at the RA-3 nuclear reactor located in Buenos Aires, Argentina, at an absorbed dose of 7.5 Gy to skin as the dose-limiting tissue. The remaining group of 14 tumor-bearing rats were left untreated and used as control. Two weeks post-BNCT, 1 x 10 6 DHD/K12/TRb cells were injected subcutaneously in the contralateral left hind flank of each of the 26 BDIX rats. Tumor volume in both legs was measured weekly for 7 weeks to determine response to BNCT in the right leg and to assess a potential influence of BNCT in the right leg on tumor development in the left leg. Within the BNCT group, a statistically significant reduction was observed in contralateral left tumor volume in animals whose right leg tumor responded to BNCT (post-treatment/pre-treatment tumor volume <1) versus animals who failed to respond (post/pre ≥1), i.e., 13 ± 15 vs 271 ± 128 mm 3 . In addition, a statistically significant reduction in contralateral left leg tumor volume was observed in BNCT-responsive animals (post/pre <1) vs untreated animals, i.e., 13 ± 15 vs 254 ± 251 mm 3 . The present study performed in a simple animal model provides proof of principle that the positive response of a tumor to BNCT is capable of inducing an abscopal effect. (orig.)

  18. ''DIANA'' - A New, Deep-Underground Accelerator Facility for Astrophysics Experiments

    International Nuclear Information System (INIS)

    Leitner, M.; Leitner, D.; Lemut, A.; Vetter, P.; Wiescher, M.

    2009-01-01

    The DIANA project (Dakota Ion Accelerators for Nuclear Astrophysics) is a collaboration between the University of Notre Dame, University of North Carolina, Western Michigan University, and Lawrence Berkeley National Laboratory to build a nuclear astrophysics accelerator facility 1.4 km below ground. DIANA is part of the US proposal DUSEL (Deep Underground Science and Engineering Laboratory) to establish a cross-disciplinary underground laboratory in the former gold mine of Homestake in South Dakota, USA. DIANA would consist of two high-current accelerators, a 30 to 400 kV variable, high-voltage platform, and a second, dynamitron accelerator with a voltage range of 350 kV to 3 MV. As a unique feature, both accelerators are planned to be equipped with either high-current microwave ion sources or multi-charged ECR ion sources producing ions from protons to oxygen. Electrostatic quadrupole transport elements will be incorporated in the dynamitron high voltage column. Compared to current astrophysics facilities, DIANA could increase the available beam densities on target by magnitudes: up to 100 mA on the low energy accelerator and several mA on the high energy accelerator. An integral part of the DIANA project is the development of a high-density super-sonic gas-jet target which can handle these anticipated beam powers. The paper will explain the main components of the DIANA accelerators and their beam transport lines and will discuss related technical challenges

  19. Effect of different BNCT protocols on DNA synthesis in precancerous and normal tissues in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    Heber, Elisa M.; Aromando, Romina; Trivillin, Veronica A.; Itoiz, Maria E.; Kreimann, Erica L.; Schwint, Amanda E.; Nigg, David W.

    2006-01-01

    We previously reported the therapeutic success of different BNCT protocols in the treatment of oral cancer, employing the hamster cheek pouch model. The aim of the present study was to evaluate the effect of these BNCT protocols on DNA synthesis in precancerous and normal tissue in this model and assess the potential lag in the development of second primary tumors in precancerous tissue. The data are relevant to potential control of field cancerized tissue and tolerance of normal tissue. We evaluated DNA synthesis in precancerous and normal pouch tissue 1-30 days post-BNCT mediated by BPA, GB-10 or BPA + GB-10 employing incorporation of bromo-deoxyuridine as an end-point. The BNCT-induced potential lag in the development of second primary tumors in precancerous tissue was monitored. A drastic, statistically significant reduction in DNA synthesis occurred in pacancerous tissue as early as 1 day post-BNCT and was sustained at virtually all time points until 30 days post-BNCT for all protocols. The histological categories evaluated individually within precancerous tissue (dysplasia, hyperplasia and NUMF [no unusual microscopic features]) responded similarly. DNA synthesis in normal tissue treated with BNCT oscillated around the very low pre-treatment values. A BNCT-induced lag in the development of second primary tumors was observed. BNCT induced a drastic fall in DNA synthesis in precancerous tissue that would be associated to the observed lag in the development of second primary tumors. The minimum variations in DNA synthesis in BNCT-treated normal tissue would correlate with the absence of normal tissue radiotoxicity. The present data would contribute to optimize therapeutic efficacy in the treatment of field-cancerized areas. (author)

  20. The Swedish facility for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Skoeld, K.; Capala, J. [Studsvik Medical AB (Sweden); Kierkegaard, J.; Haakansson, R. [Studsvik Nuclear AB (Sweden); Gudowska, I. [Karolinska Institute (Sweden)

    2000-10-01

    A BNCT (Boron Neutron Capture Therapy) facility has been constructed at the R2-0 reactor at Studsvik, Sweden. R2-0 is a 1 MW, open core, pool reactor. The reactor core is suspended on a movable tower and can be positioned anywhere in the pool. The BNCT facility includes two adjacent, parallel filter/moderator configurations and the reactor core is positioned in front of any of them as appropriate. One of the resulting neutron beams has been optimized for clinical irradiations with a filter/moderator system that allows easy variation of the neutron spectrum from the thermal to the epithermal energy range and with an extended collimator for convenient patient positioning. The other beam has been designed for radiobiological research and is equipped with a heavy water moderator and a large irradiation cavity with a uniform field of thermal neutrons. (author)

  1. The Swedish facility for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Skoeld, K.; Capala, J.; Kierkegaard, J.; Haakansson, R.; Gudowska, I.

    2000-01-01

    A BNCT (Boron Neutron Capture Therapy) facility has been constructed at the R2-0 reactor at Studsvik, Sweden. R2-0 is a 1 MW, open core, pool reactor. The reactor core is suspended on a movable tower and can be positioned anywhere in the pool. The BNCT facility includes two adjacent, parallel filter/moderator configurations and the reactor core is positioned in front of any of them as appropriate. One of the resulting neutron beams has been optimized for clinical irradiations with a filter/moderator system that allows easy variation of the neutron spectrum from the thermal to the epithermal energy range and with an extended collimator for convenient patient positioning. The other beam has been designed for radiobiological research and is equipped with a heavy water moderator and a large irradiation cavity with a uniform field of thermal neutrons. (author)

  2. INEL BNCT Research Program annual report, 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1993-05-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1992. Contributions from all the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor targeting compounds, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented, results of 21 spontaneous-tumor-bearing dogs that have been treated with BNCT at the Brookhaven National Laboratory (BNL) Medical Research Reactor (BMRR) are discussed, and predictions for an epithermal-neutron beam at the Georgia Tech Research Reactor (GTRR) are shown. Cellular-level boron detection and localization by secondary ion mass spectrometry, sputter-initiated resonance ionization spectroscopy, low atomization resonance ionization spectroscopy, and alpha track are presented. Boron detection by ICP-AES is discussed in detail. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors with BNCT is presented. Measurement of the epithermal-neutron flux at BNL and comparison to predictions are shown. Calculations comparing the GTRR and BMRR epithermal-neutron beams are also presented. Individual progress reports described herein are separately abstracted and indexed for the database.

  3. INEL BNCT Research Program annual report, 1992

    International Nuclear Information System (INIS)

    Venhuizen, J.R.

    1993-05-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1992. Contributions from all the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor targeting compounds, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented, results of 21 spontaneous-tumor-bearing dogs that have been treated with BNCT at the Brookhaven National Laboratory (BNL) Medical Research Reactor (BMRR) are discussed, and predictions for an epithermal-neutron beam at the Georgia Tech Research Reactor (GTRR) are shown. Cellular-level boron detection and localization by secondary ion mass spectrometry, sputter-initiated resonance ionization spectroscopy, low atomization resonance ionization spectroscopy, and alpha track are presented. Boron detection by ICP-AES is discussed in detail. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors with BNCT is presented. Measurement of the epithermal-neutron flux at BNL and comparison to predictions are shown. Calculations comparing the GTRR and BMRR epithermal-neutron beams are also presented. Individual progress reports described herein are separately abstracted and indexed for the database

  4. Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

    International Nuclear Information System (INIS)

    Capala, J.; Diaz, A.Z.; Chadha, M.

    1997-01-01

    The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains

  5. Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Capala, J. [Brookhaven National Lab., Upton, NY (United States); Diaz, A.Z.; Chadha, M. [Univ. Hospital, State Univ. of New York, NY (United States)] [and others

    1997-12-31

    The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains.

  6. Clinical results of BNCT for malignant gliomas using BSH and BPA simultaneously

    International Nuclear Information System (INIS)

    Miyatake, Shin-ichi; Kawabata, Shinji; Kajimoto, Yoshinaga

    2006-01-01

    Since 2002 to 2006, we applied BNCT for 41 cases of malignant gliomas. We used 3 different protocols. In each protocol, we used BSH and BPA simultaneously. In protocol 1, BSH 5g/body and BPA 250 mg/kg were used for consecutive 13 cases. Median survival time (MST) of newly diagnosed 4 cases of GB was 23 months after diagnosis. 2 cases were still alive. All cases including recurrent ones showed radiographic improvement. Eight out of 12 cases showed more than 50% mass reduction on images. Major cause of death was CSF dissemination. In protocol 2, BNCT were applied for 4 patients, two times with one to 2 week-interval. MST after BNCT was 13.3 months. In protocol 3, BPA 700 mg/kg were used with 20 to 30 Gy XRT after BNCT. XRT boost was applied especially for deeper part of the tumor. In protocol 3, 6 newly diagnosed GB patients were observed more than 16 months. 3 were dead and 3 were still alive on the preparation of this abstract. MST of these 6 patients was 17.3 months after diagnosis. In each protocol, radiation necrosis was the problem for recurrent cases, while removal of the necrosis prolonged the survival and recovered the neurological deficits. (author)

  7. SU-E-J-100: Reconstruction of Prompt Gamma Ray Three Dimensional SPECT Image From Boron Neutron Capture Therapy(BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Yoon, D; Jung, J; Suh, T [The Catholic University of Korea, College of medicine, Department of biomedical engineering (Korea, Republic of)

    2014-06-01

    Purpose: Purpose of paper is to confirm the feasibility of acquisition of three dimensional single photon emission computed tomography (SPECT) image from boron neutron capture therapy (BNCT) using Monte Carlo simulation. Methods: In case of simulation, the pixelated SPECT detector, collimator and phantom were simulated using Monte Carlo n particle extended (MCNPX) simulation tool. A thermal neutron source (<1 eV) was used to react with the boron uptake region (BUR) in the phantom. Each geometry had a spherical pattern, and three different BURs (A, B and C region, density: 2.08 g/cm3) were located in the middle of the brain phantom. The data from 128 projections for each sorting process were used to achieve image reconstruction. The ordered subset expectation maximization (OSEM) reconstruction algorithm was used to obtain a tomographic image with eight subsets and five iterations. The receiver operating characteristic (ROC) curve analysis was used to evaluate the geometric accuracy of reconstructed image. Results: The OSEM image was compared with the original phantom pattern image. The area under the curve (AUC) was calculated as the gross area under each ROC curve. The three calculated AUC values were 0.738 (A region), 0.623 (B region), and 0.817 (C region). The differences between length of centers of two boron regions and distance of maximum count points were 0.3 cm, 1.6 cm and 1.4 cm. Conclusion: The possibility of extracting a 3D BNCT SPECT image was confirmed using the Monte Carlo simulation and OSEM algorithm. The prospects for obtaining an actual BNCT SPECT image were estimated from the quality of the simulated image and the simulation conditions. When multiple tumor region should be treated using the BNCT, a reasonable model to determine how many useful images can be obtained from the SPECT could be provided to the BNCT facilities. This research was supported by the Leading Foreign Research Institute Recruitment Program through the National Research

  8. Radiation Safety of Accelerator Facility with Regard to Regulation

    International Nuclear Information System (INIS)

    Dedi Sunaryadi; Gloria Doloresa

    2003-01-01

    The radiation safety of accelerator facility and the status of the facilities according to licensee in Indonesia as well as lesson learned from the accidents are described. The atomic energy Act No. 10 of 1997 enacted by the Government of Indonesia which is implemented in Radiation Safety Government Regulation No. 63 and 64 as well as practice-specific model regulation for licensing request are discussed. (author)

  9. The MIT HEDP Accelerator Facility for education and advanced diagnostics development for OMEGA, Z and the NIF

    Science.gov (United States)

    Petrasso, R.; Gatu Johnson, M.; Armstrong, E.; Han, H. W.; Kabadi, N.; Lahmann, B.; Orozco, D.; Rojas Herrera, J.; Sio, H.; Sutcliffe, G.; Frenje, J.; Li, C. K.; Séguin, F. H.; Leeper, R.; Ruiz, C. L.; Sangster, T. C.

    2015-11-01

    The MIT HEDP Accelerator Facility utilizes a 135-keV linear electrostatic ion accelerator, a D-T neutron source and two x-ray sources for development and characterization of nuclear diagnostics for OMEGA, Z, and the NIF. The ion accelerator generates D-D and D-3He fusion products through acceleration of D ions onto a 3He-doped Erbium-Deuteride target. Fusion reaction rates around 106 s-1 are routinely achieved, and fluence and energy of the fusion products have been accurately characterized. The D-T neutron source generates up to 6 × 108 neutrons/s. The two x-ray generators produce spectra with peak energies of 35 keV and 225 keV and maximum dose rates of 0.5 Gy/min and 12 Gy/min, respectively. Diagnostics developed and calibrated at this facility include CR-39 based charged-particle spectrometers, neutron detectors, and the particle Time-Of-Flight (pTOF) and Magnetic PTOF CVD-diamond-based bang time detectors. The accelerator is also a vital tool in the education of graduate and undergraduate students at MIT. This work was supported in part by SNL, DOE, LLE and LLNL.

  10. Co-registration of the BNCT treatment planning images for clinical practice

    International Nuclear Information System (INIS)

    Salli, Eero; Seppaelae, Tiina; Kankaanranta, Leena; Asikainen, Sami; Savolainen, Sauli; Koivunoro, Hanna

    2006-01-01

    We have co-registered MRI, CT and FBPA-PET images for BNCT in clinical practice. Co-registration improves the spatial accuracy of the treatment planning by enabling use of information from all the co-registered modalities. The multimodal co-registration has been implemented as a service product provided by the Imaging Center of Helsinki University Central Hospital to other departments. To increase the accuracy of co-registration and patient positioning in the head area BNCT, a patient-specific fixation mask suitable for PET, MRI and CT was developed. The goal of the fixation mask is to normalize the orientation of the patient's head and neck. Co-registration is performed at the image processing unit by using a rigid body model, mutual-information based algorithms and partly in-house developed software tools. The accuracy of co-registration is verified by comparing the locations of the external skin markers and anatomical landmarks in different modalities. After co-registration, the images are transformed and covered into a format required by the BNCT dose-planning software and set to the dose-planning unit of the hospital. So far co-registration has been done for 22 patients. The co-registration protocol has proved to be reliable and efficient. Some registration errors are seen on some patients in the neck area because the rigid-body model used in co-registration is not fully valid for the brain-neck entity. The registration accuracy in this area could likely be improved by implementing a co-registration procedure utilizing a partly non-rigid body model. (author)

  11. Positron emission tomography and [{sup 18}F]BPA: A perspective application to assess tumour extraction of boron in BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Menichetti, L. [Department of PET and Radiopharmaceutical Chemistry, C.N.R. Institute of Clinical Physiology, Pisa (Italy)], E-mail: luca.menichetti@ifc.cnr.it; Cionini, L. [Unit of Radiotherapy, AOUP-University Hospital, Pisa (Italy); Sauerwein, W.A. [Department of Radiation Oncology, University Duisburg-Essen, University Hospital Essen (Germany); Altieri, S. [University of Pavia, Department of Nuclear Physics, Pavia (Italy); Solin, O.; Minn, H. [Turku PET Centre, University of Turku (Finland); Salvadori, P.A. [Department of PET and Radiopharmaceutical Chemistry, C.N.R. Institute of Clinical Physiology, Pisa (Italy)

    2009-07-15

    Positron emission tomography (PET) has become a key imaging tool in clinical practice and biomedical research to quantify and study biochemical processes in vivo. Physiologically active compounds are tagged with positron emitters (e.g. {sup 18}F, {sup 11}C, {sup 124}I) while maintaining their biological properties, and are administered intravenously in tracer amounts (10{sup -9}-10{sup -12} M quantities). The recent physical integration of PET and computed tomography (CT) in hybrid PET/CT scanners allows a combined anatomical and functional imaging: nowadays PET molecular imaging is emerging as powerful pharmacological tool in oncology, neurology and for treatment planning as guidance for radiation therapy. The in vivo pharmacokinetics of boron carrier for BNCT and the quantification of {sup 10}B in living tissue were performed by PET in the late nineties using compartmental models based on PET data. Nowadays PET and PET/CT have been used to address the issue of pharmacokinetic, metabolism and accumulation of BPA in target tissue. The added value of the use of L-[{sup 18}F]FBPA and PET/CT in BNCT is to provide key data on the tumour extraction of {sup 10}B-BPA versus normal tissue and to predict the efficacy of the treatment based on a single-study patient analysis. Due to the complexity of a binary treatment like BNCT, the role of PET/CT is currently to design new criteria for patient enrolment in treatment protocols: the L-[{sup 18}F]BPA/PET methodology could be considered as an important tool in newly designed clinical trials to better estimate the concentration ratio of BPA in the tumour as compared to neighbouring normal tissues. Based on these values for individual patients the decision could be made whether BNCT treatment could be advantageous due to a selective accumulation of BPA in an individual tumour. This approach, applicable in different tumour entities like melanoma, glioblastoma and head and neck malignancies, make this methodology as reliable

  12. An accelerator based steady state neutron source

    International Nuclear Information System (INIS)

    Burke, R.J.; Johnson, D.L.

    1985-01-01

    Using high current, c.w. linear accelerator technology, a spallation neutron source can achieve much higher average intensities than existing or proposed pulsed spallation sources. With about 100 mA of 300 MeV protons or deuterons, the Accelerator Based Neutron Research Facility (ABNR) would initially achieve the 10 16 n/cm 2 .s thermal flux goal of the advanced steady state neutron source, and upgrading could provide higher steady state fluxes. The relatively low ion energy compared to other spallation sources has an important impact on R and D requirements as well as capital cost, for which a range of $300-450M is estimated by comparison to other accelerator-based neutron source facilities. The source is similar to a reactor source in most respects. It has some higher energy neutrons but fewer gamma rays, and the moderator region is free of many of the design constraints of a reactor, which helps to implement sources for various neutron energy spectra, many beam tubes, etc. With the development of multi-beam concept and the basis for currents greater than 100 mA that is assumed in the R and D plan, the ABNR would serve many additional uses, such as fusion materials development, production of proton-rich isotopes, and other energy and defense program needs

  13. Design Concepts for Muon-Based Accelerators

    Energy Technology Data Exchange (ETDEWEB)

    Ryne, R. D. [Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States); Berg, J. S. [Brookhaven National Lab. (BNL), Upton, NY (United States); Kirk, H. G. [Brookhaven National Lab. (BNL), Upton, NY (United States); Palmer, R. B. [Brookhaven National Lab. (BNL), Upton, NY (United States); Stratkis, D. [Brookhaven National Lab. (BNL), Upton, NY (United States); Alexahin, Y. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Bross, A. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Gollwitzer, K. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Mokhov, N. V. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Neuffer, D. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Palmer, M. A. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Yonehara, K. [Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States); Snopok, P. [IIT, Chicago, IL (United States); Bogacz, A. [Thomas Jefferson National Accelerator Facility (TJNAF), Newport News, VA (United States); Roberts, T. J. [Muons Inc., Batavia, IL (United States); Delahaye, J. -P. [SLAC National Accelerator Lab., Menlo Park, CA (United States)

    2015-05-01

    Muon-based accelerators have the potential to enable facilities at both the Intensity and the Energy Frontiers. Muon storage rings can serve as high precision neutrino sources, and a muon collider is an ideal technology for a TeV or multi-TeV collider. Progress in muon accelerator designs has advanced steadily in recent years. In regard to 6D muon cooling, detailed and realistic designs now exist that provide more than 5 order-of-magnitude emittance reduction. Furthermore, detector performance studies indicate that with suitable pixelation and timing resolution, backgrounds in the collider detectors can be significantly reduced, thus enabling high-quality physics results. Thanks to these and other advances in design & simulation of muon systems, technology development, and systems demonstrations, muon storage-ring-based neutrino sources and a muon collider appear more feasible than ever before. A muon collider is now arguably among the most compelling approaches to a multi-TeV lepton collider. This paper summarizes the current status of design concepts for muon-based accelerators for neutrino factories and a muon collider.

  14. Work place monitoring in accelerator facilities using thermoluminescent dosimeters

    International Nuclear Information System (INIS)

    Ribeiro, M.S.; Sanches, M.P.; Osima, A.M.; Rodriguez, D.L.; Carvalho, R.N.; Somessari, R.N.

    1998-01-01

    The increase in the use of large amounts of energy and large particles accelerators in development or in industrial processes for the reticulation, polymerization and sterilization of cables and wires allowed to discover and monitor work places in facilities having particle accelerators at the Institute of Energy and Nuclear Inquiries Comissao National de Energy Nuclear. Measures previously taken by technicians in routine monitoring, show that radiation doses found in the beams tube and at the door of the accelerator area is high enough to require routine programs to monitor work places at the installation. That is why, fifteen thermoluminescent dosimeters (TLD) where placed in different points of the facility where doses must be measured along a three month period and at the same time readings must be taken from control dosimeters kept within a shielded container. The monitor had a small double layer with three pellets of TLD CaSO4 Dy inside of a route carrier adopted in routine workers dosimetry usually. Outcomes show that the radiological protection program must be implemented to ameliorate and guarantee safety procedures

  15. The radiological research accelerator facility. Progress report, December 1, 1995--November 30, 1996

    International Nuclear Information System (INIS)

    Hall, E.J.; Marino, S.A.

    1996-08-01

    The Radiological Research Accelerator Facility (RARAF) is based on a 4-MV Van de Graaff accelerator, which is used to generate a variety of well-characterized radiation beams for research in radiobiology, radiological physics, and radiation chemistry. It is part of the Center for Radiological Research (CRR) - formerly the Radiological Research Laboratory (RRL) - of Columbia University, and its operation is supported as a National Facility by the U.S. Department of Energy (DOE). As such, RARAF is available to all potential users on an equal basis and scientists outside the CRR are encouraged to submit proposals for experiments at RARAF. The operation of the Van de Graaff is supported by the DOE, but the research projects themselves must be supported separately. RARAF was conceived in the mid-1960s by Drs. Victor P. Bond of Brookhaven National Laboratory (BNL) and Harald H. Rossi of Columbia University as a research resource dedicated to radiobiology and radiological physics and was officially established on January 1, 1967. The RARAF Van de Graaff accelerator originally served as the injector for the Cosmotron, a 2-GeV accelerator operated at BNL in the 1950s and early 1960s. The immediate aim was to provide a source of monoenergetic neutrons for studies in radiation biology, dosimetry, and microdosimetry. In other major projects the energetic ions produced were utilized directly. RARAF was located at BNL from 1967 until 1980, when it was dismantled and moved to the Nevis Laboratories of Columbia University, where it was then reassembled and returned to operation. This report contains the following information on RARAF: RARAF user's guide; scientific advisory committee; research using RARAF; accelerator utilization and operation; and development of the facilities

  16. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential

    International Nuclear Information System (INIS)

    Nigg, David W.

    2012-01-01

    Boron neutron capture therapy (BNCT) combines selective accumulation of 10B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K(nido-7-CH3(CH2)15-7,8-C2B9H11) in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K(nido-7-CH3(CH2)15-7,8-C2B9H11) in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na3 (ae-B20H17NH3), administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 ± 16.1 ppm at 48 h and to 43.9 ± 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.

  17. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential

    Energy Technology Data Exchange (ETDEWEB)

    David W. Nigg

    2012-05-01

    Boron neutron capture therapy (BNCT) combines selective accumulation of 10B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na3 [ae-B20H17NH3], administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 {+-} 16.1 ppm at 48 h and to 43.9 {+-} 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.

  18. Feasibility study on BNCT-SPECT using a CdTe detector

    International Nuclear Information System (INIS)

    Murata, Isao; Mukai, Taiki; Ito, Masao; Miyamaru, Hiroyuki; Yoshida, Shigeo

    2011-01-01

    There is no doubt that boron neutron capture therapy (BNCT) is a promising cancer therapy in the near future. At present, one of the severest problems to solve is monitoring of the treatment effect during neutron irradiation. It is known to be difficult in real time. So far, activation foils, small detectors and so on were used to measure the thermal neutron fluence in a certain place of the tumor. The dose distribution is thus estimated from the measured result and prediction with a transport code. In the present study, 478 keV gamma-rays emitted from the excited state of 7 Li produced by 10 B(n,α) 7 Li reaction are directly measured to realize real time monitoring of the treatment effect of BNCT. In this paper, the result of the feasibility study carried out using a Monte Carlo transport code is summarized. We used CdTe detectors with a quite narrow collimator to obtain a BNCT image keeping good spatial resolution. The intensity of capture gamma-rays of 2223 keV produced by 1 H(n,γ) 2 H reaction is very much higher than that of 478 keV. We thus adjusted the detector efficiency by selecting an appropriate thickness so as to optimize the efficiency ratio between 478 and 2223 keV. From the result of the detector response calculation, in case of 20 mm thick CdTe detector with the collimator of 2 mm in diameter, sufficient net count of ∼1000 for 478 keV in 30 min. was realized. It means an efficient and high-resolution BNCT-SPECT image could be obtained. (author)

  19. BNCT of 3 cases of spontaneous head and neck cancer in feline patients

    Energy Technology Data Exchange (ETDEWEB)

    Rao, M.; Trivillin, V.A.; Heber, E.M.; Angeles Cantarelli, Maria de los; Itoiz, M.E.; Nigg, D.W.; Rebagliati, R.J.; Batistoni, Daniel; Schwint, A.E. E-mail: schwint@cnea.gov.ar

    2004-11-01

    Having demonstrated BPA-BNCT induced control of experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa with no damage to normal tissue we explored the feasibility and safety of treating spontaneous head and neck tumors, with particular focus on SCC, of terminal feline patients with low dose BPA-BNCT employing the thermal beam of the RA-1 Reactor within a preclinical context. The biodistribution studies showed that, in all three cases evaluated, BPA delivered absolute boron values to tumor in the range that proved therapeutically useful in the experimental model of SCC. BPA-BNCT studies showed no radiotoxic effects, partial tumor control in terms of impaired growth and partial necrosis, an improvement in clinical condition and prolonged survival beyond the terminal condition of the feline patients at the time of recruitment.

  20. Economic and education impact of building the Continuous Electron Beam Accelerator Facility

    International Nuclear Information System (INIS)

    Hartline, B.

    1996-01-01

    The Continuous Electron Beam Accelerator Facility (CEBAF) was built in Newport News, Virginia, between 1987 and 1995 and is a new basic research laboratory christened the Thomas Jefferson National Accelerator Facility (Jefferson Lab). Jefferson Lab's science and technology mission has major economic and educational benefits: basic research discoveries, improvement and application of key technologies associated with the accelerator and the experiments, extensive subcontracting with industry, and diverse employment and educational opportunities. The $600 million invested by federal, state, local and international partners to build Jefferson Lab has had substantial economic and educational benefits locally, as well as significant benefits distributed among industries and universities throughout the United States

  1. High-power liquid-lithium jet target for neutron production

    OpenAIRE

    Halfon, S.; Arenshtam, A.; Kijel, D.; Paul, M.; Berkovits, D.; Eliyahu, I.; Feinberg, G.; Friedman, M.; Hazenshprung, N.; Mardor, I.; Nagler, A.; Shimel, G.; Tessler, M.; Silverman, I.

    2013-01-01

    A compact Liquid-Lithium Target (LiLiT) was built and tested with a high-power electron gun at Soreq Nuclear Research Center. The lithium target, to be bombarded by the high-intensity proton beam of the Soreq Applied Research Accelerator Facility (SARAF), will constitute an intense source of neutrons produced by the 7Li(p,n)7Be reaction for nuclear astrophysics research and as a pilot setup for accelerator-based Boron Neutron Capture Therapy (BNCT). The liquid-lithium jet target acts both as ...

  2. Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new ''B2'' configuration of the RA-6 nuclear reactor

    International Nuclear Information System (INIS)

    Monti Hughes, Andrea; Trivillin, Veronica A.; Schwint, Amanda E.; Longhino, Juan; Boggio, Esteban; Medina, Vanina A.; Martinel Lamas, Diego J.; Garabalino, Marcela A.; Heber, Elisa M.; Pozzi, Emiliano C.C.; Itoiz, Maria E.; Aromando, Romina F.; Nigg, David W.

    2017-01-01

    Boron neutron capture therapy (BNCT) is based on selective accumulation of B-10 carriers in tumor followed by neutron irradiation. We demonstrated, in 2001, the therapeutic effect of BNCT mediated by BPA (boronophenylalanine) in the hamster cheek pouch model of oral cancer, at the RA-6 nuclear reactor. Between 2007 and 2011, the RA-6 was upgraded, leading to an improvement in the performance of the BNCT beam (B2 configuration). Our aim was to evaluate BPA-BNCT radiotoxicity and tumor control in the hamster cheek pouch model of oral cancer at the new ''B2'' configuration. We also evaluated, for the first time in the oral cancer model, the radioprotective effect of histamine against mucositis in precancerous tissue as the dose-limiting tissue. Cancerized pouches were exposed to: BPA-BNCT; BPA-BNCT + histamine; BO: Beam only; BO + histamine; CONTROL: cancerized, no-treatment. BNCT induced severe mucositis, with an incidence that was slightly higher than in ''B1'' experiments (86 vs 67%, respectively). BO induced low/moderate mucositis. Histamine slightly reduced the incidence of severe mucositis induced by BPA-BNCT (75 vs 86%) and prevented mucositis altogether in BO animals. Tumor overall response was significantly higher in BNCT (94-96%) than in control (16%) and BO groups (9-38%), and did not differ significantly from the ''B1'' results (91%). Histamine did not compromise BNCT therapeutic efficacy. BNCT radiotoxicity and therapeutic effect at the B1 and B2 configurations of RA-6 were consistent. Histamine slightly reduced mucositis in precancerous tissue even in this overly aggressive oral cancer model, without compromising tumor control. (orig.)

  3. Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new ''B2'' configuration of the RA-6 nuclear reactor

    Energy Technology Data Exchange (ETDEWEB)

    Monti Hughes, Andrea; Trivillin, Veronica A.; Schwint, Amanda E. [Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Department of Radiobiology, San Martin, Province Buenos Aires (Argentina); National Research Council (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Longhino, Juan; Boggio, Esteban [Bariloche Atomic Center, CNEA, Department of Nuclear Engineering, San Carlos de Bariloche, Province Rio Negro (Argentina); Medina, Vanina A.; Martinel Lamas, Diego J. [National Research Council (CONICET), Ciudad Autonoma de Buenos Aires (Argentina); Pontifical Catholic University of Argentina (UCA), Laboratory of Tumoral Biology and Inflammation, School of Medical Sciences, Institute for Biomedical Research (BIOMED CONICET-UCA), Ciudad Autonoma de Buenos Aires (Argentina); Garabalino, Marcela A.; Heber, Elisa M.; Pozzi, Emiliano C.C. [Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Department of Radiobiology, San Martin, Province Buenos Aires (Argentina); Itoiz, Maria E. [Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Department of Radiobiology, San Martin, Province Buenos Aires (Argentina); UBA, Department of Oral Pathology, Faculty of Dentistry, Ciudad Autonoma de Buenos Aires (Argentina); Aromando, Romina F. [UBA, Department of Oral Pathology, Faculty of Dentistry, Ciudad Autonoma de Buenos Aires (Argentina); Nigg, David W. [Idaho National Laboratory, Idaho Falls (United States)

    2017-11-15

    Boron neutron capture therapy (BNCT) is based on selective accumulation of B-10 carriers in tumor followed by neutron irradiation. We demonstrated, in 2001, the therapeutic effect of BNCT mediated by BPA (boronophenylalanine) in the hamster cheek pouch model of oral cancer, at the RA-6 nuclear reactor. Between 2007 and 2011, the RA-6 was upgraded, leading to an improvement in the performance of the BNCT beam (B2 configuration). Our aim was to evaluate BPA-BNCT radiotoxicity and tumor control in the hamster cheek pouch model of oral cancer at the new ''B2'' configuration. We also evaluated, for the first time in the oral cancer model, the radioprotective effect of histamine against mucositis in precancerous tissue as the dose-limiting tissue. Cancerized pouches were exposed to: BPA-BNCT; BPA-BNCT + histamine; BO: Beam only; BO + histamine; CONTROL: cancerized, no-treatment. BNCT induced severe mucositis, with an incidence that was slightly higher than in ''B1'' experiments (86 vs 67%, respectively). BO induced low/moderate mucositis. Histamine slightly reduced the incidence of severe mucositis induced by BPA-BNCT (75 vs 86%) and prevented mucositis altogether in BO animals. Tumor overall response was significantly higher in BNCT (94-96%) than in control (16%) and BO groups (9-38%), and did not differ significantly from the ''B1'' results (91%). Histamine did not compromise BNCT therapeutic efficacy. BNCT radiotoxicity and therapeutic effect at the B1 and B2 configurations of RA-6 were consistent. Histamine slightly reduced mucositis in precancerous tissue even in this overly aggressive oral cancer model, without compromising tumor control. (orig.)

  4. Some recent developments in treatment planning software and methodology for BNCT

    International Nuclear Information System (INIS)

    Nigg, D.W.; Wheeler, F.J.; Wessol, D.E.; Wemple, C.A.; Babcock, R.; Capala, J.

    1996-01-01

    Over the past several years/the Idaho National Engineering Laboratory (INEL) has led the development of a unique, internationally-recognized set of software modules (BNCT rtpe) for computational dosimetry and treatment planning for Boron Neutron Capture Therapy (BNCT). The computational capability represented by this software is essential to the proper administration of all forms of radiotherapy for cancer. Such software addresses the need to perform pretreatment computation and optimization of the radiation dose distribution in the target volume. This permits the achievement of the optimal therapeutic ratio (tumor dose relative to critical normal tissue dose) for each individual patient via a systematic procedure for specifying the appropriate irradiation parameters to be employed for a given treatment. These parameters include angle of therapy beam incidence, beam aperture and shape,and beam intensity as a function of position across the beam front. The INEL software is used for treatment planning in the current series of human glioma trials at Brookhaven National Laboratory (BNL) and has also been licensed for research and developmental purposes to several other BNCT research centers in the US and in Europe

  5. Some recent developments in treatment planning software and methodology for BNCT

    International Nuclear Information System (INIS)

    Nigg, D.W.; Wheeler, F.J.; Wessol, D.E.

    1996-01-01

    Over the past several years the Idaho National Engineering Laboratory (INEL) has led the development of a unique, internationally-recognized set of software modules (BNCT-rtpe) for computational dosimetry and treatment planning for Boron Neutron Capture Therapy (BNCT). The computational capability represented by this software is essential to the proper administration of all forms of radiotherapy for cancer. Such software addresses the need to perform pretreatment computation and optimization of the radiation dose distribution in the target volume. This permits the achievement of the optimal therapeutic ratio (tumor dose relative to critical normal tissue dose) for each individual patient via a systematic procedure for specifying the appropriate irradiation parameters to be employed for a given treatment. These parameters include angle of therapy beam incidence, beam aperture and shape, and beam intensity as a function of position across the beam front. The INEL software is used for treatment planning in the current series of human glioma trials at Brookhaven National Laboratory (BNL) and has also been licensed for research and developmental purposes to several other BNCT research centers in the US and in Europe

  6. Accelerator conceptual design of the international fusion materials irradiation facility

    International Nuclear Information System (INIS)

    Sugimoto, M.; Kinsho, M.; Teplyakov, V.; Berwald, D.; Bruhwiler, D.; Peakock, M.; Rathke, J.; Deitinghoff, H.; Klein, H.; Pozimski, Y.; Volk, K.; Miyahara, A.; Olivier, M.; Piechowiak, E.; Tanabe, Y.

    1998-01-01

    The accelerator system of the international fusion materials irradiation facility (IFMIF) provides the 250-mA, 40-MeV continuous-wave deuteron beam at one of the two lithium target stations. It consists of two identical linear accelerator modules, each of which independently delivers a 125-mA beam to the common footprint of 20 cm x 5 cm at the target surface. The accelerator module consists of an ion injector, a 175 MHz RFQ and eight DTL tanks, and rf power supply system. The requirements for the accelerator system and the design concept are described. The interface issues and operational considerations to attain the proposed availability are also discussed. (orig.)

  7. Tumor control induced by Boron Neutron Capture Therapy (BNCT) as a function of dose in an experimental model of liver metastases at 5 weeks follow-up

    International Nuclear Information System (INIS)

    Pozzi, E C C; Trivillin, V A; Colombo, L L; Monti Hughes, A; Thorp, S; Cardoso, J E; Garabalino, M A; Molinari, A J; Heber, E M; Curotto, Paula; Miller, M; Itoiz, M E; Aromando, R F; Nigg, D W; Schwint, A E

    2012-01-01

    BNCT has been proposed for the treatment of multifocal, non-resectable, bilobar colorectal liver metastases that do not respond to chemotherapy. We recently reported that BNCT mediated by boronophenylalanine (BPA) induced significant remission of experimental colorectal tumor nodules in rat liver at 3 weeks follow-up with no contributory liver toxicity (Pozzi et al.,2012). The aim of the present study was to evaluate tumor control and potential liver toxicity of BPA-BNCT at 5 weeks follow-up. Prescribed dose was retrospectively evaluated based on blood boron values, allowing for assessment of response over a range of delivered dose values (author)

  8. Construction Management for Conventional Facilities of Proton Accelerator

    International Nuclear Information System (INIS)

    Kim, Jun Yeon; Cho, Jin Sam; Lee, Jae Sang

    2008-05-01

    Proton Engineering Frontier Project, puts its aim to building 100MeV 20mA linear proton accelerator which is national facility for NT, BT, IT, and future technologies, expected to boost up the national industry competitiveness. This R and D, Construction Management is in charge of the supportive works as site selection, architecture and engineering of conventional facilities, and overall construction management. The major goals of this work are as follows: At first, architecture and engineering of conventional facilities. Second, construction management, audit and inspection on construction of conventional facilities. Lastly, cooperation with the project host organization for adjusting technical issues of overall construction. In this research, We reviewed the basic design and made a detail design of conventional facilities. Preparation for construction license, site improvement and access road construction is fulfilled. Also, we made the technical support for project host as follows : selection of project host organization and host site selection, construction technical work for project host organization and procedure management

  9. Optimal Neutron Source and Beam Shaping Assembly for Boron Neutron Capture Therapy

    International Nuclear Information System (INIS)

    Vujic, J.; Greenspan, E.; Kastenber, W.E.; Karni, Y.; Regev, D.; Verbeke, J.M.; Leung, K.N.; Chivers, D.; Guess, S.; Kim, L.; Waldron, W.; Zhu, Y.

    2003-01-01

    There were three objectives to this project: (1) The development of the 2-D Swan code for the optimization of the nuclear design of facilities for medical applications of radiation, radiation shields, blankets of accelerator-driven systems, fusion facilities, etc. (2) Identification of the maximum beam quality that can be obtained for Boron Neutron Capture Therapy (BNCT) from different reactor-, and accelerator-based neutron sources. The optimal beam-shaping assembly (BSA) design for each neutron source was also to e obtained. (3) Feasibility assessment of a new neutron source for NCT and other medical and industrial applications. This source consists of a state-of-the-art proton or deuteron accelerator driving and inherently safe, proliferation resistant, small subcritical fission assembly

  10. Application of HVJ envelope system to boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Nakai, Kei; Kurooka, Masaaki; Kaneda, Yasufumi; Yamamoto, Tetsuya; Matsumura, Akira; Asano, Tomoyuki

    2006-01-01

    Boron Neutron Capture Therapy (BNCT) has been used clinically for the treatment of malignant tumors. Two drugs, p-boronophenylalanine (BPA) and sulfhydral borane (BSH), have been used as boron delivery agents. These drugs seem to be taken up preferentially in solid tumors, but it is uncertain whether therapeutic quantities of boron atoms are taken up by micro-invasive or distant tumor cells. High accumulation and high selective delivery of boron into tumor tissues are the most important requirements to achieve efficient BNCT for malignant tumor. The HVJ envelope (HVJ-E) vector system is a novel fusion-mediated gene delivery system based on inactivated hemagglutinating virus of Japan (HVJ; Sendai virus). Although we developed this vector system for gene transfer, it can also deliver proteins, synthetic oligonucleotides, and drugs. HVJ-liposome, which is liposome fused with HVJ-E, has higher boron trapping efficiency than HVJ-E alone. We report the boron delivery into cultured cells with HVJ-liposome systems. The cellular 10 B concentration after 60 min incubation with HVJ-E containing BSH was 24.9 μg/g cell pellet for BHK-21 cells (baby hamster kidney cells) and 19.4 μg/g cell pellet for SCC VII cells (murine squamous cell carcinoma). These concentrations are higher than that of 60 min incubated cells with BSH containing (100μg 10 B/ml) medium. These results indicate the HVJ-E fused with tumor cell membrane and rapidly delivered boron agents, and that the HVJ-E-mediated delivery system could be applicable to BNCT. Plans are underway to begin neutron radiation experiments in vivo and in vitro. (author)

  11. Development of cancer therapy facility of HANARO

    International Nuclear Information System (INIS)

    Jun, Byung Jin; Hwang, S. Y.; Kim, M. J. and others

    2000-04-01

    Facilities of the research and clinical treatments of neutron capture therapy using HANARO are developed, and they are ready to install. They are BNCT irradiation facility and prompt gamma neutron activatiion analysis facility. Since every horizontal neutron facility of HANARO is long and narrow tangential beam tube, it is analysed that sufficient epithermal neutrons for the BNCT cannot be obtained but sufficient thermal neutrons can be obtained by a filter composed of silicon and bismuth single crystals. Since the thermal neutron penetaration increases significantly when the crystals are cooled, a filter cooled by liquid nitrogen is developed. So as to avoid interference with the reactor operation, a water shutter is developed. The irradiation room is designed for the temporary surgical operation as well. Handling tools to remove activated beam port plug and to install water shutter and filter are developed. The basic structure of the irradiation room is already installed and most of other parts are ready to install. Since no free beam port is available for the prompt gamma neutron activation analysis, a method obtaining almost pure thermal neutrons by the vertical diffraction of extra beam for the polarized neutron spectrometer is developed. This method is confirmed by analysis and experiments to give high enough neutron beam. Equipment and devices are provided to install this facility

  12. Development of cancer therapy facility of HANARO

    Energy Technology Data Exchange (ETDEWEB)

    Jun, Byung Jin; Hwang, S. Y.; Kim, M. J. and others

    2000-04-01

    Facilities of the research and clinical treatments of neutron capture therapy using HANARO are developed, and they are ready to install. They are BNCT irradiation facility and prompt gamma neutron activatiion analysis facility. Since every horizontal neutron facility of HANARO is long and narrow tangential beam tube, it is analysed that sufficient epithermal neutrons for the BNCT cannot be obtained but sufficient thermal neutrons can be obtained by a filter composed of silicon and bismuth single crystals. Since the thermal neutron penetaration increases significantly when the crystals are cooled, a filter cooled by liquid nitrogen is developed. So as to avoid interference with the reactor operation, a water shutter is developed. The irradiation room is designed for the temporary surgical operation as well. Handling tools to remove activated beam port plug and to install water shutter and filter are developed. The basic structure of the irradiation room is already installed and most of other parts are ready to install. Since no free beam port is available for the prompt gamma neutron activation analysis, a method obtaining almost pure thermal neutrons by the vertical diffraction of extra beam for the polarized neutron spectrometer is developed. This method is confirmed by analysis and experiments to give high enough neutron beam. Equipment and devices are provided to install this facility.

  13. A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba

    International Nuclear Information System (INIS)

    Aiyama, H.; Nakai, K.; Yamamoto, T.; Nariai, T.; Kumada, H.; Ishikawa, E.; Isobe, T.; Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A.

    2011-01-01

    We have evaluated the efficacy and safety of boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor using a new protocol. One of the two patients enrolled in this trial is a man with recurrent glioblastoma and the other is a woman with anaplastic meningioma. Both are still alive and no severe adverse events have been observed. Our findings suggest that NCT will be safe as a palliative therapy for malignant brain tumors. - Highlights: ► Boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor. ► Two cases with recurrent glioblastoma and anaplastic meningioma. ► No severe adverse events have been observed using BNCT. ► BNCT has a possibility of a safe palliative therapy for malignant brain tumors.

  14. Tandem-ESQ for Accelerator-Based BNCT

    International Nuclear Information System (INIS)

    Kreiner, A.J.; Kwan, J.W.; Burlon, A.A.; Di Paolo, H.; Henestroza, E.; Minsky, D.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.

    2006-01-01

    A new ultrahigh-resolution photoemission electron microscope called PEEM3 is being developed and built at the Advanced Light Source (ALS). An electron mirror combined with a much-simplified magnetic dipole separator is to be used to provide simultaneous correction of spherical and chromatic aberrations. It is installed on an elliptically polarized undulator (EPU) beamline, and will be operated with very high spatial resolution and high flux to study the composition, structure, electric and magnetic properties of complex materials. The instrument has been designed and is described. The instrumental hardware is being deployed in 2 phases. The first phase is the deployment of a standard PEEM type microscope consisting of the standard linear array of electrostatic electron lenses. The second phase will be the installation of the aberration corrected upgrade to improve resolution and throughput. This paper describes progress as the instrument enters the commissioning part of the first phase

  15. Nuclear engineering aspects of glioma BNCT research in Italy

    International Nuclear Information System (INIS)

    Curzio, G.; Mazzini, M.

    1998-01-01

    A research project on Boron Neutron Capture Therapy (BNCZ) of gliomas has been set up in Italy, with the participation of Departments of Oncology and Mechanical and Nuclear Construction (DCMN) of the University of Pisa, as well as the Neuroscience and Physics Departments of the Universities of Roma. The specific objective of DCMN Research Unit is the study of the physical-engineering aspects related to BNCT. The paper outlines the research lines in progress at DCMN: Monte Carlo calculations of neutron dose distribution for BNCT treatment planning; measurements of neutron fluxes, spectra and doses by neutron detectors specifically set up; design of modifications to the nuclear reactors of ENEA Casaccia Center. In particular, the paper emphasizes the most original contributions on dosimetric aspects, both from informatic and experimental points of view.(author)

  16. Characteristics of neutron irradiation facility and dose estimation method for neutron capture therapy at Kyoto University research reactor institute

    International Nuclear Information System (INIS)

    Kobayashi, T.; Sakurai, Y.; Kanda, K.

    2001-01-01

    The neutron irradiation characteristics of the Heavy Water Neutron Irradiation Facility (HWNIF) at the Kyoto University Research Reactor Institute (KIJRRI) for boron neutron capture therapy (BNCT), is described. The present method of dose measurement and its evaluation at the KURRI, is explained. Especially, the special feature and noticeable matters were expounded for the BNCT with craniotomy, which has been applied at present only in Japan. (author)

  17. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma

    International Nuclear Information System (INIS)

    Nariai, Tadashi; Ishiwata, Kiichi; Kimura, Yuichi; Inaji, Motoki; Momose, Toshiya; Yamamoto, Tetsuya; Matsumura, Akira; Ishii, Kenji; Ohno, Kikuo

    2009-01-01

    Introduction: To plan the optimal BNCT for patients with malignant cerebral glioma, estimation of the ratio of boron concentration in tumor tissue against that in the surrounding normal brain (T/N ratio of boron) is important. We report a positron emission tomography (PET) imaging method to estimate T/N ratio of tissue boron concentration based on pharmacokinetic analysis of amino acid probes. Methods: Twelve patients with cerebral malignant glioma underwent 60 min dynamic PET scanning of brain after bolus injection of 18 F-borono-phenyl-alanine (FBPA) with timed arterial blood sampling. Using kinetic parameter obtained by this scan, T/N ratio of boron concentration elicited by one-hour constant infusion of BPA, as performed in BNCT, was simulated on Runge-Kutta algorithm. 11 C-methionine (MET) PET scan, which is commonly used in worldwide PET center as brain tumor imaging tool, was also performed on the same day to compare the image characteristics of FBPA and that of MET. Result: PET glioma images obtained with FBPA and MET are almost identical in all patients by visual inspection. Estimated T/N ratio of tissue boron concentration after one-hour constant infusion of BPA, T/N ratio of FBPA on static condition, and T/N ratio of MET on static condition showed significant linear correlation between each other. Conclusion: T/N ratio of boron concentration that is obtained by constant infusion of BPA during BNCT can be estimated by FBPA PET scan. This ratio can also be estimated by MET-PET imaging. As MET-PET study is available in many clinical PET center, selection of candidates for BNCT may be possible by MET-PET images. Accurate planning of BNCT may be performed by static images of FBPA PET. Use of PET imaging with amino acid probes may contribute very much to establish an appropriate application of BNCT for patients with malignant glioma.

  18. Clinical practice in BNCT to the brain

    International Nuclear Information System (INIS)

    Nakagawa, Y.

    2001-01-01

    Our concept of Boron Neutron Capture Therapy (BNCT) is to selectively destroy tumour cells using the high LET particles yielded from the 10B(n,α)7Li reactions. The effort of clinical investigators has concentrated on how to escalate the radiation dose at the target point. BNCT in Japan combines thermal neutrons and BSH (Na 2 B 12 H 11 SH). The radiation dose is determined by the neutron fluence at the target point and the boron concentration in the tumour tissue. According to the recent analysis, the ratio of boron concentration (BSH) in tumour tissue and blood is nearly stable at around 1.2 to 1.69. Escalation of the radiation dose was carried out by means of improving the penetration of the thermal neutron beam. Since 1968, 175 patients with glioblastoma (n=83), anaplastic astrocytoma (n=44), low grade astrocytoma (n=16) or other types of tumour (n=32) were treated by BNCT at 5 reactors (HTR n=13, JRR-3 n=1, MulTR n=98, KUR n=30, JRR-2 n=33). The retrospective analysis revealed that the important factors related to the clinical results and QOL of the patients were minimum tumour volume radiation dose, more than 18Gy of physical dose and maximum vascular radiation dose (less than 15Gy) in the normal cortex. We have planned several trials to escalate the target radiation dose. One trial makes use of a cavity in the cortex following debulking surgery of the tumour tissue to improve neutron penetration. The other trial is introduction of epithermal neutron. KUR and JRR-4 were reconstructed and developed to be able to irradiate using epithermal neutrons. The new combination of surgical procedure and irradiation using epithermal neutrons should remarkably improve the target volume dose compared to the radiation dose treated by thermal neutrons. (author)

  19. Economic evaluation of slurry-, sewage-sludge, and crop disinfection facility applications based on industrial accelerator and 60Co radiation source

    International Nuclear Information System (INIS)

    Abelovszky, L.

    1979-01-01

    The degree of the compliance with the requirements of slurry and sewage treatment, the range of use of radiation sterilization procedures in agriculture and food industry, the possibilities of the complex application of radiation methods and factors influencing their economic efficiency, the economic evaluation of the versatile chargeable accelerators, the fixed and semi-mobile radioisotope facilities, the economic efficiency of the multipurpose utilization, the differences in the application of accelerators and radio isotopes as to the power source applied, the penetration, the dose rates and the radiation energy focusing are discussed. The radiation facility costs are compared. Conclusions concerning the choice of the most efficient applications are given. (author)

  20. Defocusing beam line design for an irradiation facility at the TAEA SANAEM Proton Accelerator Facility

    Science.gov (United States)

    Gencer, A.; Demirköz, B.; Efthymiopoulos, I.; Yiğitoğlu, M.

    2016-07-01

    Electronic components must be tested to ensure reliable performance in high radiation environments such as Hi-Limu LHC and space. We propose a defocusing beam line to perform proton irradiation tests in Turkey. The Turkish Atomic Energy Authority SANAEM Proton Accelerator Facility was inaugurated in May 2012 for radioisotope production. The facility has also an R&D room for research purposes. The accelerator produces protons with 30 MeV kinetic energy and the beam current is variable between 10 μA and 1.2 mA. The beam kinetic energy is suitable for irradiation tests, however the beam current is high and therefore the flux must be lowered. We plan to build a defocusing beam line (DBL) in order to enlarge the beam size, reduce the flux to match the required specifications for the irradiation tests. Current design includes the beam transport and the final focusing magnets to blow up the beam. Scattering foils and a collimator is placed for the reduction of the beam flux. The DBL is designed to provide fluxes between 107 p /cm2 / s and 109 p /cm2 / s for performing irradiation tests in an area of 15.4 cm × 21.5 cm. The facility will be the first irradiation facility of its kind in Turkey.

  1. 2-O-α-glucopytanosyl L-ascorbic acid reduced mutagenicity at HPRT locus of mouse splenocytes following BNCT

    International Nuclear Information System (INIS)

    Kinashi, Yuko; Masunaga, Shin-ichiro; Suzuki, Minoru; Nagata, Kanji; Ono, Koji

    2006-01-01

    In boron neutron capture therapy (BNCT), normal tissue surrounding the tumor cells sometimes take up boron compounds resulting in radiation-induced damage to normal tissue. We have previously reported the evidence for increased the mutagenicity of thermal neutron in the presence of boron. In addition, we described the biological radio-protective effects of the ascorbic acid for mutation induction following BNCT in vitro. Here, we investigated these radio-protective effects of ascorbic acid for mutation induction in mouse splenocytes on HPRT locus following a BNCT study in vivo. (author)

  2. Accelerator conceptual design of the international fusion materials irradiation facility

    Energy Technology Data Exchange (ETDEWEB)

    Sugimoto, M.; Kinsho, M. [Japan Atomic Energy Res. Inst., Tokai, Ibaraki (Japan). Intense Neutron Source Lab.; Jameson, R.A.; Blind, B. [Los Alamos National Lab., NM (United States); Teplyakov, V. [Institute for High Energy Physics, Moscow (Russian Federation); Berwald, D.; Bruhwiler, D.; Peakock, M.; Rathke, J. [Northrop Grumman Corp., Bethpage, NY (United States); Deitinghoff, H.; Klein, H.; Pozimski, Y.; Volk, K. [Johann Wolfgang Goethe Univ., Frankfurt (Germany). Inst. fur Angewandte Phys.; Ferdinand, R.; Lagniel, J.-M. [CEA Saclay LNS, Gif-sur-Yvette (France); Miyahara, A. [Teikyo Univ., Tokyo (Japan); Olivier, M. [CEA DSM, Saclay, Gif-sur-Yvette (France); Piechowiak, E. [Northrop Grumman Corp., Baltimore, MD (United States); Tanabe, Y. [Toshiba Corp., Tsurumi-ku, Yokohama (Japan)

    1998-10-01

    The accelerator system of the international fusion materials irradiation facility (IFMIF) provides the 250-mA, 40-MeV continuous-wave deuteron beam at one of the two lithium target stations. It consists of two identical linear accelerator modules, each of which independently delivers a 125-mA beam to the common footprint of 20 cm x 5 cm at the target surface. The accelerator module consists of an ion injector, a 175 MHz RFQ and eight DTL tanks, and rf power supply system. The requirements for the accelerator system and the design concept are described. The interface issues and operational considerations to attain the proposed availability are also discussed. (orig.) 8 refs.

  3. Optimization of the application of BNCT to undifferentiated thyroid cancer

    International Nuclear Information System (INIS)

    Dagrosa, M.A.; Thomasz, L.; Longhino, J.

    2006-01-01

    The possible increase in BNCT efficacy for undifferentiated thyroid carcinoma (UTC) using BPA plus BOPP and nicotinamide (NA) as a radiosensitizer on the BNCT reaction was analyzed. In these studies nude mice were transplanted with the ARO cells and after 14 days they were treated as follows: 1) Control; 2) NCT (neutrons alone); 3) NCT plus NA (100 mg/kg bw/day for 3 days); 4) BPA (350 mg/kg bw) + neutrons; 5) BPA+ NA+ neutrons; 6) BPA+BOPP (60 mg/kg bw) + neutrons. The flux of hyperthermal neutrons was 2.8 10 8 during 85 min. Neutrons alone or with NA caused some tumor growth delay, while in the BPA, BPA+NA and BPA+BOPP groups a 100% halt of tumor growth was observed. When the initial tumor volume was 50 mm 3 or less a complete cure was found in BPA+NA (2/2); BPA (1/4); BPA+BOPP (7/7). After 90 days of complete regression, recurrence of tumor was observed in 2/2 BPA/NA (2/2) and BPA+BOPP (1/7). Caspase 3 activity was increased in BPA+NA (p<0.05 vs controls). BPA plus NA increased tumor apoptosis but only the combination of BPA+BOPP increased significantly BNCT efficiency. (author)

  4. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    Energy Technology Data Exchange (ETDEWEB)

    Hampel, G.; Grunewald, C.; Schutz, C.; Schmitz, T.; Kratz, J.V. [Nuclear Chemistry, University of Mainz, D-55099 Mainz (Germany); Brochhausen, C.; Kirkpatrick, J. [Department of Pathology, University of Mainz, D-55099 Mainz (Germany); Bortulussi, S.; Altieri, S. [Department of Nuclear and Theoretical Physics University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Kudejova, P. [Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II), Technische Universitaet Muenchen, D-85748 Garching (Germany); Appelman, K.; Moss, R. [Joint Research Centre (JRC) of the European Commission, NL-1755 ZG Petten (Netherlands); Bassler, N. [University of Aarhus, Norde Ringade, DK-8000, Aarhus C (Denmark); Blaickner, M.; Ziegner, M. [Molecular Medicine, Health and Environment Department, AIT Austrian Institute of Technology GmbH (Austria); Sharpe, P.; Palmans, H. [National Physical Laboratory, Teddington TW11 0LW, Middlesex (United Kingdom); Otto, G. [Department of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Mainz, D-55099 Mainz (Germany)

    2011-07-01

    The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed in Pavia (Italy) a few years ago, where patients with liver metastases were treated by combining BNCT with auto-transplantation of the organ. Here, in Mainz, a preclinical trial has been started on patients suffering from liver metastases of colorectal carcinoma. In vitro experiments and the first animal tests have also been initiated to investigate radiobiological effects of radiation generated during BNCT. For both experiments and the treatment, a reliable dosimetry system is necessary. From work elsewhere, the use of alanine detectors appears to be an appropriate dosimetry technique. (author)

  5. Measurement of 36Cl induced in shielding concrete of various accelerator facilities

    International Nuclear Information System (INIS)

    Bessho, K.; Matsumura, H.; Matsuhiro, T.

    2003-01-01

    The concentrations of 36 Cl induced in shielding concrete of the various accelerators has been measured by accelerator mass spectrometry. For three kinds of accelerator facilities, SF cyclotron (Center for Nuclear Study, the University of Tokyo), 300 MeV electron LINAC (Laboratory of Nuclear Science, Tohoku University), and 12 GeV proton synchrotron (High Energy Accelerator Research Organization), the depth profiles of 36 Cl/ 35 Cl ratios in concrete samples near the beam lines were analyzed. The depth profiles of 36 Cl/ 35 Cl are consistent with those of the radioactive concentrations of 152 Eu and 60 Co, which are formed by thermal neutron capture reactions. These results imply that 36 Cl formed in shielding concrete of these accelerators is mainly produced by thermal neutron capture of 35 Cl. The maximum 36 Cl/ 35 Cl ratio of 3x10 -8 (300 MeV electron LINAC, depth of 8 cm) corresponds to the specific radioactivity of 2x10 -3 Bq/g, which is not serious for radioactive waste management in reconstruction or decommissioning of accelerator facilities, compared with specific radioactivity of 3 H, 152 Eu and 60 Co. (author)

  6. The Soreq Applied Research Accelerator Facility (SARAF): Overview, research programs and future plans

    Science.gov (United States)

    Mardor, Israel; Aviv, Ofer; Avrigeanu, Marilena; Berkovits, Dan; Dahan, Adi; Dickel, Timo; Eliyahu, Ilan; Gai, Moshe; Gavish-Segev, Inbal; Halfon, Shlomi; Hass, Michael; Hirsh, Tsviki; Kaiser, Boaz; Kijel, Daniel; Kreisel, Arik; Mishnayot, Yonatan; Mukul, Ish; Ohayon, Ben; Paul, Michael; Perry, Amichay; Rahangdale, Hitesh; Rodnizki, Jacob; Ron, Guy; Sasson-Zukran, Revital; Shor, Asher; Silverman, Ido; Tessler, Moshe; Vaintraub, Sergey; Weissman, Leo

    2018-05-01

    The Soreq Applied Research Accelerator Facility (SARAF) is under construction in the Soreq Nuclear Research Center at Yavne, Israel. When completed at the beginning of the next decade, SARAF will be a user facility for basic and applied nuclear physics, based on a 40 MeV, 5 mA CW proton/deuteron superconducting linear accelerator. Phase I of SARAF (SARAF-I, 4 MeV, 2 mA CW protons, 5 MeV 1 mA CW deuterons) is already in operation, generating scientific results in several fields of interest. The main ongoing program at SARAF-I is the production of 30 keV neutrons and measurement of Maxwellian Averaged Cross Sections (MACS), important for the astrophysical s-process. The world leading Maxwellian epithermal neutron yield at SARAF-I (5 × 10^{10} epithermal neutrons/s), generated by a novel Liquid-Lithium Target (LiLiT), enables improved precision of known MACSs, and new measurements of low-abundance and radioactive isotopes. Research plans for SARAF-II span several disciplines: precision studies of beyond-Standard-Model effects by trapping light exotic radioisotopes, such as 6He, 8Li and 18, 19, 23Ne, in unprecedented amounts (including meaningful studies already at SARAF-I); extended nuclear astrophysics research with higher energy neutrons, including generation and studies of exotic neutron-rich isotopes relevant to the rapid (r-) process; nuclear structure of exotic isotopes; high energy neutron cross sections for basic nuclear physics and material science research, including neutron induced radiation damage; neutron based imaging and therapy; and novel radiopharmaceuticals development and production. In this paper we present a technical overview of SARAF-I and II, including a description of the accelerator and its irradiation targets; a survey of existing research programs at SARAF-I; and the research potential at the completed facility (SARAF-II).

  7. Radioprotective agents to reduce BNCT (Boron Neutron Capture Therapy) induced mucositis in the hamster cheek pouch; Agentes radioprotectores para reducir la mucositis inducida por la terapia por captura neutrónica en boro (BNCT) en la bolsa de la mejilla del hámster

    Energy Technology Data Exchange (ETDEWEB)

    Monti Hughes, A. [Dpto. de Radiobiología, Gerencia de Química Nuclear y Ciencias de la Salud, GAATEN, Comisión Nacional de Energía Atómica (CNEA) (Argentina); Pozzi, E. C.C. [Gerencia de Reactores de Investigación y Producción, GAATEN, CNEA (Argentina); Thorp, S., E-mail: andrea.monti@cnea.gov.ar [Sub-Gerencia Instrumentación y Control, GAEN, CNEA(Argentina)

    2013-07-01

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of BNCT mediated by boronophenylalanine (BPA) in the hamster cheek pouch oral cancer and pre cancer model. Despite therapeutic efficacy, mucositis induced in premalignant tissue was dose limiting and favored, in some cases, tumor development. In a clinical scenario, oral mucositis limits the dose administered to head and neck tumors. Aim: Our aim was to evaluate the effect of the administration of different radioprotective agents, seeking to reduce BNCT-induced mucositis to acceptable levels in dose-limiting premalignant tissue; without compromising therapeutic effect evaluated as inhibition on tumor development in premalignant tissue; without systemic or local side effects; and without negative effects on the biodistribution of the boron compound used for treatment. Materials and methods: Cancerized hamsters with DMBA (dimethylbenzanthracene) were treated with BPA-BNCT 5 Gy total absorbed dose to premalignant tissue, at the RA-3 Nuclear Reactor, divided into different groups: 1-treated with FLUNIXIN; 2- ATORVASTATIN; 3-THALIDOMIDE; 4-HISTAMINE (two concentrations: Low -1 mg/ml- and High -5 mg/ml-); 5-JNJ7777120; 6-JNJ10191584; 7-SALINE (vehicle). Cancerized animals without any treatment (neither BNCT nor radioprotective therapy) were also analyzed. We followed the animals during one month and evaluated the percentage of animals with unacceptable/severe mucositis, clinical status and percentage of animals with new tumors post treatment. We also performed a preliminary biodistribution study of BPA + Histamine “low” concentration to evaluate the potential effect of the radioprotector on BPA biodistribution. Results: Histamine

  8. Proposal for an irradiation facility at the TAEK SANAEM Proton Accelerator Facility

    Science.gov (United States)

    Demirköz, B.; Gencer, A.; Kiziloren, D.; Apsimon, R.

    2013-12-01

    Turkish Atomic Energy Authority's (TAEK's) Proton Accelerator Facility in Ankara, Turkey, has been inaugurated in May 2012 and is under the process of being certified for commercial radio-isotope production. Three of the four arms of the 30 MeV cyclotron are being used for radio-isotope production, while the fourth is foreseen for research and development of novel ideas and methods. The cyclotron can vary the beam current between 12 μA and 1.2 mA, sufficient for irradiation tests for semiconductor materials, detectors and devices. We propose to build an irradiation facility in the R&D room of this complex, open for use to the international detector development community.

  9. Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo

    International Nuclear Information System (INIS)

    Fujii, Hitoshi; Tabata, Yasuhiko; Kaneda, Yasufumi; Sawa, Yoshiki; Lee, Chun Man; Matsuyama, Akifumi; Komoda, Hiroshi; Sasai, Masao; Suzuki, Minoru; Asano, Tomoyuki; Doki, Yuichiro; Kirihata, Mitsunori; Ono, Koji

    2011-01-01

    Boron neutron capture therapy (BNCT) is a cell-selective radiation therapy that uses the alpha particles and lithium nuclei produced by the boron neutron capture reaction. BNCT is a relatively safe tool for treating multiple or diffuse malignant tumors with little injury to normal tissue. The success or failure of BNCT depends upon the 10 B compound accumulation within tumor cells and the proximity of the tumor cells to the body surface. To extend the therapeutic use of BNCT from surface tumors to visceral tumors will require 10 B compounds that accumulate strongly in tumor cells without significant accumulation in normal cells, and an appropriate delivery method for deeper tissues. Hemagglutinating Virus of Japan Envelope (HVJ-E) is used as a vehicle for gene delivery because of its high ability to fuse with cells. However, its strong hemagglutination activity makes HVJ-E unsuitable for systemic administration. In this study, we developed a novel vector for 10 B (sodium borocaptate: BSH) delivery using HVJ-E and cationized gelatin for treating multiple liver tumors with BNCT without severe adverse events. We developed cationized gelatin conjugate HVJ-E combined with BSH (CG-HVJ-E-BSH), and evaluated its characteristics (toxicity, affinity for tumor cells, accumulation and retention in tumor cells, boron-carrying capacity to multiple liver tumors in vivo, and bio-distribution) and effectiveness in BNCT therapy in a murine model of multiple liver tumors. CG-HVJ-E reduced hemagglutination activity by half and was significantly less toxic in mice than HVJ-E. Higher 10 B concentrations in murine osteosarcoma cells (LM8G5) were achieved with CG-HVJ-E-BSH than with BSH. When administered into mice bearing multiple LM8G5 liver tumors, the tumor/normal liver ratios of CG-HVJ-E-BSH were significantly higher than those of BSH for the first 48 hours (p < 0.05). In suppressing the spread of tumor cells in mice, BNCT treatment was as effective with CG-HVJ-E-BSH as with BSH

  10. Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo

    Directory of Open Access Journals (Sweden)

    Ono Koji

    2011-01-01

    Full Text Available Abstract Background Boron neutron capture therapy (BNCT is a cell-selective radiation therapy that uses the alpha particles and lithium nuclei produced by the boron neutron capture reaction. BNCT is a relatively safe tool for treating multiple or diffuse malignant tumors with little injury to normal tissue. The success or failure of BNCT depends upon the 10B compound accumulation within tumor cells and the proximity of the tumor cells to the body surface. To extend the therapeutic use of BNCT from surface tumors to visceral tumors will require 10B compounds that accumulate strongly in tumor cells without significant accumulation in normal cells, and an appropriate delivery method for deeper tissues. Hemagglutinating Virus of Japan Envelope (HVJ-E is used as a vehicle for gene delivery because of its high ability to fuse with cells. However, its strong hemagglutination activity makes HVJ-E unsuitable for systemic administration. In this study, we developed a novel vector for 10B (sodium borocaptate: BSH delivery using HVJ-E and cationized gelatin for treating multiple liver tumors with BNCT without severe adverse events. Methods We developed cationized gelatin conjugate HVJ-E combined with BSH (CG-HVJ-E-BSH, and evaluated its characteristics (toxicity, affinity for tumor cells, accumulation and retention in tumor cells, boron-carrying capacity to multiple liver tumors in vivo, and bio-distribution and effectiveness in BNCT therapy in a murine model of multiple liver tumors. Results CG-HVJ-E reduced hemagglutination activity by half and was significantly less toxic in mice than HVJ-E. Higher 10B concentrations in murine osteosarcoma cells (LM8G5 were achieved with CG-HVJ-E-BSH than with BSH. When administered into mice bearing multiple LM8G5 liver tumors, the tumor/normal liver ratios of CG-HVJ-E-BSH were significantly higher than those of BSH for the first 48 hours (p . In suppressing the spread of tumor cells in mice, BNCT treatment was as

  11. A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba

    Energy Technology Data Exchange (ETDEWEB)

    Aiyama, H. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Nakai, K., E-mail: knakai@Neurosurg-tsukuba.com [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Yamamoto, T. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyouku (Japan); Kumada, H. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Ishikawa, E. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Isobe, T. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan)

    2011-12-15

    We have evaluated the efficacy and safety of boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor using a new protocol. One of the two patients enrolled in this trial is a man with recurrent glioblastoma and the other is a woman with anaplastic meningioma. Both are still alive and no severe adverse events have been observed. Our findings suggest that NCT will be safe as a palliative therapy for malignant brain tumors. - Highlights: Black-Right-Pointing-Pointer Boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor. Black-Right-Pointing-Pointer Two cases with recurrent glioblastoma and anaplastic meningioma. Black-Right-Pointing-Pointer No severe adverse events have been observed using BNCT. Black-Right-Pointing-Pointer BNCT has a possibility of a safe palliative therapy for malignant brain tumors.

  12. Retrospective review of the clinical BNCT trial at Brookhaven National Laboratory

    International Nuclear Information System (INIS)

    Diaz, A.Z.; Chanana, A.D.; Coderre, J.A.; Ma, R.

    2000-01-01

    The primary objective of the phase I/II dose escalation studies was to evaluate the safety of the boronophenylalanine-fructose (BPA-F) mediated boron neutron capture therapy (BNCT) in subjects with glioblastoma multiforme (GBM). A secondary objective was to retrospectively assess the palliation of GBM by BNCT. Fifty-three subjects with GBM were treated under multiple dose escalation protocols at the Brookhaven Medical Research Reactor (BMRR). Twenty-six subjects were treated using one field, 17 subjects were treated using 2 fields and 10 subjects were treated using 3 fields. BPA-F related toxicity was not observed. The maximum radiation dose to a volume of approximately 1 cc of the normal brain varied from 8.9 to 15.9 gray-equivalent (Gy-Eq). The volume-weighted average radiation dose to normal brain varied from 1.9 to 9.5 Gy-Eq. Six RTOG (Radiation Therapy Oncology Group) grade 3 or 4 toxicities were attributed to BNCT. Four of the 53 subjects are still alive with 3 of them free of recurrent disease with over two years follow-up. The median times to progression and median survival time from diagnosis were 28.4 weeks and 12.8 months respectively. (author)

  13. Engineered and Administrative Safety Systems for the Control of Prompt Radiation Hazards at Accelerator Facilities

    International Nuclear Information System (INIS)

    Liu, James C.; SLAC; Vylet, Vashek; Walker, Lawrence S.

    2007-01-01

    The ANSI N43.1 Standard, currently in revision (ANSI 2007), sets forth the requirements for accelerator facilities to provide adequate protection for the workers, the public and the environment from the hazards of ionizing radiation produced during and from accelerator operations. The Standard also recommends good practices that, when followed, provide a level of radiation protection consistent with those established for the accelerator communities. The N43.1 Standard is suitable for all accelerator facilities (using electron, positron, proton, or ion particle beams) capable of producing radiation, subject to federal or state regulations. The requirements (see word 'shall') and recommended practices (see word 'should') are prescribed in a graded approach that are commensurate with the complexity and hazard levels of the accelerator facility. Chapters 4, 5 and 6 of the N43.1 Standard address specially the Radiation Safety System (RSS), both engineered and administrative systems, to mitigate and control the prompt radiation hazards from accelerator operations. The RSS includes the Access Control System (ACS) and Radiation Control System (RCS). The main requirements and recommendations of the N43.1 Standard regarding the management, technical and operational aspects of the RSS are described and condensed in this report. Clearly some aspects of the RSS policies and practices at different facilities may differ in order to meet the practical needs for field implementation. A previous report (Liu et al. 2001a), which reviews and summarizes the RSS at five North American high-energy accelerator facilities, as well as the RSS references for the 5 labs (Drozdoff 2001; Gallegos 1996; Ipe and Liu 1992; Liu 1999; Liu 2001b; Rokni 1996; TJNAF 1994; Yotam et al. 1991), can be consulted for the actual RSS implementation at various laboratories. A comprehensive report describing the RSS at the Stanford Linear Accelerator Center (SLAC 2006) can also serve as a reference

  14. Boron neutron capture therapy (BNCT) for high-grade gliomas of the brain: a cautionary note

    International Nuclear Information System (INIS)

    Laramore, George E.; Spence, Alexander M.

    1996-01-01

    Purpose/Objective: Boron neutron capture therapy (BNCT) is a method of treating high-grade gliomas of the brain that involves incorporating 10 B into the tumor using appropriate pharmacological agents and then irradiating the tumor with thermal or epithermal neutron beams. To date, over 120 patients have been treated in this manner by Japanese investigators using a thermal neutron beam from a nuclear reactor. Favorable reports on outcome have motivated considerable current research in BNCT. The purpose of this study is to provide an independent analysis of the Japanese data by identifying the subset of patients from the United States who received this treatment in Japan and comparing their outcomes relative to a matched cohort who received conventional therapy in various Radiation Therapy Oncology Group (RTOG) studies. Methods and Materials: The principal referral sources of patients to Japan for BNCT were identified and the names of patients sent for treatment obtained. The treating physicians in Japan were also contacted to see if additional patients from the United States had been treated. Either the patients or their next of kin were contacted, and permission was obtained to retrieve medical records including tumor pathology for central review. Prognostic variables according to an analysis of the RTOG brain tumor database by Curran et al. were determined from these records and used to construct a matched cohort of patients treated conventionally. Results: A total of 14 patients were identified who had traveled to Japan for BNCT treatment between July, 1987 and June, 1994. In the case of one patient (deceased), it was not possible to contact the next of kin. Material was obtained on the other 13 patients and review of the pathology indicated that 1 patient had a central nervous system lymphoma rather than a high-grade glioma. Survival data was analyzed for the other 12 patients on an actuarial basis, and this showed no difference compared to survival data for a

  15. Accelerator shield design of KIPT neutron source facility

    International Nuclear Information System (INIS)

    Zhong, Z.; Gohar, Y.

    2013-01-01

    Argonne National Laboratory (ANL) of the United States and Kharkov Institute of Physics and Technology (KIPT) of Ukraine have been collaborating on the design development of a neutron source facility at KIPT utilizing an electron-accelerator-driven subcritical assembly. Electron beam power is 100 kW, using 100 MeV electrons. The facility is designed to perform basic and applied nuclear research, produce medical isotopes, and train young nuclear specialists. The biological shield of the accelerator building is designed to reduce the biological dose to less than 0.5-mrem/hr during operation. The main source of the biological dose is the photons and the neutrons generated by interactions of leaked electrons from the electron gun and accelerator sections with the surrounding concrete and accelerator materials. The Monte Carlo code MCNPX serves as the calculation tool for the shield design, due to its capability to transport electrons, photons, and neutrons coupled problems. The direct photon dose can be tallied by MCNPX calculation, starting with the leaked electrons. However, it is difficult to accurately tally the neutron dose directly from the leaked electrons. The neutron yield per electron from the interactions with the surrounding components is less than 0.01 neutron per electron. This causes difficulties for Monte Carlo analyses and consumes tremendous computation time for tallying with acceptable statistics the neutron dose outside the shield boundary. To avoid these difficulties, the SOURCE and TALLYX user subroutines of MCNPX were developed for the study. The generated neutrons are banked, together with all related parameters, for a subsequent MCNPX calculation to obtain the neutron and secondary photon doses. The weight windows variance reduction technique is utilized for both neutron and photon dose calculations. Two shielding materials, i.e., heavy concrete and ordinary concrete, were considered for the shield design. The main goal is to maintain the total

  16. Improvement in performance and operational experience of 14 UD Pelletron accelerator facility, BARC-TIFR

    International Nuclear Information System (INIS)

    Bhagwat, P.V.

    2002-01-01

    14 UD Pelletron accelerator facility at Mumbai has been operational since 1989. The project MEHIA (Medium Energy Heavy Ion Accelerator) started in 1982 and was formally inaugurated on 30th December 1988. Since then the accelerator has been working round the clock. Improvement in accelerator performance and operational experience are described. (author)

  17. Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: Combined administration of BSH and BPA

    Energy Technology Data Exchange (ETDEWEB)

    D.W. Nigg; William Bauer; Various Others

    2014-06-01

    Sodium mercaptoundecahydro-closo-dodecaborate (BSH) is being investigated clinically for BNCT. We examined the biodistribution of BSH and BPA administered jointly in different proportions in the hamster cheek pouch oral cancer model. The 3 assayed protocols were non-toxic, and showed preferential tumor boron uptake versus precancerous and normal tissue and therapeutic tumor boron concentration values (70–85 ppm). All 3 protocols warrant assessment in BNCT studies to contribute to the knowledge of (BSH+BPA)-BNCT radiobiology for head and neck cancer and optimize therapeutic efficacy.

  18. Developing a clinical proton accelerator facility: Consortium-assisted technology transfer

    International Nuclear Information System (INIS)

    Slater, J.M.; Miller, D.W.; Slater, J.W.

    1991-01-01

    A hospital-based proton accelerator facility has emerged from the efforts of a consortium of physicists, engineers and physicians from several high-energy physics laboratories, industries and universities, working together to develop the requirements and conceptual design for a clinical program. A variable-energy medical synchrotron for accelerating protons to a prescribed energy, intensity and beam quality, has been placed in a hospital setting at Loma Linda University Medical Center for treating patients with localized cancer. Treatments began in October 1990. Scientists from Fermi National Accelerator Laboratory; Harvard Cyclotron Laboratory; Lawrence Berkeley Laboratories; the Paul Scherrer Institute; Uppsala, Sweden; Argonne, Brookhaven and Los Alamos National Laboratories; and Loma Linda University, all cooperated to produce the conceptual design. Loma Linda University contracted with Fermi National Accelerator Laboratory to design and build a 250 MeV synchrotron and beam transport system, the latter to guide protons into four treatment rooms. Lawrence Berkeley Laboratories consulted with Loma Linda University on the design of the beam delivery system (nozzle). A gantry concept devised by scientists at Harvard Cyclotron Laboratory, was adapted and fabricated by Science Applications International Corporation. The control and safety systems were designed and developed by Loma Linda University Radiation Research Laboratory. Presently, the synchrotron, beam transport system and treatment room hardware have been installed and tested and are operating satisfactorily

  19. Therapeutic efficacy and toxicity of a single and double application of boron neutron capture therapy (BNCT) in a hamster cheek pouch oral precancer model

    International Nuclear Information System (INIS)

    Monti Hughes, A; Pozzi, E C C; Thorp, S; Garabalino, M A; Farias, R O; Gonzalez, S J; Heber, E M; Itoiz, M E; Aromando, R F; Molinari, A J; Miller, M; Nigg, D W; Curotto, P; Trivillin, V A; Schwint, A E

    2012-01-01

    Tumor development from tissue with potentially malignant disorders (PMD) gives rise to second primary tumors. We previously demonstrated the partial inhibitory effect on tumor development of Boron Neutron Capture Therapy (BNCT) mediated by the boron compounds BPA (boronophenylalanine) and decahydrodecaborate (GB-10) in a hamster pouch oral precancer model. Seeking to optimize BNCT, the aim of the present study was to contribute to the knowledge of BNCT radiobiology for oral precancer and assess new BNCT protocols in terms of inhibition of tumor development and radiotoxicity. Groups of cancerized hamsters were locally exposed to single or double applications (2 weeks apart) of BPA-BNCT or (GB-10 + BPA)-BNCT at a total dose of 8Gy to tissue with PMD; to a single application of BPA-BNCT at 6Gy and to a double application (4 weeks apart) of BPA-BNCT or (BPA + GB-10)-BNCT at a total dose of 10Gy. Cancerized, sham-irradiated hamsters served as controls. Clinical status, tumor development from tissue with PMD and mucositis were followed for 8 months. The marked therapeutic efficacy of single applications of BNCT at 6 and 8Gy were associated to severe radiotoxicity. Dose fractionation into 2 applications reduced mucositis but also reduced therapeutic efficacy, depending on dose and interval between applications. A double application (4 weeks apart) of (GB-10 + BPA)-BNCT at a total dose of 10Gy rendered the best therapeutic advantage, i.e. 63% - 100% inhibition of tumor development with only slight mucositis in 67% of cases. The data reported herein show that issues such as dose levels and dose fractionation, interval between applications, and choice of boron compounds are pivotal to therapeutic advantage and must be tailored for a particular pathology and anatomic site. The present study determined treatment conditions that would contribute to optimize BNCT for precancer and that would warrant cautious assessment in a clinical scenario (author)

  20. NIST Accelerator Facilities And Programs In Support Of Industrial Radiation Research

    International Nuclear Information System (INIS)

    Bateman, F.B.; Desrosiers, M.F.; Hudson, L.T.; Coursey, B.M.; Bergstrom, P.M. Jr.; Seltzer, S.M.

    2003-01-01

    NIST's Ionizing Radiation Division maintains and operates three electron accelerators used in a number of applications including waste treatment and sterilization, radiation hardness testing, detector calibrations and materials modification studies. These facilities serve a large number of governmental, academic and industrial users as well as an active intramural research program. They include a 500 kV cascaded-rectifier accelerator, a 2.5 MV electron Van de Graaff accelerator and a 7 to 32 MeV electron linac, supplying beams ranging in energy from a few keV up to 32 MeV. In response to the recent anthrax incident, NIST along with the US Postal Service and the Armed Forces Radiobiology Research Institute (AFRRI) are working to develop protocols and testing procedures for the USPS mail sanitization program. NIST facilities and personnel are being employed in a series of quality-assurance measurements for both electron- and photon-beam sanitization. These include computational modeling, dose verification and VOC (volatile organic compounds) testing using megavoltage electron and photon sources

  1. Simulation study of accelerator based quasi-mono-energetic epithermal neutron beams for BNCT.

    Science.gov (United States)

    Adib, M; Habib, N; Bashter, I I; El-Mesiry, M S; Mansy, M S

    2016-01-01

    Filtered neutron techniques were applied to produce quasi-mono-energetic neutron beams in the energy range of 1.5-7.5 keV at the accelerator port using the generated neutron spectrum from a Li (p, n) Be reaction. A simulation study was performed to characterize the filter components and transmitted beam lines. The feature of the filtered beams is detailed in terms of optimal thickness of the primary and additive components. A computer code named "QMNB-AS" was developed to carry out the required calculations. The filtered neutron beams had high purity and intensity with low contamination from the accompanying thermal, fast neutrons and γ-rays. Copyright © 2015 Elsevier Ltd. All rights reserved.

  2. Overview of high intensity proton accelerator facility, J-PARC

    International Nuclear Information System (INIS)

    Ikeda, Y.

    2010-01-01

    The J-PARC project of high intensity proton accelerator research complex, conducted jointly by JAERI and KEK, has been completed with demonstration of all beam productions in 2009 as the facility construction phase, and the operation started to offer the secondary beams of neutron, muon, kaon, and neutrino, to the advanced scientific experimental research aiming at making breakthroughs in materials and life science, nuclear and elementary physics, etc. This text describes the overview of the J-PARC present status with emphasis of a performance toward to 1MW power as user facilities. (author)

  3. Shielding Aspects of Accelerators, Targets and Irradiation Facilities - SATIF-11 Workshop Proceedings Report

    International Nuclear Information System (INIS)

    2013-01-01

    Particle accelerators have evolved over the last decades from simple devices to powerful machines. In recent years, new technological and research applications have helped to define requirements while the number of accelerator facilities in operation, being commissioned, designed or planned has grown significantly. Their parameters, which include the beam energy, currents and intensities, and target composition, can vary widely, giving rise to new radiation shielding issues and challenges. Particle accelerators must be operated in safe ways to protect operators, the public and the environment. As the design and use of these facilities evolve, so must the analytical methods used in the safety analyses. These workshop proceedings review the state of the art in radiation shielding of accelerator facilities and irradiation targets. They also evaluate progress in the development of modelling methods used to assess the effectiveness of such shielding as part of safety analyses. The transport of radiation through shielding materials is a major consideration in the safety design studies of nuclear power plants, and the modelling techniques used may be applied to many other types of scientific and technological facilities. Accelerator and irradiation facilities represent a key capability in R and D, medical and industrial infrastructures, and they can be used in a wide range of scientific, medical and industrial applications. High-energy ion accelerators, for example, are now used not only in fundamental research, such as the search for new super-heavy nuclei, but also for therapy as part of cancer treatment. While the energy of the incident particles on the shielding of these facilities may be much higher than those found in nuclear power plants, much of the physics associated with the behaviour of the secondary particles produced is similar, as are the computer modelling techniques used to quantify key safety design parameters, such as radiation dose and activation levels

  4. In vitro studies of the cellular response to boron neutron capture therapy (BNCT) in thyroid carcinoma

    International Nuclear Information System (INIS)

    Rodriguez, C; Carpano, M; Perona, M; Thorp, S; Curotto, P; Pozzi, E; Casal, M; Juvenal, G; Pisarev, M; Dagrosa, A

    2012-01-01

    Background: Previously, we have started to study the mechanisms of DNA damage and repair induced by BNCT in thyroid carcinoma some years ago. We have shown different genotoxic patterns for tumor cells irradiated with gamma rays, neutrons alone or neutrons plus different compounds, boronophenylalanine (BPA) or α, β - dihydroxyethyl)-deutero-porphyrin IX (BOPP). In the present study we analyzed the expression of Ku70, Rad51 and Rad54 components of non homologous end-joing (NHEJ) and homologous recombination repair (HRR) pathways, respectively, induced by BNCT in human cells of thyroid carcinoma. Methods: A human cell line of follicular thyroid carcinoma (WRO) in exponential growth phase was distributed into the following groups: 1) Gamma Radiation, 2) Radiation with neutrons beam (NCT), 3) Radiation with n th in presence of BPA (BNCT). A control group for each treatment was added. The cells were irradiated in the thermal column facility of the RA-3 reactor (flux= 1.10 10 n/cm 2 sec) or with a source of 60 Co. The irradiations were performed during different lapses in order to obtain a total physical dose of 3 Gy (±10%). The mRNA expressions of Ku70, Rad 51 and Rad 54 were analysed by reverse transcription-polymerase chain reaction (RT-PCR) at different times post irradiation (2, 4, 6, 24 and 48 h). DNA damage was evaluated by immunofluorescence using an antibody against the phosphorylation of histone H2AX, which indicates double strand breaks in the DNA. Results: The expression of Rad51 increased at 2 h post-irradiation and it lasted until 6 h only in the neutron and neutron + BPA groups (p<0.05). Rad54 showed an up-regulation from 2 to 24 h in both groups irradiated with the neutron beam (with and without BPA) (p<0.05). On the other hand, Ku70 mRNA did not show a modification of its expression in the irradiated groups respect to the control group. Conclusion: these results would indicate an activation of the HRR pathway in the thyroid carcinoma cells treated by

  5. The Brookhaven Accelerator Test Facility

    International Nuclear Information System (INIS)

    Batchelor, K.; Chou, T.S.; Fernow, R.C.

    1988-01-01

    The Brookhaven Accelerator Test Facility (ATF) will consist of a 50--100 MeV/c electron linac and a 100 GW CO 2 laser system. A high brightness RF-gun operating at 2856 MHz is to be used as the injector into the linac. The RF-gun contains a Nd:Yag-laser-driven photocathode capable of producing a stream of six ps electron pulses separated by 12.5 ns. The maximum charge in a micropulse will be one nano-Coulomb. The CO 2 laser pulse length will be a few picoseconds and will be synchronized with the electron pulse. The first experimental beam is expected in Fall 89. The design electron beam parameters are given and possible initial experiments are discussed. 9 refs., 1 fig., 3 tabs

  6. Proposal for an accelerator-based neutron generator

    International Nuclear Information System (INIS)

    Grand, P.

    1975-07-01

    An Accelerator-based Neutron Generator is described that consists of a 30-MeV deuteron linear accelerator using a flowing liquid lithium target. With a continuous deuteron current of 100 milliamperes, a source intensity of more than 10 16 neutrons per second will be produced. The neutrons will be emitted in a roughly collimated beam. The proposed facility can be divided into two areas: the 30-MeV linear accelerator and the multiple-target experimental area. The 30-MeV accelerator will consist of eight rf accelerating cavities in a single vacuum tank, each cavity being powered by its own rf power amplifier operating at 50 MHz. To shield the beam bunches from the rf field when it is in the decelerating direction, 66 ''drift tubes'' will be included; the drift-tube structures will include quadrupole magnets which will keep the beam focused. The accelerator will produce a continuous beam of 100 milliamperes. Beam power will thus be 3.0 megawatts; total power including rf losses in the accelerating cavities will be 4.5 megawatts. The injectors for the linear accelerator will be two 500-kV dc accelerators, one for injection of D + ions and the other for D - ions. They can be used simultaneously or one can serve as a spare in case of breakdown or maintenance of the other. (U.S.)

  7. SUPER-FMIT, an accelerator-based neutron source for fusion components irradiation testing

    International Nuclear Information System (INIS)

    Burke, R.J.; Holmes, J.J.; Johnson, D.L.; Mann, F.M.; Miles, R.R.

    1984-01-01

    The SUPER-FMIT facility is proposed as an advanced accelerator based neutron source for high flux irradiation testing of large-sized fusion reactor components. The facility would require only small extensions to existing accelerator and target technology originally developed for the Fusion Materials Irradiation Test (FMIT) facility. There, neutrons would be produced by a 0.1 ampere beam of 35 MeV deuterons incident upon a liquid lithium target. The volume available for high flux (> 10 14 n/cm 2 -s) testing in SUPER-FMIT would be 14 liters, about a factor of 30 larger than in the FMIT facility. This is because the effective beam current of 35 MeV deuterons on target can be increased by a factor of ten to 1.0 amperes or more. Such a large increase can be accomplished by acceleration of multiple beams of molecular deuterium ions (D 2 +) to 70 MeV in a common accelerator sructure. The availability of multiple beams and large total current allows great variety in the testing that can be done. For example, fluxes greater than 10 16 n/cm 2 -s, multiple simultaneous experiments, and great flexibility in tailoring of spatial distributions of flux and spectra can be achieved

  8. The Radiological Research Accelerator Facility. Progress report, December 1, 1993--November 30, 1994

    International Nuclear Information System (INIS)

    Hall, E.J.; Marino, S.A.

    1994-04-01

    This document begins with a general description of the facility to include historical and up-to-date aspects of design and operation. A user's guide and a review of research using the facility follows. Next the accelerator utilization and operation and the development of the facilities is given. Personnel currently working at the facility are listed. Lastly, recent publications and literature cited are presented

  9. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma

    Energy Technology Data Exchange (ETDEWEB)

    Nariai, Tadashi [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan)], E-mail: nariai.nsrg@tmd.ac.jp; Ishiwata, Kiichi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Nakacho, Itabashi-ku, Tokyo (Japan); Kimura, Yuichi [Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba (Japan); Inaji, Motoki; Momose, Toshiya [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan); Yamamoto, Tetsuya; Matsumura, Akira [Department of Neurosurgery, University of Tsukuba, Tennodai, Tsukuba, Igaraki (Japan); Ishii, Kenji [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Nakacho, Itabashi-ku, Tokyo (Japan); Ohno, Kikuo [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan)

    2009-07-15

    Introduction: To plan the optimal BNCT for patients with malignant cerebral glioma, estimation of the ratio of boron concentration in tumor tissue against that in the surrounding normal brain (T/N ratio of boron) is important. We report a positron emission tomography (PET) imaging method to estimate T/N ratio of tissue boron concentration based on pharmacokinetic analysis of amino acid probes. Methods: Twelve patients with cerebral malignant glioma underwent 60 min dynamic PET scanning of brain after bolus injection of {sup 18}F-borono-phenyl-alanine (FBPA) with timed arterial blood sampling. Using kinetic parameter obtained by this scan, T/N ratio of boron concentration elicited by one-hour constant infusion of BPA, as performed in BNCT, was simulated on Runge-Kutta algorithm. {sup 11}C-methionine (MET) PET scan, which is commonly used in worldwide PET center as brain tumor imaging tool, was also performed on the same day to compare the image characteristics of FBPA and that of MET. Result: PET glioma images obtained with FBPA and MET are almost identical in all patients by visual inspection. Estimated T/N ratio of tissue boron concentration after one-hour constant infusion of BPA, T/N ratio of FBPA on static condition, and T/N ratio of MET on static condition showed significant linear correlation between each other. Conclusion: T/N ratio of boron concentration that is obtained by constant infusion of BPA during BNCT can be estimated by FBPA PET scan. This ratio can also be estimated by MET-PET imaging. As MET-PET study is available in many clinical PET center, selection of candidates for BNCT may be possible by MET-PET images. Accurate planning of BNCT may be performed by static images of FBPA PET. Use of PET imaging with amino acid probes may contribute very much to establish an appropriate application of BNCT for patients with malignant glioma.

  10. Characterization of the radiation environment at the UNLV accelerator facility during operation of the Varian M6 linac

    International Nuclear Information System (INIS)

    Hodges, M.; Barzilov, A.; Chen, Y.; Lowe, D.

    2016-01-01

    The bremsstrahlung photon flux from the UNLV particle accelerator (Varian M6 model) was determined using MCNP5 code for 3 MeV and 6 MeV incident electrons. Human biological equivalent dose rates due to accelerator operation were evaluated using the photon flux with the flux-to-dose conversion factors. Dose rates were computed for the accelerator facility for M6 linac use under different operating conditions. The results showed that the use of collimators and linac internal shielding significantly reduced the dose rates throughout the facility. It was shown that the walls of the facility, in addition to the earthen berm enveloping the building, provide equivalent shielding to reduce dose rates outside to below the 2 mrem/h limit. - Highlights: • A 3/6 MeV electron accelerator equipped with a high energy x-ray target was studied. • Monte Carlo modeling of photon flux was carried out for three accelerator configurations. • Human biological equivalent doses were evaluated within the accelerator facility building.

  11. Logic Estimation of the Optimum Source Neutron Energy for BNCT of Brain Tumors

    International Nuclear Information System (INIS)

    Dorrah, M.A.; Gaber, F.A.; Abd Elwahab, M.A.; Kotb, M.A.; Mohammed, M.M.

    2012-01-01

    BNCT is very complicated technique; primarily due to the complexity of element composition of the brain. Moreover; numerous components contributes to the over all radiation dose both to normal brain and to tumor. Simple algebraic summation cannot be applied to these dose components, since each component should at first be weighed by its relative biological effectiveness (RBE) value. Unfortunately, there is no worldwide agreement on these RBE values. For that reason, the parameters required for accurate planning of BNCT of brain tumors located at different depths in brain remained obscure. The most important of these parameters is; the source neutron energy. Thermal neutrons were formerly employed for BNCT, but they failed to prove therapeutic efficacy. Later on; epithermal neutrons were suggested proposing that they would be enough thermalized while transporting in the brain tissues. However; debate aroused regarding the source neutrons energy appropriate for treating brain tumors located at different depths in brain. Again, the insufficient knowledge regarding the RBE values of the different dose components was a major obstacle. A new concept was adopted for estimating the optimum source neutrons energy appropriate for different circumstances of BNCT. Four postulations on the optimum source neutrons energy were worked out, almost entirely independent of the RBE values of the different dose components. Four corresponding condition on the optimum source neutrons energy were deduced. An energy escalation study was carried out investigating 65 different source neutron energies, between 0.01 eV and 13.2 MeV. MCNP4B Monte C arlo neutron transport code was utilized to study the behavior of neutrons in the brain. The deduced four conditions were applied to the results of the 65 steps of the neutron energy escalation study. A source neutron energy range of few electron volts (eV) to about 30 keV was estimated to be the most appropriate for BNCT of brain tumors located at

  12. Accelerator-based intense neutron source for materials R ampersand D

    International Nuclear Information System (INIS)

    Jameson, R.A.

    1990-01-01

    Accelerator-based neutron sources for R ampersand D of materials in nuclear energy systems, including fusion reactors, can provide sufficient neutron flux, flux-volume, fluence and other attractive features for many aspects of materials research. The neutron spectrum produced from the D-Li reaction has been judged useful for many basic materials research problems, and to be a satisfactory approximation to that of the fusion process. The technology of high-intensity linear accelerators can readily be applied to provide the deuteron beam for the neutron source. Earlier applications included the Los Alamos Meson Physics Facility and the Fusion Materials Irradiation Test facility prototype. The key features of today's advanced accelerator technology are presented to illustrate the present state-of-the-art in terms of improved understanding of basic physical principles and engineering technique, and to show how these advances can be applied to present demands in a timely manner. These features include how to produce an intense beam current with the high quality required to minimize beam losses along the accelerator and transport system that could cause maintenance difficulties, by controlling the beam emittance through proper choice of the operating frequency, balancing of the forces acting on the beam, and realization in practical hardware. A most interesting aspect for materials researchers is the increased flexibility and opportunities for experimental configurations that a modern accelerator-based source could add to the set of available tools. 8 refs., 5 figs

  13. Radiobiology of BNCT mediated by GB-10 and GB-10+BPA in experimental oral cancer

    Energy Technology Data Exchange (ETDEWEB)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Nigg, David; Calzetta, Osvaldo; Blaumann, Herman; Longhino, Juan; Schwint, Amanda E. E-mail: schwint@cnea.gov.ar

    2004-11-01

    We previously reported biodistribution and pharmacokinetic data for GB-10 (Na{sub 2}{sup 10}B{sub 10}H{sub 10}) and the combined administration of GB-10 and boronophenylalanine (BPA) as boron delivery agents for boron neutron capture therapy (BNCT) in the hamster cheek pouch oral cancer model. The aim of the present study was to assess, for the first time, the response of hamster cheek pouch tumors, precancerous tissue and normal tissue to BNCT mediated by GB-10 and BNCT mediated by GB-10 and BPA administered jointly using the thermalized epithermal beam of the RA-6 Reactor at the Bariloche Atomic Center. GB-10 exerted 75.5% tumor control (partial+complete remission) with no damage to precancerous tissue around tumor or to normal tissue. Thus, GB-10 proved to be a therapeutically efficient boron agent in this model despite the fact that it is not taken up selectively by oral tumor tissue. GB-10 exerted a selective effect on tumor blood vessels leading to significant tumor control with a sparing effect on normal tissue. BNCT mediated by the combined administration of GB-10 and BPA resulted in a reduction in the dose to normal tissue and would thus allow for significant escalation of dose to tumor without exceeding normal tissue tolerance.

  14. Radiobiology of BNCT mediated by GB-10 and GB-10+BPA in experimental oral cancer

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Nigg, David; Calzetta, Osvaldo; Blaumann, Herman; Longhino, Juan; Schwint, Amanda E.

    2004-01-01

    We previously reported biodistribution and pharmacokinetic data for GB-10 (Na 2 10 B 10 H 10 ) and the combined administration of GB-10 and boronophenylalanine (BPA) as boron delivery agents for boron neutron capture therapy (BNCT) in the hamster cheek pouch oral cancer model. The aim of the present study was to assess, for the first time, the response of hamster cheek pouch tumors, precancerous tissue and normal tissue to BNCT mediated by GB-10 and BNCT mediated by GB-10 and BPA administered jointly using the thermalized epithermal beam of the RA-6 Reactor at the Bariloche Atomic Center. GB-10 exerted 75.5% tumor control (partial+complete remission) with no damage to precancerous tissue around tumor or to normal tissue. Thus, GB-10 proved to be a therapeutically efficient boron agent in this model despite the fact that it is not taken up selectively by oral tumor tissue. GB-10 exerted a selective effect on tumor blood vessels leading to significant tumor control with a sparing effect on normal tissue. BNCT mediated by the combined administration of GB-10 and BPA resulted in a reduction in the dose to normal tissue and would thus allow for significant escalation of dose to tumor without exceeding normal tissue tolerance

  15. Results of the RAMI analyses performed for the IFMIF accelerator facility in the engineering design phase

    Energy Technology Data Exchange (ETDEWEB)

    Bargalló, Enric, E-mail: enric.bargallo@esss.se [Fusion Energy Engineering Laboratory (FEEL), Technical University of Catalonia (UPC) Barcelona-Tech, Barcelona (Spain); Arroyo, Jose Manuel [Laboratorio Nacional de Fusión por Confinamiento Magnético – CIEMAT, Madrid (Spain); Abal, Javier; Dies, Javier; De Blas, Alfredo; Tapia, Carlos [Fusion Energy Engineering Laboratory (FEEL), Technical University of Catalonia (UPC) Barcelona-Tech, Barcelona (Spain); Moya, Joaquin; Ibarra, Angel [Laboratorio Nacional de Fusión por Confinamiento Magnético – CIEMAT, Madrid (Spain)

    2015-10-15

    Highlights: • RAMI methodology used for IFMIF accelerator facility is presented. • Availability analyses and results are shown. • Main accelerator design changes are proposed. • Consequences and conclusions of the RAMI analyses are described. - Abstract: This paper presents a summary of the RAMI (Reliability Availability Maintainability Inspectability) analyses done for the IFMIF (International Fusion Materials Irradiation Facility) Accelerator facility in the Engineering Design Phase. The methodology followed, the analyses performed, the results obtained and the conclusions drawn are described. Moreover, the consequences of the incorporation of the RAMI studies in the IFMIF design are presented and the main outcomes of these analyses are shown.

  16. Results of the RAMI analyses performed for the IFMIF accelerator facility in the engineering design phase

    International Nuclear Information System (INIS)

    Bargalló, Enric; Arroyo, Jose Manuel; Abal, Javier; Dies, Javier; De Blas, Alfredo; Tapia, Carlos; Moya, Joaquin; Ibarra, Angel

    2015-01-01

    Highlights: • RAMI methodology used for IFMIF accelerator facility is presented. • Availability analyses and results are shown. • Main accelerator design changes are proposed. • Consequences and conclusions of the RAMI analyses are described. - Abstract: This paper presents a summary of the RAMI (Reliability Availability Maintainability Inspectability) analyses done for the IFMIF (International Fusion Materials Irradiation Facility) Accelerator facility in the Engineering Design Phase. The methodology followed, the analyses performed, the results obtained and the conclusions drawn are described. Moreover, the consequences of the incorporation of the RAMI studies in the IFMIF design are presented and the main outcomes of these analyses are shown.

  17. Cable systems for experimental facilities in JAERI TANDEM ACCELERATOR BUILDING

    International Nuclear Information System (INIS)

    Tukihashi, Yoshihiro; Yoshida, Tadashi; Takekoshi, Eiko

    1979-03-01

    Measuring cable systems for experimental facilities in JAERI TANDEM ACCELERATOR BUILDING were completed recently. Measures are taken to prevent penetration of noises into the measuring systems. The cable systems are described in detail, including power supplies and grounding for the measuring systems. (author)

  18. Noise countermeasures for accelerator facilities as seen from earth

    Energy Technology Data Exchange (ETDEWEB)

    Yasumoto, Masaru [Tokyo Univ. (Japan). Research Center for Nuclear Science and Technology

    1996-12-01

    As seen from the viewpoint of noise countermeasures, the earth system for various experimental facilities is generally improper, for example independent earth method. It is considered that only by changing this to the earth system which is suitable to noise countermeasures, the antinoise property can be largely heightened. Also it is important to make earth system into that, to which the countermeasure technology suitable to the features of facilities is applied. The features of large accelerators and their building structures related to noise circulation are explained. As to the basic technology of the earth system that heightens antinoise property, induction shielding, the resistance-dependent and inductance-dependent zones in its frequency characteristics, the lowering of impedance, the shielding characteristics of various cables, the method of realizing low impedance, the method of absorbing same phase noise, the characteristics of superhigh permeability materials, and the restraint of interference noise voltage by reducing common impedance and restraining circulating noise current are discussed. As the concrete countermeasures, the earth system in accelerator buildings and beam lines are shown. (K.I.)

  19. Noise countermeasures for accelerator facilities as seen from earth

    International Nuclear Information System (INIS)

    Yasumoto, Masaru

    1996-01-01

    As seen from the viewpoint of noise countermeasures, the earth system for various experimental facilities is generally improper, for example independent earth method. It is considered that only by changing this to the earth system which is suitable to noise countermeasures, the antinoise property can be largely heightened. Also it is important to make earth system into that, to which the countermeasure technology suitable to the features of facilities is applied. The features of large accelerators and their building structures related to noise circulation are explained. As to the basic technology of the earth system that heightens antinoise property, induction shielding, the resistance-dependent and inductance-dependent zones in its frequency characteristics, the lowering of impedance, the shielding characteristics of various cables, the method of realizing low impedance, the method of absorbing same phase noise, the characteristics of superhigh permeability materials, and the restraint of interference noise voltage by reducing common impedance and restraining circulating noise current are discussed. As the concrete countermeasures, the earth system in accelerator buildings and beam lines are shown. (K.I.)

  20. In vivo tyrosinase mini-gene transfer enhances killing effect of BNCT on amelanotic melanoma

    International Nuclear Information System (INIS)

    Kondoh, H.; Mishima, Y.; Hiratsuka, J.; Iwakura, M.

    2000-01-01

    Using accentuated melanogenesis principally occurring within melanoma cells, we have successfully treated human malignant melanoma (Mm) with 10 B-BPA BNCT. Despite this success, there are still remaining issues for poorly melanogenic Mm and further non-pigment cell tumors. We found the selective accumulation of 10 B-BPA to Mm is primarily due to the complex formation of BPA and melanin-monomers activity synthesized within Mm cells. Then, we succeeded in transferring the tyrosinase gene into amelanotic to substantially produce melanin monomers. These cells has demonstrated increased boron accumulation and enhanced killing effect of BNCT. Further, transfection of TRP-2 (DOPAchrome tautomerase) gene into poorly eumelanotic and slightly phenomelanotic Mm cells in culture cell systems also led to increased BPA accumulation. Thereafter, we studied in vivo gene transfer. We transferred the tyrosinase mini-gene by intra-tumor injection into poorly melanotic Mm proliferating subcutaneously in hamster skin, and performed BNCT. Compared to control tumors, gene-transferred tumors showed increased BPA accumulation leading to enhanced killing effect. (author)

  1. 7-MeV electron LINAC based pulse radiolysis facility at RPCD, BARC

    International Nuclear Information System (INIS)

    Naik, C.B.; Nadkarni, S.A.; Toley, M.A.; Shinde, S.J.; Naik, P.D.

    2017-01-01

    7-MeV electron LINAC based pulse radiolysis facility is operational in Chemistry Group of BARC since 1986. The Accelerator is housed in B-132 room in basement of Modular Labs. BARC Accelerator was procured from Radiation Dynamics Inc. UK and its detection system was indigenously developed

  2. The Brookhaven Accelerator Test Facility

    International Nuclear Information System (INIS)

    Batchelor, K.; Chou, T.S.; Fernow, R.C.; Fischer, J.; Gallardo, J.; Kirk, H.G.; Koul, R.; Palmer, R.B.; Pellegrini, C.; Sheehan, J.; Srinivasan-Rao, T.; Ulc, S.; Woodle, M.; Bigio, I.; Kurnit, N.; McDonald, K.T.

    1989-01-01

    The Brookhaven Accelerator Test Facility ATF will consist of a 50-100 MeV/c electron linac and a 100 GW CO 2 laser system. A high brightness RF-gun operating at 2,856 MHz is to be used as the injector into the linac. The RF-gun contains a Nd:Yag-laser-driven photocathode capable of producing a stream of six ps electron pulses separated by 12.5 ns. The maximum charge in a micropulse will be one nano-Coulomb. The CO 2 laser pulse length will be a few picoseconds and will be synchronized with the electron pulse. The first experimental beam is expected in Fall 89. The design electron beam parameters are given and possible initial experiments are discussed. 9 refs., 1 fig., 3 tabs

  3. Advanced Accelerator Applications in Medicine

    International Nuclear Information System (INIS)

    Rimjiaem, Sakhorn

    2015-01-01

    besides the original purpose on development of particle acceleratora as research tools in nuclear and high-energy physics, there are large variety of accelerators used in various fileds from fundamental research to industrial usesand applications chemistry, biology and medicine. Pratical accelators used in various field of medical applications since serveral decades. Even through, a large fraction of applications is emphasized on cancer therappy, the number of accelerators used in midicine for other diagnostics and treatments has increased steady over the years. Several types of accelerated particles are used including electron, proton, neutron and ions. Presently, relativistic electron beams and radiation from linear accelerators (linas) are widely used. A combination of positron emission tomography (PRT) and radiotherapy is an example of excellent invention early detection and treat of cancer tumors. The most developments for proton and heavy ion therapy as well as a modern boron neutron capture therapy (BNCT) are also great incoming effective systems. This talk will focus on developments of the accelrator systems as well as overview on biophysical properties and medical aspects of the diacnostics and treatments.

  4. Artificial neural networks to evaluate the boron concentration decreasing profile in Blood-BPA samples of BNCT patients

    Energy Technology Data Exchange (ETDEWEB)

    Garcia-Reiriz, Alejandro, E-mail: garciareiriz@gmail.com [Department of Analytical Chemistry, Faculty of Biochemical and Pharmaceutical Sciences, National University of Rosario, Rosario Institute of Chemistry (IQUIR-CONICET), Suipacha 531, Rosario S2002LRK (Argentina); Magallanes, Jorge [Comision Nacional de Energia Atomica, Av. Gral. Paz 1499, San Martin, B1650KNA, Buenos Aires (Argentina); Zupan, Jure [National Institute of Chemistry, Hajdrihova 19, SLO-1000 Ljubljana, Eslovenia (Slovenia); Liberman, Sara [Comision Nacional de Energia Atomica, Av. Gral. Paz 1499, San Martin, B1650KNA, Buenos Aires (Argentina)

    2011-12-15

    For the prediction of decay concentration profiles of the p-boronophenylalanine (BPA) in blood during BNCT treatment, a method is suggested based on Kohonen neural networks. The results of a model trained with the concentration profiles from the literature are described. The prediction of the model was validated by the leave-one-out method. Its robustness shows that it is mostly independent on small variations. The ability to fit retrospective experimental data shows an uncertainty lower than the two compartment model used previously. - Highlights: Black-Right-Pointing-Pointer We predicted decaying concentration profiles of BPA in blood during BNCT therapy. Black-Right-Pointing-Pointer Is suggested a method based on Kohonen neural networks. Black-Right-Pointing-Pointer The results show that it is very robust and mostly independent of small variations. Black-Right-Pointing-Pointer It has a better ability to fit retrospective experimental data. Black-Right-Pointing-Pointer The model could be progressively improved by adding new data to the training matrix.

  5. Artificial neural networks to evaluate the boron concentration decreasing profile in Blood-BPA samples of BNCT patients

    International Nuclear Information System (INIS)

    García-Reiriz, Alejandro; Magallanes, Jorge; Zupan, Jure; Líberman, Sara

    2011-01-01

    For the prediction of decay concentration profiles of the p-boronophenylalanine (BPA) in blood during BNCT treatment, a method is suggested based on Kohonen neural networks. The results of a model trained with the concentration profiles from the literature are described. The prediction of the model was validated by the leave-one-out method. Its robustness shows that it is mostly independent on small variations. The ability to fit retrospective experimental data shows an uncertainty lower than the two compartment model used previously. - Highlights: ► We predicted decaying concentration profiles of BPA in blood during BNCT therapy. ► Is suggested a method based on Kohonen neural networks. ► The results show that it is very robust and mostly independent of small variations. ► It has a better ability to fit retrospective experimental data. ► The model could be progressively improved by adding new data to the training matrix.

  6. Upgrading of the AMS facility at the Koffler 14UD Pelletron accelerator

    CERN Document Server

    Berkovits, D; Bordeanu, C; Ghelberg, S; Hass, M; Heber, O; Paul, M; Shahar, Y; Verri, G; 10.1016/j.nimb.2004.04.033

    2004-01-01

    The AMS facility based on a 14UD Pelletron tandem accelerator has been upgraded in recent years to support an active and diversified research program. A new dedicated AMS ion source beam line merging at 45 degrees with the existing injection line through a 45 degrees electrostatic deflector is in operation. The multi-sample high- intensity Cs sputter ion source stands on a separate 120 kV platform and is remote-controlled through a hybrid infrared-fiber-optics link operated either manually or by the accelerator-control computer, ensuring safe and reliable operation. Independent current preamplifiers are used in Faraday cup current readings down to the pA range. The accelerator computer-control system was upgraded to Lab View 6.1, allowing a PC server to control and read out all hardware components while one or more remote PC clients run the AMS software. Ad hoc sequences of commands, written in a script macro language, are run from a client computer to perform an automated AMS measurement. The present capabil...

  7. Tumor blood vessel "normalization" improves the therapeutic efficacy of boron neutron capture therapy (BNCT) in experimental oral cancer

    Energy Technology Data Exchange (ETDEWEB)

    D. W. Nigg

    2012-01-01

    We previously demonstrated the efficacy of BNCT mediated by boronophenylalanine (BPA) to treat tumors in a hamster cheek pouch model of oral cancer with no normal tissue radiotoxicity and moderate, albeit reversible, mucositis in precancerous tissue around treated tumors. It is known that boron targeting of the largest possible proportion of tumor cells contributes to the success of BNCT and that tumor blood vessel normalization improves drug delivery to the tumor. Within this context, the aim of the present study was to evaluate the effect of blood vessel normalization on the therapeutic efficacy and potential radiotoxicity of BNCT in the hamster cheek pouch model of oral cancer.

  8. Tumor blood vessel 'normalization' improves the therapeutic efficacy of boron neutron capture therapy (BNCT) in experimental oral cancer

    International Nuclear Information System (INIS)

    Nigg, D.W.

    2012-01-01

    We previously demonstrated the efficacy of BNCT mediated by boronophenylalanine (BPA) to treat tumors in a hamster cheek pouch model of oral cancer with no normal tissue radiotoxicity and moderate, albeit reversible, mucositis in precancerous tissue around treated tumors. It is known that boron targeting of the largest possible proportion of tumor cells contributes to the success of BNCT and that tumor blood vessel normalization improves drug delivery to the tumor. Within this context, the aim of the present study was to evaluate the effect of blood vessel normalization on the therapeutic efficacy and potential radiotoxicity of BNCT in the hamster cheek pouch model of oral cancer.

  9. Collaborative Physical and Biological Dosimetry Studies for Neutron Capture Therapy at the RA-1 Research Reactor Facility

    Energy Technology Data Exchange (ETDEWEB)

    David W. Nigg; Amanda E. Schwint; John K. Hartwell; Elisa M. Heber; Veronica Trivillin; Jorge Castillo; Luis Wentzeis; Patrick Sloan; Charles A. Wemple

    2004-10-01

    Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminiscent dosimeters to characterize the BNCT irradiation facility developed at the RA-1 research reactor operated by the Argentine National Atomic Energy Commission in Buenos Aires. Some biological scoping irradiations have also been completed using a small-animal (hamster) oral mucosa tumor model. Results indicate that the RA-1 neutron source produces useful dose rates but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications.

  10. Collaborative Physical and Biological Dosimetry Studies for Neutron Capture Therapy at the RA-1 Research Reactor Facility

    Energy Technology Data Exchange (ETDEWEB)

    Nigg, D.W.; Schwint, A.E.; Hartwell, J.K.; Heber, E.M.; Trivillin, V.; Castillo, J.; Wentzeis, L.; Sloan, P.; Wemple, C.A.

    2004-10-04

    Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminiscent dosimeters to characterize the BNCT irradiation facility developed at the RA-1 research reactor operated by the Argentine National Atomic Energy Commission in Buenos Aires. Some biological scoping irradiations have also been completed using a small-animal (hamster) oral mucosa tumor model. Results indicate that the RA-1 neutron source produces useful dose rates but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications.

  11. Decontamination/decommissioning of the Princeton Pennsylvania Accelerator Facility

    International Nuclear Information System (INIS)

    Bair, W.A.

    1990-01-01

    The Princeton Pennsylvania Accelerator Facility was a 3 GeV proton synchrotron operated jointly by Princeton University and the University of Pennsylvania from 1962 to 1972 on Princeton University's Forrestal Campus. During synchrotron operations, certain portions of the PPA central accelerator chamber and structural members became neutron activated. Upon termination of accelerator operations due to funding problems, Princeton desired to utilize the PPA site for other purposes, and commissioned a study to investigate Decommissioning and Decontamination options and methodologies. The study investigated several methods for in-place, surgically removing the neutron activated from the uncontaminated concrete. Since each technique produced different volumes of removed concrete all methods investigated were studied from the total economics of the problem and the cost of limiting and clean-up of secondary contamination. The decontamination method selected used a diamond wire cutting technique to sever in-place, the activated concrete from the uncontaminated. Large, intact, activated structural segments were cut and removed from the central accelerator chamber's floor, outer walls, internal columns and ceiling. Nonactivated portions of the structure, and the remainder of the central chamber were subsequently razed by conventional demolition methods. The paper describes the decontamination methodology, its effectiveness, disposal economics and radiological safety problems related thereto

  12. The rare isotope accelerator (RIA) facility project

    International Nuclear Information System (INIS)

    Christoph Leemann

    2000-01-01

    The envisioned Rare-Isotope Accelerator (RIA) facility would add substantially to research opportunities for nuclear physics and astrophysics by combining increased intensities with a greatly expanded variety of high-quality rare-isotope beams. A flexible superconducting driver linac would provide 100 kW, 400 MeV/nucleon beams of any stable isotope from hydrogen to uranium onto production targets. Combinations of projectile fragmentation, target fragmentation, fission, and spallation would produce the needed broad assortment of short-lived secondary beams. This paper describes the project's background, purpose, and status, the envisioned facility, and the key subsystem, the driver linac. RIA's scientific purposes are to advance current theoretical models, reveal new manifestations of nuclear behavior, and probe the limits of nuclear existence [3]. Figures 1 and 2 show, respectively, examples of RIA research opportunities and the yields projected for pursuing them. Figure 3 outlines a conceptual approach for delivering the needed beams

  13. Treatment optimization of a brain tumor in BNCT by Monte Carlo method

    International Nuclear Information System (INIS)

    Nejat, S.; Binesh, A.; Karimian, A.

    2012-01-01

    Brain cancers are one of the most important diseases. BNCT (Boron Neutron Capture Therapy) is used to brain tumor treatment. In this method the 1 0B (n,α) 7 Li reaction is used. The purpose of this study is absorbed dose evaluation of tumoral and healthy parts of brain. To achieve this aim the brain was simulated by a cylindrical phantom with the dimensions of 20 cm in diameter and height. In BNCT treatment the BSH (Na 2 B 12 H 11 SH) is injected to the human body and absorbed in the healthy and tumoral parts by the ratios of 18 and 65 ppm respectively. So in this research the absorption of BSH in tumoral and healthy parts of brain was considered as the mentioned ratio. Then the neutron with the energy range of 50 eV - 10 keV was exposed to the brain and maximum absorbed dose in healthy and tumoral parts of brain were calculated for a cylindrical tumor with the thickness of about 1 cm which was considered in 5.5 cm depth of brain. This research showed the suitable energy to treat this tumor by BNCT is interval 4 keV- 6keV. The average of dose which is met with healthy and tumor tissue was gained for 6 keV energy of brain 1.18x10 -12 cGy/n and 5.98x10 -12 cGy/n respectively. Maximum of dose which is met with healthy tissue was 4.3 Gy which is much less than standard amount 12.6 Gy. Therefore BNCT method is known as an effective way in the therapy of this kind of tumor. (authors)

  14. Construction of voxel head phantom and application to BNCT dose calculation

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Choon Sik; Lee, Choon Ik; Lee, Jai Ki [Hanyang Univ., Seoul (Korea, Republic of)

    2001-06-15

    Voxel head phantom for overcoming the limitation of mathematical phantom in depicting anatomical details was constructed and example dose calculation for BNCT was performed. The repeated structure algorithm of the general purpose Monte Carlo code, MCNP4B was applied for voxel Monte Carlo calculation. Simple binary voxel phantom and combinatorial geometry phantom composed of two materials were constructed for validating the voxel Monte Carlo calculation system. The tomographic images of VHP man provided by NLM(National Library of Medicine) were segmented and indexed to construct voxel head phantom. Comparison od doses for broad parallel gamma and neutron beams in AP and PA directions showed decrease of brain dose due to the attenuation of neutron in eye balls in case of voxel head phantom. The spherical tumor volume with diameter, 5cm was defined in the center of brain for BNCT dose calculation in which accurate 3 dimensional dose calculation is essential. As a result of BNCT dose calculation for downward neutron beam of 10keV and 40keV, the tumor dose is about doubled when boron concentration ratio between the tumor to the normal tissue is 30{mu}g/g to 3 {mu}g/g. This study established the voxel Monte Carlo calculation system and suggested the feasibility of precise dose calculation in therapeutic radiology.

  15. Hyaluronic acid as a potential boron carrier for BNCT: Preliminary evaluation

    International Nuclear Information System (INIS)

    Zaboronok, A.; Yamamoto, T.; Nakai, K.; Yoshida, F.; Uspenskii, S.; Selyanin, M.; Zelenetskii, A.; Matsumura, Akira

    2015-01-01

    Hyaluronic acid (HA), a nonimmunogenic, biocompatible polymer found in different biological tissues, has the potential to attach to CD44 receptors on the surface of certain cancer cells, where the receptor is overexpressed compared with normal cells. Boron–hyaluronic acid (BHA) was tested for its feasibility as a potential agent for BNCT. BHA with low-viscosity 30 kDa HA could be administered by intravenous injection. The compound showed a certain degree of cytotoxicity and accumulation in C6 rat glioma cells in vitro. Instability of the chelate bonds between boron and HA and/or insufficient specificity of CD44 receptors on C6 cells to BHA could account for the insufficient in vitro accumulation. To ensure the future eligibility of BHA for BNCT experiments, using alternative tumor cell lines and chemically securing the chelate bonds or synthesizing BHA with boron covalently attached to HA might be required. - Highlights: • Hyaluronic acid (HA) is a nonimmunogenic, biocompatible polymer. • Boron–HA (BHA) acid can contain a large number of boron atoms for BNCT. • Active targeting can be realized with CD44 and other HA receptors on tumor cells. • BHA showed a certain degree of toxicity against C6 tumor cells and V79 fibroblasts. • BHA was injected into rats via the tail vein, boron was detected in tumors in vivo.

  16. Acceleration of radioactive ions

    International Nuclear Information System (INIS)

    Laxdal, R.E.

    2003-01-01

    There is an intense interest world-wide in the use of radioactive ion beams (RIBs) for experiment. In many existing or proposed facilities ions are produced or collected at source potential, ionized and re-accelerated. Within the past year three new ISOL based facilities have added dedicated post-accelerators to deliver accelerated RIBs to experiment. The paper gives an overview of RIB accelerators present and future, and explores the inherent features in the various acceleration methods with an emphasis on heavy ion linacs. The ISAC-I and ISAC-II post-accelerators are discussed as examples. Commissioning results and initial operating experience with ISAC-I will be presented

  17. 78 FR 73144 - Acceleration of Broadband Deployment by Improving Wireless Facilities Siting Policies

    Science.gov (United States)

    2013-12-05

    ... license is required, which in turn extends to any apparatus for the transmission of energy, or... No. 11-59; FCC 13-122] Acceleration of Broadband Deployment by Improving Wireless Facilities Siting... of new wireless facilities and on rules to implement statutory provisions governing State and local...

  18. Breakdowns and solutions in 15 UD pelletron ion accelerator facility at Inter-University Accelerator Centre, New Delhi

    International Nuclear Information System (INIS)

    Joshi, R.; Singh, P.; Suraj; Nishal, S.M.; Panwar, N.S.; Singh, M.P.; Kumar, R.; Prasad, J.; Sota, M.; Patel, V.P.; Sharma, R.P.; Kumar, Pankaj; Devi, K.D.; Ojha, S.; Gargari, S.; Chopra, S.; Kanjilal, D.

    2013-01-01

    15UD Pelletron accelerator, installed in Inter-University Accelerator Centre (IUAC), New Delhi, is a tandem ion accelerator and is performing well since its commissioning. Constant efforts have been put to keep high uptime and better performance of the accelerator for more than two decades. In recent years, the facility was improved by many modifications and up gradations. It has also gone through a few major breakdowns related to charging system and fiber optic cables. Out of two charging systems, one system failed and devices housed in tank stopped working due to the damage of fiber optic cables. The reasons for both of these breakdowns were studied thoroughly. The entire charging system and fiber optic cable network have been rebuilt and tested. The diagnostic techniques and maintenance methods for these two breakdowns will be discussed in this paper. (author)

  19. The use of positron emission tomography in BNCT treatment planning for metastatic malignant melanoma and glioblastoma multiforme

    International Nuclear Information System (INIS)

    Kabalka, G.; Nichols, T.; Smith, G.; Miller, L.; Kahn, M.

    2000-01-01

    Positron emission tomography (PET) evaluations of six glioblastoma multiforme (GBM) and one metastatic melanoma (MM) patient have been carried out utilizing fluorine-18 labeled p-boronophenylalanine. Four of the GBM patients were imaged both prior to and post BNCT. In one GBM patient, biopsy derived boron distribution data compared favorably to the PET derived data. The PET data have been used as input to dosimetry calculations and the results vary from those obtained using current protocols. In addition, PET images of the thorax would indicate that the utility of PET for staging tumors for BNCT may extend beyond the brain. However, higher than anticipated levels of activity in the lungs (as also seen in salivary glands) indicate the more effective BNCT agents will be required. (author)

  20. Defocusing beam line design for an irradiation facility at the TAEA SANAEM Proton Accelerator Facility

    CERN Document Server

    Gencer, A.; Efthymiopoulos, I.; Yiğitoğlu, M.

    2016-01-01

    Electronic components must be tested to ensure reliable performance in high radiation environments such as Hi-Limu LHC and space. We propose a defocusing beam line to perform proton irradiation tests in Turkey. The Turkish Atomic Energy Authority SANAEM Proton Accelerator Facility was inaugurated in May 2012 for radioisotope production. The facility has also an R&D room for research purposes. The accelerator produces protons with 30 MeV kinetic energy and the beam current is variable between View the MathML source10μA and View the MathML source1.2mA. The beam kinetic energy is suitable for irradiation tests, however the beam current is high and therefore the flux must be lowered. We plan to build a defocusing beam line (DBL) in order to enlarge the beam size, reduce the flux to match the required specifications for the irradiation tests. Current design includes the beam transport and the final focusing magnets to blow up the beam. Scattering foils and a collimator is placed for the reduction of the beam ...

  1. Proceedings of the specialists' meeting on accelerator-based transmutation

    International Nuclear Information System (INIS)

    Wenger, H.U.

    1992-09-01

    The meeting was organised under the auspices of OECD Nuclear Agency's International Information Exchange Programme on Actinide and Fission Product Partitioning and Transmutation. In the original announcement for the meeting the following sessions were proposed: 1) Concepts of accelerator-based transmutation systems, 2) Nuclear design problems of accelerator-based transmutation systems with emphasis on target facilities and their interfaces with accelerators, 3) Data and methods for nuclear design of accelerator-based transmutation systems, 4) Related cross-section measurements and integral experiments, 5) Identification of discrepancies and gaps and discussion of desirable R+D and benchmark activities. Due to the large number of papers submitted it was necessary to split session 2 into two parts and to reassign some papers in order to balance the sessions more evenly. No papers were submitted for session 5 and this was replaced by a summary and general discussion session. These proceedings contain all 30 papers in the order they were presented at the meeting. They are copies of the duplication-ready versions given to us during or shortly after the meeting. In the Table of Contents, the papers are listed together with the name of the presenter. (author) figs., tabs., refs

  2. Accelerator-TEM interface facility and application

    International Nuclear Information System (INIS)

    Liu Chuansheng; Li Ming; He Jun; Yang Zheng; Zhou Lin; Wang Zesong; Guo Liping; Jiang Changzhong; Yang Shibo; Fu Dejun; Fan Xiangjun; Liu Jiarui; Lee J C

    2010-01-01

    An accelerator-TEM interface facility has been established at Wuhan University in 2008. The system consists of an H800 TEM linked to a 200 kV ion implanter and a 2 x 1.7 MV tandem accelerator. Nitrogen ions at 115 keV were successfully transported from the implanter into the TEM chamber through the interface system, and the ion currents measured at the entrance of the TEM column were between 20 and 180 nA. Structural evolution caused by ion irradiation in Si, GaAs, nanocrystal Ag was observed in situ. The in situ observation showed that the critical implantation dose for amorphization of Si is 10 14 cm -2 . The nuclear material C276 samples implanted with 115 keV Ar + was also studied, and dislocation loops sized at 3-12 nm were clearly observed after implantation to doses of over 1 x 10 15 cm -2 . The density of the loops increased with the dose. Evolution to polycrystalline and amorphous structures were observed at 5 x l0 15 cm -2 and 3 x 10 16 cm -2 , respectively. An in situ RBS/C chamber was installed on the transport line of the accelerator-TEM interface system. This enables in situ measurement of composition and location of the implanted species in lattice of the samples. In addition, a 50 kV low-energy gaseous ion generator was installed close to the TEM chamber, which facilitates in situ TEM observation of helium bubbles formed in helium-implanted materials. (authors)

  3. Accelerator-based atomic physics experiments with photon and ion beams

    International Nuclear Information System (INIS)

    Johnson, B.M.; Jones, K.W.; Meron, M.

    1984-01-01

    Accelerator-based atomic physics experiments at Brookhaven presently use heavy-ion beams from the Dual MP Tandem Van de Graaff Accelerator Facility for atomic physics experiments of several types. Work is presently in progress to develop experiments which will use the intense photon beams which will be available in the near future from the ultraviolet (uv) and x-ray rings of the National Synchrotron Light Source (NSLS). Plans are described for experiments at the NSLS and an exciting development in instrumentation for heavy-ion experiments is summarized

  4. Analysis of conditions to safety and radiological protection of Brazilian research particle accelerators facilities

    International Nuclear Information System (INIS)

    Lourenco, Manuel Jacinto Martins

    2010-01-01

    Eleven institutions of education and research in Brazil use particle accelerators, which fulfill different functions and activities. Currently, these institutions employ a total of fifteen accelerators. In this paper, the object of study is the radiological protection of occupationally exposed individuals, the general public and the radiation safety of particle accelerators. Research facilities with accelerators are classified in categories I and II according to the International Atomic Energy Agency or groups IX and X in accordance with the Brazilian National Commission of Nuclear Energy. Of the 15 accelerators in use for research in Brazil, four belong to category I or group X and eleven belong to category II or group IX. The methodology presented and developed in this work was made through the inspection and assessment of safety and radiological protection of thirteen particle accelerators facilities, and its main purpose was to promote safer use of this practice by following established guidelines for safety and radiological protection. The results presented in this work showed the need to create a program, in our country, for the control of safety and radiological protection of this ionizing radiation practice. (author)

  5. Bioimaging of cells and tissues using accelerator-based sources.

    Science.gov (United States)

    Petibois, Cyril; Cestelli Guidi, Mariangela

    2008-07-01

    A variety of techniques exist that provide chemical information in the form of a spatially resolved image: electron microprobe analysis, nuclear microprobe analysis, synchrotron radiation microprobe analysis, secondary ion mass spectrometry, and confocal fluorescence microscopy. Linear (LINAC) and circular (synchrotrons) particle accelerators have been constructed worldwide to provide to the scientific community unprecedented analytical performances. Now, these facilities match at least one of the three analytical features required for the biological field: (1) a sufficient spatial resolution for single cell (pros and cons of the most popular techniques that have been implemented on accelerator-based sources to address analytical issues on biological specimens.

  6. In vivo tyrosinase mini-gene transfer enhances killing effect of BNCT on amelanotic melanoma

    Energy Technology Data Exchange (ETDEWEB)

    Kondoh, H.; Mishima, Y. [Mishima Institute for Dermatological Research, Kobe, Hyogo (Japan); Hiratsuka, J. [Kawasaki Medical School, Dept. of Radiation Oncology, Kurashiki, Okayama (Japan); Iwakura, M. [Kobe Univ. (Japan). School of Medicine

    2000-10-01

    Using accentuated melanogenesis principally occurring within melanoma cells, we have successfully treated human malignant melanoma (Mm) with {sup 10}B-BPA BNCT. Despite this success, there are still remaining issues for poorly melanogenic Mm and further non-pigment cell tumors. We found the selective accumulation of {sup 10}B-BPA to Mm is primarily due to the complex formation of BPA and melanin-monomers activity synthesized within Mm cells. Then, we succeeded in transferring the tyrosinase gene into amelanotic to substantially produce melanin monomers. These cells has demonstrated increased boron accumulation and enhanced killing effect of BNCT. Further, transfection of TRP-2 (DOPAchrome tautomerase) gene into poorly eumelanotic and slightly phenomelanotic Mm cells in culture cell systems also led to increased BPA accumulation. Thereafter, we studied in vivo gene transfer. We transferred the tyrosinase mini-gene by intra-tumor injection into poorly melanotic Mm proliferating subcutaneously in hamster skin, and performed BNCT. Compared to control tumors, gene-transferred tumors showed increased BPA accumulation leading to enhanced killing effect. (author)

  7. CERN accelerator school: Antiprotons for colliding beam facilities

    International Nuclear Information System (INIS)

    Bryant, P.; Newman, S.

    1984-01-01

    This is a specialized course which addresses a wide spectrum of theoretical and technological problems confronting the designer of an antiproton facility for high-energy-physics research. A broad and profound basis is provided by the lecturers' substantial experience gained over many years with CERN's unique equipment. Topics include beam optics, special lattices for antiproton accumulation and storage rings, antiproton production, stochastic cooling, acceleration and storage, r.f. noise, r.f. beam manipulations, beam-beam interaction, beam stability due to ion accumulation, and diagnostics. The SPS (Super Proton Synchrotron) panti p collider, LEAR (the Low Energy Antiproton Ring at CERN), antiprotons in the ISR (Intersecting Storage Rings), the new antiproton collector (ACOL) and gas jet targets are also discussed. A table is included listing the parameters of all CERN's accelerators and storage rings. See hints under the relevant topics. (orig./HSI)

  8. Accelerated radiation damage test facility using a 5 MV tandem ion accelerator

    International Nuclear Information System (INIS)

    Wady, P.T.; Draude, A.; Shubeita, S.M.; Smith, A.D.; Mason, N.; Pimblott, S.M.; Jimenez-Melero, E.

    2016-01-01

    We have developed a new irradiation facility that allows to perform accelerated damage tests of nuclear reactor materials at temperatures up to 400 °C using the intense proton (<100 μA) and heavy ion (≈10 μA) beams produced by a 5 MV tandem ion accelerator. The dedicated beam line for radiation damage studies comprises: (1) beam diagnosis and focusing optical components, (2) a scanning and slit system that allows uniform irradiation of a sample area of 0.5–6 cm"2, and (3) a sample stage designed to be able to monitor in-situ the sample temperature, current deposited on the sample, and the gamma spectrum of potential radio-active nuclides produced during the sample irradiation. The beam line capabilities have been tested by irradiating a 20Cr–25Ni–Nb stabilised stainless steel with a 3 MeV proton beam to a dose level of 3 dpa. The irradiation temperature was 356 °C, with a maximum range in temperature values of ±6 °C within the first 24 h of continuous irradiation. The sample stage is connected to ground through an electrometer to measure accurately the charge deposited on the sample. The charge can be integrated in hardware during irradiation, and this methodology removes uncertainties due to fluctuations in beam current. The measured gamma spectrum allowed the identification of the main radioactive nuclides produced during the proton bombardment from the lifetimes and gamma emissions. This dedicated radiation damage beam line is hosted by the Dalton Cumbrian Facility of the University of Manchester.

  9. SwissFEL injector conceptual design report. Accelerator test facility for SwissFEL

    International Nuclear Information System (INIS)

    Pedrozzi, M.

    2010-07-01

    This comprehensive report issued by the Paul Scherrer Institute (PSI) in Switzerland takes a look at the design concepts behind the institute's SwissFEL X-ray Laser facility - in particular concerning the conceptual design of the injector system. The SwissFEL X-ray FEL project at PSI, involves the development of an injector complex that enables operation of a FEL system operating at 0.1 - 7 nm with permanent-magnet undulator technology and minimum beam energy. The injector pre-project was motivated by the challenging electron beam requirements necessary to drive the SwissFEL accelerator facility. The report takes a look at the mission of the test facility and its performance goals. The accelerator layout and the electron source are described, as are the low-level radio-frequency power systems and the synchronisation concept. The general strategy for beam diagnostics is introduced. Low energy electron beam diagnostics, the linear accelerator (Linac) and bunch compressor diagnostics are discussed, as are high-energy electron beam diagnostics. Wavelength selection for the laser system and UV pulse shaping are discussed. The laser room for the SwissFEL Injector and constructional concepts such as the girder system and alignment concepts involved are looked at. A further chapter deals with beam dynamics, simulated performance and injector optimisation. The facility's commissioning and operation program is examined, as are operating regimes, software applications and data storage. The control system structure and architecture is discussed and special subsystems are described. Radiation safety, protection systems and shielding calculations are presented and the lateral shielding of the silo roof examined

  10. Radiological Research Accelerator Facility. Progress report, April 1, 1984-March 31, 1985

    International Nuclear Information System (INIS)

    Rossi, H.H.

    1985-01-01

    The aim of the Radiological Research Accelerator Facility (RARAF) was to provide a source of monoenergetic neutrons for studies in radiation biology, dosimetry and microdosimetry. The research has provided insight into the biological action of radiation and its relation to energy distribution in the cell as described by the theory of dual radiation action. This status report on the facility includes descriptions of the capabilities and layout, staffing, radiation safety, and a chronological account of the development and use of the facilities. 5 references, 2 figures

  11. Ultra high vacuum activities and required modification at 14 UD BARC-TIFR pelletron accelerator facility

    International Nuclear Information System (INIS)

    Sharma, S.C.; Ninawe, N.G.; Ramjilal; Bhagwat, P.V.; Salvi, S.B.

    2003-01-01

    Full text: The 14 UD pelletron accelerator is working round the clock since 1989. The accelerator is housed inside a tank which is 6 meter in diameter and 25 meter long. The accelerator tank is pressurized with SF 6 at 80 to 100 PSIG in order to achieve 14MV. In pelletron, ions are extracted from SNICS are pre-accelerated up to 300 keV before being injected into low energy accelerator tube. In the terminal which is at high potential (4MV to 14 MV), the ion beam pass through the stripper and positive ions with high charge states are produced. The high energy beams are focussed and analyzed by 90 deg magnet. The analyzed beam is then transported to the various experimental ports. In order to achieve uniform ultra high vacuum (to reduce the loss of intensity and spread in the energy of ions beams) in more than 100 metre and 100 mm diameter beam lines including magnet chambers and various beam diagnostic devices, combination of getter-ion pumps and turbo pumps are being used at Pelletron Accelerator Facility. The 14 UD pelletron is equipped with a combination of foil and gas stripper in high voltage terminal section. The foil and gas stripper in the terminal section are mainly used for stripping of light and heavy ions respectively. The gas stripper plays a great role for stripping of heavy ions and its efficiency depends on gas stripper parameters and supporting pumps. The gas stripper is originally installed with getter pumps. These pumps required periodic replacement of titanium cartridges and slowly the pumping speed used to diminish with time. A new recirculation turbo molecular pumps based system is being designed to improve good beam transmission. Details of design will be presented. Proton beam of tens of MeV energy and μA range current is in demand to carry out specific radiochemistry experiments in this facility. It is proposed to built and accommodate a proton experimental setup in the tower area of the existing facility. Details of required UHV system for

  12. The results of a non-linear mathematical model for the kinetics of 10B after BPA-F infusion in BNCT

    International Nuclear Information System (INIS)

    Ryynaenen, P.; Savolainen, S.; Hiismaeki, P.; Kangasmaeki, A.

    2001-01-01

    The aim of this study was to create a model for the kinetics of 10 B in glioma patients after p-boronophenylalanine fructose complex (BPA-F) infusion in order to predict the 10 B concentration in blood during the neutron irradiations in BNCT. The more specific aim was to create a flexible model that would work with variable infusion duration and variable amounts of infused BRA, by forehand carrying out only 1 to 2 kinetic studies per different trials. Previously used bi-exponential fitting and open compartmental model are capable, but, however, heavy kinetic studies are needed before they are reliable enough. A model probe with a memory effect based on phenomenological findings was created. The model development was based on the data from 10 glioblastoma multiforme patients from the Brookhaven National Laboratory BNCT trials. These patients received i.v. 290 mg BPA/kg body weight as a fructose complex during two hours. Blood samples were collected during and after the infusion. The accuracy of the model was verified with distinctive fitting of 10 new glioma patient data from the Finnish BNCT-trials. The 10 B- concentration in whole blood samples was determined by ICP-AES method. In the study it is concluded that the constructed non-linear model is flexible and capable in describing the kinetics of 10 B concentration in blood after a single infusion of BPA-F. (author)

  13. 201Tl/99mTc-MIBI SPECT to evaluate therapy effect of BNCT with BSH and BPA for malignant brain tumor

    International Nuclear Information System (INIS)

    Shibata, Yasushi; Katayama, Wataru; Yamamoto, Tetsuya; Nakai, Kei; Endo, Kiyoshi; Matsuda, Masahide; Matsushita, Akira; Matsumura, Akira

    2006-01-01

    201 Tl/ 99m Tc-MIBI SPECT are imaging modalities to evaluate the malignancy and viability of brain tumor. We reviewed these SPECT findings before and after BNCT, and evaluated the usefulness of SPECT. The study includes total 11 patients admitted in our hospital between 1999 and 2005, 8 with glioblastoma, 2 with anaplastic astrocytoma and 2 with anaplastic oligodendroglioma. SPECT was taken with multidetector SPECT at 15 minutes and 3 hours after intravenous injection of Tl 74 MBq or MIBI 740 MBq. Region of interests were set on tumor and contralateral white matter and radioactivity ratios were calculated as Tl, MIBI indexes. For patients with no residual tumor in MRI, Tl/MIBI indexes were low. For patients with large residual tumor the indexes were high. For the patients with recurrent tumor the indexes were very high. Tl/MIBI indexes before BNCT correlated with survival and progression-free period after BNCT. SPECT indexes decreased after BNCT. For 8 patients with recurrent tumor, the indexes increased. Tl and MIBI SPECT are valuable to evaluate malignancy, viability, survival and recurrence of malignant glioma in BNCT. (author)

  14. Lessons from shielding retrofits at the LAMPF/LANSCE/PSR accelerator, beam lines and target facilities

    International Nuclear Information System (INIS)

    Macek, R.J.

    1994-01-01

    The experience in the past 7 years to improve the shielding and radiation control systems at the Los Alamos Meson Physics Facility (LAMPF) and the Manuel Lujan Jr. Neutron Scattering Center (LANSCE) provides important lessons for the design of radiation control systems at future, high beam power proton accelerator facilities. Major issues confronted and insight gained in developing shielding criteria and in the use of radiation interlocks are discussed. For accelerators and beam lines requiring hands-on-maintenance, our experience suggests that shielding criteria based on accident scenarios will be more demanding than criteria based on routinely encountered beam losses. Specification and analysis of the appropriate design basis accident become all important. Mitigation by active protection systems of the consequences of potential, but severe, prompt radiation accidents has been advocated as an alternate choice to shielding retrofits for risk management at both facilities. Acceptance of active protection systems has proven elusive primarily because of the difficulty in providing convincing proof that failure of active systems (to mitigate the accident) is incredible. Results from extensive shielding assessment studies are presented including data from experimental beam spill tests, comparisons with model estimates, and evidence bearing on the limitations of line-of-sight attenuation models in complex geometries. The scope and significant characteristics of major shielding retrofit projects at the LAMPF site are illustrated by the project to improve the shielding beneath a road over a multiuse, high-intensity beam line (Line D)

  15. Report of the Panel on Electron Accelerator Facilities, DOE/NSF Nuclear Science Advisory Committee

    International Nuclear Information System (INIS)

    1983-04-01

    This Panel finds that the highest priority for new accelerator construction in the US nuclear physics program is for an electron accelerator of high duty factor capable of producing beams at any energy in the range from 500 to 4000 MeV. After detailed study and consideration of the proposals for such facilities submitted to it, the Panel recommends: that the proposal submitted by the Southeastern University Research Association (SURA) be accepted and funded for the construction of a new National Electron Accelerator Laboratory (NEAL) centering on a 4 GeV linear accelerator-stretcher ring system capable of delivering intense, high duty factor, electron beams in the energy range from 500 to 4000 MeV. Additional recommendations relating to this principal one are to be found in the body of this report. As modified by the Panel consequent to its own studies and analyses, the estimated cost (in 1983 dollars) of the accelerator complex is 111.8 million dollars; of the entire laboratory is 146.8 million dollars; and the operating cost averaged over the first five years of operation is 18.1 million dollars per year. The projected 15 year total cost of the project is 418.3 million dollars. The construction period is estimated to be 4.5 years. The NEAL Laboratory, from the outset will be constructed and managed as a national rather than a regional facility and will provide the United States with a truly unique facility for research in electromagnetic physics

  16. Vibrational Stability of SRF Accelerator Test Facility at Fermilab

    Energy Technology Data Exchange (ETDEWEB)

    McGee, M.W.; Volk, J.T.; /Fermilab

    2009-05-01

    Recently developed, the Superconducting Radio Frequency (SRF) Accelerator Test Facilities at Fermilab support the International Linear Collider (ILC), High Intensity Neutrino Source (HINS), a new high intensity injector (Project X) and other future machines. These facilities; Meson Detector Building (MDB) and New Muon Lab (NML) have very different foundations, structures, relative elevations with respect to grade level and surrounding soil composition. Also, there are differences in the operating equipment and their proximity to the primary machine. All the future machines have stringent operational stability requirements. The present study examines both near-field and ambient vibration in order to develop an understanding of the potential contribution of near-field sources (e.g. compressors, ultra-high and standard vacuum equipment, klystrons, modulators, utility fans and pumps) and distant noise sources to the overall system displacements. Facility vibration measurement results and methods of possible isolation from noise sources are presented and discussed.

  17. Plasma-based accelerator structures

    International Nuclear Information System (INIS)

    Schroeder, Carl B.

    1999-01-01

    Plasma-based accelerators have the ability to sustain extremely large accelerating gradients, with possible high-energy physics applications. This dissertation further develops the theory of plasma-based accelerators by addressing three topics: the performance of a hollow plasma channel as an accelerating structure, the generation of ultrashort electron bunches, and the propagation of laser pulses is underdense plasmas

  18. Use of the TACL [Thaumaturgic Automated Control Logic] system at CEBAF [Continuous Electron Beam Accelerator Facility] for control of the Cryogenic Test Facility

    International Nuclear Information System (INIS)

    Navarro, E.; Keesee, M.; Bork, R.; Grubb, C.; Lahti, G.; Sage, J.

    1989-01-01

    A logic-based control software system, called Thaumaturgic Automated Control Logic (TACL), is under development at the Continuous Electron Beam Accelerator Facility in Newport News, VA. The first version of the software was placed in service in November, 1987 for control of cryogenics during the first superconducting RF cavity tests at CEBAF. In August, 1988 the control system was installed at the Cryogenic Test Facility (CTF) at CEBAF. CTF generated liquid helium in September, 1988 and is now in full operation for the current round of cavity tests. TACL is providing a powerful and flexible controls environment for the operation of CTF. 3 refs

  19. The radiological research accelerator facility: Progress report for the period December 1, 1986-November 30, 1987

    International Nuclear Information System (INIS)

    1987-04-01

    Experiments performed at the Radiological Research Accelerator Facility (RARAF) during the period of July 1986 through April 1987 are listed, as well as experiments run prior to that period and expected to eventually resume. The experiments run since July 1, 1986 or expected to run before November 30, 1987 are briefly described. Accelerator use and operation is summarized, as well as facilities development and activities of the Scientific Advisory Committee

  20. Electron accelerator shielding design of KIPT neutron source facility

    Energy Technology Data Exchange (ETDEWEB)

    Zhong, Zhao Peng; Gohar, Yousry [Argonne National Laboratory, Argonne (United States)

    2016-06-15

    The Argonne National Laboratory of the United States and the Kharkov Institute of Physics and Technology of the Ukraine have been collaborating on the design, development and construction of a neutron source facility at Kharkov Institute of Physics and Technology utilizing an electron-accelerator-driven subcritical assembly. The electron beam power is 100 kW using 100-MeV electrons. The facility was designed to perform basic and applied nuclear research, produce medical isotopes, and train nuclear specialists. The biological shield of the accelerator building was designed to reduce the biological dose to less than 5.0e-03 mSv/h during operation. The main source of the biological dose for the accelerator building is the photons and neutrons generated from different interactions of leaked electrons from the electron gun and the accelerator sections with the surrounding components and materials. The Monte Carlo N-particle extended code (MCNPX) was used for the shielding calculations because of its capability to perform electron-, photon-, and neutron-coupled transport simulations. The photon dose was tallied using the MCNPX calculation, starting with the leaked electrons. However, it is difficult to accurately tally the neutron dose directly from the leaked electrons. The neutron yield per electron from the interactions with the surrounding components is very small, ∼0.01 neutron for 100-MeV electron and even smaller for lower-energy electrons. This causes difficulties for the Monte Carlo analyses and consumes tremendous computation resources for tallying the neutron dose outside the shield boundary with an acceptable accuracy. To avoid these difficulties, the SOURCE and TALLYX user subroutines of MCNPX were utilized for this study. The generated neutrons were banked, together with all related parameters, for a subsequent MCNPX calculation to obtain the neutron dose. The weight windows variance reduction technique was also utilized for both neutron and photon dose

  1. CEBAF [Continuous Electron Beam Accelerator Facility] design overview and project status

    International Nuclear Information System (INIS)

    Leemann, C.

    1988-01-01

    This paper discusses the design and specifications of the Continuous Electron Beam Accelerator Facility. Beam performance objectives are discussed, as well as the recirculating linac concept, the injector, cavities, cryogenic system, beam transport and optics, rf system and construction progress. 19 refs., 10 figs

  2. Fixed Base Modal Testing Using the NASA GRC Mechanical Vibration Facility

    Science.gov (United States)

    Staab, Lucas D.; Winkel, James P.; Suarez, Vicente J.; Jones, Trevor M.; Napolitano, Kevin L.

    2016-01-01

    The Space Power Facility at NASA's Plum Brook Station houses the world's largest and most powerful space environment simulation facilities, including the Mechanical Vibration Facility (MVF), which offers the world's highest-capacity multi-axis spacecraft shaker system. The MVF was designed to perform sine vibration testing of a Crew Exploration Vehicle (CEV)-class spacecraft with a total mass of 75,000 pounds, center of gravity (cg) height above the table of 284 inches, diameter of 18 feet, and capability of 1.25 gravity units peak acceleration in the vertical and 1.0 gravity units peak acceleration in the lateral directions. The MVF is a six-degree-of-freedom, servo-hydraulic, sinusoidal base-shake vibration system that has the advantage of being able to perform single-axis sine vibration testing of large structures in the vertical and two lateral axes without the need to reconfigure the test article for each axis. This paper discusses efforts to extend the MVF's capabilities so that it can also be used to determine fixed base modes of its test article without the need for an expensive test-correlated facility simulation.

  3. Plasma-based and novel accelerators

    International Nuclear Information System (INIS)

    Sugihara, Ryo; Nishida, Yasushi

    1992-05-01

    This publication is a collection of papers presented at Workshop on Plasma-Based and Novel Accelerators held at National Institute for Fusion Science, Nagoya, on December 19-20, 1991. Plasma-based accelerators are attracting considerable attention in these days a new, exciting field of plasma applications. The study gives rise to and spurs study of other unique accelerators like laser-based accelerators. The talks in the Workshop encompassed beat-wave accelerator (BWA), plasma wake field accelerator (PWFA), V p x B accelerator, laser-based accelerators and some novel methods of acceleration. They also covered the topics such as FEL, cluster acceleration and plasma lens. Small scale experiments as those in universities have exhibited brilliant results while larger scale experiments like BWA in Institute of Laser Engineering, Osaka University, and PWFA in KEK start showing significant results as well. (J.P.N.)

  4. Bystander effect-induced mutagenicity in HPRT locus of CHO cells following BNCT neutron irradiation: Characteristics of point mutations by sequence analysis

    Energy Technology Data Exchange (ETDEWEB)

    Kinashi, Yuko [Research Reactor Institute, Kyoto University, Kumatori-cho, Sennan-gun, Osaka (Japan)], E-mail: kinashi@rri.kyoto-u.ac.jp; Suzuki, Minoru; Masunaga, Shinichiro; Ono, Koji [Research Reactor Institute, Kyoto University, Kumatori-cho, Sennan-gun, Osaka (Japan)

    2009-07-15

    To investigate bystander mutagenic effects induced by alpha particles during boron neutron capture therapy (BNCT), we mixed cells that were electroporated with borocaptate sodium (BSH), which led to the accumulation of {sup 10}B inside the cells, with cells that did not contain the boron compound. BSH-containing cells were irradiated with {alpha} particles produced by the {sup 10}B(n,{alpha}){sup 7}Li reaction, whereas cells without boron were only affected by the {sup 1}H(n,{gamma}){sup 2}H and {sup 14}N(n,{rho}){sup 14}C reactions. The frequency of mutations induced in the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus was examined in Chinese hamster ovary (CHO) cells irradiated with neutrons (Kyoto University Research Reactor: 5 MW). Neutron irradiation of 1:1 mixtures of cells with and without BSH resulted in a survival fraction of 0.1, and the cells that did not contain BSH made up 99.4% of the surviving cell population. Using multiplex polymerase chain reactions (PCRs), molecular structural analysis indicated that most of the mutations induced by the bystander effect were point mutations and that the frequencies of total and partial deletions induced by the bystander effect were lower than those resulting from the {alpha} particles produced by the {sup 10}B(n,{alpha}){sup 7}Li reaction or the neutron beam from the {sup 1}H(n,{gamma}){sup 2}H and {sup 14}N(n,{rho}){sup 14}C reactions. The types of point mutations induced by the BNCT bystander effect were analyzed by cloning and sequencing methods. These mutations were comprised of 65.5% base substitutions, 27.5% deletions, and 7.0% insertions. Sequence analysis of base substitutions showed that transversions and transitions occurred in 64.7% and 35.3% of cases, respectively. G:C{yields}T:A transversion induced by 8-oxo-guanine in DNA occurred in 5.9% of base substitution mutants in the BNCT bystander group. The characteristic mutations seen in this group, induced by BNCT {alpha} particles

  5. The therapeutic ratio in BNCT: Assessment using the Rat 9L gliosarcoma brain tumor and spinal cord models

    International Nuclear Information System (INIS)

    Coderre, J.A.; Micca, P.L.; Nawrocky, M.M.; Fisher, C.D.; Bywaters, A.; Morris, G.M.; Hopewell, J.W.

    1996-01-01

    During any radiation therapy, the therapeutic tumor dose is limited by the tolerance of the surrounding normal tissue within the treatment volume. The short ranges of the products of the 10 B(n,α) 7 Li reaction produced during boron neutron capture therapy (BNCT) present an opportunity to increase the therapeutic ratio (tumor dose/normal tissue dose) to levels unprecedented in photon radiotherapy. The mixed radiation field produced during BNCT comprises radiations with different linear energy transfer (LET) and different relative biological effectiveness (RBE). The short ranges of the two high-LET products of the 'B(n,a)'Li reaction make the microdistribution of the boron relative to target cell nuclei of particular importance. Due to the tissue specific distribution of different boron compounds, the term RBE is inappropriate in defining the biological effectiveness of the 10 B(n,α) 7 Li reaction. To distinguish these differences from true RBEs we have used the term open-quotes compound biological effectivenessclose quotes (CBE) factor. The latter can be defined as the product of the true, geometry-independent, RBE for these particles times a open-quotes boron localization factorclose quotes, which will most likely be different for each particular boron compound. To express the total BNCT dose in a common unit, and to compare BNCT doses with the effects of conventional photon irradiation, multiplicative factors (RBEs and CBEs) are applied to the physical absorbed radiation doses from each high-LET component. The total effective BNCT dose is then expressed as the sum of RBE-corrected physical absorbed doses with the unit Gray-equivalent (Gy-Eq)

  6. Spectroscopic measurements of plasma emission light for plasma-based acceleration experiments

    International Nuclear Information System (INIS)

    Filippi, F.; Mostacci, A.; Palumbo, L.; Anania, M.P.; Biagioni, A.; Chiadroni, E.; Ferrario, M.; Cianchi, A.; Zigler, A.

    2016-01-01

    Advanced particle accelerators are based on the excitation of large amplitude plasma waves driven by either electron or laser beams. Future experiments scheduled at the SPARC-LAB test facility aim to demonstrate the acceleration of high brightness electron beams through the so-called resonant Plasma Wakefield Acceleration scheme in which a train of electron bunches (drivers) resonantly excites wakefields into a preformed hydrogen plasma; the last bunch (witness) injected at the proper accelerating phase gains energy from the wake. The quality of the accelerated beam depends strongly on plasma density and its distribution along the acceleration length. The measurements of plasma density of the order of 10 16 –10 17  cm −3 can be performed with spectroscopic measurements of the plasma-emitted light. The measured density distribution for hydrogen filled capillary discharge with both Balmer alpha and Balmer beta lines and shot-to-shot variation are here reported.

  7. Spectroscopic measurements of plasma emission light for plasma-based acceleration experiments

    Science.gov (United States)

    Filippi, F.; Anania, M. P.; Biagioni, A.; Chiadroni, E.; Cianchi, A.; Ferrario, M.; Mostacci, A.; Palumbo, L.; Zigler, A.

    2016-09-01

    Advanced particle accelerators are based on the excitation of large amplitude plasma waves driven by either electron or laser beams. Future experiments scheduled at the SPARC_LAB test facility aim to demonstrate the acceleration of high brightness electron beams through the so-called resonant Plasma Wakefield Acceleration scheme in which a train of electron bunches (drivers) resonantly excites wakefields into a preformed hydrogen plasma; the last bunch (witness) injected at the proper accelerating phase gains energy from the wake. The quality of the accelerated beam depends strongly on plasma density and its distribution along the acceleration length. The measurements of plasma density of the order of 1016-1017 cm-3 can be performed with spectroscopic measurements of the plasma-emitted light. The measured density distribution for hydrogen filled capillary discharge with both Balmer alpha and Balmer beta lines and shot-to-shot variation are here reported.

  8. Organisation and management of the first clinical trial of BNCT in Europe (EORTC Protocol 11961)

    International Nuclear Information System (INIS)

    Sauerwein, W.; Rassow, J.; Hideghety, K.; Sack, H.; Moss, R.; Stecher-Rasmussen, F.; Wolbers, J.G.

    1999-01-01

    Boron Neutron Capture Therapy is based on the ability of the isotope 10 B to capture thermal neutrons and to disintegrate instantaneously producing high LET particles. The only neutron beam available in Europe for such a treatment is based at the European High Flux Reactor HFR at Petten (The Netherlands). The European Commission, owners of the reactor, decided that the potential benefit of the facility should be opened to all European citizens and therefore insisted on a multinational approach to perform the first clinical trial in Europe on BNCT. This precondition had to be respected as well as the national laws and regulations. Together with the Dutch authorities actions were undertaken to overcome the obvious legal problems. Furthermore, the clinical trial at Petten takes place in a nuclear research reactor, which apart from being conducted in a non-hospital environment, is per se known to be dangerous. It was therefore of the utmost importance that special attention is given to safety, beyond normal rules, and to the training of staff. In itself, the trial is an unusual Phase I study, introducing a new drug with a new irradiation modality, with really an unknown dose-effect relationship. This trial must follow optimal procedures, which underscore the quality and qualified manner of performance. (orig.)

  9. Medical Isotope Production With The Accelerator Production of Tritium (APT) Facility

    International Nuclear Information System (INIS)

    Buckner, M.; Cappiello, M.; Pitcher, E.; O'Brien, H.

    1998-01-01

    In order to meet US tritium needs to maintain the nuclear weapons deterrent, the Department of Energy (DOE) is pursuing a dual track program to provide a new tritium source. A record of decision is planned for late in 1998 to select either the Accelerator Production of Tritium (APT) or the Commercial Light Water Reactor (CLWR) as the technology for new tritium production in the next century. To support this decision, an APT Project was undertaken to develop an accelerator design capable of producing 3 kg of tritium per year by 2007 (START I requirements). The Los Alamos National Laboratory (LANL) was selected to lead this effort with Burns and Roe Enterprises, Inc. (BREI) / General Atomics (GA) as the prime contractor for design, construction, and commissioning of the facility. If chosen in the downselect, the facility will be built at the Savannah River Site (SRS) and operated by the SRS Maintenance and Operations (M ampersand O) contractor, the Westinghouse Savannah River Company (WSRC), with long-term technology support from LANL. These three organizations (LANL, BREI/GA, and WSRC) are working together under the direction of the APT National Project Office which reports directly to the DOE Office of Accelerator Production which has program authority and responsibility for the APT Project

  10. Proceedings of the Advanced Hadron Facility accelerator design workshop

    International Nuclear Information System (INIS)

    Thiessen, H.A.

    1989-01-01

    The International Workshop on Hadron Facility Technology was held February 22-27, 1988, at the Study Center at Los Alamos National Laboratory. The program included papers on facility plans, beam dynamics, and accelerator hardware. The parallel sessions were particularly lively with discussions of all facets of kaon factory design. The workshop provided an opportunity for communication among the staff involved in hadron facility planning from all the study groups presently active. The recommendations of the workshop include: the need to use h=1 RF in the compressor ring; the need to minimize foil hits in painting schemes for all rings; the need to consider single Coulomb scattering in injection beam los calculations; the need to study the effect of field inhomogeneity in the magnets on slow extraction for the 2.2 Tesla main ring of AHF; and agreement in principle with the design proposed for a joint Los Alamos/TRIUMF prototype main ring RF cavity

  11. A preclinical study of boron neutron capture therapy (BNCT) of spontaneous tumors in cats at RA-6 in Argentina

    International Nuclear Information System (INIS)

    Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Schwint, Amanda E.; Calzetta, Osvaldo A.; Blaumann, Hernan R.; Longhino, J.; Rao, Monica; Cantarelli, Maria de los A.

    2005-01-01

    BNCT is a binary treatment modality that combines irradiation with a thermal or epithermal neutron beam with tumor-seeking, boron containing drugs to produce selective irradiation of tumor tissue. Having demonstrated that BNCT mediated by boronophenylalanine (BPA) induced control of experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa with no damage to normal tissue we explored the feasibility and safety of treating spontaneous head and neck tumors, with particular focus on SCC, of terminal feline patients with low dose BPA-BNCT employing the thermal beam of RA-1. Having demonstrated partial tumor control with no radio toxic effects, the aim of the present study was to evaluate the effect of BPA-BNCT on tumor and normal tissue in 3 cases of spontaneous SCC in feline patients employing a higher neutron fluence than in the previous study. The present study was performed at RA-6 with the thermalized epithermal neutron beam. All three irradiations were successful. Except for an initial, moderate and reversible mucositis, no significant radio toxic effects were observed in terms of clinical follow-up, histological examination, biochemical analysis and assessment of autopsy material. Partial tumor control was evidenced in terms of growth inhibition and partial necrosis and improvement in the quality of life during the survival period. Optimization of the therapeutic efficacy of BNCT would require improvement in boron tumor targeting and strategies to increase in-depth dose in large tumors. (author)

  12. Synthesis and in-vivo detection of boronated compounds for use in BNCT

    International Nuclear Information System (INIS)

    Kabalka, G.W.

    1990-04-01

    The primary objective of the DOE Program at the University of Tennessee Biomedical Imaging Center is the development of new technology to detect boron compounds in-vivo. The research focuses on the development of multinuclear magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques for verifying and measuring BNCT agents in-vivo. A small but significant portion of the effort is directed toward the design of boron-containing neutron-capture-therapy agents. The UT -- DOE program is unique in that it has access to two state-of-the-art multinuclear magnetic resonance imaging units housed in the Biomedical Imaging Center at the University of Tennessee Medical Center at Knoxville. Included in this report are two sections describing research accomplishments in multinuclear magnetic resonance imaging and synthesis of potential BNCT agents

  13. Early phase II study on BNCT in metastatic malignant melanoma using the boron carrier BPA (EORTC protocol 11011)

    International Nuclear Information System (INIS)

    Wittig, Andrea; Sauerwein, Wolfgang; Moss, Raymond

    2006-01-01

    The aim of the trial is to examine the clinical response of metastatic melanoma following BNCT with BPA. The trial contains an optional biodistribution sub-study, which is done if operable metastases are removed prior BNCT. BNCT is applied in 2 fractions at the HFR in Petten. In cases of diffuse brain metastases the whole brain is irradiated homogeneously using 5 irradiation beams from different directions. Up to now 4 patients suffering from multiple brain metastases (more than 20) have been included. In all cases we observed a partial response or no change in the irradiated volume. However, none of the patients survived more than 3 months. The pharmacokinetic of the BPA can be predicted very precisely using a two-compartment model. The treatment can be performed safety. (author)

  14. Spallation Neutron Source Accelerator Facility Target Safety and Non-safety Control Systems

    International Nuclear Information System (INIS)

    Battle, Ronald E.; DeVan, B.; Munro, John K. Jr.

    2006-01-01

    The Spallation Neutron Source (SNS) is a proton accelerator facility that generates neutrons for scientific researchers by spallation of neutrons from a mercury target. The SNS became operational on April 28, 2006, with first beam on target at approximately 200 W. The SNS accelerator, target, and conventional facilities controls are integrated by standardized hardware and software throughout the facility and were designed and fabricated to SNS conventions to ensure compatibility of systems with Experimental Physics Integrated Control System (EPICS). ControlLogix Programmable Logic Controllers (PLCs) interface to instruments and actuators, and EPICS performs the high-level integration of the PLCs such that all operator control can be accomplished from the Central Control room using EPICS graphical screens that pass process variables to and from the PLCs. Three active safety systems were designed to industry standards ISA S84.01 and IEEE 603 to meet the desired reliability for these safety systems. The safety systems protect facility workers and the environment from mercury vapor, mercury radiation, and proton beam radiation. The facility operators operated many of the systems prior to beam on target and developed the operating procedures. The safety and non-safety control systems were tested extensively prior to beam on target. This testing was crucial to identify wiring and software errors and failed components, the result of which was few problems during operation with beam on target. The SNS has continued beam on target since April to increase beam power, check out the scientific instruments, and continue testing the operation of facility subsystems

  15. Beam Position Monitor and Energy Analysis at the Fermilab Accelerator Science and Technology Facility

    Energy Technology Data Exchange (ETDEWEB)

    Lopez, David Juarez [Univ. of Guanajuato (Mexico)

    2015-08-01

    Fermilab Accelerator Science and Technology Facility has produced its first beam with an energy of 20 MeV. This energy is obtained by the acceleration at the Electron Gun and the Capture Cavity 2 (CC2). When fully completed, the accelerator will consist of a photoinjector, one International Liner Collider (ILC)-type cryomodule, multiple accelerator R&D beamlines, and a downstream beamline to inject 300 MeV electrons into the Integrable Optics Test Accelerator (IOTA). We calculated the total energy of the beam and the corresponding energy to the Electron Gun and CC2. Subsequently, a Beam Position Monitors (BPM) error analysis was done, to calculate the device actual resolution.

  16. Accelerated radiation damage test facility using a 5 MV tandem ion accelerator

    Science.gov (United States)

    Wady, P. T.; Draude, A.; Shubeita, S. M.; Smith, A. D.; Mason, N.; Pimblott, S. M.; Jimenez-Melero, E.

    2016-01-01

    We have developed a new irradiation facility that allows to perform accelerated damage tests of nuclear reactor materials at temperatures up to 400 °C using the intense proton (spectrum of potential radio-active nuclides produced during the sample irradiation. The beam line capabilities have been tested by irradiating a 20Cr-25Ni-Nb stabilised stainless steel with a 3 MeV proton beam to a dose level of 3 dpa. The irradiation temperature was 356 °C, with a maximum range in temperature values of ±6 °C within the first 24 h of continuous irradiation. The sample stage is connected to ground through an electrometer to measure accurately the charge deposited on the sample. The charge can be integrated in hardware during irradiation, and this methodology removes uncertainties due to fluctuations in beam current. The measured gamma spectrum allowed the identification of the main radioactive nuclides produced during the proton bombardment from the lifetimes and gamma emissions. This dedicated radiation damage beam line is hosted by the Dalton Cumbrian Facility of the University of Manchester.

  17. Small accelerator-based pulsed cold neutron sources

    International Nuclear Information System (INIS)

    Lanza, Richard C.

    1997-09-01

    Small neutron sources could be used by individual researchers with the convenience of an adequate local facility. Although these sources would produce lower fluxes than the national facilities, for selected applications, the convenience and availability may overcome the limitations on source strength. Such sources might also be useful for preliminary testing of ideas before going to a larger facility. Recent developments in small, high-current pulsed accelerators makes possible such a local source for pulsed cold neutrons.

  18. A spallation-based irradiation test facility for fusion and future fission materials

    CERN Document Server

    Samec, K; Kadi, Y; Luis, R; Romanets, Y; Behzad, M; Aleksan, R; Bousson, S

    2014-01-01

    The EU’s FP7 TIARA program for developing accelerator-based facilities has recently demonstrated the unique capabilities of a compact and powerful spallation source for irradiating advanced nuclear materials. The spectrum and intensity of the neutron flux produced in the proposed facility fulfils the requirements of the DEMO fusion reactor for ITER, ADS reactors and also Gen III / IV reactors. Test conditions can be modulated, covering temperature from 400 to 550°C, liquid metal corrosion, cyclical or static stress up to 500 MPa and neutron/proton irradiation damage of up to 25 DPA per annum. The entire “TMIF” facility fits inside a cube 2 metres on a side, and is dimensioned for an accelerator beam power of 100 kW, thus reducing costs and offering great versatility and flexibility.

  19. Theoretical Investigations of Plasma-Based Accelerators and Other Advanced Accelerator Concepts

    International Nuclear Information System (INIS)

    Shuets, G.

    2004-01-01

    Theoretical investigations of plasma-based accelerators and other advanced accelerator concepts. The focus of the work was on the development of plasma based and structure based accelerating concepts, including laser-plasma, plasma channel, and microwave driven plasma accelerators

  20. Summaries on various researches aiming at the closed head BNCT

    International Nuclear Information System (INIS)

    Ono, Koji

    2000-01-01

    As in the boron neutron capture therapy (BNCT) flight of alpha particle formed by reaction of neutron and boron is nearly equal to diameter of cancer cell, when a boron compound accumulates selectively to a cancer cell to be radiated onto the cell by enough amount of neutron beam the alpha particles are irradiated onto the cancer cells nearly selectively. Like this, this is a curing means capable of overcoming a problem undecidable by a paradigm of radiation remedy in the 20th Century, a micro dose amount effect supposing to be a paradigm in the 21st Century, the very (biological) dose concentration into cancer cell is a curing method matching to upgrading on rate of cancer control and improvement on post-cure of the patients without increase of subreaction in every tumors. Here were summarized on characteristic comparison of thermal outer-neutron beams in KUR, JRR-4 and the Peten HFR reactors, development of new boron compounds, effect of BNCT on re-oxygenation of the cancer, and induction of mutation by neutron beam. (G.K.)

  1. 2 MeV, 60 kW dual-beam type electron accelerator irradiation facility

    International Nuclear Information System (INIS)

    Yotsumoto, Keiichi; Kanazawa, Takao; Haruyama, Yasuyuki; Agematsu, Takashi; Mizuhashi, Kiyoshi; Sunaga, Hiromi; Washino, Masamitsu; Tamura, Naoyuki

    1984-02-01

    The specification of new irradiation facility which has been constructed from 1978 through 1981 as the replacement of 1st Accelerator of JAERI, TRCRE are described. The accelerator is the Cockcroft-Walton type and both vertical and horizontal accelerating tubes are arranged on a single high voltage generator. Transferring of the high voltage to the horizontal accelerating tube is performed with the high voltage changing system in the pressure vessel. The output ratings of the accelerator are 2 MV of acceleration voltage and 30 mA of beam current. By providing the dual beam system, two irradiation rooms, one for vertical and the other for horizontal beam, are independently operationable. Persons can enter the horizontal irradiation room for experimental setting even when the vertical irradiation room is in operation. The specification of the buildings, the exhaust air treatment system, the irradiation conveyor and the safety observation system are also described. (author)

  2. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies.

    Science.gov (United States)

    Fujimoto, T; Andoh, T; Sudo, T; Fujita, I; Imabori, M; Moritake, H; Sugimoto, T; Sakuma, Y; Takeuchi, T; Sonobe, H; Epstein, Alan L; Akisue, T; Kirihata, M; Kurosaka, M; Fukumori, Y; Ichikawa, H

    2011-12-01

    Clear cell sarcoma (CCS), a rare malignant tumor with a predilection for young adults, is of poor prognosis. Recently however, boron neutron capture therapy (BNCT) with the use of p-borono-L-phenylalanine (BPA) for malignant melanoma has provided good results. CCS also produces melanin; therefore, the uptake of BPA is the key to the application of BNCT to CCS. We describe, for the first time, the high accumulation of boron in CCS and the CCS tumor-bearing animal model generated for BNCT studies. Copyright © 2011 Elsevier Ltd. All rights reserved.

  3. Characterization of the radiation environment at the UNLV accelerator facility during operation of the Varian M6 linac

    Science.gov (United States)

    Hodges, M.; Barzilov, A.; Chen, Y.; Lowe, D.

    2016-10-01

    The bremsstrahlung photon flux from the UNLV particle accelerator (Varian M6 model) was determined using MCNP5 code for 3 MeV and 6 MeV incident electrons. Human biological equivalent dose rates due to accelerator operation were evaluated using the photon flux with the flux-to-dose conversion factors. Dose rates were computed for the accelerator facility for M6 linac use under different operating conditions. The results showed that the use of collimators and linac internal shielding significantly reduced the dose rates throughout the facility. It was shown that the walls of the facility, in addition to the earthen berm enveloping the building, provide equivalent shielding to reduce dose rates outside to below the 2 mrem/h limit.

  4. Radiation risk management at DOE accelerator facilities

    International Nuclear Information System (INIS)

    Dyck, O.B. van.

    1997-01-01

    The DOE accelerator contractors have been discussing among themselves and with the Department how to improve radiation safety risk management. This activity-how to assure prevention of unplanned high exposures-is separate from normal exposure management, which historically has been quite successful. The ad-hoc Committee on the Accelerator Safety Order and Guidance [CASOG], formed by the Accelerator Section of the HPS, has proposed a risk- based approach, which will be discussed. Concepts involved are risk quantification and comparison (including with non-radiation risk), passive and active (reacting) protection systems, and probabilistic analysis. Different models of risk management will be presented, and the changing regulatory environment will also be discussed

  5. IOTA (Integrable Optics Test Accelerator): facility and experimental beam physics program

    Science.gov (United States)

    Antipov, S.; Broemmelsiek, D.; Bruhwiler, D.; Edstrom, D.; Harms, E.; Lebedev, V.; Leibfritz, J.; Nagaitsev, S.; Park, C. S.; Piekarz, H.; Piot, P.; Prebys, E.; Romanov, A.; Ruan, J.; Sen, T.; Stancari, G.; Thangaraj, C.; Thurman-Keup, R.; Valishev, A.; Shiltsev, V.

    2017-03-01

    The Integrable Optics Test Accelerator (IOTA) is a storage ring for advanced beam physics research currently being built and commissioned at Fermilab. It will operate with protons and electrons using injectors with momenta of 70 and 150 MeV/c, respectively. The research program includes the study of nonlinear focusing integrable optical beam lattices based on special magnets and electron lenses, beam dynamics of space-charge effects and their compensation, optical stochastic cooling, and several other experiments. In this article, we present the design and main parameters of the facility, outline progress to date and provide the timeline of the construction, commissioning and research. The physical principles, design, and hardware implementation plans for the major IOTA experiments are also discussed.

  6. IOTA (Integrable Optics Test Accelerator): Facility and experimental beam physics program

    International Nuclear Information System (INIS)

    Antipov, Sergei; Broemmelsiek, Daniel; Bruhwiler, David; Edstrom, Dean; Harms, Elvin

    2017-01-01

    The Integrable Optics Test Accelerator (IOTA) is a storage ring for advanced beam physics research currently being built and commissioned at Fermilab. It will operate with protons and electrons using injectors with momenta of 70 and 150 MeV/c, respectively. The research program includes the study of nonlinear focusing integrable optical beam lattices based on special magnets and electron lenses, beam dynamics of space-charge effects and their compensation, optical stochastic cooling, and several other experiments. In this article, we present the design and main parameters of the facility, outline progress to date and provide the timeline of the construction, commissioning and research. Finally, the physical principles, design, and hardware implementation plans for the major IOTA experiments are also discussed.

  7. Plasma based charged-particle accelerators

    International Nuclear Information System (INIS)

    Bingham, R; Mendonca, J T; Shukla, P K

    2004-01-01

    Studies of charged-particle acceleration processes remain one of the most important areas of research in laboratory, space and astrophysical plasmas. In this paper, we present the underlying physics and the present status of high gradient and high energy plasma accelerators. We will focus on the acceleration of charged particles to relativistic energies by plasma waves that are created by intense laser and particle beams. The generation of relativistic plasma waves by intense lasers or electron beams in plasmas is important in the quest for producing ultra-high acceleration gradients for accelerators. With the development of compact short pulse high brightness lasers and electron positron beams, new areas of studies for laser/particle beam-matter interactions is opening up. A number of methods are being pursued vigorously to achieve ultra-high acceleration gradients. These include the plasma beat wave accelerator mechanism, which uses conventional long pulse (∼100 ps) modest intensity lasers (I ∼ 10 14 -10 16 W cm -2 ), the laser wakefield accelerator (LWFA), which uses the new breed of compact high brightness lasers ( 10 18 W cm -2 , the self-modulated LWFA concept, which combines elements of stimulated Raman forward scattering, and electron acceleration by nonlinear plasma waves excited by relativistic electron and positron bunches. In the ultra-high intensity regime, laser/particle beam-plasma interactions are highly nonlinear and relativistic, leading to new phenomena such as the plasma wakefield excitation for particle acceleration, relativistic self-focusing and guiding of laser beams, high-harmonic generation, acceleration of electrons, positrons, protons and photons. Fields greater than 1 GV cm -1 have been generated with particles being accelerated to 200 MeV over a distance of millimetre. Plasma wakefields driven by positron beams at the Stanford Linear Accelerator Center facility have accelerated the tail of the positron beam. In the near future

  8. Linear Accelerator Test Facility at LNF Conceptual Design Report

    CERN Document Server

    Valente, Paolo; Bolli, Bruno; Buonomo, Bruno; Cantarella, Sergio; Ceccarelli, Riccardo; Cecchinelli, Alberto; Cerafogli, Oreste; Clementi, Renato; Di Giulio, Claudio; Esposito, Adolfo; Frasciello, Oscar; Foggetta, Luca; Ghigo, Andrea; Incremona, Simona; Iungo, Franco; Mascio, Roberto; Martelli, Stefano; Piermarini, Graziano; Sabbatini, Lucia; Sardone, Franco; Sensolini, Giancarlo; Ricci, Ruggero; Rossi, Luis Antonio; Rotundo, Ugo; Stella, Angelo; Strabioli, Serena; Zarlenga, Raffaele

    2016-01-01

    Test beam and irradiation facilities are the key enabling infrastructures for research in high energy physics (HEP) and astro-particles. In the last 11 years the Beam-Test Facility (BTF) of the DA{\\Phi}NE accelerator complex in the Frascati laboratory has gained an important role in the European infrastructures devoted to the development and testing of particle detectors. At the same time the BTF operation has been largely shadowed, in terms of resources, by the running of the DA{\\Phi}NE electron-positron collider. The present proposal is aimed at improving the present performance of the facility from two different points of view: extending the range of application for the LINAC beam extracted to the BTF lines, in particular in the (in some sense opposite) directions of hosting fundamental physics and providing electron irradiation also for industrial users; extending the life of the LINAC beyond or independently from its use as injector of the DA{\\Phi}NE collider, as it is also a key element of the electron/...

  9. The Continuous Electron Beam Accelerator Facility: Project status and physics outlook

    International Nuclear Information System (INIS)

    Grunder, H.A.

    1989-01-01

    Nuclear physics research program planning, accelerator tunnel construction, and accelerator component development, assembly, and testing are under way at the Continuous Electron Beam Accelerator Facility, Newport News, Virginia. CEBAF's 4-GeV, 200-μA superconducting recirculating accelerator will provide cw beam to simultaneous experiments in three end stations for studies of the nuclear many-body system, its quark substructure, and the strong and electroweak interactions governing this form of matter. An experimental program is being defined in collaboration with the user community. The experimental halls have been designed, and preliminary experimental equipment conceptual designs have been prepared. Planned for Hall A are two 4-GeV/c high-resolution (δp/p ≤ 10 -4 ) spectrometers (HRS) with moderate acceptance (∼8 msr) for a program of completely exclusive experiments in which the nuclear final state has to be fully specified. A CEBAF large acceptance spectrometer (CLAS) is planned for the program of Hall B, which will include bias-free investigation of hadronic final states in inelastic electron scattering and detection of multiple-particle final states. The CLAS will be a multi-gap device based on a toroidal magnet with six superconducting coils arranged around the beamline to produce an essentially circular magnetic field. Hall C is envisioned as serving a diversity of interests, including form factor measurements, parity violation investigations, form factors of nucleon resonances, and a high-Q 2 baryon resonance program. A moderate-resolution, high-momentum, 6-GeV/c spectrometer (HMS) together with several specialized second arms -- in particular, a symmetric toroidal array spectrometer -- are being planned to carry out Hall C experimentation. 14 figs., 8 tabs

  10. A spallation-based irradiation test facility for fusion and future fission materials

    International Nuclear Information System (INIS)

    Samec, K.; Fusco, Y.; Kadi, Y.; Luis, R.; Romanets, Y.; Behzad, M.; Aleksan, R.; Bousson, S.

    2014-01-01

    The EU's FP7 TIARA program for developing accelerator-based facilities has recently demonstrated the unique capabilities of a compact and powerful spallation source for irradiating advanced nuclear materials. The spectrum and intensity of the neutron flux produced in the proposed facility fulfils the requirements of the proposed DEMO fusion reactor, ADS reactors and also Gen III / IV reactors. Test conditions can be modulated, covering temperature from 400 to 550 deg. C, liquid metal corrosion, cyclical or static stress up to 500 MPa and neutron/proton irradiation damage of up to 25 DPA per annum over a volume occupying one litre. The entire 'TMIF' facility fits inside a cube 2 metres on a side, and is dimensioned for an accelerator beam power of 100 kW, thus reducing costs and offering great versatility and flexibility. (authors)

  11. Specific contributions of the Dutch progamme ''RAS'' towards accelerator-based transmutation

    International Nuclear Information System (INIS)

    Abrahams, K.; Franken, W.M.P.; Bultman, J.H.; Heil, J.A.; Koning, A.J.

    1994-09-01

    Accelerator-based transmutation is being studied by ECN within its general nuclear waste transmutation programme RAS. In this paper the following contributions are presented: (1) Evaluation of cross sections at intermediate energies, within an international frame given by NEA, (2) Cell calculations on the equilibration of transuranium actinides in thermal molten-salt transmuters, (3) Irradiation facilities at the European research reactor HFR in Petten, which have been constructed with the purpose to demonstrate and investigate the transmutation of waste in a high neutron flux, (4) Studies of accelerator-based neutron generating systems to transmute neptunium and technetium, (5) Comparison of several systems on the basis of criteria for successful nuclear waste-management. (orig.)

  12. SATIF-2 shielding aspects of accelerators, targets and irradiation facilities

    International Nuclear Information System (INIS)

    1995-01-01

    Particle accelerators have evolved over the last 50 years from simple devices to powerful machines, and will continue to have an important impact on research, technology and lifestyle. Today they cover a wide range of applications, from television and computer displays in households to the investigation of the origin and structure of matter. It has become common practice to use them for material science and medical applications. In recent years, requirements from new technological and research applications have emerged, such as increased particle beams intensities, higher flexibility, etc., giving rise to new radiation shielding aspects and problems. These proceedings review recent progress in radiation shielding of accelerator facilities, and evaluate advancements with respect to international co-operation in this field

  13. Advanced Superconducting Test Accelerator (ASTA)

    Data.gov (United States)

    Federal Laboratory Consortium — The Advanced Superconducting Test Accelerator (ASTA) facility will be based on upgrades to the existing NML pulsed SRF facility. ASTA is envisioned to contain 3 to 6...

  14. A design of 3 GeV CW electron accelerator facility

    International Nuclear Information System (INIS)

    Boldyshev, V.F.; Vishnyakov, V.A.; Gladkikh, P.N.

    1987-01-01

    A further progress of high-energy nuclear physics is related to the possibility of obtaining continuous intense polarized beams of 2-4 GeV electrons and gamma-quanta with low emittance and energy spread. A design of the accelerator facility proposed for these purposes is briefly outlined in this report. The design is based on the upgrading of the 2 GeV Kharkov electron linac (ELA) and the construction of a stretcher ring (SR) at its termination. Operation in the beam storage mode is intended also for nuclear physics experiments using internal targets and for producing synchrotron radiation. Reported are general characteristics of the ELA-SR complex, and the results of numerical computer simulation of a slow beam extraction at the third-order resonance of horizontal free oscillations with due regard for the radiation and synchronous oscillations

  15. Boron neutron capture therapy combined with fractionated photon irradiation for glioblastoma: A recursive partitioning analysis of BNCT patients

    International Nuclear Information System (INIS)

    Nakai, K.; Yamamoto, T.; Aiyama, H.; Takada, T.; Yoshida, F.; Kageji, T.; Kumada, H.; Isobe, T.; Endo, K.; Matsuda, M.; Tsurubuchi, T.; Shibata, Y.; Takano, S.; Mizumoto, M.; Tsuboi, K.; Matsumura, A.

    2011-01-01

    Eight patients to received Boron Neutron Capture Therapy (BNCT) were selected from 33 newly diagnosed glioblastoma patients (NCT(+) group). Serial 42 glioblastoma patients (NCT(−) group) were treated without BNCT. The median OS of the NCT(+) group and NCT (−) group were 24.4 months and 14.9 months. In the high risk patients (RPA class V), the median OS of the NCT(+) group tended to be better than that of NCT(−) group. 50% of BNCT patients were RPA class V. - Highlights: ► We treated 8 patients with boron neutron capture therapy (NCT) for glioblastoma. ► We compare the overall survival between NCT including series and without NCT series. ► The median overall survival of the NCT including series was 24.4 months. ► In the high risk patients, the median OS of NCT including series tended to be better.

  16. Current utilization and long term strategy of the Finnish TRIGA research reactor FiR 1

    International Nuclear Information System (INIS)

    Auterinen, Iiro; Salmenhaara, Seppo

    2008-01-01

    FiR 1 (TRIGA Mark II, 250 kW) has an important international role in the development of boron neutron capture therapy (BNCT) for cancer. The safety and efficacy of BNCT is studied for several different cancers: - primary glioblastoma, a highly malignant brain tumour (since 1999); - recurrent glioblastoma or anaplastic astrocytoma (since 2001); - recurrent inoperable head and neck carcinoma (since 2003). It is one of the few facilities in the world providing this kind of treatments. The successes in the BNCT development have now created a demand for these treatments, although they are given on an experimental basis. Well over 100 patients treated now since May 1999: - at least 1 patient irradiation / week, often 2 (Tuesday and Thursday) - patients are referred to BNCT-treatments from several hospitals, also outside research protocols; - the hospitals pay for the treatment. The FiR 1 reactor has proven to be a reliable neutron source for the BNCT treatments; no patient irradiations have been cancelled because of a failure of the reactor. The BNCT facility has become a center of extensive academic research especially in medical physics. Nuclear education and training continue to play also a role at FiR 1 in the form of university courses and training of nuclear industry personnel. FiR 1 is one of the two sources in Scandinavia for short lived radioisotopes used in tracer studies in industry. The main isotope produced is Br-82 in the form of either KBr or ethylene bromide. Other typical isotopes are Na-24, Ar-41, La-140. The isotopes are used mainly in tracer studies in industry (Indmeas Inc., Finland). Typical activity of one irradiated Br-sample is 20 - 80 GBq; total activity produced in one year is over 3 TBq; the reactor operating time needed for the isotope production is one or two days per week. Accelerator based neutron sources are developed for BNCT. The prospect is that when BNCT will achieve a status of a fully accepted and efficient treatment modality for

  17. Future HEP Accelerators: The US Perspective

    Energy Technology Data Exchange (ETDEWEB)

    Bhat, Pushpalatha [Fermilab; Shiltsev, Vladimir [Fermilab

    2015-11-02

    Accelerator technology has advanced tremendously since the introduction of accelerators in the 1930s, and particle accelerators have become indispensable instruments in high energy physics (HEP) research to probe Nature at smaller and smaller distances. At present, accelerator facilities can be classified into Energy Frontier colliders that enable direct discoveries and studies of high mass scale particles and Intensity Frontier accelerators for exploration of extremely rare processes, usually at relatively low energies. The near term strategies of the global energy frontier particle physics community are centered on fully exploiting the physics potential of the Large Hadron Collider (LHC) at CERN through its high-luminosity upgrade (HL-LHC), while the intensity frontier HEP research is focused on studies of neutrinos at the MW-scale beam power accelerator facilities, such as Fermilab Main Injector with the planned PIP-II SRF linac project. A number of next generation accelerator facilities have been proposed and are currently under consideration for the medium- and long-term future programs of accelerator-based HEP research. In this paper, we briefly review the post-LHC energy frontier options, both for lepton and hadron colliders in various regions of the world, as well as possible future intensity frontier accelerator facilities.

  18. Accelerating complex for basic researches in the nuclear physics

    NARCIS (Netherlands)

    Dovbnya, A.N.; Guk, I.S.; Kononenko, S.G.; Peev, F.A.; Tarasenko, A.S.; Botman, J.I.M.

    2009-01-01

    In 2003 in NSC KIPT was begun the work on development the project of accelerator, base facility IHEPNP NSC KIPT electron recirculator SALO. The accelerator will be disposed in target hall of accelerator LU 2000 complex. It is projected first of all as facility for basic researches in the field of

  19. Synthesis and evaluation of boronated folates for BNCT

    International Nuclear Information System (INIS)

    Shukla, S.; Sekido, M.; Guo, W.; Mueller, R.; Sudimack, J.; Lee, R.J.; Tjarks, W.; Adams, D.M.; Barth, R.F.

    2000-01-01

    To study the possible utilization of folic acid as the 10 B carrier for BNCT, folic acid conjugated boron containing liposomes and starburst dendrimers were prepared. In both systems folic acid was used as the recognition part and polyethylene glycol (PEG) as the spacer. In vitro studies were carried out using folate receptor overexpressing 24JK-FBP and KB cells. The results indicated that these boronated folic acid conjugates were incorporated into the tumor cells via receptor-mediated endocytosis. (author)

  20. Neutron-photon mixed field dosimetry by TLD-700 glow curve analysis and its implementation in dose monitoring for Boron Neutron Capture Therapy (BNCT) treatments

    Energy Technology Data Exchange (ETDEWEB)

    Boggio, E. F.; Longhino, J. M. [Centro Atomico Bariloche, Departamento de Fisica de Reactores y Radiaciones / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina); Andres, P. A., E-mail: efboggio@cab.cnea.gov.ar [Centro Atomico Bariloche, Division Proteccion Radiologica / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina)

    2015-10-15

    BNCT is a cancerous cells selective, non-conventional radiotherapy modality to treat malignant tumors such as glioblastoma, melanoma and recurrent head and neck cancer. It consists of a two-step procedure: first, the patient is injected with a tumor localizing drug containing a non-radioactive isotope (Boron-10) with high slow neutron capture cross-section. In a second step, the patient is irradiated with neutrons, which are absorbed by the Boron-10 agent with the subsequently nuclear reaction B- 10(n,a)Li-7, thereby resulting in dose at cellular level due to the high-Let particles. The neutron fields suitable for BNCT are characterized by high neutron fluxes and low gamma dose. Determination of each component is not an easy task, especially when the volume of measurement is quite small or inaccessible for a miniature ionization chamber, for example. A method of measuring the photon and slow neutron dose(mainly by N-14 and B-10) from the glow curve (GC) analysis of a single {sup 7}LiF thermoluminescence detector is evaluated. This method was suggested by the group headed by Dr. Grazia Gambarini. The dosemeters used were TLD-600 ({sup 6}LiF:Mg,Ti with 95.6% {sup 6}Li) and TLD-700 ({sup 7}LiF:Mg,Ti with 99.9% {sup 7}LiF) from Harshaw. Photon dose measurement using the GC analysis method with TLD-700 in mixed fields requires the relation of the two main peaks of a TLD-600 GC shape obtained from an exposition to the same neutron field, and a photon calibrated GC with TLD-700. The requirements for slow neutron dose measurements are similar. In order to properly apply the GC analysis method at the Ra-6 Research Reactor BNCT facility, measurements were carried out in a standard water phantom, fully characterized on the BNCT beam by conventional techniques (activation detectors and paired ionization chambers technique). Next, the method was implemented in whole body dose monitoring of a patient undergoing a BNCT treatment, using a Bo MAb (Bottle Manikin Absorption) phantom

  1. Radiation protection in BNCT patients

    International Nuclear Information System (INIS)

    Blaumann, Hernan R.; Scharnichia, E.; Levanon, I.; Fernandez, C.; Facchini, Guillermo; Longhino, J.; Calzetta, Osvaldo; Pereira, M.

    2008-01-01

    Full text: Boron Neutron Capture Therapy (BNCT) is a technique that selectively targets cancer cells while sparing normal tissues by virtue of the differential uptake of a 10 B carrier compound in tumor. The National Atomic Energy Commission (CNEA) and the Oncology Institute 'Angel H. Roffo' (IOAR) began a BNCT programme in 2003 for treating cutaneous skin melanomas in extremities. The neutron beam used is the hyperthermal one developed at the RA-6 Reactor of the Bariloche Atomic Centre (CAB). The prescribed dose is delivered in one fraction and therefore patient positioning and knowledge of the dose received by normal tissue are crucial. 10 irradiations have been done since 2003, all of them in legs and feet and the dose prescription was determined by the maximum tolerable skin dose. Due to the characteristics of this treatment the patient body might be exposed not only to the primary beam but also to the secondary photon beam produced by neutron capture at the target itself. Thus a patient radiation-monitoring plan was implemented in order to evaluate the gamma dose delivered to sensible organs of each patient. An acrylic water-filled whole body phantom was used for preliminary gamma dose and thermal neutron flux measurements at positions related to patient's body sensible organs considering tentative patient positions. The beam port shielding was, in this way, optimized. TLD-700 and Manganese foils were used for gamma and thermal neutron detection. The TLD-700 thermal neutron response was previously evaluated by using the in-phantom beam dosimetry characterization. In-vivo dosimetry with TLD is routinely implemented in order to evaluate gamma dose to sensible organs of each patient. These organs are chosen depending on its distance from the zone to be irradiated and its radio-sensibility. All TLDs have been positioned well outside the irradiation field. Maximum gamma dose received outside the radiation field in healthy tissues was well below tolerance dose for

  2. ISABELLE: a proposal for construction of a proton--proton storage accelerator facility

    International Nuclear Information System (INIS)

    1976-05-01

    The construction of an Intersecting Storage Accelerator Facility (ISA or ISABELLE) at Brookhaven National Laboratory is proposed. ISABELLE will permit the exploration of proton-proton collisions at center-of-mass energies continuously variable from 60 to 400 GeV and with luminosities of 10 32 to 10 33 cm -2 sec -1 over the entire range. An overview of the physics potential of this machine is given, covering the production of charged and neutral intermediate vector bosons, the hadron production at high transverse momentum, searches for new, massive particles, and the energy dependence of the strong interactions. The facility consists of two interlaced rings of superconducting magnets in a common tunnel about 3 km in circumference. The proton beams will collide at eight intersection regions where particle detectors will be arranged for studying the collision processes. Protons of approximately 30 GeV from the AGS will be accumulated to obtain the design current of 10A prior to acceleration to final energy. The design and performance of existing full-size superconducting dipoles and quadrupoles is described. The conceptual design of the accelerator systems and the conventional structures and buildings is presented. A preliminary cost estimate and construction schedule are given. Possible future options such as proton-antiproton, proton-deuteron and electron-proton collisions are discussed

  3. Feasibility study on the utilization of boron neutron capture therapy (BNCT) in a rat model of diffuse lung metastases

    Energy Technology Data Exchange (ETDEWEB)

    Bakeine, G.J. [Department of Clinical Medicine and Neurology, Cattinara Hospital, University of Trieste (Italy)], E-mail: jamesbakeine1@yahoo.com; Di Salvo, M. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); Bortolussi, S.; Stella, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi 6, Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); Bertolotti, A.; Nano, R. [Department of Animal Biology University of Pavia, Piazza Botta, Pavia (Italy); Clerici, A.; Ferrari, C.; Zonta, C. [Department of Surgery University of Pavia, Piazza Botta, Pavia (Italy); Marchetti, A. [Scientific Research Office, Fondazione San Matteo University Policlinic, Pavia (Italy); Altieri, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi 6, Pavia (Italy)

    2009-07-15

    In order for boron neutron capture therapy (BNCT) to be eligible for application in lung tumour disease, three fundamental criteria must be fulfilled: there must be selective uptake of boron in the tumour cells with respect to surrounding healthy tissue, biological effectiveness of the radiation therapy and minimal damage or collateral effects of the irradiation on the surrounding tissues. In this study, we evaluated the biological effectiveness of BNCT by in vitro irradiation of rat colon-carcinoma cells previously incubated in boron-enriched medium. One part of these cells was re-cultured in vitro while the other was inoculated via the inferior vena cava to induce pulmonary metastases in a rat model. We observed a post-irradiation in vitro cell viability of 0.05% after 8 days of cell culture. At 4 months follow-up, all animal subjects in the treatment group that received irradiated boron-containing cells were alive. No animal survived beyond 1 month in the control group that received non-treated cells (p<0.001 Kaplan-Meier). These preliminary findings strongly suggest that BNCT has a significant lethal effect on tumour cells and post irradiation surviving cells lose their malignant capabilities in vivo. This radio-therapeutic potential warrants the investigation of in vivo BNCT for lung tumour metastases.

  4. Feasibility study on the utilization of boron neutron capture therapy (BNCT) in a rat model of diffuse lung metastases

    International Nuclear Information System (INIS)

    Bakeine, G.J.; Di Salvo, M.; Bortolussi, S.; Stella, S.; Bruschi, P.; Bertolotti, A.; Nano, R.; Clerici, A.; Ferrari, C.; Zonta, C.; Marchetti, A.; Altieri, S.

    2009-01-01

    In order for boron neutron capture therapy (BNCT) to be eligible for application in lung tumour disease, three fundamental criteria must be fulfilled: there must be selective uptake of boron in the tumour cells with respect to surrounding healthy tissue, biological effectiveness of the radiation therapy and minimal damage or collateral effects of the irradiation on the surrounding tissues. In this study, we evaluated the biological effectiveness of BNCT by in vitro irradiation of rat colon-carcinoma cells previously incubated in boron-enriched medium. One part of these cells was re-cultured in vitro while the other was inoculated via the inferior vena cava to induce pulmonary metastases in a rat model. We observed a post-irradiation in vitro cell viability of 0.05% after 8 days of cell culture. At 4 months follow-up, all animal subjects in the treatment group that received irradiated boron-containing cells were alive. No animal survived beyond 1 month in the control group that received non-treated cells (p<0.001 Kaplan-Meier). These preliminary findings strongly suggest that BNCT has a significant lethal effect on tumour cells and post irradiation surviving cells lose their malignant capabilities in vivo. This radio-therapeutic potential warrants the investigation of in vivo BNCT for lung tumour metastases.

  5. Cyclotron Development and Technical Aspects on Accelerator Based Laboratory Development

    International Nuclear Information System (INIS)

    Sunarhadijoso

    2000-01-01

    BATAN is planning to establish an accelerator-based laboratory at P3TM Yogyakarta as an effort in the development and use of accelerator technology for improving industrial performance and public welfare. This paper reviews several aspects of cyclotron technology and describes the combination of a linear accelerator - cyclotron system as an alternative to be considered in the planing of the laboratory. The progress of cyclotron technology is discussed covering three generations, i.e. conventional cyclotron, synchrocyclotron and AVF cyclotron generations. The planning should not consider the accelerator application for radioisotope production because it is established in Serpong with the existing negative ion cyclotron. The proposed facility at P3TM may comprise two linear accelerators coupled with a positive ion cyclotron of synchrocyclotron generation. In fact, the attachment of the synchrocyclotron unit is flexible and it can be installed subsequently if the higher energy particle beam, which can not be produced by the linear accelerators, is extremely needed. Some technical aspects related to ion beam application, building construction and infrastructure, human resources, and specification of function test are discussed for additional information in the implementation of the planning. (author)

  6. A study for the fabulously of introducing an acceleration mass spectrometer facility (ABMs) for carbon-14 applications

    International Nuclear Information System (INIS)

    Aly, A.I.M.; Comsan, N.; Sadek, M.

    2004-01-01

    In this work a study was conducted to show the importance and feasibility of introducing an accelerating mass spectrometer facility for carbon-14 analysis in the environmental levels. The different applications of Carbon-14 (e.g. dating and identification of food additives of synthetic origin) are discussed. There are two methods for C- 14 measurements, beta decay counting and accelerator mass spectrometry (AMS). The beta decay method requires gram quantities of the sample carbon, compared to few milligram quantities in case of AMS method. The Central Lab. for Environmental Isotope Hydrology of the National Center for Nuclear Safety and Radiation Control has a Carbon-14 analysis facility based on beta decay counting using a liquid scintillation counter after sample preparation in the form of benzene through rather complicated chemical conversion steps. This strongly limits the capacity of the laboratory to about 100-150 samples per year. Also, the amount of sample required limits our expansion for some very important applications like dating of archaeological small samples and especially old bone samples which normally have a low concentration of organic compounds. These applications are only possible by using the AMS method. For some applications only AMS could be used e.g measuring C-14 in atmospheric gases such as methane and carbon dioxide is virtually impossible using decay counting but quite feasible with AMS. The importance of purchasing an AMS facility or upgrading the existing accelerator is discussed in view of the shortage of such a facility in Africa and the Middle East. Acquiring an AMS in Egypt will make it possible to accurately date the Egyptian antiquities and to act as a regional laboratory and to enter into new applications where the amount of sample is limiting

  7. The Phase I/II BNCT Trials at the Brookhaven medical research reactor: Critical considerations

    International Nuclear Information System (INIS)

    Diaz, A.Z.

    2001-01-01

    A phase I/II clinical trial of boronophenylalanine-fructose (BPA-F) mediated boron neutron capture therapy (BNCT) for Glioblastoma Multiforme (GBM) was initiated at Brookhaven National Laboratory (BNL) in 1994. Many critical issues were considered during the design of the first of many sequential dose escalation protocols. These critical issues included patient selection criteria, boron delivery agent, dose limits to the normal brain, dose escalation schemes for both neutron exposure and boron dose, and fractionation. As the clinical protocols progressed and evaluation of the tolerance of the central nervous system (CNS) to BPA-mediated BNCT at the BMRR continued new specifications were adopted. Clinical data reflecting the progression of the protocols will be presented to illustrate the steps taken and the reasons behind their adoption. (author)

  8. Monte Carlo simulations of the cellular S-value, lineal energy and RBE for BNCT

    International Nuclear Information System (INIS)

    Liu Chingsheng; Tung Chuanjong

    2006-01-01

    Due to the non-uniform uptake of boron-containing pharmaceuticals in cells and the short-ranged alpha and lithium particles, microdosimetry provides useful information on the cellular dose and response of boron neutron capture therapy (BNCT). Radiation dose and quality in BNCT may be expressed in terms of the cellular S-value and the lineal energy spectrum. In the present work, Monte Carlo simulations were performed to calculate these microdosimetric parameters for different source-target configurations and sizes in cells. The effective relative biological effectiveness (RBE) of the Tsing Hua Open-pool Reactor (THOR) epithermal neutron beam was evaluated using biological weighting functions that depended on the lineal energy. RBE changes with source-target configurations and sizes were analyzed. (author)

  9. Health physics manual of good practices for accelerator facilities

    International Nuclear Information System (INIS)

    Casey, W.R.; Miller, A.J.; McCaslin, J.B.; Coulson, L.V.

    1988-04-01

    It is hoped that this manual will serve both as a teaching aid as well as a useful adjunct for program development. In the context of application, this manual addresses good practices that should be observed by management, staff, and designers since the achievement of a good radiation program indeed involves a combined effort. Ultimately, radiation safety and good work practices become the personal responsibility of the individual. The practices presented in this manual are not to be construed as mandatory rather they are to be used as appropriate for the specific case in the interest of radiation safety. As experience is accrued and new data obtained in the application of this document, ONS will update the guidance to assure that at any given time the guidance reflects optimum performance consistent with current technology and practice.The intent of this guide therefore is to: define common health physics problems at accelerators; recommend suitable methods of identifying, evaluating, and managing accelerator health physics problems; set out the established safety practices at DOE accelerators that have been arrived at by consensus and, where consensus has not yet been reached, give examples of safe practices; introduce the technical literature in the accelerator health physics field; and supplement the regulatory documents listed in Appendix D. Many accelerator health physics problems are no different than those at other kinds of facilities, e.g., ALARA philosophy, instrument calibration, etc. These problems are touched on very lightly or not at all. Similarly, this document does not cover other hazards such as electrical shock, toxic materials, etc. This does not in any way imply that these problems are not serious. 160 refs

  10. The target laboratory of the Pelletron Accelerator's facilities

    Energy Technology Data Exchange (ETDEWEB)

    Ueta, Nobuko; Pereira Engel, Wanda Gabriel [Nuclear Physics Department - University of Sao Paulo (Brazil)

    2013-05-06

    A short report on the activities developed in the Target Laboratory, since 1970, will be presented. Basic target laboratory facilities were provided to produce the necessary nuclear targets as well as the ion beam stripper foils. Vacuum evaporation units, a roller, a press and an analytical balance were installed in the Oscar Sala building. A brief historical report will be presented in commemoration of the 40{sup th} year of the Pelletron Accelerator.

  11. An Integration Testing Facility for the CERN Accelerator Controls System

    CERN Document Server

    Stapley, N; Bau, J C; Deghaye, S; Dehavay, C; Sliwinski, W; Sobczak, M

    2009-01-01

    A major effort has been invested in the design, development, and deployment of the LHC Control System. This large control system is made up of a set of core components and dependencies, which although tested individually, are often not able to be tested together on a system capable of representing the complete control system environment, including hardware. Furthermore this control system is being adapted and applied to CERN's whole accelerator complex, and in particular for the forthcoming renovation of the PS accelerators. To ensure quality is maintained as the system evolves, and toimprove defect prevention, the Controls Group launched a project to provide a dedicated facility for continuous, automated, integration testing of its core components to incorporate into its production process. We describe the project, initial lessons from its application, status, and future directions.

  12. Observation of Neutron Skyshine from an Accelerator Based Neutron Source

    Energy Technology Data Exchange (ETDEWEB)

    Franklyn, C. B. [Radiation Science Department, Necsa, PO Box 582, Pretoria 0001 (South Africa)

    2011-12-13

    A key feature of neutron based interrogation systems is the need for adequate provision of shielding around the facility. Accelerator facilities adapted for fast neutron generation are not necessarily suitably equipped to ensure complete containment of the vast quantity of neutrons generated, typically >10{sup 11} n{center_dot}s{sup -1}. Simulating the neutron leakage from a facility is not a simple exercise since the energy and directional distribution can only be approximated. Although adequate horizontal, planar shielding provision is made for a neutron generator facility, it is sometimes the case that vertical shielding is minimized, due to structural and economic constraints. It is further justified by assuming the atmosphere above a facility functions as an adequate radiation shield. It has become apparent that multiple neutron scattering within the atmosphere can result in a measurable dose of neutrons reaching ground level some distance from a facility, an effect commonly known as skyshine. This paper describes a neutron detection system developed to monitor neutrons detected several hundred metres from a neutron source due to the effect of skyshine.

  13. Evaluation of pelletron accelerator facility to study radiation effects on semiconductor devices

    Energy Technology Data Exchange (ETDEWEB)

    Prakash, A. P. Gnana; Pushpa, N.; Praveen, K. C.; Naik, P. S.; Revannasiddaiah, D. [Department of Studies in Physics, University of Mysore, Manasagangotri, Mysore-570006, Karnataka (India)

    2012-06-05

    In this paper we present the comprehensive results on the effects of different radiation on the electrical characteristics of different semiconductor devices like Si BJT, n-channel MOSFETs, 50 GHz and 200 GHz silicon-germanium heterojunction bipolar transistor (SiGe HBTs). The total dose effects of different radiation are compared in the same total dose ranging from 100 krad to 100 Mrad. We show that the irradiation time needed to reach very high total dose can be reduced by using Pelletron accelerator facilities instead of conventional irradiation facilities.

  14. Evaluation of pelletron accelerator facility to study radiation effects on semiconductor devices

    International Nuclear Information System (INIS)

    Prakash, A. P. Gnana; Pushpa, N.; Praveen, K. C.; Naik, P. S.; Revannasiddaiah, D.

    2012-01-01

    In this paper we present the comprehensive results on the effects of different radiation on the electrical characteristics of different semiconductor devices like Si BJT, n-channel MOSFETs, 50 GHz and 200 GHz silicon-germanium heterojunction bipolar transistor (SiGe HBTs). The total dose effects of different radiation are compared in the same total dose ranging from 100 krad to 100 Mrad. We show that the irradiation time needed to reach very high total dose can be reduced by using Pelletron accelerator facilities instead of conventional irradiation facilities.

  15. Evaluation and analysis of the residual radioactivity for the 15UD Pelletron accelerator facility

    International Nuclear Information System (INIS)

    Sonkawade, R. G.

    2007-01-01

    For the assessment of radiological impact of the accelerators, it will be better to have the documented information on activation of metal parts of the accelerator components. It is very much essential to get reliable data on these subjects. During acceleration of light ion, the residual radioactivity in the accelerator facility was found near the Analyzing Magnet, single slit, Beam Profile Monitors (BPM), Faraday Cups (FC), bellows, beginning of switching magnet bellows, at the target and the ladder. Study with HPGE detector gives an insight of the formation of the short or long lived radionuclides. The different targets used in the light ion experiment were also monitored and proper decommissioning and decontamination steps were followed. This paper presents the data of residual radioactivity in the 15UD Pelletron accelerator infrastructure. (author)

  16. Accelerator mass spectrometry - Indian scenario. PD-1-1

    International Nuclear Information System (INIS)

    Kailas, S.

    2007-01-01

    Accelerator based ultra sensitive Mass Spectrometry (AMS) programmes are being vigorously pursued world over for the past three decades. There are more than 50 accelerator facilities devoted to this multidisciplinary activity. Realizing the importance of this programme, the work related to AMS has commenced at three major accelerator facilities in India: Institute of Physics, Bhubaneswar; Interuniversity Accelerator Centre, Delhi; BARC - TIFR Pelletron accelerator facility, Mumbai. At Bhubaneswar, facilities have been set up to carry our high precision 14 C based AMS programmes using the 3 MV Pelletron. A magnetic bouncer, an electrostatic analyzer and a chemistry lab for making samples in graphite form are some of the important features of this AMS facility. A number of users have already got their samples analysed using this AMS facility. The AMS programme has used upto 20 % of beam time available from the 3 MV Pelletron at Bhubaneswar. At Delhi efforts are underway and initial success has been achieved for carrying out 10 Be based AMS programme. Novel method based on simultaneously injecting oxide of Be - ( 9 Be and 17 O) and ( 10 Be and 16 O) has been tried to obtain the ratio of 9 Be / 10 Be. A velocity filter is also available for this programme. Both at Bhubaneswar and Delhi, provision exists in the form of a multi cathode target wheel for carrying out measurements for a number of samples. At Mumbai the emphasis has been in precision measurement of 36 Cl in samples. Segmented anode detector has been developed for the separation of interfering 36 S and 36 Cl isobars

  17. CONCERT A high power proton accelerator driven multi-application facility concept

    CERN Document Server

    Laclare, J L

    2000-01-01

    A new generation of High Power Proton Accelerator (HPPA) is being made available. It opens new avenues to a long series of scientific applications in fundamental and applied research, which can make use of the boosted flux of secondary particles. Presently, in Europe, several disciplines are preparing their project of dedicated facility, based on the upgraded performances of HPPAs. Given the potential synergies between these different projects, for reasons of cost effectiveness, it was considered appropriate to look into the possibility to group a certain number of these applications around a single HPPA: CONCERT project left bracket 1 right bracket . The ensuing 2-year feasibility study organized in collaboration between the European Spallation Source and the CEA just started. EURISOL left bracket 2 right bracket project and CERN participate in the steering committee.

  18. The JAERI-KEK joint project on high intensity proton accelerator and overview of nuclear transmutation experimental facilities

    International Nuclear Information System (INIS)

    Ikeda, Yujiro

    2001-01-01

    A status of the JAERI/KEK joint project on High Intensity Proton Accelerator is overviewed. It is highlighted that Experimental facilities for development of the accelerator driven system (ADS) for nuclear transmutation technology is proposed under the project. (author)

  19. Simulation of Cascaded Longitudinal-Space-Charge Amplifier at the Fermilab Accelerator Science & Technology (Fast) Facility

    Energy Technology Data Exchange (ETDEWEB)

    Halavanau, A. [Northern Illinois U.; Piot, P. [Northern Illinois U.

    2015-12-01

    Cascaded Longitudinal Space Charge Amplifiers (LSCA) have been proposed as a mechanism to generate density modulation over a board spectral range. The scheme has been recently demonstrated in the optical regime and has confirmed the production of broadband optical radiation. In this paper we investigate, via numerical simulations, the performance of a cascaded LSCA beamline at the Fermilab Accelerator Science & Technology (FAST) facility to produce broadband ultraviolet radiation. Our studies are carried out using elegant with included tree-based grid-less space charge algorithm.

  20. Proposed medical applications of the National Accelerator Centre facilities

    International Nuclear Information System (INIS)

    Jones, D.T.L.

    1982-01-01

    The National Accelerator Centre is at present under construction at Faure, near Cape Town. The complex will house a 200 MeV separated-sector cyclotron which will provide high quality beams for nuclear physics and related diciplines as well as high intensity beams for medical use. The medical aspects catered for will include particle radiotherapy, isotope production and possibly proton radiography. A 30-bed hospital is to be constructed on the site. Building operations are well advanced and the medical facilities should be available for use by the end of 1984

  1. {sup 124}Sb–Be photo-neutron source for BNCT: Is it possible?

    Energy Technology Data Exchange (ETDEWEB)

    Golshanian, Mohadeseh [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Department of Physics, Shahrood University, Shahrood (Iran, Islamic Republic of); Rajabi, Ali Akbar [Department of Physics, Shahrood University, Shahrood (Iran, Islamic Republic of); Kasesaz, Yaser, E-mail: ykasesaz@aeoi.org.ir [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of)

    2016-11-01

    In this research a computational feasibility study has been done on the use of {sup 124}SbBe photo-neutron source for Boron Neutron Capture Therapy (BNCT) using MCNPX Monte Carlo code. For this purpose, a special beam shaping assembly has been designed to provide an appropriate epithermal neutron beam suitable for BNCT. The final result shows that using 150 kCi of {sup 124}Sb, the epithermal neutron flux at the designed beam exit is 0.23×10{sup 9} (n/cm{sup 2} s). In-phantom dose analysis indicates that treatment time for a brain tumor is about 40 min which is a reasonable time. This high activity {sup 124}Sb could be achieved using three 50 kCi rods of {sup 124}Sb which can be produced in a research reactor. It is clear, that as this activity is several hundred times the activity of a typical cobalt radiotherapy source, issues related to handling, safety and security must be addressed.

  2. Neutron research and facility development at the Oak Ridge Electron Linear Accelerator 1970 to 1995

    International Nuclear Information System (INIS)

    Peelle, R.W.; Harvey, J.A.; Maienschein, F.C.; Weston, L.W.; Olsen, D.K.; Larson, D.C.; Macklin, R.L.

    1982-07-01

    This report reviews the accomplishments of the first decade of operation of the Oak Ridge Electron Linear Accelerator (ORELA) and discusses the plans for the facility in the coming decade. Motivations for scientific and applied research during the next decade are included. In addition, ORELA is compared with competing facilities, and prospects for ORELA's improvement and even replacement are reported. Development efforts for the next few years are outlined that are consistent with the anticipated research goals. Recommendations for hardware development include improving the electron injection system to give much larger short-pulse currents on a reliable basis, constructing an Electron Beam Injector Laboratory to help make this improvement possible, continuing a study of possibly replacing the electron accelerator with a proton machine, and replacing or upgrading the facility's data-acquistion and immediate-analysis computer systems. Increased operating time and more involvement of nuclear theorists are recommended, and an effective staff size for optimum use of this unique facility is discussed. A bibliography of all ORELA-related publications is included

  3. Approach to the open advanced facilities initiative for innovation (strategic use by industry) at the University of Tsukuba, Tandem Accelerator Complex

    International Nuclear Information System (INIS)

    Sasa, K.; Tagishi, Y.; Naramoto, H.; Kudo, H.; Kita, E.

    2010-01-01

    The University of Tsukuba, Tandem Accelerator Complex (UTTAC)